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QUANTIFICATION OF IMRT SEVERITY SCORES FOR IMPROVEMENT OF FMEA RESULTS 
 
Jacqueline Tonigan Faught, M.S. 
Supervisory Professor: David S. Followill, Ph.D.  
 
Accurate delivery of intensity modulation radiation therapy (IMRT) requires perfect execution of a long, 
complicated chain of events; failure of any component of this process may contribute to dose delivery 
errors, compromising treatment quality and, more importantly, patient safety. Prospective, process-wide 
risk mitigation techniques are becoming more prevalent in radiotherapy to establish comprehensive 
quality management (QM) programs, such as failure modes and effects analysis (FMEA). The subjective 
nature of the ordinal scores used for FMEA leads questionable reliability and validity of the results.  
Additionally, physics components are commonly grouped together, leaving out valuable details  
important to physics QM. While the process of performing an FMEA is beneficial, it does not guarantee 
accurate assessment of failure modes. The objective of this project was to provide quantitative severity 
scores for IMRT delivery failure modes to decrease variability and increase the validity and applicability 
of FMEA results for improvement of physics QM. The hypothesis of this proposed work was that 
quantified IMRT physical failure mode severity scores were significantly more likely to describe the true 
severity compared to conventional qualitative scores. To test this hypothesis, physical failure modes were 
simulated in clinical IMRT patient treatment plans and the ability of qualitative subjective scores and 
quantitative scores to accurately describe the magnitude of the resultant dose discrepancies in clinical 
plans were compared. Qualitative subjective scores were obtained through an online survey of the 
medical physicist community. Quantitative scores were obtained through phantom treatment planning 
studies and measurements. Each set of severity data for the identified failure modes were compared to the 
true clinical severities in ten oropharyngeal patient treatment plans using Wilcoxon Signed Rank Tests. 
8/11 failure mode true severity scores were predicted by quantitative approaches and 6/11 were predicted 
by qualitative approaches (p<0.05). We concluded that the quantitative severity scores did better predict 
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the true severity scores for our failure modes. However, the qualitative severity scores provided useful 
information and the more important conclusion of this project was that while this process is very 
complicated the more information available to inform scoring decisions, the more reliable and accurate 
the severity scoring will be. 
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Chapter 1: Introduction 
1.1 Background  
Despite continuous improvements to the prevention, detection, and treatment of cancer, 25% of 
deaths in the United States can be attributed to cancer and over 1.6 million new cancer cases were 
diagnosed in 20141. There are a variety of treatment options available today, with the most elemental 
categories being surgery, chemotherapy, and radiation therapy. Currently, about two thirds of all cancers 
are treated with a form of radiation therapy either alone or in conjunction with another form of therapy2.  
With our present level of knowledge, experience, and advanced technologies, a high level of safety, 
quality, and efficiency are expected of radiation treatments. However, as with any medical procedure, 
radiotherapy presents potentially very serious risks to the patient and errors have been known to occur. 
Compounding with the inherent risks associated with radiotherapy, complicated advanced 
techniques such as various forms of intensity modulated radiation therapy (IMRT), precise delivery of 
Stereotactic Body Radiation Therapy (SBRT), and Image Guided Radiation Therapy (IGRT) present 
additional challenges in the clinic and may lead to increased risk if not implemented correctly and 
properly maintained. Recent advancements in imaging, targeting, and treatment techniques allow precise 
delivery of very high radiation doses to diseased tissue while sparing adjacent healthy tissue and critical 
organs using a variety of modalities. These advanced techniques have the potential for superior tumor 
control while maintaining minimal normal tissue complications or toxicities. With the advantages of 
advanced techniques, comes increased treatment complexity and risk of errors that requires an increase in 
the quality management of these techniques. Although reduced error rates have been reported with the 
implementation of advanced, automated treatment techniques over time3-5, increased treatment 
complexities have also been shown to significantly increase the rate of undetected errors6.  The long chain 
of events making up the radiation therapy process relies upon complex machinery and software, highly 
trained staff, and various interfaces between these components. The extensive and complicated nature of 
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the external beam radiation therapy (EBRT) process is well demonstrated in the 269 node process map 
from Ford, et. al. shown in Figure 17. Procedures, dose calculations, and delivery requirements are more 
complicated today than ever, leaving more potential for error. Figure 2 from Kalapurakal, et al. shows 
more simply a standard EBRT process demonstrating several of the potential failure points, personnel, 
and check points8. It is clear that from this figure that many potential points of failure exist, however this 
is not the whole picture. Behind many of the listed actions/errors lie several more steps, especially physics 
steps such as those required for proper dose calculations and dose delivery. In addition to the complicated 
advance treatment processes, the increased demand on staff, hardware, and software is a concern. With 
the challenges of busier clinics, advanced treatment techniques, and increased patient risk, the 
radiotherapy community is faced with complex challenges in safety and quality. Evidence of these 
challenges and the risks present in radiation therapy can been found in increasingly publicized error 
reports4,9-13. 
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Figure 1: EBRT process map from used to evaluate the safety of the process in Ford, et. al (2009). 269 process nodes are 
shown and those highlighted in black indicate the top 15 most risky as defined by risk probability number (RPN)7.A
                                                          
A Reprinted from Int. J of Rad Onc Bio Phys 74(3), Ford, E. C. , Gaudetter, L. M., Vanderver, B., Engineer, L., Zellars, R., Song, D. Y., Wong, J., 
DeWeese, T. L., “Evaluation of safety in radiation oncology setting using failure mode and effects analysis.” pp. 852-858. Copyright (2009), with 
permission from Elsevier. 
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Figure 2: EBRT process with potential errors, Radiation oncology personnel, and common barriers or checklists/timeouts 
to catch errors8.B 
Although the true rate of errors in radiation therapy is unknown, several studies to date have 
reported on the error rates captured by incident reporting systems. Error rates reported by single 
institutions using incident reporting systems vary from 0.1% to approximately 5% per treatment course4,9-
13. Multi-institutional data is becoming available as national and international reporting databases gain 
popularity.  Shafiq, et al. performed a review of all radiation therapy events published between 1976 and 
2007, reporting 7741 incidents and near misses with 3125 of those resulting in some level of patient harm 
including 38 patient deaths due to overdose toxicities or under-dose failures14. These errors can originate 
from any point in the process and have a multitude of causes. One detailed example of this comes from a 
retrospective review and categorizations of 59 EBRT accidents which resulted in the compilation of 
initiating events and descriptions shown in Table 1.15. One consistent factor in error reporting is the 
prevalence of human errors, which lead to over 50% of incidents of potentially high severity reported by 
Terezakis, et al16. “One error is an error too many” is the common mentality amongst Radiation Oncology 
                                                          
B Reprinted from Int. J of Rad Onc Bio Phys 86(2). Kalapurakal, J. A., Zafirovski, A., Smith, J., Fisher, P., Sathiaseelan, V., Barnard, C., Rademaker, 
A.W., Rave, N., Mittal, B.B. “A comprehensive quality assurance program for personnel and procedures in radiation oncology: value of voluntary 
error reporting and checklists.” pp. 241-248. Copyright (2013), with permission from Elsevier. 
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Table 1: Initiating events in 59 EBRT accidents for categorization. (E) indicates equipment failure15.C 
                                                          
C Reprinted from Radiat Oncol J. 31(2), Kim, J. “ Categorizing accident sequences in the external radiotherapy for risk analysis.” pp. 88-96 
Copyright (2013) under the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/).  
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professionals and so while these error rates indicate that radiation therapy is actually one of the safer areas 
of modern medicine, with these generally low probabilities of incident occurrence in comparison to the 
recently estimated 210,000 annual deaths due to preventable harm in hospitals, efforts to thoroughly 
understand and mitigate risks are critical 17,18.  
Although reported radiation oncology error rates are dominated by small errors that are often not 
clinically significant, they still pose a threat to our uncertainty goals and open the door to potentially 
larger, more severe errors. Hunt et al. recently reported dose errors exceeding 5% per fraction in 52% of 
treatment events including one dose error exceeding 50% per fraction9-11,13. Several more severe incidents 
were brought to the attention of the public with a series of New York Times articles published in 201019-
21. One article, for example, described an incident in 2005 in which a head and neck treatment plan did 
not save correctly, leaving out multi-leaf collimator (MLC) files. The resultant open field irradiations of 
the patient’s head and neck persisted for three fractions before being caught. Overall the patient received 
over seven times the intended dose and ultimately suffered a painful and slow death22. While this is an 
extreme example, such detrimental consequences are not acceptable and we must question - are those 
expectations of efficiency, quality, and safety being fulfilled?  
To address the risks in radiation therapy, extensive quality management efforts are made. Quality 
management aims to maintain that the intended dose is delivered to the intended location at the intended 
time for all patients. Goals of treatment uncertainty are discussed at length in the literature. Generally, the 
goal of ±5% uncertainty of the absolute dose delivered to the target required by ICRU Report 24 is 
considered the overall goal and this is based on the responses of tumor control probability and normal 
tissue complication probability23,24. However, this takes into account a large number of variables and 
superior accuracy in each variable must be achieved in order to meet this goal. To aid in achieving this 
goal, routine quality assurance practices are commonly documented for technical aspects of radiation 
therapy techniques by national and international bodies such as the American Association of Physicists in 
Medicine (AAPM) and the International Atomic Energy Agency (IAEA).  Secondary checks are another 
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essential tool for radiation therapy, where a simple oversight by a single individual can easily result in the 
mistreatment of a patient or worse yet, become a systematic error that affects many patients. An accepted 
method for detecting and assisting to correct errors is the use of external independent audits, which are 
widely encouraged and are required in many instances such as when clinics are participating in multi-
institutional clinical trials or as a Department of Health regulation. In radiation therapy, the Imaging and 
Radiation Oncology Core in Houston (IROC-H) is one group that serves this purpose for radiotherapy 
institutions participating in the National Cancer Institute’s funded clinical trials through mailed output 
checks, chart reviews, site visits, and end-to-end phantom assessments. The external audit of one widely 
used modality, intensity modulated radiation therapy (IMRT), using IROC-H’s head and neck phantom 
initially had a 33% failure and even today, a decade later, still has nearly a 15% failure rate despite the 
generous pass criteria of 7% absolute dose agreement and 4 mm distance-to-agreement25. It is evident that 
changes are needed if improvements to the safety and quality performance are going to be made in the 
rapidly-advancing and high pressure environment radiation therapy is in.  
To more thoroughly, effectively, and efficiently address potential errors in radiation therapy and 
attempt to eliminate severe consequences from radiation therapy treatments, risk mitigation techniques, 
largely borrowed from other high risk industries, are being highlighted. The initiative for new approaches 
to quality management has led the Radiation Oncology community to include more process-wide risk 
mitigation techniques, recognizing that understanding the entire process is necessary when errors may 
propagate from any point in the system to eventually reach the patient. Retrospective approaches such as 
root cause analysis (RCA) have been in use formally and informally in response to errors that are caught 
and deemed sufficiently threatening to justify the investment. This approach is being encouraged as is the 
reactive approach of incident reporting and learning, as mentioned previously. With widespread 
implementation of these risk mitigation techniques, we can learn not only from our own mistakes, but 
experiences in other clinics, and potentially make large global improvements in the direction of more 
safe, high quality treatments.  Additionally, several prospective risk analysis and mitigation tools are 
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being implemented for this cause including process mapping, fault tree analysis, and failure modes and 
effects analysis (FMEA)26-28. Each of these tools offer benefits to the radiotherapy process and may be 
implemented concurrently. FMEA in particular is gaining popularity in radiotherapy with studies 
published from several institutions and a soon to be published report by the American Association of 
Physicists in Medicine (AAPM) Task Group 1007,29-36.  
 Failure Modes and Effects Analysis 
The overall goal of an FMEA in radiation therapy is to identify potential points of weakness in 
the process and prioritize them in accordance to the risk they present to the process goal of safely and 
efficiently delivering a specific dose to a specific location at a specific time. An FMEA is conducted by a 
multi-disciplinary panel of personnel experienced in the process to be evaluated, starting with a detailed 
outline of the processes commonly in the form of a process map. The panel then identifies every failure 
mode possible for each step of each process and each of these failure modes is assigned three scores: 
likelihood of occurrence (O), likelihood it will go undetected (D), and the severity of the consequences 
(S). Each of these scores has a predetermined scale generally ranking from 1 (smallest risk) to 10 (largest 
risk). The product of the three scores for each failure mode results in the risk probability number (RPN), 
which is then used to rank the failure modes in order of their potential impact on the patient and the clinic. 
Generally, a threshold RPN value is assigned by the panel, and failure modes with an RPN score above 
the threshold require attention to reduce their potential impact. In addition, it is common to re-evaluate 
failure modes with high severity scores (≥ 8) because the perceived patient safety concerns are 
unacceptably large. After improvements to the process are implemented and the high severity scores are 
believed to have been reduced, an FMEA may be performed again to reevaluate the risks associated with 
potential failures. To date, FMEA has been performed on a number of radiation therapy processes. A 
commonly cited example is the FMEA of external beam radiation therapy (EBRT) at Johns Hopkins 
University by Ford, et al. In this study, they generated a process map of 269 nodes with 127 potential 
failure modes. RPNs ranged from 2 to 160, with process improvements implemented for the fifteen most 
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risky failure modes7. While this study is an excellent start to the implementation of a risk mitigation 
technique in radiation therapy, there are still no standards by which to judge at what level an RPN score 
requires attention.  
FMEA of radiotherapy processes, while subjective, still provides many benefits to patients and 
the Radiation Oncology department participating in the processes being evaluated. Performing an FMEA 
of a process allows for a thorough understanding and recognition of the process as a whole and its 
component interactions. Also, this analysis clearly results in improvements to the overall treatment 
process and therefore reduced risk. Inter-disciplinary bonds and respect are achieved as the importance of 
each step of the process becomes evident and the challenges of each member's tasks can be further 
appreciated. This comprehensive analysis can be very time consuming, but in another EBRT study by 
Ford, et al. the time was significantly reduced by streamlining the process, obtaining a failure mode 
ranking with just four one-hour meetings (total of 55 hours staff time)37. The resultant ranking was 
beneficial to the entire process team as they developed a better understanding of the process components, 
their interactions, and the potential risks.  
In spite of the aforementioned benefits of FMEA, limitations and weaknesses of this tool may 
compromise its utility.  The primary limitation of an FMEA is the subjective nature of the process and the 
use of ordinal scoring to obtain risk information. This results in large variability in failure mode 
identification, scoring, and prioritization which calls into question the reliability of the results of an 
FMEA. In one study by Shebl, et. al. two independent teams each identified 50 failure modes for a 
common process, but only 17 were identified by both groups and none of the top five failure modes as 
ranked by RPN were shared38. Another study showed that scoring by average versus consensus of team 
scores also yielded different results39. The validity of FMEA results are also questionable as the assigned 
scores lack evidence of accuracy and are often biased. The mathematical principles behind FMEA have 
even been called into question with respect to the validity of results, primarily noting that ordinal numbers 
cannot be meaningfully multiplied and the relative values of RPNs lack quantitative meaning and may 
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lack consistency. For example, is a failure mode with an RPN of 180 twice as risky as one with an RPN 
of 9040,41? In addition to the potential issues that arise due to the subjective, ordinal scoring of FMEA, 
process-wide radiotherapy and, specifically, IMRT FMEAs present potential for grouping together 
physics-specific components such as "Linac hardware," leaving out valuable information about the 
treatment planning and delivery stages and the associated necessary quality management. While the 
systematic aspect of this approach is desired in the implementation of FMEA, detailed information is 
required to make meaningful quality improvements and physics is a very active aspect of this. 
Motivation 
With the present identified deficiencies, the application of FMEA to physics-specific delivery 
processes and further investigation into the values of these scores is needed. As called for by the 
American Society for Radiation Oncology (ASTRO), several incident reporting systems are becoming 
available for the community including an international system known as the Radiation Oncology Safety 
Information System (ROSIS)42. Such systems will be one way to quantify the likelihood of occurrence. 
Lack of detectability will be slightly more challenging to quantify because of the vast array of safety 
barrier configurations and detection systems, with large variances between institutions. However, the 
effectiveness of detecting failures can be evaluated for specific safety barriers individually and a recent 
attempt to qualitatively analyze the effectiveness of several QA techniques has been published43. The 
severity of failure modes, arguably the most important of the three scores, is theoretically directly 
measureable and was the focus of the present study. 
1.2 Objective 
The objective of this work was to compute and/or measure the severity for IMRT delivery 
physical failure modes, improving upon two current weaknesses of FMEA; reducing the subjectivity of 
the scoring and examining physics-related failure modes individually. The end goal was to provide key 
information to medical physicists and linac engineers for improvement of patient safety that to date has 
not been determined and can potentially be used in future FMEA for radiation therapy. 
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1.3 Hypothesis and Specific Aims  
Failure modes and effects analysis (FMEA) provides a prospective end-to-end risk evaluation of 
radiotherapy processes by means of a subjective qualitative scoring system. The objective of this work 
was to reduce the subjectivity of IMRT delivery FMEA severity scores for physics components by 
providing quantitative data on the effects of these failures. The central hypothesis was that quantified 
IMRT dose delivery failure mode severity scores that are based on measurement were significantly more 
likely to describe the true clinical consequences than conventional subjective scores. The rationale for this 
research was that even though quantitative severity scores are called for in the literature, they are not 
currently available and their application will improve the results of an FMEA for physics applications to 
radiotherapy quality management. The hypothesis was tested with the following Specific Aims: 
 
1. Identify qualitative and quantitative severity scores for IMRT delivery physical failure 
modes.  
The working hypothesis of this specific aim was that subjective qualitative severity scores 
obtained through a conventional FMEA were significantly different than quantitative severity 
scores generated from computed and measured data. The IMRT delivery process was outlined 
and critical physical failure modes identified. Qualitative scores were obtained through 
conventional FMEA methods and on a larger scale through a survey. Quantitative scores were 
obtained through treatment planning studies and physical measurements using an 
anthropomorphic phantom. The hypothesis was tested by performing a one-sample Wilcoxon 
Signed Rank Test. 
2. Evaluate and compare the ability of qualitative and quantitative severity scores to 
accurately describe the error magnitude induced in clinical cases by each physical failure 
mode. 
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The working hypothesis of this specific aim was that quantitative severity scores were 
significantly more likely to match true severity scores than qualitative scores. True severity scores 
for each of the physical failure modes were evaluated by modeling errors in the treatment 
planning system and calculating the resultant magnitude of error in ten clinical patient treatment 
plans. We then evaluated how well the qualitative and quantitative severity scores from specific 
aim 1 matched these true severity scores. The qualitative and quantitative severity data were each 
compared to the true clinical data with an independent sample and one-sample Wilcoxon Signed 
Rank Test, respectively.  
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Chapter 2: Methods and Materials 
2.1 Specific Aim 1: Identify qualitative and quantitative severity scores for 
IMRT delivery physical failure modes. 
The objective of this specific aim was to obtain and compare qualitative and quantitative FMEA 
severity scores for the identified critical physical failure modes. The working hypothesis of this specific 
aim was that subjective qualitative severity scores obtained through a conventional FMEA would be 
significantly different than quantitative severity scores generated from computed and measured data. The 
rationale of this specific aim was that completion of a traditional FMEA allowed us to obtain qualitative, 
subjective scores of the specific process we are analyzing. The subjective, qualitative scores found in a 
conventional radiotherapy FMEA have an unknown reliability, consistency and validity. To improve 
upon this risk analysis tool, computation and physical measurement of the magnitude of dose delivery 
errors induced by failure modes were used for more accurate assignment of severity scores as called for in 
the literature. The severity scores obtained allowed for comparison of the qualitative subjective severity 
scores to the quantitative severity scores. Additionally, examples of FMEA in radiotherapy available in 
the literature today analyze processes as a whole with the benefit of comprehensive understanding of the 
process and error propagation, but neglecting process details such as those applicable to physics quality 
management. Expansion of physics-based process components will provide a more detailed investigation 
of physical failure modes. Verified physical failure mode severity scores will allow for more confident 
risk-based ranking, but more importantly, knowing error magnitudes associated with physical failure 
modes will allow physicists to appropriately assess and implement their quality management programs.  
2.1.1 Radiotherapy process focus and failure mode identification 
This study focused on the process of step-and-shoot head and neck IMRT delivery and was be 
based on the radiation therapy delivery process used at M. D. Anderson Cancer Center (MDACC) 
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utilizing. In order to follow AAPM TG-100 and compare directly to the outcomes of the task group 
report, we focused on the same process used in their example: IMRT. Step-and-shoot is a basic and 
widely familiar form of IMRT dose delivery and results generated for this process can be built upon for 
more advanced IMRT techniques. This project utilized measurement tools of the Imaging and Radiation 
Oncology Core in Houston (IROC-H), specifically an IMRT head and neck phantom44. This phantom is 
well established in the measurement of step-and-shoot IMRT deliveries, with more than twice as many 
segmental irradiations than any other IMRT technique. It is reported that >85% of credentialing 
irradiations of this phantom that fail a generous 7%/4mm criteria are caused by true treatment delivery 
errors as opposed to one-time physicist errors25. The ability of this phantom to detect the small failures 
subject to this project was of interest.  
As at the beginning of any FMEA, the process we examined was outlined in detail to provide a 
comprehensive description and basis for identifying potential points of failure. A failure mode is defined 
as an error or shortcoming of any component, step or sub-step that compromises the goal of the process. 
In our case the process goal was to safely and efficiently deliver the correct radiation dose to the correct 
anatomic location at the intended time. Further, in our study a physical failure mode was a failure mode 
that involves a physics-based component of the radiation dose calculation or delivery and comprises of 
both hardware and software components. To identify failure modes, one must consider how the process 
could fail while examining the process tree. What could go wrong at each step that could result in an error 
in the dose delivery? The process tree and failure mode identification was completed by a small group of 
experienced physicists with review and confirmation by the Advisory Committee on this project.  
The approach to creating this list was to include potential errors that are relatively common and 
could occur by a mechanical failure or by an incorrect calibration/commissioning. Based on experiences 
in the clinic, experiences of the IROC-H at other clinics, and the group’s knowledge of the literature, the 
below general process tree (Figure 3) and list of failure modes was determined and are shown below.  
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Figure 3: General IMRT Process Tree 
IMRT physical delivery failure modes identified: 
1. Beam quality 
2. Beam Symmetry 
3. MLC Position 
4. Gantry angle 
5. Collimator angle 
6. Couch angle  
7. MU linearity 
8. MLC leakage and transmission modeling  
9. MLC tongue-and-groove modeling  
10. MLC leaf end modeling  
11. CT number to electron density table in treatment planning system 
 
Magnitude of Failure 
The magnitude of the error induced (the magnitude of failure) was determined by the current 
criteria held in a common clinic which adheres to recommendations of the AAPM. We evaluated the 
severity at the tolerance level or just outside that level to simulate situations in which the clinic may or 
may not react to the failure. This approach to define the magnitude of failure differs from that of a 
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conventional FMEA, in which the worst effect is considered when evaluating severity45. The reason for 
this departure was that, while rare catastrophic failures and their causes should be considered, the 
relatively small failures considered in this study are more clinically relevant. Failures of this magnitude 
occur with moderate frequency and are handled in different manners, depending on the clinic. Resultant 
data on failures of this magnitude will be useful for direct evaluation of the common quality assurance 
programs implemented in the clinic today and will serve to expand the functionality of an FMEA. The 
magnitude of failure evaluated in each situation will be described in the sections to follow. 
2.1.2 Obtain qualitative severity scores by means of a traditional FMEA of the IMRT delivery 
process 
Overview 
Assignment of failure mode scores O, D, and S for an FMEA is conventionally completed by a 
multidisciplinary team of experts based on their opinions of the expected appropriate values. In order to 
obtain these qualitative scores, a survey of medical physicists was conducted. This served to evaluate the 
range of possible responses as well as the potential variability in interpretation. This survey also allowed 
us to gather the opinions of a wide range of physicists, with the target audience being therapy physicists 
that are active in the Radiation Oncology community. 
Survey Design 
Eleven different physical failure modes in step-and-shoot IMRT at or just outside commonly 
accepted tolerance criteria levels were briefly described and are listed in Table 2. Respondents were 
asked to estimate the worst case scenario percent dose error in a head and neck patient for each of the 
failure modes keeping in mind both target structures and organs at risk. Respondents were also asked to 
assign the three FMEA scores: Occurrence (O), Detectability (D), and Severity (S). The scales used in 
this survey for FMEA scores were based on conventional scales used in other radiotherapy FMEA studies 
and were color coordinated for ease of use as shown in Table 3. As described in the introduction, these 
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scales lack quantitative definitions for severity scores. The following demographic data was also 
collected: current IMRT clinical practices used including linear accelerator manufacturer, treatment 
planning system, and delivery technique, years of experience in medical physics, percent of time 
dedicated to clinical work, familiarity with FMEA, clinic location, and board certification.  
Several factors were considered when designing this survey. Key components of the survey 
design  were clarity and ease of completion. This topic of study presents challenges in meeting those 
goals. The identification of the process being evaluated with the survey, step-and-shoot head and neck 
IMRT, is very important to the scoring. However, description of the process could not be too specific or 
too broad so as to lead the respondent. The assignment of scores and percent dose errors can be confusing 
and had to be described clearly. FMEA is a new concept to most physicists and therefore could be 
intimidating or could discourage individuals from responding if they didn’t feel qualified to answer. It 
was also important that the survey didn’t take too long, was interesting, and felt worth the time to 
complete. Balancing these considerations with a complicated topic and the desire for the maximum 
amount of information possible was challenging. Some measures we took to address these challenges 
included the use of simple, concise language in the instructions. Color coding was used to help 
respondents quickly and easily use the scoring scale table. The scoring scale table was printed on each 
scoring sheet so respondents did not have to flip the pages back and forth. A pilot survey was conducted 
to assist with design and set up response expectations for our study. 
The pilot survey was printed and handed out to colleagues at the 2013 AAPM Annual Meeting. 
An attempt was made to have individuals complete the survey at the IROC-H booth at this meeting, but 
this approach was not successful. A total of eleven responses were collected. Despite our efforts to make 
the survey easy to complete, many respondents complained that it took too long and this fact was 
considered heavily in the revision. 
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As a result of the pilot study, we decided to change the survey format in several ways to 
encourage participation. We used the tailored design survey method to guide our improvements to 
establish trust, increase the benefits of participation, and decrease the cost of participation46. First, the 
survey was recreated for electronic completion on a web-based application called Survey Gizmo 
(https://app.surveygizmo.com). This allowed us to use simplified response formats such as drop down 
menus and check boxes which improve clarity. The order of the questions was changed to have the 
demographic questions at the end and scoring at the beginning. This was done to ensure that the 
participants focused on the specific process and scoring and to reduce distractions that may come from 
wondering what we are judging them on in the demographic questions. This also can help to make the 
survey feel legitimate and secure.  Additionally, this enabled us to remove any mention of FMEA from 
the survey until the end when the respondent was asked about their familiarity with FMEA. Mention of 
FMEA was removed from the title and instructions with the intention of making the survey less 
intimidating and more familiar and appealing. Some of the language in the failure mode description was 
also clarified. Failure modes were presented one at a time so that respondents didn’t feel distracted by 
how many questions were left or what was next. Since in-person efforts to distribute the survey had not 
proven effective, it was decided that this survey would be distributed by email and sent from the IROC-H 
office. This allowed for respondents to complete the survey on their own time. It also created a sense of 
being part of a larger study, which adds to the legitimacy and importance of the survey. In addition to the 
scoring described above, several groups completed the survey and before assigning scores as in the 
individual survey, they assigned quantitative error measures (percent dose error) to the severity scoring 
scale i.e., what does a severity score of “1” mean quantitatively? The remainder of the group survey was 
the same as the individual survey. Demographics collected from the groups were also the same, but were 
collected for the group overall. The full surveys can be found in Appendix A. 
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Failure Mode Magnitude of Failure 
1. Beam energy 1% 
2. Beam symmetry 2% 
3. MLC systematically in one bank 2 mm 
4. Gantry angle systematically 2.0° 
5. Collimator angle systematically 2.0° 
6. Couch angle systematically 2.0° 
7. MU linearity for < 5 MU systematically 6% 
8. MLC transmission and leakage modeling 0.5% 
9. MLC tongue-and-groove modeling 0.5% 
10. MLC leaf end modeling 0.5% 
11. CT number to electron density table systematically 2% 
Table 2: Physics-specific failure modes evaluated in survey 
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Table 3: FMEA scoring scale used in survey. 
 
 
Rank Occurrence (O) Detectability (D) Severity (S) 
 Qualitative Frequency Qualitative Estimated probability of 
failure going undetected 
Qualitative Categorization 
1 Failure 
Unlikely 
0.01% Never undetected 0.01% No effect  
2  0.02% Very low likelihood 
undetected 
0.2% Inconvenience Inconvenience 
3 Relatively 
few failures 
0.05%  0.5%   
4  0.1% Low likelihood 
undetected 
1% Minor dosimetric 
error 
Suboptimal plan or 
treatment 
5  < 0.2%  2% Limited toxicity or 
tumor underdose 
Wrong dose, dose 
distribution, location 
or volume 
6 Occasional 
failures 
< 0.5%  5%   
7  < 1% Moderate 
likelihood 
undetected 
10% Recordable event, 
Potentially serious 
toxicity or tumor 
underdose 
 
8 Repeated 
failures 
< 2%  15%   
9  <5% High likelihood 
undetected 
20% Reportable event, 
Possible very 
serious toxicity or 
tumor underdose 
Very wrong dose, dose 
distribution, location 
or volume 
10 Failures 
inevitable 
> 5% Always undetected > 20% Catastrophic  
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Survey Distribution 
The final survey for this study was distributed via email to approximately 2000 medical physicists 
worldwide that participate in quality assurance services provided by IROC-H. The survey was accessed 
online and was completed anonymously. Additionally, ten individuals were emailed the survey with the 
request to complete it using a group of experts at their clinic. 
Analysis of survey results 
Post survey collection analysis included RPN calculation and failure mode ranking according to 
RPN as well as each of the individual scores. This was done in order to assess the priority assigned to 
each failure mode in addition to magnitude of responses. In addition to visual inspection and direct 
comparisons, data was coded and statistically analyzed using IBM SPSS (International Business 
Machines Corp., New York). To investigate the relationship between percent dose error and severity 
scores, which in theory should be directly related, we used Spearman Rank Order Correlation 
(Spearman’s rho) to look for a correlation between the two values over all the failure modes. The Chi-
Squared Test was used to look for significant association between scoring and categorical demographic 
data (treatment planning system, linear accelerator manufacturer, familiarity with FMEA, etc.) with 
Bonferroni adjustments applied to the alpha levels. Spearman’s rho was used to investigate the 
relationship between scoring and percent of time dedicated to clinical work or years of experience. 
Additionally, in the literature both consensus and averages have been used to evaluate FMEA scores, so 
both methodologies will be examined in this study using the Chi-Squared Test to look for differences 
between group and individual scoring39.  Extreme outliers (as conventionally defined on Tukey box-and-
whisker plots, greater than 3 times the interquartile range from the bottom of the first quartile or top of the 
third) were excluded from statistical analysis.  
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2.1.3 Quantify the severity of head and neck IMRT delivery physical failure modes 
by means of computation and physical measurement. 
In order to obtain quantitative severity scores for this specific process, all of the identified 
physical failure modes were simulated on a H&N phantom in the treatment planning system and the dose 
difference induced was calculated. Also when possible, these failure modes were physically induced and 
the resultant dose was measured in the same phantom used for treatment planning studies.  
Evaluation of Severity 
In both treatment planning studies and physical measurements, an anthropomorphic phantom was 
used to assess the effects of each failure mode on a head and neck step and shoot IMRT delivery. For 
physical measurements, two conditions were used to evaluate a baseline “correct” delivery and 
subsequent deliveries with failures. Open fields were used to assess the dose output and to evaluate the 
flatness and symmetry. Changes in beam output induced by failure modes were factored out of 
measurements to ensure isolation of each failure mode, as an output error should be a failure mode of its 
own.  
The Phantom  
The phantom used in this study is the IROC-H’s head and neck IMRT phantom which mimics an 
oropharyngeal primary tumor and lymph node along with the spinal cord (see Figure 4). This phantom is 
used for end-to-end evaluation of institutions participating in IMRT clinical trials and is representative of 
a complex clinical IMRT case.  
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Figure 4: IROC-H’s IMRT head and neck phantom (left), superior half of the phantom insert (right). 
Structure Dosimetric Criteria 
Primary PTV D95% ≥ 6.6 Gy 
D99% ≥ 6.14 Gy 
Secondary PTV D95% ≥ 5.4 Gy 
D99% ≥6.03 Gy 
OAR (Spinal Cord) Max Dose < 4.5 Gy 
Normal Tissue Max Dose ≤ 7.26 Gy 
Table 4: IROC-H’s IMRT head and neck phantom dosimetric criteria for the planning target volumes (PTVs), organ at 
risk (OAR), and normal tissue. 
This phantom contains eight thermoluminescent dosimeters (TLD) and radiochromic film in the 
axial and sagittal planes. Treatment plans for this phantom followed the dosimetric criteria assigned by 
the IROC-H shown in the table in Table 544. Treatment plans followed MDACC protocol utilizing 6 MV 
photons and nine coplanar beam angles (0°, 40°, 80°, 120°, 160°, 200°, 240°, 280°, and 320°) which are 
shown along with the placement of isocenter in Figure 5. We used one treatment plan of averageD 
complexity and one of high complexity as defined by the number of monitor units (MU), segments, and 
modulation complexity score (MCS)47. Increased treatment plan complexity has been the concern of 
several studies proposing resultant dose delivery errors48-50. A previous study with the IROC-H’s IMRT 
head and neck phantom has indicated otherwise, with no significant errors caused by increased treatment 
                                                          
D Based on previous irradiations of the IROC-H’s head and neck IMRT phantom by various irradiations 
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plan complexity, but the question remains whether small errors caused by complexity could result in 
compounding effects when other errors are introduced51. 
 
Figure 5: Treatment isocenter (left) and beam angles (right) for treatment plans using the IROC-H IMRT H&N phantom. 
Quantifying the Severity 
To assess the effects of each failure mode, we evaluated the difference in the dose distribution 
resultant from the induced failure mode compared to the unaltered baseline dose distribution (without any 
failures). For each failure mode, percent dose error to each of the primary structures (PTVs and OAR) 
was evaluated at using the prescription points as the evaluation criteria. The prescription points in the 
phantom are the PTVs prescribed to 95% of the volume and the OAR maximum point dose as a 
constraint.  The error magnitude, or severity, of each failure mode was then assigned as the maximum of 
these dose errors. This means that out of the planning target volumes (PTV) and primary organs at risk 
(OAR), the largest deviation from the baseline dose as prescribed to that structure (Dx% or constraint 
level) was considered the magnitude of the error caused by that failure mode. This was chosen because 
each structure represents a critical component of the overall objective of the IMRT process and the dose 
volume prescriptions and constraints reflect those most important to the patient outcome. The maximum 
potential error in a treatment from the failure modes is our central concern. These values were obtained 
through our treatment planning studies. 
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Treatment Planning Studies 
The Pinnacle treatment planning system (Philips Medical, Madison, WI) was used as our primary 
means to evaluate the effects of each of the physical failure modes on the phantom IMRT plan. A baseline 
plan was first established by calculating the phantom plan doses without any failure modes using a 
clinical MDACC beam model in order to provide a basis of comparison. This was the Varian TrueBeam1 
model. Each of the physical failure modes was then simulated in the treatment planning system by means 
of altering the set up parameters or the beam modeling parameters. Utilizing our clinically implemented 
treatment planning system (TPS) as our means of dose calculation allowed for direct comparison with 
physical measurements as the beam model in the TPS corresponds to the beams used for irradiation. Most 
importantly, treatment planning studies allowed for evaluation of the volumetric dose distribution 
information through dose-volume histograms (DVH), enabling quantification of severity as described 
above. 
All dose calculations used for treatment planning studies were performed with the Pinnacle CC 
Convolution algorithm. Treatment couches were removed from the planning CT image and a dose grid 
resolution of 2 mm x 2 mm x 2 mm was used.  
Physical Measurement 
Physical measurements were also made to further investigate the failure modes and with the 
intention of supporting our treatment planning studies. In many cases, physical measurement was 
dependent on altering a linear accelerator in a manner which would continue to affect the dose delivery 
after experiments, rendering it unable to appropriately deliver treatments clinically. Because of this, it was 
required that we were granted time on a clinical linear accelerator going out of commission. This 
measurement time was granted on three occasions and included four different Varian linear accelerators 
equipped with the Varian Millennium 120 MLC. These linear accelerators were in use clinically before 
our measurements were performed and were calibrated following the AAPM TG-51 protocol to 1.000 
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cGy/MU in muscle at dmax under reference conditions of 100 cm SSD and 10 x 10 cm2 field size. The 
basic information for these irradiation sets are listed in Table 5. 
Irradiation Set   Date Machine Failure Modes 
1 January 2012 Varian 2100 Energy, Symmetry, MLC Position 
2 June 2012 Varian 2100 Energy, Symmetry, MLC Position 
3 August 2013 Varian 6EX (2) Gantry Angle, Collimator Angle, Couch Angle 
Table 5: Failure mode physical measurements made on machines going out of commission. 
For each irradiation set, the baseline condition of the machines and baseline phantom dose 
delivery with no failures were established in order to reference changes seen with the induced failure 
modes. To establish the baseline conditions of the machines, output measurements were performed in an 
open field using an ion chamber in a solid water phantom or water phantom. Ion chamber measurements 
at two or more different depths were used to characterize the beam energy. Also, the MatriXX ion 
chamber array (IBA Dosimetry, Schwarzenbruck, Germany) was used to measure open field photon beam 
flatness and symmetry. Basic warm up procedures for the ion chamber and MatriXX were followed 
including warm up irradiations of around 2000 MU before the start of each set of measurements. A 
baseline IMRT dose delivery to the head and neck phantom was performed for each irradiation set using 
the exact same phantom and beam configurations as subsequent failure irradiations. Failure mode 
conditions were established after each adjustment made to the beam, using the same methods as used to 
establish the baseline condition. These adjustments will be described in more detail in the following 
failure mode sections. Failure mode conditions were then used for IMRT dose delivery to the phantom. 
Resultant absolute doses measured with TLD and planar dose distributions measured with radiochromic 
film were used for comparison between baseline and failure mode delivery and between physically 
measured and computationally evaluated severities. The TLD and film were analyzed following the well-
established protocol in practice at the IROC-H52,53. TLD absolute doses in the PTVs for this IROC-H 
phantom are evaluated at the 7% agreement level. Planar dose distributions from the film are analyzed 
using a 3D gamma analysis with a 7%/4mm criteria, with 85% of pixels required to pass for IROC-H 
credentialing54,55. Distance-to-agreement (DTA) between the primary PTV and OAR on the sagittal film 
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with a 4 mm criterion was previously used for this credentialing as well; however the gamma analysis is 
now the primary method for assessing the planar dose distributions25. For this study, the TLD doses, 
DTA, and gamma analysis percent of pixels passing at both 7%/4mm and 5%/3mm criteria were 
compared directly between failure mode irradiations and baseline irradiations. When possible, irradiations 
were performed three times in order to account for the uncertainty in the measurements and account for 
potential set up errors. The TLD system has a precision of 3% and agrees with ion chamber measurements 
within ±4% at a 90% confidence level52. The film as read by the CCD100 Microdensitometer 
(Photoelectron Corporation, Lexington, MA) has a resolution of 0.3 mm and is registered within a 1 mm 
2D and 3D RMS. 
The time for each irradiation set was very limited, as was our ability to fully control all of the 
beam characteristics as desired. The baseline conditions and a summary of failure mode irradiations for 
each for each of the irradiation sets are described here. Failure mode irradiation details are described in 
each failure mode section. 
Irradiation set #1 
The first set of irradiations was performed on January 27, 2012 on the MDACC 2105 Varian 
Clinac 2100CD, which was set to be removed the following day. The IROC-H’s head and neck IMRT 
phantom #21 was used with a complex treatment plan having 3533 MU, 216 segments, and a MCS of 
0.181. A baseline irradiation of the phantom was performed. The TMR2010 was measured in a water tank 
to establish the baseline energy. This measurement was performed using a 10 x 10 cm jaw-defined field 
with a source to axis distance (SAD) of 100 cm and 100 MU. The resultant TMR2010 was 0.669. Next, the 
baseline flatness and symmetry were measured using the MatriXX at 100 cm source to surface distance 
(SSD), a 20 x 20 cm field, 50 MU, and 10 cm of solid water. The baseline symmetry was 0.04% cross 
plane and 0.2% in plane with flatness of 4.9% and 4.7%, respectively. 
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Following the baseline condition evaluation and phantom irradiation, the following failure mode 
irradiations were performed in the specified order: 
1. In plane symmetry adjustment and phantom irradiation 
2. Return to baseline 
3. Cross plane symmetry adjustment and phantom irradiation 
4. Return to baseline 
5. Increase in energy and phantom irradiation 
6. Return to baseline 
7. Decrease in energy and phantom irradiation 
8. Return to baseline 
9. MLC positional error phantom irradiations 
All TMR2010 and symmetry measurements were performed using the same methods as the baseline 
measurements and were all done in service mode. The phantom TLD and film was changed and it was 
realigned using the lasers between each irradiation, which were done in clinical mode. 
Several lessons were learned from this set of irradiations. First, we gained an appreciation for the 
amount of time such measurements would take. Adjustment of the steering and bending magnet currents 
by hand adjusting the potentiometers is very sensitive and difficult to control; therefore it is challenging to 
precisely control the resultant symmetry and energy and requires several measurements along the way to 
reach the desired adjustments. We also noted that we did not account for changes in the output with 
adjustments, which could cause errors. This was useful in planning our next set of irradiations that needed 
to be much more complete. 
Irradiation set #2 
The second set of irradiations was performed on June 27th through the 29th of 2012, with 
establishment of the baseline conditions on day one following the last patient treatment. These 
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measurements were performed on the MDACC 2104 Varian Clinac 2100CD which was removed the day 
following the conclusion of our measurements. AAPM TG-51’s protocol for photon beam output 
calibration was followed to establish the baseline beam output in the reference field of 10 x 10 cm at 100 
cm SSD with 100 MU in a water tank. The resultant output was 1.013 cGy/MU. To ease the subsequent 
output measurements, the calibration factor was calculated for ion chamber measurement in polystyrene 
using a 10 x 10 cm field at 100 cm SSD and a depth of 5 cm with 100 MU and corrected for temperature 
and pressure. This calibration factor was calculated using Equation 1 and was determined to be 0.05719. 
This calibration factor was then used to assess future beam output using only the temperature and pressure 
corrected ion chamber reading at 5 cm polystyrene depth as done to find the calibration factor. The 
polystyrene phantom was used for TMR145 measurements. This ratio was selected for ease of 
measurement with the specific configuration of polystyrene that was available at the time. At 100 cm 
SAD with a 10 x 10 cm2 field and 100 MU, the TMR145 was measured to be 0.612. Baseline flatness and 
symmetry were measured with the MatriXX using a 20 x 20 cm2 field at 100 cm SSD and a depth of 
polystyrene of 10 cm with 100 MU. Flatness was measured as 2.4% and 1.1% and symmetry as 2.3% and 
0.9% for the in plane and cross plane profile directions, respectively. Following these measurements, 
baseline phantom irradiations were performed with both standard and complex treatment plans. The 
IROC-H’s head and neck IMRT phantom #21 was used with both a standard and a complex treatment 
plan with complexity metrics as described in Table 7. All phantom irradiations in this irradiation set were 
performed three times. 
𝐶𝐹 =
𝐷𝑜𝑠𝑒𝑤𝑎𝑡𝑒𝑟
𝑅5𝑝𝑜𝑙𝑦 × 𝑘𝑇𝑃𝑝𝑜𝑙𝑦
 
Equation 1: Calibration factor equation where Dosewater is the output determined by TG-51, R5poly is the ion chamber 
reading at 5 cm depth in polystyrene, and kTPpoly is the temperature and pressure correction factor for the polystyrene 
measurement, all under baseline conditions. 
Plan MU Number of segments MCS 
Standard 1948 90 0.482 
Complex 3189 216 0.171 
Table 6: Treatment plan complexity metrics for plans used in second irradiation set. 
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On day two, the baseline level was re-evaluated to ensure consistency. The output was calculated to 
be 1.019 cGy/MU.  TMR145 was measured to be 0.617. Flatness was 2.9% and 2.3% and symmetry was 
1.6% and 1.2% for the in plane and cross plane directions, respectively. After the baseline conditions for 
the day were established, the following failure mode irradiations were performed in the specified order: 
1. MLC positional error phantom irradiations 
2. Re-establish to baseline 
3. Increase in energy and phantom irradiations 
4. Return to baseline 
5. Decrease in energy and phantom irradiations 
On the third and final day of this irradiation set, we began by returning the beam to baseline energy 
conditions. The TMR145 we reached was 0.612. The beam was then altered for further failure mode 
irradiations and the conditions were evaluated as before for the following measurements: 
1. Angular in plane symmetry adjustments and phantom irradiations 
2. Return to baseline in plane 
3. Angular cross plane symmetry adjustments and phantom irradiations 
4. Return to baseline cross plane 
5. Positional in plane symmetry adjustments and phantom irradiations 
Once again, all output, TMR145, and symmetry measurements were performed using the same 
methods as the baseline measurements and were all done in service mode. The phantom TLD and film 
was changed and it was realigned using the lasers between each irradiation, which were done in clinical 
mode three times for each standard and complex treatment plans. Upon analysis, the output determined 
for each failure mode relative to the baseline output was factored out the TLD absolute dose results.  
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Irradiation set #3 
The final set of irradiations was performed on August 21st through 23rd in 2013 on the MDACC 
600 and 602 Varian Clinac 600 EX machines, which were removed from the clinic following our 
measurements. The original goal of this set of measurements was to take commissioning data for beams 
with energy or symmetry errors and irradiate the phantoms with the same altered beams. This commission 
data would then be used to create beam models for the treatment planning studies. However, we were not 
able to adjust the energy (PDD10) of the machine by more than 0.5% from the baseline. We also were not 
able to adjust the symmetry on these machines because the symmetry and flatness are adjusted upon 
installation by physically adjusting the level of the flattening filter since there is no bending magnet. 
Adjusting the flattening filter would have required removal of the shielding which was  too intensive and 
intrusive for us to perform. Therefore, this irradiation time was used to perform gantry, collimator, and 
couch angle failure mode irradiations using the 602 machine which had not been altered at all.  
The MatriXX was used to establish the baseline conditions of this machine, which would not be 
altered for these irradiations. The PDD105 was found to be 0.77 using solid water in a 10 x 10 cm2 field 
with 100 cm SSD and 100 MU. In a 10 x 10 cm2 field at 100 cm SSD and 10 cm depth of solid water, the 
flatness was 2.4% and 2.9% and the symmetry was 0.5% and 1.2% in the cross plane and in plane 
directions, respectively. The IROC-H’s head and neck phantom #16 was used with the same standard 
treatment plan as the previous irradiation set having 1948 MU, 90 segments, and an MCS of 0.482. The 
baseline irradiation was performed three times. The phantom TLD and film were changed between each 
irradiation, which was performed in clinical mode three times for each failure mode. The phantom was 
aligned before each irradiation using the field crosshairs because the lasers were found to be several 
millimeters off. Failure mode irradiations were completed after baseline irradiations in the following 
order: 
1. Gantry angle failure mode irradiation 1 
2. Collimator angle failure mode irradiation 1 
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3. Gantry angle failure mode irradiation 2 
4. Collimator angle failure mode irradiation 2 
5. Another baseline phantom irradiation 
6. Gantry angle failure mode irradiation 3 
7. Collimator angle failure mode irradiation 3 
8. Couch angle failure mode irradiations (3 total), performed the next day. 
Assignment of Severity Scores 
The error magnitude assigned to each of the failure modes was used to determine the severity 
score. These scores are important in two ways. As mentioned, severity scores are used to generate the 
RPN, but they are also evaluated independently to identify failure modes with extreme consequences that 
are unacceptable at any rate of occurrence and detectability. We used a unique severity score scale as 
described in the follow section. 
Severity Score Scale  
Currently, there is not a standardized scale for radiotherapy FMEA scores. Generally each score 
is assigned a scale from 1-5 or 1-10, with predetermined qualitative meaning assigned to the range of 
scores. Severity scales commonly assign a score of 1 to “no effect” and 10 to “death” or “catastrophic”7,34. 
In order to achieve our goal of providing quantitative information for physics quality management on a 
clinically relevant scale, our severity score scale was be slightly different. We chose to maintain the 
commonplace 1-10 range and each score is assigned both qualitative meaning, more commonly seen in 
any FMEA, and a specific range of percent dose error, as required by the quantitative nature of our 
research. The qualitative definitions have been adapted from the upcoming AAPM TG-100 and an FMEA 
publication by Ford, et al 7. The quantitative components were influenced by commonplace practices, 
regulations, and published radiation consequences. Our severity score scale is shown in Table 8. For a 
severity score of 2, deviation below the common clinical threshold for patient-specific IMRT QA 
measurements of 3% absolute dose agreement should be of minimal to no consequence, whereas if the 
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IMRT QA threshold is breached, at least a re-measurement would be made (an inconvenience)56. A 
severity score of 4 indicates that the International Commission on Radiation Units and Measurements 
(IRCU) goal of 5% uncertainty has been surpassed, which is likely to result in a suboptimal plan and/or 
minor treatment consequences such as a few percent loss of tumor control probability57. A dose deviation 
of 7% can cause observable biological consequences both with respect to tumor control and normal tissue 
complications, which has been assigned to the severity score of 558. Severity scores of 7-9 follow previous 
NRC regulations stating that a dose deviation of 10% is a “recordable event” and 20% is a reportable 
misadministration, which now fall under “medical event” criteria59. The highest severity score of 10 
quantitatively corresponds to a dose deviation of greater than or equal to 50%. This extreme level of 
failure has been reported in the past due to calibration errors at multiple institutions and while the 
consequences are not entirely clear, such an extreme deviation from expected dose has the potential for 
catastrophic consequences depending on the circumstances19,21. 
Severity Score (S) Qualitative Definition Quantitative Definition 
1 No effect 0% - 2.9% 
2 Inconvenience 3% - 3.9% 
3  4% - 4.9% 
4 Minor dosimetric error, suboptimal plan or treatment 5% - 6.9% 
5 Limited toxicity or tumor under dose. Wrong dose, dose 
distribution, location, or volume. 
7% - 8.9% 
6  9% - 9.9% 
7 Recordable event. Potentially serious toxicity or tumor under 
dose 
10% - 14.9% 
8  15% - 19.9% 
9 Reportable event. Possible very serious toxicity or tumor 
under dose. Very wrong dose, dose distribution, location, or 
volume. 
20%-49.9% 
10 Catastrophic ≥50% 
Table 7: Our unique quantitative severity scoring scale 
 
Failure mode investigation 
As described, treatment planning studies with the head and neck phantom were performed for 
each failure mode investigated in this study. Several failure modes were also investigated using physical 
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measurement of the dose delivered to the phantom. The failure modes and the specific methods to 
investigate each are described in detail in this section. 
Failure mode 1: Beam energy 
Overview 
The energy of a photon beam produced by a linear accelerator for radiation therapy is 
fundamental to the calibration of the beam and the calculation of dose distributions in patients. The 
energy spectra and angular distribution of intensity of a photon beam is determined by the energy of the 
accelerated electrons striking the x-ray target. Penetrating ability and dose deposition increase with 
increasing photon beam energy, as demonstrated in Figure 6. These beams are commonly named for the 
nominal energy of the electrons at the accelerating structure window, which is approximately the 
maximum bremsstrahlung photon energy produced at the output of the linear accelerator. Measurement of 
the full energy spectra is challenging and not practical in the general radiation oncology setting, so the 
central axis depth dose information and specifically the ratio of doses at two depths are used to clinically 
characterize the beam energy. Commonly, this parameter is the ratio of the tissue maximum ratio (TMR) 
at 20 cm and 10 cm depth, denoted TMR2010, or the percent depth dose at 10 cm depth (PDD10). These are 
both recommended to be kept within 1% of the baseline established upon commissioning and checked 
annually in the AAPM Task Group 142 report60. As mentioned, only 6 MV photon beams were 
investigated in this study.  
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Figure 6: Photon beam central axis percent depth dose curves of varying energies (Khan, pg 143). All beams have a field 
size of 10 x 10 cm with source to surface distance (SSD) of 100 cm except the 3.0 mm Cu HVL beam which has an SSD of 
50 cm.61 
Practical adjustment of the photon beam energy on a medical linear accelerator is limited to small 
range around the nominal energies designated by the manufacturer. Clinical adjustments are made in high 
energy machines by altering the bending magnet current. This does not change the energy of the electrons 
in the accelerating structure, but rather changes the energy spectra and intensity distribution of the 
electrons that make it to the x-ray target. In Varian linear accelerators with photon energies greater than 6 
MV, a 270 degree bending magnet steers and focuses the beam of electrons exiting the accelerating 
structure to be incident on the x-ray target. The energy spectra of the electrons that reach the x-ray target 
is bounded by a physical slit within the bending magnet, shown in Figure 7. This filters off the electrons 
on the low and high end of the energy spectrum. When the bending magnet current is altered, the spread 
of the electrons in the 270 degree turn shifts that is shown in the figure, becomes tighter or looser and 
therefore, either a higher energy or lower energy component of the electron beam is included in the 
spectrum that reaches the x-ray target. This change in the bending magnet current is approximately 
linearly proportional to the resultant change in the photon beam energy62. The magnitude of this 
adjustment is first limited by the energy spectrum that exists for a nominal x-ray energy, as set by the 
manufacturer. Further, the fluence of electrons is decreasing on the high and low ends of the energy 
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spectra and too large of an adjustment results in notable loss of x-ray fluence, such that the desired dose 
rate may not be achievable and the dose servo will halt the beam to prevent under dosing. This dose servo 
function can be overridden, however, insufficient dose rate may result in decreased output and under 
dosing.  
 
Figure 7: Schematic diagram of achromatic (270°) electron beam bending magnet with energy slit. E 
 
Treatment planning studies 
To simulate beam energy failures in the treatment planning system, it was necessary to create 
separate beam models with varied depth dose curves. To accomplish this, the depth dose and dose profile 
data from the established 6MV model for MDACC Varian TrueBeam linear accelerators was altered and 
used to generate new beam models.  The alterations made to the depth dose and dose profile data was 
determined using data acquired at the Varian headquarters in Nevada by Dr. Peter Balter and Dr. Song 
Gao for research into characterizing beam energy changes63. Using 5 x 5 cm2, 10 x 10 cm2, and 30 x 30 
                                                          
E Image from Karzmark, C.J., Advances in linear accelerator design for radiotherapy, Med Phys (11): 105-128, 1984 
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cm2 dose profiles and 30 x 30 cm2 central axis percent depth dose data, patterns for changes from baseline 
beam data for 6 MV photon beams with ±10% bending magnet current adjustments were determined.  
For percent depth dose curves, it was determined that the difference for both +10% and -10% 
beam energy models, the change from the baseline beam was approximately the same regardless of field 
size at depths shallower than 2.55 cm. Beyond 2.55 cm, linear trend lines originating at one point were fit 
to the change in percent depth dose from baseline for each field size. Larger field sizes changed less 
overall and had more constant amount of change with increasing depth. This is shown in Figure 8 for the -
10% beam and Figure 9 for the +10% beam, where the curves have been shifted to the left by 2.55 cm so 
that each trend line could intersect at y=0, making the origination from the same point more simple. Small 
adjustments were made in the y intersection to maximize the coefficient of determination (R2) for each 
trend line. To adjust the depth dose curves of field sizes that we did not have data for, we linearly 
interpolated between the shown trend lines. It can be seen that there is about a 2% difference in percent 
depth dose at depth of 10 cm from baseline for both energy adjustments. 
For dose profiles, the differences within the field between baseline and energy adjusted beams 
were found to be approximately linear extending from central axis to either field edge, as shown in Figure 
10 and Figure 11for energy -10% and Figure 12 and Figure 13 for energy +10%. Linear trend lines were 
fit to the data within 97.5% of the full width half max and used for adjustment. The profiles were not 
exactly symmetric, so the larger difference of the negative and positive sides was used. We only had 
energy adjusted profiles for a 30 x 30 cm2 field, so it was decided that these depth specific linear trends 
would be truncated and applied to smaller fields sizes. Changes in the penumbra and out of field dose 
were assumed to be negligible because the large differences beyond the field edge are largely due to the 
rapid falloff and appear artificially large out of field because of the small doses being dealt with. 
Additionally, only cross plane profiles (x) were modeled and in plane profiles are assumed to be the same.  
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Figure 8: The percent difference in percent depth dose from the baseline beam (6 MV TrueBeam with no energy 
adjustments) of a beam with -10% energy. Curves were shifted 2.55 cm to the left for trend lines to intersect at 
approximately y=0. Data shown for field sizes of 30 x 30 cm2, 10 x 10 cm2, and 5 x 5 cm2 and respective trend line 
equations and coefficients of determination (R2) are shown. 
 
Figure 9: The percent difference in percent depth dose from the baseline beam (6 MV TrueBeam with no energy 
adjustments) of a beam with +10% energy. Curves were shifted 2.55 cm to the left for trend lines to intersect at 
approximately y=0. Data shown for field sizes of 30 x 30 cm2, 10 x 10 cm2, and 5 x 5 cm2 and respective trend line 
equations and coefficients of determination (R2) are shown. 
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Figure 10: 30 x 30 cm2 dose profiles at a depth of 1.5 cm for the baseline beam (6 MV TrueBeam with no energy 
adjustments) in black and the beam with -10% energy in blue, as well as the percent difference between them in green. 
Linear trend lines, respective equations, and coefficients of determination (R2) are shown with purple being the negative 
trend line and orange being the positive trend line. 
 
Figure 11: 30 x 30 cm2 dose profiles at a depth of 10 cm for the baseline beam (6 MV TrueBeam with no energy 
adjustments) in black and the beam with -10% energy in blue, as well as the percent difference between them in green. 
Linear trend lines, respective equations, and coefficients of determination (R2) are shown with purple being the negative 
trend line and orange being the positive trend line. 
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Figure 12: 30 x 30 cm2 dose profiles at a depth of 1.5 cm for the baseline beam (6 MV TrueBeam with no energy 
adjustments) in black and the beam with +10% energy in red, as well as the percent difference between them in green. 
Linear trend lines, respective equations, and coefficients of determination (R2) are shown with purple being the negative 
trend line and orange being the positive trend line. 
 
Figure 13: 30 x 30 cm2 dose profiles at a depth of 10 cm for the baseline beam (6 MV TrueBeam with no energy 
adjustments) in black and the beam with +10% energy in red, as well as the percent difference between them in green. 
Linear trend lines, respective equations, and coefficients of determination (R2) are shown with purple being the negative 
trend line and orange being the positive trend line. 
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Figure 14: Depth dose curves for a 10 x 10 cm2 field defined by the MLC for the original MDACC TrueBeam model and 
the adjusted TrueBeam models with +10% energy and -10% energy. 
 
Figure 15: Dose profiles of a 10 x 10 cm2 field defined by the MLC at 1.5 cm depth (approximately dmax) for the original 
MDACC TrueBeam model and the adjusted TrueBeam models with +10% energy and -10% energy. 
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Figure 16: Dose profiles of a 10 x 10 cm2 field defined by the MLC at 10 cm depth for the original MDACC TrueBeam 
model and the adjusted TrueBeam models with +10% energy and -10% energy. 
Beam models using the altered depth dose and dose profile data were generated in Pinnacle by 
resetting the original TrueBeam model energy spectra to allow for up to 8 MV photons and then running 
the auto-model tool. When applied to the TrueBeam model, a -1.2% and 1.3% change in the PDD2010 ratio 
that would be used to clinically characterize the beams was seen for the -10% and +10% energy changes, 
respectively. The depth dose curves computed by the Pinnacle models are shown for a 10 x 10 cm2 field 
in Figure 14. Examples of the computed dose profiles for each of the models are shown in Figure 15 and 
Figure 16. When comparing computed beam characteristics using the newly generated models to the input 
altered data (the “measured” data), they qualitatively matched well and the accuracy was comparable to 
that of the original TrueBeam model.  Computed depth doses qualitatively matched very well and were 
mostly within ±1% of the altered input depth dose data for depths greater than dmax. Computed profiles 
were mostly within ±1% of the input “measured” data within the field. The output factors from the 
original TrueBeam model were input to each of the energy altered models and the computed output 
factors agreed within 5%. These levels of accuracy are similar to those used for the clinical beam models 
and pushing beyond this had the potential for introducing unknown errors, so we kept the models as 
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similar as possible. This agreement can be seen in the examples of computed and altered input 
(“measured”) depth dose data that are shown in Figure 17 and Figure 18. Agreement between computed 
and altered input or “measured” dose profiles is demonstrated for the -10% energy model in Figure 19 
and for the +10% energy model in Figure 20. 
 
Figure 17: Computed and input altered (“measured”) depth dose data for 2 x 2 cm2 and 10 x 10 cm2 field sizes defined by 
the MLC for beam model of 6 MV – 10%. 
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Figure 18: Computed and input altered (“measured”) depth dose data for 2 x 2 cm2 and 10 x 10 cm2 field sizes defined by 
the MLC for beam model of 6 MV + 10%. 
 
Figure 19: Computed and input altered (“measured”) dose profiles for 10 x 10 cm2 field size defined by the MLC at 1.5 
cm (left) and 10 cm (right) depth for beam model of 6 MV -10%. 
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Figure 20: Computed and input altered (“measured”) dose profiles for 10 x 10 cm2 field size defined by the MLC at 1.5 
cm (left) and 10 cm (right) depth for beam model of 6 MV +10%. 
Physical measurements 
To induced changes in beam energy for physical measurements, the bending magnet current was 
adjusted with the assistance of the MDACC linear accelerator engineers. Phantom measurements under 
these conditions were performed on two occasions and the details of each are described.  
Beam energy adjustment and measurements: Irradiation set #1 
After establishing the baseline conditions and baseline phantom irradiation the energy of the 
beam was adjusted by altering the bending magnet current. This was done by physically adjusting the 
potentiometer in a slow, stepping fashion with measurements of TMR2010 after each adjustment. It was our 
goal to first increase the TMR2010 by 3%, however the linear accelerator interlocked several time due to 
low dose rate. The TMR2010 after several adjustments was at maximum 0.68 which was a difference of 
about 1.6%. The beam was steered to reset the symmetry at the new energy, resulting in cross plane 
symmetry of 0.2% and in plane symmetry of 0.2%.  The phantom was irradiated. Next the beam energy 
was adjusted with the goal of decreasing the TMR2010 by 3%. A TMR2010 of 0.652 was reached, which is a 
difference of about -2.5%. The symmetry was adjusted to be 0.6% cross plane and 0.5% in plane and an 
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irradiation of the phantom was attempted, however, the linac could not maintain the dose rate due to loss 
of fluence and so this phantom irradiation could not be completed. 
Beam energy adjustment and measurements: Irradiation set #2 
After the baseline conditions were re-established for this irradiation set engineers assisted in 
changing the bending magnet current by altering the shunt, with ion chamber readings at polystyrene 
depths of 5 and 14 cm after each adjustment. The original potentiometer reading was 13.7 mV for a 
baseline TMR145 of 0.618. The goal was to adjust the energy as much as possible while maintaining the 
ability to operate the accelerator in clinical mode (up to a +2% TMR ratio). After adjusting a couple of 
times we only reached a 0.4% change in the TMR145 with a 14.6 mV reading and TMR145 of 0.62. 
Adjusting the bending magnet current potentiometer the next step to 15.05 mV, we ran into under-dosing 
interlocks shutting off the beam. After making several other adjustments including increasing the RF 
driver and reducing the dose rate from 600 MU/min to 300 MU/min, we were able to reach a TMR145 of 
0.624, which was about a 1.1% change from baseline TMR145 that day. The flatness and symmetry were 
adjusted as well to account for the change in energy. The resultant flatness was 3.5% and 3.0% and 
symmetry was 0.7% and 1.1% in the cross plane and in plane directions, respectively. The output was 
determined to be 1.083 cGy/MU. Standard and complex treatment plans were delivered to the phantom 
three times each, with TLD and film changed between each irradiation. 
The beam energy was then adjusted to be low by slowly adjusting the potentiometer to 12.4 mV, 
resulting in a TMR145 of 0.609. Although we were able to tune the beam this low, the resultant dose rate 
was too low and caused interlocks that prevented irradiations in clinical mode. A slight adjustment was 
made to 12.9 mV which resulted in a TMR145 of 0.612, an approximately -1% change from baseline and 
similar to the energy increase. MatriXX measurements determined that the flatness was 1.8% and 2.0% 
and symmetry was 1.3% and 1.1% in the cross plane and in plane directions, respectively. The output was 
determined to be 0.969 cGy/MU. Standard and complex treatment plans were delivered to the phantom 
three times each, with TLD and film changed between each irradiation. 
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Summary of beam energy physical measurements 
Beam energy errors were induced on clinical linear accelerators going out of commission on two 
occasions. IROC-H IMRT head and neck phantoms were irradiated under these failure mode conditions 
with both standard and complex treatment plans. A summary of these adjustments and irradiations is 
summarized in Table 8. 
Failure Mode Magnitude  Phantom Plans  
Energy High 1.6% TMR2010 Complex x1 
 1.1% TMR145 Standard x3, Complex x3 
Energy Low -0.8% TMR145 Standard x3, Complex x3 
Table 8: Summary of energy failure physical measurements made. 
Failure mode 2: Beam Symmetry 
Overview 
The characteristics of a photon beam field are commonly described by the dose profile flatness 
and symmetry. These characteristics are commonly assessed for the central 80% of the full width half 
maximum of the field, which is shown in Figure 21. Several different methods for computing beam 
symmetry are used and in our work we used Equation 2. Measurement and monitoring of the flatness and 
symmetry are key to ensuring that dose distributions are being delivered as intended. A photon beam 
coming directly from the x-ray target in a linear accelerator is forward peaked and for ease of planning 
treatments with uniform and/or conformal dose distributions, it is generally useful for the beam exiting 
the linear accelerator head to have a flat and symmetric shape. This is accomplished with a flattening 
filter which attenuates primarily in the center of the forward peaked photon beam. The photon beam 
flatness and symmetry are very sensitive and can be affected by a variety of things. For example, if the 
forward peaked beam is not properly incident on the flattening filter as it was designed to be, the flatness 
and symmetry will be off, as demonstrated in Figure 22. Even slight changes in the beam energy, as 
discussed in the previous section, will affect the beam flatness and symmetry. Often times, other objects 
are intentionally in the path of the beam and alter the flatness and symmetry, such as when wedges are 
used to create angled beam profiles to conform to the shape of the patient and/or target. However, slight 
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steering changes are commonly not intentional and it is possible that a photon beam may drift over time 
away from proper incidence on the x-ray target and/or flattening filter, resulting in a beam with less than 
optimal flatness and symmetry.  It is recommended in the AAPM Task Group 142 report that a 1% 
tolerance on the photon beam flatness and symmetry be maintained with specific verification annually 
and profile constancy verified monthly.60 It is common practice for the flatness and symmetry to be 
verified during daily output checks. 
𝑆𝑦𝑚𝑚𝑒𝑡𝑟𝑦 =
𝐷𝑜𝑠𝑒𝑛𝑒𝑔80%−𝐷𝑜𝑠𝑒𝑝𝑜𝑠80%
𝐷𝑜𝑠𝑒𝐶𝐴𝑋
× 100%  Eq. 2 
Equation 2: Equation used to compute beam symmetry where Doseneg80% is the dose value at the negative edge of the 80% 
FWHM, Dosepos80% is the dose value at the positive end of the 80% FWHM, and DoseCAX is the dose value at the central 
axis (commonly 100 or 1.00).  
 
Figure 21: A dose profile example showing the central 80% of FWHM, where the minima and maxima would be used to 
compute field flatness and points at the edges, equidistant from the central axis, would be used to compute symmetry.F  
Treatment planning studies 
To simulate beam symmetry errors in the treatment planning system, physical wedges were 
modeled and added to each beam in each plan. Currently, MDACC only utilizes electronic dynamic 
                                                          
F Image from Khan, FM. The physics of radiation therapy, 4th ed. Lippincott Williams & Wilkins, 2010. 
Doseneg80% Dosepos80% 
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Figure 22: Flattening filters are used to create flat photon dose distributions from forward peaked photon beam (a) but 
the flatness and symmetry of the photon beam are affected by the angle (b), position (c), and energy spectra (d) incident 
on the flattening filter.G  
wedges (EDWs) on the Varian linear accelerators. EDWs work by closing one of the collimating jaws 
while the beam is on, creating a profile of varying dose along the axis of the moving jaw. The angle of 
this “wedge” is dependent upon the speed of the jaw and the dose rate. Although there is flexibility in the 
angle of the wedge created which is desirable for our study, EDWs would not work for our IMRT 
treatment planning studies because they would need to be applied to each field individually. With the 
number of individual fields in an IMRT treatment plan, this is highly impractical and would be 
challenging to implement in Pinnacle.  
Instead, physical wedges were created in our copy of the existing Varian TrueBeam model. We 
chose to use this technique to model symmetry errors of 2% which is just outside of tolerance criteria, 
3.5% which was what we were able to achieve for our more robust set of physical measurements, and 
10% as an extreme case. First, the wedge angle required to create the desired symmetry errors was 
                                                          
G Image from Salehpour, M.  lecture , “Therapy electron linear accelerators explained” 
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approximated by interpolation using known wedge angles of 0°, 15°, 30°, and 45° and their respective 
symmetries of about 0%, 22%, 45%, and 70% in a 20 x 20 cm field at 10 cm depth. These wedge angles 
were determined to be 2°, 3°, and 7° for 2%, 3.5%, and 10% symmetry, respectively. Dose profiles from 
the MDACC TrueBeam model used for our baseline with no wedge and with a 15° EDW for field sizes of 
5 x 5 cm2, 10 x 10 cm2, and 20 x 20 cm2 at depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm were pulled into 
MATLAB (The Mathworks, Inc.). These profiles were added with weighting proportional to the wedge 
angle desired to created profiles for each of these field sizes and depths for the three wedges we wanted to 
model. For example, a 7.5° wedge would be created by adding the profiles with no wedge weighted by 
50% and the profiles with a 15° wedge weighted by 50%. The symmetry of the resultant profiles was 
computed. The fact that wedged field dose profile data was not available at a depth of 10 cm where we 
would want to define the symmetry in the 20 x 20 cm2 field made things slightly difficult. Ideally, the 
desired symmetry would lie between the symmetry at 6 cm and 12.5 cm depth. The symmetry for each 
model was slightly higher than intended. Since the beam modeling would not be exact and the wedges are 
so small and in the interest of time, these profiles were not further adjusted. A polynomial equation was 
fit to the symmetry according to depth for each wedge model and used to estimate the symmetry at 10 cm 
depth. These estimates as well as the symmetry for each of these 20 x 20 cm profiles are summarized in 
Table 9.  The 20 x 20 cm2 profiles for each of the wedges are shown in Figure 23, Figure 24, and Figure 
25.  
Approximate 
Wedge Angle 
Symmetry 
Error Modeled 
(at d = 10 cm) 
Symmetry 
Interpolated 
Symmetry 
d = 1.5 cm d = 6 cm d = 12.5 cm d = 22 cm d = 10 cm 
2° 2% 2.4% 2.31% 2.19% 1.94% 2.29% 
3° 3.5% 4.01% 3.86% 3.66% 3.24% 3.79% 
7° 10% 11.71% 11.09% 10.51% 9.31% 10.7% 
Table 9: Symmetry of 20 x 20 cm2 wedged fields at depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm which were used to 
interpolate the symmetry at a depth of 10 cm, which is slightly larger than the desired symmetry for each model. 
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Figure 23: Dose profiles for a 20 x 20 cm2 wedged field at depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm used to model a 
symmetry error of approximately 2% at a depth of 10 cm. 
 
Figure 24: Dose profiles for a 20 x 20 cm2 wedged field at depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm used to model a 
symmetry error of approximately 3.5% at a depth of 10 cm. 
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Figure 25: Dose profiles for a 20 x 20 cm2 wedged field at depths of 1.5 cm, 6 cm, 12.5 cm, and 22 cm used to model a 
symmetry error of approximately 10% at a depth of 10 cm. 
These wedge profiles were input for the three separate wedge models along with the percent 
depth dose curves for the same fields without a wedge. Wedge models were created with iron, which was 
not ideal, however we were unable to get the wedge model to produce good computed profiled when 
made of water. The density of iron used was 11.36 g/cc. It was determined that since the wedges are 
small, the beam hardening from the iron should be minimal. Each wedge used the typical Varian values 
for source to wedge (SWD) distance of 58.8 cm and length of 26 cm64. The width of the wedges was 
assumed to be 18.2 cm, as listed for a Varian 15° wedge with maximum field size of 30 x 40 cm in Cheng 
et al 64.  The physical thickness of the wedges had to be estimated for the models. We began by 
attempting to model the wedge resulting in 10% symmetry by estimating the thickness of lead required to 
attenuate the beam by 10% on the thick side. Using an attenuation coefficient for lead (6MeV) of 0.0305 
cm2/g, we calculated the need for approximately 0.21 cm of lead using basic exponential attenuation. This 
was used as a starting point and then iteratively adjusted after running the wedge automodeling script 
(FineTuneAllForWedge) until the best computed profile fit was achieved. The final wedge physical 
profiles for each of the wedge models are shown in Table 10. The first row in each profile table with 
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positional offset of -9.10 cm must be 0.00 for the model to accept the wedge. Resulting modeled wedge 
profiles agreed with the input “measured” data within ±1% in the field. The typical wedge factor for 
Varian physical wedges of 0.5 was used. These wedges were then applied to each beam of each plan in 
each of the four directions: Top (Y2) to bottom (Y1) (“In plane 1”), bottom to top (“In plane 2”), left (X1) 
to right (X2) (“Cross plane 1”), and right to left (“Cross plane 2”), where X1 and X2 denote opposing set 
of jaws aligned with the MLC. 
2% Symmetry Wedge Model 3.5% Symmetry Wedge Model 10% Symmetry Wedge Model 
Offset (cm) Thickness(cm) Offset (cm) Thickness(cm) Offset (cm) Thickness(cm) 
-9.10 0.00 -9.10 0.00 -9.10 0.00 
-9.10 0.14 -9.10 0.17 -9.10 0.45 
0.00 0.07 0.00 0.12 0.00 0.18 
6.00 0.04 5.00 0.07 4.00 0.13 
9.10 0.00 9.10 0.00 6.50 0.09 
    9.10 0.09 
Table 10: Physical wedge profiles for wedge models simulating symmetry errors of 2%, 3.5%, and 10%.  
Physical measurements 
To induced changes in beam symmetry for physical measurements, the steering magnets were 
adjusted with the assistance of the MDACC linear accelerator engineers. Phantom measurements under 
these conditions were performed on two occasions and the details of each are described.  
Beam symmetry adjustment and measurements: Irradiation set #1 
Following the establishment of baseline conditions and irradiation of the baseline phantom, the in 
plane symmetry was adjusted by altering the angular steering magnet current with the goal of adjusting it 
as much as possible. The symmetry was monitored real-time during the adjustment by using the movie 
mode in the OmniPro-I’mRT software (IBA Dosimetry GmbH, Schwarzenbruck) with the MatriXX and 
was adjusted to 5.1%. The phantom was then set up and irradiated. The in plane symmetry was then 
returned to 0.2% and the cross plane symmetry was adjusted; however dosimetry interlocks prevented the 
steering from going beyond 3.3% symmetry. The phantom was irradiated again under these conditions. 
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Beam symmetry adjustment and measurements: Irradiation set #2 
After establishing the baseline conditions on the third day of measurements for this irradiation 
set, the angular steering was adjusted with the goal of achieving 3% symmetry in plane. The symmetry 
was monitored real-time during the adjustment with the MatriXX in movie mode. With an adjustment of 
the potentiometer from 12.9 mV to 13.7 mV, an in plane symmetry of 3.5% was achieved with 0.9% 
cross plane symmetry. The flatness for this condition was 2.5% in plane and 3.6% cross plane. The output 
was 1.013 cGy/MU and TMR145 was 0.616 which was about 0.7% higher than the baseline from that day. 
Standard and complex treatment plans were delivered to the phantom three times each, with TLD and 
film changed between each irradiation. 
The angular steering was then adjusted to 3.7% cross plane and 1.1% in plane with 4.2% and 
2.1% flatness for each plane, respectively. The potentiometer readings were not recorded. The output was 
measured to be 1.013 cGy/MU and TMR145 was 0.618. Standard and complex treatment plans were 
delivered to the phantom three times each, with TLD and film changed between each irradiation. 
Finally, the angular steering was adjusted back to baseline and steering was performed with the 
positional steering magnets. A symmetry of 3.8% in the in plane was achieved with 1.3% symmetry in the 
cross plane. Flatness was 3.7% in the in plane and 3.0% in the cross plane. The output was 1.059 cGy/mu 
and TMR145 was 0.636, which is almost 4% higher than the day three baseline and about 3% higher than 
the overall baseline. This is likely caused by the change in the position on the x-ray target that the electron 
beam is incident upon, resulting in a changed energy spectra. Standard and complex treatment plans were 
delivered to the phantom three times each, with TLD and film changed between each irradiation.  
Positional steering was not used to adjust the cross plane symmetry due to time constraints.  
Summary of beam symmetry physical measurements 
Beam symmetry errors were induced on clinical linear accelerators going out of commission on 
two occasions. IROC-H IMRT head and neck phantoms were irradiated under these failure mode 
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conditions with both standard and complex treatment plans. A summary of these adjustments and 
irradiations is summarized in Table 11. 
Failure Mode Steering Magnitude  Phantom Plans  
In plane symmetry  Angular 5.1% Complex x1 
 Angular 3.6% Standard x3, Complex x3 
 Positional 3.8% Standard x3, Complex x3 
Cross plane symmetry Angular 3.3% Complex x1 
 Angular 3.7% Standard x3, Complex x3 
Table 11: Summary of symmetry failure physical measurements made. 
Failure mode 3: MLC Position 
Overview 
IMRT utilizes multi-leaf collimators (MLCs) to modulate photon fluence by creating several 
complex field shapes for multiple beam angles. MLC positional accuracy, precision, and reproducibility 
are critical for proper IMRT dose delivery. Unlike conventional treatments, IMRT segment field edges 
not only block the borders of the targets, but often overlap targets and OARS. This compounds with the 
fact that IMRT commonly utilizes many segments with small areas and high MUs, increasing the 
importance of accurate MLC performance. 
The dosimetric effects of MLC positional errors and the ability of routine QA practices to catch 
them have been studied in many cases. Luo et al found a 1% change in the prostate target dose for every 
error of 0.2 mm systematic leaf position in a Monte Carlo study65. LoSasso et al found a similar 
magnitude of dose delivery error for dynamic-MLC IMRT with an average window width of 2 cm66. With 
a 1 mm systematic leaf positional error, Rangel et al reported an average effect of 2.7%  and 5.6% on the 
equivalent uniform dose (EUD) to CTVs in prostate and head and neck treatments, respectively67. Mu et 
al also investigated the effects of 1 mm systematic errors on head and neck plans and saw a 4% average 
change in the target D95% in simple treatment plans (with less than 50 segments) and 8% change in more 
complex plans (with more than 100 segments) as well as 9% and 13% dose changes in the parotid glands 
for simple and complex plans, respectively. It was also noted that these plans were unaffected by random 
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MLC errors48. Using film measurements for step and shoot IMRT head and neck patient QA, Sastre-Padro 
et al measured a median dose difference of up 1.5% as a result of a 2 mm systematic leaf positional 
error68.  
While good MLC positional accuracy is generally expected of modern technology, miscalibration 
or drifting can occur. Bayouth, et al discovered up to 1.2 mm positional errors immediately following 
calibration due to a slight rotation of the MLC calibration tool69. A drift of 1 mm static MLC gap width 
over 8 weeks was seen by Sasaki, et al after thorough weekly monitoring of their Siemens Primus linear 
accelerator70.  
These errors can be difficult to consistently detect with current patient specific IMRT QA 
practices. Yan et al found that gamma analysis performed with a 2%/2mm criteria on the MapCHECK® 
diode array (Sun Nuclear Corporation, Melbourne, FL) was more sensitive than the same analysis with 
radiochromic film, however neither system could detect random errors up to 2 mm or 1 mm systematic 
MLC positional error71.  Rangel et al investigated the sensitivity of the MapCHECK® device and 
Varian’s aS100 EPID with Portal Vision to 0.5 mm and 1 mm leaf offsets in both banks of leaves and 1 
mm offsets in one bank in both prostate and head and neck patients. These QA devices were more 
sensitive to the changes in the more modulated head and neck plans than the prostate plans; however the 
authors concluded that neither approach was sufficiently sensitive as the smaller errors were not reliably 
detected and a tight criteria of 2%/2mm was required to detect the 1 mm offsets72. Finally, Moiseenko et 
al presented an interesting treatment planning study on the sensitivity of IMRT QA with ion chamber 
point doses and 3D gamma analysis to MLC systematic offsets of up to 2 mm and related this to the 
biological consequences of these errors. Similar to the study by Rangel et al, the increased modulation in 
head and neck treatment plans led to pronounced sensitivity MLC offsets over prostate plans. Although 
these QA methods were largely able to identify MLC offsets leading to 2% change in the generalized 
EUD (gEUD) in prostate and rectum, some plans with 3% changes were able to pass the 2% ion chamber 
criteria or the 3%/3mm with 95% of pixels passing. In head and neck patients, this QA was able to catch 
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MLC offsets resulting in 4% gEUD changes in the PTV and 5% changes in the maximum dose to the 
brainstem. It was noted that if the criteria was loosened to 3% for the ion chamber or 90% for the gamma 
analysis, up to 5% changes in the head and neck PTV and up to 8% changes in the brainstem maximum 
dose could pass QA73. 
Due to the heavy reliance of correct IMRT dose delivery upon the MLC positional accuracy, 
MLC QA has been specially recommended for linear accelerators performing IMRT. The AAPM Task 
Group 142 recommends weekly qualitative QA, for example using picket fence patterns, a monthly leaf 
positional accuracy tolerance of 1 mm at four cardinal gantry angles, and leaf position repeatability within 
1 mm annually among other MLC tests60. 
Treatment planning studies 
To simulate systematic MLC positional errors in the treatment planning system, a script was 
written to systematically shift all open MLC leaves in each segment by the specified distance in the 
specified direction. This script was used to apply ± 1 mm and ± 2 mm systematic shifts in each MLC 
bank, X1 and X2. A positive shift in the MLC indicates that the leaves are moving out, creating the 
segment area or window width larger, and a negative shift indicates the leaves are moving in. These 
systematic shifts were applied to both the baseline standard and complex plans, generating eight new 
plans for each, and the dose was computed with the new MLC positions just as for the baseline plans.  
Physical measurements 
To induced MLC positional errors for physical measurements, the script used for treatment 
planning studies was used to apply systematic MLC shifts to baseline plans. Phantom measurements were 
performed on two occasions with these altered treatment plans and the details of each are described.  
MLC positional error measurements: Irradiation set #1 
After energy and symmetry failures were investigated in this irradiation set, there was time 
remaining to perform irradiations so we decided to also do some MLC positional error measurements. 
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The energy was readjusted back to baseline to have a TMR2010 of 0.669 and steering set the symmetry to 
0.4% cross plane and 0.1% in plane. Phantom irradiations were performed using the same complex 
treatment plan, but with the MLC in both banks systematically moved out by 1 mm. This was also done 
with the MLC in both banks systematically moved out by 3 mm. TLD and film were changed and the 
phantom set up was verified between each irradiation.  
MLC positional error measurements: Irradiation set #2 
After the baseline conditions were established on day two (before any alterations were made to 
the beam), standard and complex plans with the X1 MLC shifted out by 2 mm were delivered to the 
phantom. TLD and film were changed and the phantom set up was verified between each irradiation.  
Summary of MLC positional error physical measurements 
Beam energy errors were induced on clinical linear accelerators going out of commission on two 
occasions. IROC-H IMRT head and neck phantoms were irradiated under these failure mode conditions 
with both standard and complex treatment plans. A summary of these adjustments and irradiations is 
summarized in Table 12. 
Adjustment Magnitude  Phantom Plans  
MLC systematic shift  
1 mm out (both banks) Complex x1 
3 mm out (both banks) Complex x1 
2 mm out (one bank) Standard x3, Complex x3 
Table 12: Summary of MLC positional failure physical measurements made. 
 
Failure mode 4: Gantry Angle 
Overview 
IMRT utilizes multiple gantry angles to create conformal, heterogeneous dose distributions within 
patients. It is key that IMRT treatment plans are delivered as planned in order assure the desired dose 
distribution and resultant outcomes. Systematic angular misalignment of the gantry by 2° has been shown 
to cause up to 40% dose errors within a modulated field 10 cm away from isocenter in a pelvic 
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treatment74. In a lumbar-vertebra patient, Xing et al demonstrated an almost 40% increase in the 
maximum spinal cord dose from a systematic error of 5° in the gantry angle. Even random errors such as 
a 5° gantry error in just one of the nine beam angles in the same lumbar-vertebra patient resulted in a 
1.5% decrease in the minimum dose to the target and 5.1% change in the maximum dose to the cord75. 
The AAPM Task Group 142 recommends gantry angle read out to be consistent within 1° at cardinal 
angles, checked on a monthly basis. The gantry rotation isocenter should be annually maintained within 1 
mm of the baseline isocenter60. 
Treatment planning studies 
To simulate systematic gantry angle errors in the treatment planning system, the angle for each 
beam in the standard and complex baseline plans was adjusted by +2° and doses were recomputed with no 
other changes. An increase in the gantry angle results in counterclockwise rotation of the gantry when 
looking at it from the isocenter. The same method was followed using a gantry angle adjustment of -2°.  
Physical measurements 
To induce gantry angle errors in physical measurements, the same methodology used in the 
treatment planning studies was used to generate a plan for delivery with a +2° gantry angle error. 
Phantom measurements under these conditions were performed during irradiation set #3. As described in 
Section, after baseline conditions were established on the second day, the standard treatment plan with 
+2° gantry angle errors were delivered to the phantom three times. TLD and film were changed and 
phantom alignment was verified between each irradiation. 
Failure mode 5: Collimator Angle 
Overview 
Another degree of freedom present in IMRT plans is the collimator angle. Selection of the 
collimator angle determines the direction in which the MLC leaves may travel to modulate the field. The 
resultant dose distribution is sensitive to changes in this set up, with a study on collimator angle errors of 
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2° showing up to 20% dose errors in a modulated pelvic plan with the isocenter shifted from the central 
axis74. As with the gantry angle, the AAPM Task Group 142 recommends collimator angle read out to be 
consistent within 1° at cardinal angles, checked on a monthly basis. The collimator rotation isocenter 
should be annually maintained within 1 mm of the baseline isocenter60. 
Treatment planning studies 
To simulate systematic collimator angle errors in the treatment planning system, the collimator 
angle for each beam in the standard and complex baseline plans was adjusted by +2° and doses were 
recomputed with no other changes. An increase in the collimator angle results in counterclockwise 
rotation of the collimator when looking at it from the position of the source (beams eye view or BEV). 
The same method was followed using a collimator angle adjustment of -2°.  
Physical measurements 
To induce collimator angle errors in physical measurements, the same methodology used in the 
treatment planning studies was used a generate plan for delivery with a +2° collimator angle error. 
Phantom measurements under these conditions were performed during irradiation set #3. As described in 
Section, after baseline conditions were established on the second day, the standard treatment plan with 
+2° collimator angle errors were delivered to the phantom three times, interspersed with the gantry angle 
error deliveries. TLD and film were changed and phantom alignment was verified between each 
irradiation. 
Failure mode 6: Couch Angle 
Overview 
Yet another degree of freedom in the mechanical set up of IMRT treatments is the couch angle. 
The couch is commonly “kicked” to a different angle to allow non-coplanar beams to distribute dose 
through different angles in the patient. Our study is limited to the use of co-planar beams and the effects 
of couch angle errors from the single baseline position. Errors in the couch position directly result in 
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deviations from the desired patient set up as initialized in the simulation. Though it has been noted that 
angular misalignments of the couch may not result in as large of errors as translational couch 
displacements, angular errors have the potential to create dose errors similar in magnitude to gantry and 
collimator angle errors75. Similar to gantry and collimator, the AAPM Task Group 142 recommends the 
couch rotation isocenter should be annually maintained within 1 mm of the baseline isocenter60. We 
extended the monthly recommendations for gantry and collimator of 1° degree tolerance here to the couch 
and therefore chose to examine couch angle errors of 2°. 
Treatment planning studies 
To simulate systematic couch angle errors in the treatment planning system, the couch angle for 
each beam in the standard and complex baseline plans was adjusted by +2° and doses were recomputed 
with no other changes. An increase in the couch angle results in counterclockwise rotation of the couch 
when looking at it from the position of the collimator down when the gantry is straight up at 180°. The 
same method was followed using a collimator angle adjustment of -2°.  
Physical measurements 
To induce couch angle errors in physical measurements, the same methodology used in the 
treatment planning studies was used a generate plan for delivery with a +2° couch angle error. Phantom 
measurements under these conditions were performed during irradiation set #3. As described in Section, 
the standard treatment plan with +2° couch angle errors were delivered to the phantom three times on day 
three. TLD and film were changed and phantom alignment was verified between each irradiation. 
Failure mode 7: MU linearity 
Overview 
The stability and accuracy of the dose monitor unit system in a linear accelerator is another 
critical component required for accurate and safe treatment delivery. Since IMRT utilizes a large number 
of segments and commonly smaller number of MU per segment, i.e. commonly only 1 or 2 MU/segment, 
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dose linearity at these low MU levels is especially important. Step-and-shoot IMRT adds the challenge of 
starting and stopping the beam multiple times. Several studies have been published on the challenge of 
control of the output for small number of MU, particularly on older linear accelerators with separate MLC 
controllers that can exhibit an “overshoot” effect due to a communication time delay76. Beams of less than 
5 MU have been reported to have errors around 5%, with 1 MU beams having up to 32% error in the 
literature77,78. These effects have been noted to increase with higher dose rates.  In some cases, the 
overshoot effect is smeared out due to the nature of IMRT, however there is the potential for these small 
errors to accumulate and have a clinical impact79. The AAPM Task Group 142 report recommends 
maintaining MU linearity on IMRT machines for 2-4 MU within 5% and ≥5 MU within 2% 60. 
Treatment planning studies 
To simulate MU linearity errors in the phantom treatment plans, the MU for each segment was 
adjusted according to three scenarios, each in the positive (A) and negative (B) directions. These 
scenarios are shown in Table 13. The MU weightings and MU values for all beam segments as well as 
total MU per beam for the baseline standard and complex phantom treatment plans were exported from 
the treatment planning system. These values were then run through a MATLAB script which reassigned 
the MU value for each segment according to the three scenarios and output a Pinnacle script to execute 
these reassignments within the treatment planning system. This Pinnacle script was then run on the 
treatment plans and beam MU adjusted appropriately, resulting in 6 new treatment plans with segment 
MU according to the described scenarios for the standard and complex plans. The distribution of 
segments with low MU in the standard and complex baseline treatment plans are shown in Figure 26 and 
Figure 27. 
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Scenario MU/segment 
Adjustment 
A B 
1 1 +6% -6% 
2 +5% -5% 
3 +4% -4% 
4 +3% -3% 
5 +2% -2% 
2 1 +30% -30% 
2 +15% -15% 
3 +7.5% -7.5% 
4 +3.25% -3.25% 
5 +1.875% -1.875% 
3 1-5 +6% -6% 
Table 13: MU linearity error scenarios for treatment planning studies. 
 
Figure 26: MU per segment for the nine beams in the standard phantom treatment plan used in treatment planning 
studies. 
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Figure 27: MU per segment for the nine beams in the complex phantom treatment plan used in treatment planning 
studies. 
Failure mode 8: MLC transmission and leakage 
Overview 
Characterization of MLC transmission and leakage is important for accurate dose calculation, 
especially in heavily blocked fields with small segment sizes. Transmission and leakage doses can build 
up in complex IMRT treatments where the MLC are heavily utilized to block OARs. The average 
transmission and leakage (both mid-leaf and inter-leaf) is about 1.5% in Varian MLCs80,81. Leakage 
between adjacent leaves (inter-leaf) has been reported between 1.8% and 2.7%66,82.  This additional 
leakage is modeled in the treatment planning system through the addition of a percentage transmission up 
to 10%, with a value of 1% recommended for a Varian MLC. The AAPM Task Group 142 report 
recommends annually maintaining that the MLC transmission (the average of leaf and interleaf) within 
±0.5% of baseline60. 
Treatment planning studies 
To simulate MLC transmission and leakage errors in the phantom treatment plans, two separate 
beam models were created with altered additional interleaf leakage transmission values. The baseline 
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value used for the MDACC TrueBeam model is 0. 8%. Beam models were created with the extreme 
transmission values of 0% and 10% in order to assess the maximum effect of this specific parameter.  
Failure mode 9: MLC tongue-and-groove effect 
Overview 
To reduce primary inter-leaf leakage, Varian leaves have overlapping side in the form of a 
tongue-and-groove cross sectional design, as shown in Figure 28. The width of the tongue affects the 
penumbra width of MLC-defined fields. This design also affects field edges that are defined by the 
stepped sides of the leaves, potentially resulting in a 10-25% under dose80,82,83.  When considering IMRT 
treatment plans with multiple beam angles, the tongue-and-groove effect is less severe. Even when the 
effect is smeared throughout the an IMRT dose distribution, Li et al showed up to about a 5% change in 
PTV dose83,84.  
       
Figure 28:  (a) Cross sectional view of Varian MLC leaves (looking from front) showing tongue-and-groove design. (b) Top view of 
MLC with the dashed line showing the tongue width. 
Treatment planning studies 
To simulate MLC tongue-and-groove effect errors in the phantom treatment plans, two separate 
beam models were created with altered MLC tongue-and-groove width values. The baseline width value 
used for the MDACC TrueBeam model is 0.04 cm. Beam models were created with the extreme width 
(a) Cross sectional or front view of MLC 
Tongue 
Groove 
Tongue 
width 
(b) Top view of MLC 
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values of 0.005 cm and 0.200 cm in order to assess the maximum effect of this specific parameter. An 
increase in the width increases the beam penumbra. 
Failure mode 10: MLC leaf end effects 
Overview 
The Varian MLCs utilize a linear motion and rounded leaf end to match the divergence of the 
photon beam and maintain a relatively constant geometric penumbra as a function of leaf position. An 
example of the rounded leaf end is shown in Figure 29. The width of the penumbra depends on the 
curvature of the rounded end, which is approximated by the radius of a circle in the treatment planning 
system. Decreasing the leaf end radius increases the penumbra width66,85. 
 
Figure 29: Varian rounded MLC leaf end with radius of curvature of 8 cm..  
Treatment planning studies 
To simulate MLC leaf end effect errors in the phantom treatment plans, three separate beam 
models were created with altered MLC rounded leaf end radius values. The baseline radius value used for 
the MDACC TrueBeam model is 8 cm. Beam models were created with the extreme width values of 4 
and 20 cm in order to assess the maximum effect of this specific parameter. We also investigate the use of 
a radius value of 15 cm, which is commonly used for Elekta linear accelerators. 
r 
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Failure mode 11: CT table  
Overview 
Computed tomography (CT) images are used to correct for tissue inhomogeneities by providing 
electron density information for treatment planning calculations. In order to achieve this, a conversion 
table from Hounsfield Unit (HU), which is the radiodensity read from the CT image, to electron density is 
applied within the treatment planning system. HU values can be scanner dependent, particularly those of 
high density materials, which can influence the calibration87. Small changes in the dose of up to about 2% 
were demonstrated for tolerance level errors in CT tables for conformal radiation treatments88. 
Treatment planning studies 
To simulate CT table errors in the phantom treatment plans, three alternate CT tables were used. 
Two of the alternate tables were based on the clinically used MDACC CT table which was systematically 
increased by 2% and decreased by 2%. The third alternate CT table was taken from a positron emission 
tomography (PET) CT scanner which exhibited larger differences at the low and high higher ends, 
representing non-uniform variations seen in scanners clinically. These CT tables are shown in Figure 30 
and Figure 31. 
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Figure 30: CT tables used for treatment planning studies including the clinically used baseline MDACC CT Table #1, 2% 
high, and 2% low. 
  
Figure 31: CT tables used for treatment planning studies: the clinically used baseline MDACC CT Table #1 and a CT 
table generate from a PET CT scanner. 
 
2.1.4 Compare qualitative and quantitative severity data. 
The qualitative and quantitative data were compared directly as well as statistically. In order to 
evaluate whether or not the severity data obtained by our two methods were statistically different, a one-
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sample Wilcoxon Signed Rank Test was used, with the qualitatively assigned score as the test value, µ0. 
We also looked for exact matches and compared the 95% confidence interval of the median values from 
the survey severity scores to the values obtained through our treatment planning studies for each failure 
mode. T-tests were used to perform the same analysis with the percent dose errors estimated with in the 
survey and the maximum percent dose errors found in our phantom treatment planning studies. 
2.2 Specific Aim 2: Evaluate and compare the ability of qualitative and quantitative 
severity scores to accurately describe the error magnitude induced in clinical cases 
by each physical failure mode. 
The objective of this specific aim was to compare the validity of the quantitative and qualitative 
scores by evaluating the true severity for each failure mode in clinical H&N patients. The working 
hypothesis of this specific aim was that quantitative severity scores were significantly more likely than 
qualitative subjective scores to describe true clinical consequences. The rationale for this specific aim was 
that there is not a gold standard or a “correct” answer when it comes to severity scores. In order to assess 
whether the quantitative severity scores were an improvement upon the subjective qualitative scores, we 
first needed to determine what the goal or “correct” answer might be. We expected to see an improvement 
of the validity of these scores with quantification, meaning that they truly corresponded to the error that 
would be seen if each failure mode occurred in the clinic. This was done by evaluating ten actual clinical 
cases with each of the physical failure modes simulated in the treatment planning system and comparing 
the ability of each set of severity scores to accurately identify the magnitude of error induced by each. 
2.2.1 Evaluate the magnitude of error induced by each physical failure mode in clinical patient 
treatment plans to find the “true” severity. 
Overview 
Each failure mode was simulated in the treatment planning system and these were applied to ten 
randomly selected step and shoot IMRT oropharyngeal patients previously treated at MDACC following 
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the same methodology described for the phantom treatment planning studies in Specific Aim 1. The PTVs 
and primary OARs were evaluated for max dose deviation and the severity score of each failure mode in 
each patient plan was assigned in the same manner as for the phantom. This resulted in ten true sets of 
severity data for each failure mode.  
Patient descriptions 
The ten patients randomly selected for this study consisted of six base of tongue (BOT) cases, 
two oropharynx cases, and two tonsil cases. These patients each had three to five PTVs and were 
prescribed 54-70 Gy over 22-33 fractions. Nine co-planar IMRT beams were used for each patient. 
Additional beams for supraclavicular nodes (SCV), midline block (MNB), and midneck boost (MNB) are 
included when done with 6 MV photons. Only beams using 6MV photons were used for this study. All 
patient doses were computed in Pinnacle using the CC Convolution algorithm and 0.2 cm x 0.2 cm x 0.2 
cm dose grids. The couch was removed as was done in the clinical plan for each patient. Baseline plans 
for each patient were computed using the MDACC TrueBeam1 model. All patients had brainstem, spinal 
cord, and parotid gland organs at risk. Additional organs at risk considered on a patient-by-patient basis 
were determined by those with optimization constraints and those with DVH evaluation and these 
included cochlea, brain, mandible, larynx, esophagus, submandibular gland, orbit, lens, optic nerve, and 
chiasm. Normal tissue structures excluding the PTVs were also evaluated. The targets and organs at risk 
for each patient are shown in Table 14 and Table 15.  
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Patient Site PTV/CTV levels 
1 Oropharynx 70 Gy, 66 Gy, 63 Gy, 57 Gy 
2 BOT 70 Gy, 63 Gy, 57 Gy 
3 Tonsil 66 Gy, 63 Gy, 60 Gy, 54 Gy 
4 Right Oropharynx 66 Gy, 60 Gy, 54 Gy 
5 Tonsil 69.96 Gy, 60 Gy, 54 Gy 
6 Right BOT 66 Gy, 60 Gy, 54 Gy 
7 BOT 70 Gy, 66 Gy, 63 Gy, 57 Gy 
8 BOT 69.30 Gy, 66 Gy, 63 Gy, 60 Gy, 57 Gy 
9 Left BOT 70 Gy, 66 Gy, 63 Gy, 57 Gy 
10 BOT 66 Gy, 60 Gy, 54 Gy 
Table 14: Patient sites, planning target volume (PTV), and clinical target volume (CTV) levels. 
  
Patient Organs at Risk Evaluated 
1 Brainstem, Cord, L/R Parotid, L/R Cochlea, Brain, Mandible 
2 Brainstem, Cord, L/R Parotid, L/R Cochlea, Brain, Mandible, Larynx, Esophagus 
3 Brainstem, Cord, L/R Parotid, L/R Cochlea 
4 Brainstem, Cord, L/R Parotid, L/R Cochlea 
5 Brainstem, Cord, L/R Parotid, Mandible 
6 Brainstem, Cord, L/R Parotid, Mandible, L Submandibular Gland 
7 Brainstem, Cord, L/R Parotid, L/R Cochlea, L/R Submandibular Gland, L/R Orbit, L/R Lens 
8 Brainstem, Cord, L/R Parotid, L/R Submandibular Gland 
9 Brainstem, Cord, L/R Parotid, L/R Cochlea, L/R Submandibular Gland, Mandible, Larynx, 
Esophagus 
10 Brainstem, Cord, L/R Parotid, Mandible, L/R Orbit, L/R Lens, L/R Optic Nerve, Chiasm 
Table 15: Patient organs at risk used to evaluate severity. 
For severity scoring, all PTVs and CTVs were evaluated at D95%. Organs at risk were evaluated at 
the published Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) normal tissue 
tolerance levels. These values are shown in Table 16. The difference from baseline in each of these values 
for each failure mode was computed. The severity scores corresponding to each of these differences for 
all structures were then determined for each failure mode. The maximum severity score of all structures in 
a given patient was used to assign a score for each failure for that patient.  
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Structures Evaluation parameter(s) 
PTV D95% 
CTV D95% 
Brainstem D100% Max to 1 cc 
Spinal Cord Max 
Parotid Glands Mean D50% 
Cochlea Mean D05% 
Orbit Mean Max 
Lens Max 
Optic Nerve Max 
Chiasm Max 
Mandible Max Max to 1 cc 
Brain Max 
Submandibular Gland Mean 
Esophagus Mean D33% D15% 
Larynx Mean D27% 
Table 16: Evaluation parameters used for each structure to assign a severity score for each failure mode to patient 
treatment plans. 
2.2.2 Compare the validity of qualitative and quantitative severity scores. 
The objective of this study was to compare the ability of each set of severity scores to accurately 
identify the true magnitude of error induced by each failure mode. The rationale for this specific aim was 
that current conventional methods of evaluating severity result in subjective scores of questionable 
validity. Our goal in this project was to improve FMEA by providing quantitative data on the effects of 
IMRT delivery physical failure modes to reduce the subjectivity of FMEA severity scores. To verify 
improvement, we had to compare the accuracy of qualitatively and quantitatively assigned severity 
scores. 
For each physical failure mode individually, the percent dose difference assigned qualitatively 
and that found quantitatively were compared to the ten true differences. We first looked at them 
qualitatively by comparing the distributions of the scores as well as looking for exact matches in the 
scores. In order to determine if the qualitatively assigned severity scores were significantly different than 
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the true severity scores, a one-sample Wilcoxon Signed Rank Test was used, with the qualitatively 
assigned score as the test value, µ0. The same test was performed to compare the qualitatively assigned 
severity scores to the true scores. These results were used to compare the likelihood of each set of scores 
to describe the true clinical consequences. An alpha level of 0.05 was used for these tests. 
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Chapter 3 Results and Discussion 
3.1 Specific Aim 1 
3.1.1 Qualitative severity scoring  
Pilot Survey Study Results 
A total of 11 responses were collected for the pilot survey that was administered at the 2013 
AAPM Annual Meeting, collecting the three FMEA scores for the listed failure modes as well as the 
perceived percent dose error and select demographic information. A summary of the demographics are 
shown in Table 17. The results for severity are tabulated below in Table 18.  
Subject Response (number respondents) 
Linac Varian (9) Siemens (1) Other (1) 
TPS Pinnacle (7) Eclipse (2) Other (2) 
Technique Step and Shoot (8) Sliding Window (2) Other (1) 
Familiarity with FMEA Slightly (4) Somewhat (5) Very (2) 
Table 17: Demographics for pilot survey. Subject of the question is listed in the left column, possible responses and 
corresponding number of responses out of 11 total reported. 
Failure Mode (Magnitude of Failure) 
Assigned Severity 
Score Ave. % dose 
difference (σ) 
Range Average 
Beam energy (1%) 1 - 6 2.9 1.94 (2.18) 
Beam symmetry (2%) 2 - 5 3.4 1.82 (1.29) 
MLC systematically in one bank (2 mm) 4 - 8 6 9.41 (9.42) 
Gantry angle systematically (2.0°) 2 - 7 3.9 14.32 (27.76) 
Collimator angle systematically (2.0°) 2 - 6 3.9 13.75 (26.36) 
Couch angle systematically (2.0°) 2 - 6 3.8 12.57 (26.33) 
MU linearity for < 5 MU systematically (6%) 3 - 7 4 2.67 (1.94) 
MLC transmission and leakage modeling (0.5%) 2 - 7 3.9 2.93 (1.88) 
MLC tongue-and-groove modeling (0.5%) 2 - 7 3.8 2.30 (0.91) 
MLC leaf end modeling (0.5%) 2 - 8 4.7 4.50  (3.55) 
CT number to electron density table systematically (2%) 1 - 7 2.9 1.11 (0.80) 
Table 18: Pilot survey results, failure mode (magnitude of the failure) are listed with the range and average of Severity 
scores assigned as well as the average percent dose error assigned (standard deviation). 
From the 11 responses gathered, 5 matched the specifics of the IMRT dose delivery process used 
in this study: Varian linear accelerator, Pinnacle treatment planning system (TPS), and Step-and-shoot 
IMRT technique. Overall, respondents most often used Varian machines (9/11) and with the Pinnacle 
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TPS (7/11). Step-and-shoot IMRT was the most used amongst respondents (8/11), supporting the notion 
that many are familiar with this fundamental form of IMRT. All respondents were at least slightly 
familiar with FMEA, as none responded with “Not familiar.” Ranges of severity scores assigned were 
large, as predicted. The standard deviation of the percent dose error reported for each failure mode is also 
large, indicating a large spread in opinions amongst the respondents. Average percent dose errors 
assigned were the largest for systematic angular displacements in gantry, collimator and couch.  
Full FMEA Survey Results 
A total of 184 complete responses were received for the individual FMEA survey. Three 
responses were discounted because respondent comments displayed lack of comprehension or lack of 
following instructions. Three medical physics groups also completed the group survey. 
Demographics 
The respondent demographic data collected are show in Figure 32, Figure 33, and Figure 34. 
Fourteen countries on four continents were represented in the responses, with 84% of all responses 
coming from North America and 95% of those from the United States.  Most (76%) individual 
respondents dedicated at least 80% of their time to clinical work, with a large portion dedicated entirely to 
the clinic (36%). Almost all respondents (92%) were certified by a national organization, with the 
majority having American Board of Radiology certification (72%). Respondent experience in medical 
physics ranged from 2.5-45 years, with an average of 18 years.  Just over half of individual respondents 
were at least somewhat familiar with FMEA (52%), while 17% were reportedly not familiar. Several 
IMRT techniques, linear accelerator models, and treatment planning systems were listed as those 
primarily used for head and neck IMRT treatments at respondent clinics as shown in Figure 34. Current 
practice of step-and-shoot and sliding window IMRT techniques were almost equally represented, with 
41% and 47% of responses, respectively. Most respondents primarily used Varian linear accelerators 
(73%) and the most popular treatment planning system amongst respondents was the Varian Eclipse 
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(54%) system. The most represented IMRT technique/accelerator make/TPS combination amongst 
respondents was Sliding Window using Eclipse treatment planning on Varian linear accelerators (43%).  
 
Figure 32: Demographics of the respondents for (left) years of experience and (right) time dedicated to clinical work. 
 
Figure 33: Demographics of the respondents for their current continent, certification, and familiarity with FMEA. 
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Figure 34: Distribution of linear accelerator manufacturer, treatment planning system, and IMRT technique listed as 
primarily used by respondents for head and neck cases.  
Scores and Ranking  
The details of values and variability in O, D, and S scores assigned for each failure mode and 
resultant RPNs are best presented in the box plots shown in Figure 35 and Figure 36, respectively. In 
these figures, it can be seen that all failure modes were scored in the mid- to low-risk ranges with median 
O, D, and S score values between 2 and 6 and median RPN values between 15 and 85. Interestingly, each 
of the eleven failure modes received scores ranging from 1-10 for occurrence, at least 1-9 for 
detectability, and at least 1-7 for severity. The largest mean severity score was 5 for failure mode 3 (MLC 
position shifted systematically in one bank by 2 mm), which also had the largest range in values 
excluding outliers. A large spread was also seen in the RPN scores, with the smallest spread in scores by 
different respondents for any one failure mode being 261 for failure mode 6 (couch angle offset of 2 
degrees) and the largest spread being 575 for failure mode 7 (MU linearity error of 6% for <5 MU). These 
large spread in the data were indicative of the wide variation and subjectivity of assigning FMEA scores. 
The ranking of failure modes according to RPN also resulted in large variability, with each failure 
mode being ranked both most risky (1st ) and least risky (11th) by different respondents. Identical rankings 
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were given by only two respondents, in which case both respondents assigned scores of “1” across the 
board for O, D, and S, giving all failure modes equal ranking. The distribution of respondent RPN 
rankings is demonstrated in Figure 37. Based on the distribution of RPN scores, the respondents indicated 
more concern for failure modes 7-10 and less concern for failure modes 1, 4, 5, and 6. Failure modes 7-10 
represent MU linearity and three MLC modeling parameters, respectively, tend to be ranked the highest in 
risk. 
In addition to the FMEA scores and rankings, the respondent estimated percent dose error, 
keeping in mind both the target and OAR structures, for the worst case scenario of each failure mode was 
also collected. All failure modes had median estimated errors of 1-3% with the exception of failure mode 
3 (MLC position shifted systematically in one bank by 2 mm) which had a median estimated error of 5%. 
The lowest mean percent dose errors are shown to be less than 2% for failure modes 1 and 11, 
corresponding to beam energy and CT number vs. electron density table, respectively. These values are 
shown in the box plots in Figure 38. Maximum extreme outliers, noted by purple crosses, are not 
displayed in the figure to preserve visibility of the data. These maximum extreme outliers included 50% 
errors for failure modes 3-6 and 8 assigned by various respondents. Maximum outliers, also included in 
failure modes 3-6, were assigned 100% error by a single respondent and failure mode 7 was assigned a 
maximum error of 105% by one other respondent. As observed with the FMEA O, D, S, and RPN scores, 
the variability in the estimated percent dose errors associated with the worst case failure modes was very 
large. Perceived severity is typically directly associated with estimates of dose error. The variability in 
this data from our survey shows the need for more accurate and consistent estimates of dose error 
associated with the failure modes. Having these better estimates would provide quantitative guidance for 
the medical physics community to estimate severity scores with less variability. 
Overall, the eleven surveyed failure modes were evaluated to be low to medium risk as one would 
expect, with average RPNs under the commonly cited arbitrary threshold value of 1257,30,33-35. Since the 
magnitude of these failures was just outside the currently established tolerance criteria levels which aim at 
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maintaining highly accurate dose deliver, it makes sense that the perception of their risk is not high; 
otherwise the tolerance levels would be different. Variability in the responses of the individuals assigning 
scores was expected, especially in this situation of a survey because of the large range of professional 
experiences possible in different clinics and individual career specialization. However, the variability 
demonstrated in the survey responses was extreme. This variability existed in both the scores themselves 
as well as the resultant ranking of the failure modes. The magnitude of the scores themselves was 
important, with respect to both predetermined thresholds that may be put in place as well as when 
assessing quantitative features of the scores and failures.  There was no clear ranking of the failure modes 
agreed upon because of the very large variability in the rankings. This is especially important to note 
since the overall results of an FMEA rely primarily on the ranking of the failure modes, not just the 
magnitude of scores assigned. The fact that each failure mode was ranked both most risky and least risky 
by different respondents really underlines the fact that the FMEA process is extremely subjective and the 
results may be of questionable reliability. From our data, general groupings were made when examining 
Figure 37 such that failure modes 8-10 were ranked as high risk, 1, 4, and 5 were low risk but this clearly 
would not have been the conclusion drawn by all of the respondents if they were performing this process 
separately. 
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Figure 35: Occurrence, lack of detectability, and severity scores for N=184 responses (including 3 groups) for eleven 
failure modes (as numbered on page 15). Box plots are shown with red representing the second quartile and blue 
representing the third quartile. Red circles represent the mean score, open circles represent outliers, and stars represent 
extreme outliers. 
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Figure 36: Risk Probability Number (RPN) calculated for N=184 responses (including 3 groups) for eleven failure modes 
(as numbered on page 15). Box plots are shown with red representing the second quartile and blue representing the third 
quartile. Red circles represent the mean score, open circles represent outliers, and stars represent extreme outliers. 
 
 
Figure 37: Ranking of failure modes in order of the risk they present using the RPN. The most risky failure mode would 
have the highest RPN and would be ranked “1”. The size of the bubbles in the chart indicate the frequency at which each 
failure mode was assigned each rank according to the RPNs calculated. 
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Figure 38: Estimated percent error assigned for N=184 responses (including 3 groups) for eleven failure modes (as 
numbered on page 15. Box plots are shown with red representing the second quartile and blue representing the third 
quartile. Red circles represent the mean score, open circles represent outliers, and stars represent extreme outliers. 
Purple crosses indicate that the maximum extreme outliers not shown. 
Relationships 
The severity score assigned to each failure mode in theory should increase with the estimated 
percent dose error resulting from each failure mode since they are both attempting to assess the outcome 
or consequences of the specific failure. As expected, a positive correlation of all respondent data was 
found between their estimated percent dose error and severity scores for each failure mode (data not 
shown). The strength of the correlation varied between failure modes, with the Spearman correlation 
coefficients falling between 0.3 and 0.6 and with each result being statistically significant at the p<0.01 
level.  This correlation indicates that estimated percent dose error and severity scores monotonically 
increase together. Another way we assessed the relationship between percent dose error and severity 
scores was by evaluating the dose errors that were represented by each severity score as shown in Table 
19, indirectly answering the question: what do the severity scores mean quantitatively? The three 
respondent groups directly assigned quantitative values to the severity scores and these are shown in 
Table 20. Although the ranges are not entirely consistent, the average percent dose error assigned for each 
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severity score flows nicely from least to greatest with the exception of S=10. This can be attributed to the 
fact that only one respondent assigned a catastrophic severity score of 10 for any failure mode and 
therefore the average does not represent the cohort distribution. The group-assigned quantitative 
meanings were fairly consistent across the three groups and had similar values to the average percent dose 
errors corresponding to severity scores from the individual responses. Despite the variability in the 
percent dose errors corresponding to severity scores, it seemed overall that quantitative definitions for 
severity scores could easily be agreed upon. 
None of the various demographic data universally resulted in significant associations (Chi 
Squared) or correlations (Spearman’ Rho) in any of the scores or estimated percent dose errors. Even 
though none of the demographics appeared to significantly relate to any score overall, several statistically 
significant differences and correlations were noted throughout the data. All of the significant results are 
presented in Table 21, according to demographic. The most interesting of these significant results include 
negative correlations between detectability scores (D) and percent of time dedicated to clinical work for 
the four failure modes regarding beam modeling (8-11). These negative correlations indicated that those 
physicists with more time dedicated to clinical work believed that such modeling errors would be more 
likely to be detected (lower detectability score). Although these correlations were significant, it is 
important to note that the strength of the relationships was very weak, with a rho of ±1 indicative of a 
perfectly monotonous relationship. This was the case for all significant demographic correlations found, 
with the strongest correlation found between failure mode 1 (beam energy off by 1%) severity score and 
respondent years of experience with rho = -0.281. This relationship indicates that respondents with more 
experience tended to think that the consequences of a 1% beam energy error would be less severe than 
those with less experience, but again, although this relationship was statistically significant, the 
relationship was weak. It was also interesting to note that all correlations were negative, indicating those 
with more years of experience or those with more time dedicated to clinical work generally assigned 
lower scores for the failure modes and scores specified.  
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Severity Score 
Estimated Percent Dose Error 
Min Max Average Median 
1 0% 5% 0.62% 0.60% 
2 0% 20% 1.08% 0.99% 
3 0% 20% 1.74% 1.77% 
4 0% 50% 2.77% 2.87% 
5 0% 50% 4.00% 4.07% 
6 0.01% 105% 6.13% 5.98% 
7 0% 100% 12.06% 9.68% 
8 1% 50% 16.80% 11.18% 
9 3% 100% 20.22% 13.75% 
10 15% 15% 15% 15% 
Table 19: Percent dose errors estimated by survey respondents and corresponding severity scores that were assigned. 
Severity Score 
Quantitative Value 
Min Max 
1 0% 3% 
2 0% 4% 
3 - - 
4 2% 5% 
5 - - 
6 - - 
7 10% >20% 
8 - - 
9 20% >30% 
10 50% >50% 
Table 20: Quantitative values assigned to severity scoring scale by groups (N=3). 
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Demographic Response Statistical Relationship 
Failure Mode 1: Energy 
Years of Experience O p=0.008, rho=-0.194 
Years of Experience S p=0.000, rho=-0.281 
Years of Experience RPN p=0.000, rho=-0.267 
Failure Mode 2: Symmetry 
Years of Experience S p=0.018, rho=-0.175 
Failure Mode 3: MLC Position 
Linac Manufacturer % error p=0.000, V=0.000 
Failure Mode 4: Gantry Angle 
Years of Experience S p=0.049, rho=-0.149 
Continent RPN p=0.000, V=0.000 
Failure Mode 8: MLC tongue & groove modeling 
Clinical Time D p=0.011, rho=-0.187 
Failure Mode 9: MLC leakage & transmission modeling 
Clinical Time D p=0.024, rho=-0.166 
Linac Manufacturer % error p=0.000, V=0.000 
Continent D p=0.000, V=0.000 
Failure Mode 10: MLC leaf end modeling 
Clinical Time D p=0.006, rho=-0.201 
Certification D p=0.000, V=0.000 
Failure Mode 11: CT table 
Clinical Time D p=0.025, rho=-0.165 
Table 21: Statistically significant relationships between demographics and FMEA scores or estimated percent dose errors 
for each failure mode. Rho value is given for Spearman’s Rho correlations, Cramer’s V (V) is given for Chi Squared Test 
for Association. Linac = linear accelerator.  
Surprisingly, there were no strong universal correlations between any of the scores, rankings, or 
dose errors with any of the demographics. This indicates that the demographic information collected was 
not sufficient to categorize the individual experiences or interpretations, both of which would be expected 
causes of variability in the scoring. The negative correlations seen between time dedicated to clinical 
work and detectability for modeling errors (failure modes 8-11) could indicate a difference in 
understanding of the modeling parameters between those who practice mostly clinically and those who do 
not or it could be a reflection of one group having more or less experience with beam modeling. Since the 
relationships were very weak, these conclusions cannot be definitively drawn. The lack of strong 
relationships supports the notion that the scoring process is very complex and that individual clinics will 
need to assess their radiation oncology treatment processes on their own to find the scores that are most 
appropriate to their specific situation. However, it is of note that the FMEA findings between clinics most 
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likely will be very different if the variability observed with our survey is any indication of the opinions of 
the medical physics community. 
Limitations and biases 
This FMEA survey study provided insight into the variability present in opinions on basic IMRT 
dose delivery quality assurance failures at or just exceeding the AAPM’s recommended tolerance limits. 
While the expectation for variability in opinions could be extended to FMEA scoring of all processes, the 
results of this survey were very specific. The process evaluated by an FMEA must be very specific, which 
limited this study in two ways. The first of these limitations was that the specific scores obtained apply 
only to step and shoot head and neck (H&N) IMRT. The second limitation was that although the process 
was described in detail to the respondents, the interpretation by each individual of the process, the failure 
modes, and the scoring could be different, and this likely influenced the results. Of course, these same 
limiting factors could also play a role in a conventional FMEA, but one would expect it to influence the 
results to a much lesser degree with an in-person team working in the same environment and discussing 
each failure mode in detail.  
Another factor that may have added to the variability in the scoring could be that low level 
failures such as those near tolerance criteria levels may be more difficult to estimate the consequences and 
impact on a complex treatment such as IMRT than large scale, catastrophic failures. This was 
corroborated by the wide spread in estimated percent dose errors and severity scores from the survey 
respondents for each failure mode. 
Summary of qualitative severity scores 
The results of this survey provide valuable information with respect to the application of FMEA 
to physics-specific failure modes near tolerance criteria levels. More importantly for this project, the 
severity scores collected represented the subjective qualitative assessment approach to an FMEA of our 
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specific IMRT process. The percent dose estimates collected also allowed us to relate the qualitative 
scores to a quantitative definition. A summary of the qualitative severity scores is shown in Table 22. 
Qualitative Severity Scores 
Failure Mode Median Average Std Dev 
1: Beam Energy 3 2.97 1.42 
2: Beam Symmetry 4 3.68 1.21 
3: MLC Position 5 5.09 1.77 
4: Gantry Angle 4 3.85 1.51 
5: Collimator Angle 4 4.06 1.47 
6: Couch Angle 4 3.75 1.51 
7: MU Linearity 4 4.20 1.48 
8: MLC Leakage & Transmission Modeling 4 3.99 1.48 
9: MLC Tongue & Groove Modeling 4 3.67 1.39 
10: MLC Leaf End Modeling 4 3.96 1.39 
11: CT Table 3 3.17 1.44 
Table 22: Qualitative severity scores obtained from online survey (N=184). 
  
3.1.2 Quantitative severity scoring  
Baseline phantom 
Treatment planning studies 
Evaluation of DVH data for each of our eleven failure modes from treatment planning studies on 
the IROC-H H&N IMRT phantom was the primary means for quantitatively assessing severity in this 
study. Each of the failure modes was compared to baseline phantom plans, both standard and complex. 
The doses to the two targets, OAR, and normal tissue structures in the phantom for each plan type (i.e. 
basic and complex) are summarized in Table 23 and Table 24 and the DVHs are shown in Figure 39 and 
Figure 40. These plans did not quite meet the dosimetric criteria required by the IROC-H for 
credentialing, however this was acceptable since this was a comparative study. 
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Baseline Standard Phantom Treatment Plan Structure Doses 
Structure 
Min. Dose Max. Dose Mean Dose Std. Dev. D95% D99% Max to 1 cc 
(cGy) 
Primary PTV 602.83 738.05 680.46 14.15 657.15 652.15 710.55 
Secondary 
PTV 
530.16 578.31 553.46 6.82 542.83 538.17 563.76 
Spinal Cord 3.91 434.05 170.99 142.90 8.96 5.29 355.48 
Normal Tissue 0.40 721.99 106.49 141.52 2.79 1.58 683.47 
Table 23: Summary of structure doses for the standard phantom treatment plan. 
Baseline Complex Phantom Treatment Plan Structure Doses 
Structure 
Min. Dose Max. Dose Mean Dose Std. Dev. D95% D99% Max to 1 cc 
(cGy) 
Primary PTV 605.14 747.59 680.51 16.60 653.74 637.54 717.05 
Secondary 
PTV 
496.26 636.50 549.65 18.51 529.36 524.87 567.55 
Spinal Cord 4.53 425.12 160.42 134.94 9.01 7.58 336.99 
Normal Tissue 0.31 739.38 107.89 138.78 2.71 1.71 669.61 
Table 24: Summary of structure doses for the complex phantom treatment plan. 
 
Figure 39: DVHs for baseline standard phantom treatment plan. 
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Figure 40: DVHs for baseline complex phantom treatment plan. 
Physical Measurements 
Irradiation Set #1 
The baseline irradiation of the H&N phantom for this irradiation set was evaluated against the 
treatment planning system predicted doses as done for IROC-H credentialing. The absolute dose results 
from the eight TLD in the phantom insert are shown in Table 25. The calculated planned dose reported is 
the mean dose to a contour of the TLD. The distance-to-agreement (DTA) between the primary PTV and 
spinal cord OAR on the axial film was 1.7 mm. Gamma analysis assessing the agreement between 
computed planned dose distributions and those measured on the full axial and sagittal films was 
performed with criteria of 7%/4mm and 5%/3mm. The percent of pixels passing these analyses are shown 
in Table 26. 
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Structure TLD position 
Measured Dose 
(cGy) 
Planned Dose 
(cGy) 
% Difference 
Primary PTV Superior Anterior 650.3 690.9 -5.9% 
Primary PTV Inferior Anterior 654.5 693.1 -5.6% 
Primary PTV Superior Posterior 627.3 627.4 0.0% 
Primary PTV Inferior Posterior 676.1 662.5 2.1% 
Secondary PTV Superior 515.6 558.1 -7.6% 
Secondary PTV Inferior 524.5 574 -8.6% 
Spinal Cord Superior 196.5 249.4 -21.2% 
Spinal Cord Inferior 197.6 246.5 -19.8% 
Table 25: Baseline TLD results from the first irradiation set with a complex treatment plan. 
Film Criterion Pixels Passing 
Axial 
7%/4mm 71.6% 
5%/3mm 50.9% 
Sagittal 
7%/4mm 79.9% 
5%/3mm 54.6% 
Table 26: Baseline gamma analysis results for axial and sagittal films within the phantom for the first irradiation set. 
This baseline irradiation was not perfect, with TLD dose differences from the planned dose 
exceeding 7% in the secondary PTV. There were also large dose differences in the spinal cord TLD, but 
this was generally expected since the spinal cord was in a steep dose gradient region. The DTA in this 
steep dose gradient region showed acceptable agreement of the delivered dose with the planned dose. The 
gamma results were overall rather poor. The film was normalized to the PTV TLD and therefore the 
absolute dose differences seen in the TLD results were reflected in the gamma analysis results. The 
measured dose was largely lower than the planned dose. The output of the machine may have been low 
during these measurements and since this was more of a pilot study to examine the feasibility of 
performing measurements by altering the beam, we did not plan or have time to measure the output. This 
set of measurements also had increased uncertainty since phantom irradiations were only performed once 
for each scenario (baseline or induced failure mode). Regardless of how well the planned doses predicted 
the measured doses in this case, a comparison of the failure mode irradiations to this set of measured data 
still demonstrated the differences in delivery. 
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Irradiation Set #2 
The baseline irradiations of the H&N phantom with the standard and complex treatment plans for 
the second irradiation set were also evaluated against the treatment planning system predicted doses. The 
absolute dose results are shown in Table 27 and  
Complex Phantom Treatment Plan 
Structure TLD position 
Measured Dose 
(cGy) 
Std Dev. 
Planned Dose 
(cGy) 
% Difference 
Primary PTV Superior Anterior 634.3 0.20% 682.2 -7.0% 
Primary PTV Inferior Anterior 623.0 0.09% 670.2 -7.0% 
Primary PTV Superior Posterior 649.3 1.83% 685.2 -5.2% 
Primary PTV Inferior Posterior 653.8 1.10% 687.2 -4.9% 
Secondary PTV Superior 522.6 0.47% 548.7 -4.8% 
Secondary PTV Inferior 521.6 0.58% 547.1 -4.7% 
Spinal Cord Superior 252.5 0.73% 276.4 -8.6% 
Spinal Cord Inferior 243.9 1.46% 270.9 -10.0% 
Table 28 for the standard and complex plans, respectively. The measured dose reported for each 
TLD was the average over three irradiations. The average DTA between the primary PTV and spinal cord 
OAR on the axial film for three irradiations was 0.9 mm for the standard plan and 1.7 mm for the 
complex plan. The average gamma analysis results on the full axial and sagittal films for three irradiations 
of both the standard and complex plans are shown in Table 29. Gamma maps are also shown in Figure 41-
Figure 44 for each of the three irradiations for this irradiation set. 
Standard Phantom Treatment Plan 
Structure TLD position 
Measured Dose 
(cGy) 
Std Dev. 
Planned Dose 
(cGy) 
% Difference 
Primary PTV Superior Anterior 640.2 0.78% 680.8 -6.0% 
Primary PTV Inferior Anterior 628.3 0.41% 675.0 -6.9% 
Primary PTV Superior Posterior 652.4 0.37% 691.2 -5.6% 
Primary PTV Inferior Posterior 645.2 0.45% 680.8 -5.2% 
Secondary PTV Superior 544.0 0.36% 555.5 -2.1% 
Secondary PTV Inferior 537.3 0.99% 561.0 -4.2% 
Spinal Cord Superior 291.2 1.11% 311.1 -6.4% 
Spinal Cord Inferior 288.8 0.27% 310.7 -7.0% 
Table 27: Baseline TLD results from the second irradiation set with the standard treatment plan. 
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Complex Phantom Treatment Plan 
Structure TLD position 
Measured Dose 
(cGy) 
Std Dev. 
Planned Dose 
(cGy) 
% Difference 
Primary PTV Superior Anterior 634.3 0.20% 682.2 -7.0% 
Primary PTV Inferior Anterior 623.0 0.09% 670.2 -7.0% 
Primary PTV Superior Posterior 649.3 1.83% 685.2 -5.2% 
Primary PTV Inferior Posterior 653.8 1.10% 687.2 -4.9% 
Secondary PTV Superior 522.6 0.47% 548.7 -4.8% 
Secondary PTV Inferior 521.6 0.58% 547.1 -4.7% 
Spinal Cord Superior 252.5 0.73% 276.4 -8.6% 
Spinal Cord Inferior 243.9 1.46% 270.9 -10.0% 
Table 28: Baseline TLD results from the second irradiation set with the complex treatment plan. 
Film Criterion 
Standard Plan Complex Plan 
Pixels Passing Std Dev. Pixels Passing Std Dev. 
Axial 
7%/4mm 80.3% 12.66% 65.6% 2.70% 
5%/3mm 55.7% 12.39% 37.7% 2.50% 
Sagittal 
7%/4mm 81.5% 4.58% 69.6% 2.45% 
5%/3mm 66.9% 1.85% 55.7% 2.19% 
Table 29: Baseline gamma analysis results for axial and sagittal films within the phantom for the second irradiation set. 
 
Figure 41: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan 
(bottom). 
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Figure 42: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan 
(bottom). 
 
Figure 43: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan 
(bottom). 
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Figure 44: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan 
(bottom). 
As with the first irradiation set, the baselines for this set of irradiations were not perfect. The 
average TLD in the PTVs and the DTA results would have passed the IROC-H criteria of 7% and 4 mm, 
respectively, however they were very close. The measured doses were again overall low, however this 
could not be explained by the output which was measured to be about 1% high (1.013 cGy/MU). The 
standard deviation of the TLD doses and gamma analysis percent of pixels passing were generally low, 
indicating that the irradiations were mostly consistent across the three irradiations. The gamma maps 
demonstrated where the failures occur and are shown with a 5%/3mm criterion to increase the visibility of 
the failure areas. The complex plan films failed in similar areas across the three irradiations, largely in the 
targets. This could have potentially been a result of a less homogenous dose in the targets due to the 
increased complexity. The simple plan films have larger differences in the gamma maps across the three 
irradiations. This could indicate that external factors such as small set up errors were responsible for these 
differences and the overall difference from the planned dose. It was also important to note that imperfect 
alignment of the two halves of the sagittal film was likely to play a role in decreased percent of pixels 
passing gamma analysis. Once again, the overall objective of this study was to compare the failure mode 
irradiations to the baseline irradiations. Although the baseline irradiations appear to have been imperfect 
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since they do not match the planned dose exactly, the set-up, measurement, and evaluation processes for 
this set of irradiations was controlled and consistent, enabling us to make meaningful comparisons. 
Irradiation Set #3 
The absolute dose results of the baseline irradiations for the third and final irradiation set are 
shown in Table 30. The planned dose reported was the mean dose to a contour of the TLD. The DTA 
between the primary PTV and spinal cord OAR on the axial film was 1.2 mm. The percent of pixels 
passing gamma analyses on the axial and sagittal films are shown in Table 31. The corresponding gamma 
maps for this baseline irradiation set are shown in Figure 45 and Figure 46. 
Structure TLD position 
Measured Dose 
(cGy) 
Std Dev. 
Planned Dose 
(cGy) 
% Difference 
Primary PTV Superior Anterior 673.7 0.60% 688.0 -2.1% 
Primary PTV Inferior Anterior 673.8 0.43% 687.0 -1.9% 
Primary PTV Superior Posterior 655.0 1.18% 659.3 -0.6% 
Primary PTV Inferior Posterior 664.2 0.82% 666.2 -0.3% 
Secondary PTV Superior 537.6 0.70% 556.2 -3.4% 
Secondary PTV Inferior 540.7 0.27% 558.9 -3.3% 
Spinal Cord Superior 347.7 0.22% 358.0 -2.9% 
Spinal Cord Inferior 349.4 0.35% 360.9 -3.2% 
Table 30: Baseline TLD results from the third irradiation set, with the measured dose reported as the average of three 
measurements. 
Film Criterion Pixels Passing Film 
Axial 
7%/4mm 99.1% 0.34% 
5%/3mm 92.3% 1.86% 
Sagittal 
7%/4mm 99.2% 0.30% 
5%/3mm 94.3% 0.12% 
Table 31: Baseline gamma analysis results for axial and sagittal films within the phantom for the third irradiation set. 
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Figure 45: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the baseline standard treatment 
plan for irradiation set #3 (bottom). 
 
Figure 46: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the baseline standard treatment 
plan for irradiation set #3 (bottom). 
The agreement of this set of baseline irradiations with the planned dose was much better than the 
first two, with deviations between the average measured TLD dose and the planned TLD dose of up to 
3.4% in the secondary PTV and 2.1% in the primary PTV. The gamma analysis results were also much 
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better with almost perfect agreement using 7%/4mm criterion and greater than 90% agreement using 
5%/3mm criterion. The axial gamma maps showed that the small amount of failure was primarily in the 
PTVs and along the posterior edge of the film. On the sagittal film gamma maps, the small amount of 
failure was along the superior and inferior edges of the PTV, which was a region of relatively high dose 
gradient where the PTV dose dropped off and was collimated by the jaw. This baseline irradiation set may 
have been better than the other sets from increased experience with the process. The set up uncertainty 
may also have been decreased since the cross-hairs were used for each alignment instead of the lasers. 
Failure mode evaluation 
The severity scores for phantom treatment plans were evaluated at D95% and D99% for the PTVs 
and the maximum dose for the spinal cord OAR and normal tissue. The scoring scale determined was 
applied to the difference from baseline in the values and the scores were color coded as shown in Table 
32. This color-coding system was applied for all severity scores for the remainder of this project. 
Severity Score (S) 
Quantitative 
Definition 
1 0% - 2.9% 
2 3% - 3.9% 
3 4% - 4.9% 
4 5% - 6.9% 
5 7% - 8.9% 
6 9% - 9.9% 
7 10% - 14.9% 
8 15% - 19.9% 
9 20%-49.9% 
10 ≥50% 
Table 32: Color-coding used for severity scoring, corresponding to the scoring scale presented in Section. 
Failure mode 1: Beam Energy 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for energy changes 
of +10% and -10% are summarized in Table 33 and Table 34 for both standard and phantom plans, 
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respectively. All structure dosimetry evaluation criteria had less than a 3% change from baseline with the 
exception of the dose to 99% of the primary PTV in the standard phantom treatment plan, which was 
under-dosed by 4% when the energy was decreased by 10%.  As a result of this 4% under-dosing, this 
failure mode was assigned a severity score of 3 which is indicated in Table 33 and Table 34 by the color-
coding described in Table 32. 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
Energy +10% Energy -10% 
Change from baseline 
Primary PTV 
D95% 0.13% -1.49% 
D99% 0.03% -4.02% 
Secondary PTV 
D95% -0.02% 0.18% 
D99% -0.33% 0.16% 
Spinal Cord Max Dose -1.29% -2.71% 
Normal Tissue Max Dose 0.02% 0.71% 
Table 33: Dosimetric changes from baseline used for severity scoring for beam energy changes of +10% and -10% for the 
standard phantom treatment plan. 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
Energy +10% Energy -10% 
Change from baseline 
Primary PTV 
D95% 0.24% -0.14% 
D99% -0.01% -0.80% 
Secondary PTV 
D95% 0.66% 0.42% 
D99% 0.22% 0.60% 
Spinal Cord Max Dose -2.07% -1.06% 
Normal Tissue Max Dose 0.22% 1.92% 
Table 34: Dosimetric changes from baseline used for severity scoring for beam energy changes of +10% and -10% for the 
complex phantom treatment plan. 
The DVHs for this failure mode are shown in Figure 47 and Figure 48. The loss of coverage in 
the primary PTV in the standard plan was evident, as was the slight decrease is spinal cord dose in the 
complex plan. Other differences in the DVHs from baseline were very small. 
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Figure 47: DVHs for phantom structures in the standard treatment plan with energy changes of 10%, with dashed lines 
showing baseline DVHs. 
 
Figure 48: DVHs for phantom structures in the complex treatment plan with energy changes of 10%, with dashed lines 
showing baseline DVHs. 
100 
 
The differences in the energy altered dose distributions from baseline were mostly a result of the 
differences in the shape of the dose profiles off-axis. Since the isocenter is approximately in the center of 
the phantom insert (see Figure in methods), the far edge of the primary PTV was about 4 cm off axis 
where small changes in the profiles were evident. This compounded with the small change in depth dose 
and resulted in a slightly more heterogeneous dose distribution in the standard phantom plan and therefore 
a reduction in coverage.  
Physical measurement results 
Beam energy adjustment and measurements: Irradiation set #1 
The differences in the doses measured to the phantom TLD for the irradiation with a beam energy 
adjustment of +1.6% TMR2010 from the baseline irradiation for the first irradiation set are shown in Table 
35 where a positive difference indicates that the failure mode dose was higher than the baseline dose. On 
average, the dose to the primary PTV was 5.5% higher than baseline and the secondary PTV dose was 
5.8% higher than baseline. The dose to the spinal cord TLD was also higher than the baseline by an 
average of 6.9%. The DTA between the primary PTV and OAR on the axial field was 0.7 mm lower for 
the beam energy adjusted irradiation than the baseline irradiation. The absolute differences in the percent 
of pixels passing gamma analysis with 7%/4mm and 5%/3mm criteria are shown in Table 36, where a 
positive value indicates that the failure mode percent of pixels passing was higher than that for the 
baseline. The energy adjusted irradiation had almost 20% more pixels passing the 7%/4mm axial film 
gamma analysis and 16% more passing on the sagittal film. 
Structure TLD position Difference in Dose from Baseline 
Primary PTV Superior Anterior 7.3% 
Primary PTV Inferior Anterior 5.1% 
Primary PTV Superior Posterior 4.7% 
Primary PTV Inferior Posterior 4.8% 
Secondary PTV Superior 6.3% 
Secondary PTV Inferior 5.2% 
Spinal Cord Superior 8.2% 
Spinal Cord Inferior 5.6% 
Table 35: TLD differences from baseline from the first irradiation set with an energy adjustment of +1.6% TMR2010. 
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Film Criterion Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 19.6% 
5%/3mm 25.3% 
Sagittal 
7%/4mm 16.1% 
5%/3mm 34.6% 
Table 36: Differences from baseline in gamma analysis results for axial and sagittal films within the phantom for the first 
irradiation set with an energy adjustment of +1.6% TMR2010. 
Beam energy adjustment and measurements: Irradiation set #2 
The differences in the doses measured to the phantom TLD for the irradiations with a beam 
energy adjustments of +1.1% and -0.8% TMR145 from the baseline irradiation for the first irradiation set 
are shown in Table 37 and Table 39 where a positive difference indicates that the failure mode dose was 
higher than the baseline dose. For both the increase and decrease in energy in the standard plan, the 
average dose to the primary PTV TLD increased by around 1.5%. The dose to the secondary PTV also 
increased for both energy changes in the standard plan, on average 1% for the increased energy and 1.6% 
for the decreased energy. Finally, the spinal cord dose in the standard plan increased on average just over 
5% for the increased energy irradiation, and was on average 0.6% high for the decreased energy 
irradiation. For the complex plan, we again saw increases in the primary PTV TLD doses, on average 
2.4% for the increased energy irradiation and 1.7% for the decreased energy irradiation. The secondary 
PTV and spinal cord had increases in the average TLD dose for the increased energy irradiation of 1.4% 
and 3.9%, respectively. These two structures both had decreases in the average TL D dose for the 
decreased energy irradiation or -0.7% and -1.8%, respectively. The average DTA between the primary 
PTV and OAR on the axial field for the standard plan for the increased energy irradiation was 0.7 mm 
smaller than the baseline irradiation and 0.2 mm larger for the decreased energy irradiation. For the 
complex plan, the DTA for the increased energy irradiation was 0.1 mm larger for the increased energy 
irradiation with than the baseline irradiation and the average DTA for the decreased energy irradiation 
was 0.6 mm larger. The differences in the percent of pixels passing gamma analysis with 7%/4mm and 
5%/3mm criteria are shown in Table 38 and Table 40, where a positive value indicates that the failure 
mode percent of pixels passing was higher than that for the baseline. The corresponding gamma maps for 
the increased and decreased energy changes with 5%/3mm criteria are shown in Figure 49 - Figure 52 for 
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the standard plan Figure 53 - Figure 56 for the complex plan. Smaller differences from baseline were seen 
in the percent of pixels passing the 7%/4mm gamma with the decreased energy irradiations on both the 
standard and complex plans, than the increased energy irradiations. For the increased energy irradiations, 
a 15.6% change from baseline on the axial film and 9.5% on the sagittal was seen for the standard plan 
and 19.5% change on the axial and 15.4% on the sagittal for the complex plan. In the axial film gamma 
maps for the standard plan, the failures followed a similar pattern to baseline but were obviously less 
prevalent. Similarly for the standard plan sagittal film gamma maps, the distribution of failures was not 
greatly different than the baseline with failure pretty evenly spread throughout the PTV. For the high 
energy complex plan films, there appear to be two foci of failure on the axial film: in the posterior left 
corner of the primary PTV and in the anterior right corner of the film. On the sagittal film, the failure is 
concentrated in the PTV again, with a denser failure region in the superior half. For the decreased energy, 
the 7%/4mm percent of pixels passing the standard plan was 5.4% higher than baseline on the axial film 
and 4.6% higher on the sagittal. The complex plan had 9.2% more pixels passing the 7%/4mm criteria on 
the axial film with the increased energy irradiation and 5.9% more on the sagittal film. On the standard 
plan axial gamma maps, the failures seems to be concentrated more in the secondary PTV and are slightly 
heavier on the anterior side of the film that on the baseline axial films, but the overall failure is decreased. 
Sagittal gamma map failures for the standard plan are concentrated mostly on the superior and inferior 
edges of the PTV, which is different than in the baseline plan. Failures on the low energy complex plan 
films are concentrated in the PTVs, particularly in the superior half of the sagittal film.  
As we saw in the treatment planning studies, the changes in energy can result in a more 
heterogeneous dose distribution within the PTVs. TLD within the PTVs did not capture the volumetric 
effects that we saw in the treatment planning studies, such as the reduction in primary PTV coverage of 
4%. However, the increases in dose to the TLD may have been coming from hot spots in the PTVs that 
were a result of the increased heterogeneity.  It was also likely that the TLD did not capture the under-
dosing due to their central location within the PTV since the change in the dose from baseline should 
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increase with increasing off-axis distance. The dose to the spinal cord TLD in the complex plan for the 
low energy irradiation decreased, which was in line with the low energy treatment planning studies. This 
was not the case for the standard treatment plan, which similar to the complex treatment plan, had a 
decrease in the maximum dose to the spinal cord in our treatment planning studies but the dose to the 
TLDs did not correspondingly decrease. This was likely due to the fact that while the maximum dose to 
the spinal cord increased in the standard plan, the dose to the volume as a whole was mostly unchanged as 
you can see in the DVHs. But the spinal cord DVHs for the complex plan reflect a decrease in the dose to 
the spinal cord volume overall. While these decreases in the spinal cord dose did not affect our severity 
scoring since we were solely concerned with increased OAR doses and decreased PTV doses, the 
treatment planning studies and measurements appear to have had consistent results within the spinal cord 
structure. 
The distribution of failures on the gamma maps, especially on the decreased energy films, were 
different than those of the baseline plans, which also supports the notion that these dose distributions had 
increased heterogeneity. The foci of failure on increased energy axial film gamma maps may be a result 
of the rounder shoulder of the high energy profiles. Ideally, we could directly compare the TLD 
measurement results to the doses with the TLD structures on our treatment planning studies. But since our 
energy altered beam models were not based off of data from the same energy altered beams that the 
measurements were made with, we cannot assume that the dose distributions would be the same. 
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Standard Phantom Treatment Plan Irradiation – TLD Results 
Structure TLD position 
+1.1% TMR145 -0.8% TMR145 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 1.5% 1.9% 
Primary PTV Inferior Anterior 2.2% 1.8% 
Primary PTV Superior Posterior 1.2% 1.6% 
Primary PTV Inferior Posterior 1.0% 1.6% 
Secondary PTV Superior 1.0% 1.0% 
Secondary PTV Inferior 1.0% 2.2% 
Spinal Cord Superior 4.5% 0.8% 
Spinal Cord Inferior 5.6% 0.4% 
Table 37: Average TLD differences from baseline from the second irradiation set with energy adjustments of +1.1% and -
0.8% TMR145 for the standard plan. 
 
Standard Phantom Treatment Plan Irradiation – Gamma Analysis Results 
Film Criterion 
+1.1% TMR145 -0.8% TMR145 
Absolute Difference in Average Pixels Passing from Baseline 
Axial 
7%/4mm 15.6% 5.4% 
5%/3mm 0.9% -21.3% 
Sagittal 
7%/4mm 9.5% 4.6% 
5%/3mm -7.9% -11.8% 
Table 38: Average differences from baseline in gamma analysis results for axial and sagittal films within the phantom for 
the second irradiation set with an energy adjustment of +1.1% and -0.8% TMR145 for the standard plan. 
 
Complex Phantom Treatment Plan Irradiation – TLD Results 
Structure TLD position 
+1.1% TMR145 -0.8% TMR145 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 3.6% 1.7% 
Primary PTV Inferior Anterior 3.3% 2.2% 
Primary PTV Superior Posterior 1.3% 2.2% 
Primary PTV Inferior Posterior 1.2% 0.8% 
Secondary PTV Superior 0.9% -1.4% 
Secondary PTV Inferior 1.8% 0.1% 
Spinal Cord Superior 3.9% -1.4% 
Spinal Cord Inferior 3.8% -2.1% 
Table 39: Average TLD differences from baseline from the second irradiation set with energy adjustments of +1.1% and -
0.8% TMR145 for the complex plan. 
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Complex Phantom Treatment Plan Irradiation – Gamma Analysis Results 
Film Criterion 
+1.1% TMR145 -0.8% TMR145 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 19.5% 9.2% 
5%/3mm -8.8% -18.7% 
Sagittal 
7%/4mm 15.4% 5.9% 
5%/3mm -3.8% -11.9% 
Table 40: Average differences from baseline in gamma analysis results for axial and sagittal films within the phantom for 
the second irradiation set with an energy adjustment of +1.1% and -0.8% TMR145 for the complex plan. 
 
Figure 49: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
decreased energy (-0.8% TMR145 ) (bottom). 
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Figure 50: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
decreased energy (-0.8% TMR145 ) (bottom). 
 
Figure 51: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
increased energy (+1.1% TMR145 ) (bottom). 
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Figure 52: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
increased energy (+1.1% TMR145 ) (bottom). 
 
Figure 53: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
decreased energy (-0.8% TMR145 ) (bottom). 
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Figure 54: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
decreased energy (-0.8% TMR145). 
 
Figure 55: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
increased energy (+1.1% TMR145 ) (bottom). 
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Figure 56: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
increased energy (+1.1% TMR145 ) (bottom). 
Beam energy phantom studies summary 
Changes in the beam energy in our treatment planning studies resulted in primarily small changes 
in the doses to the phantom structures, with some under-dosing of the primary PTV in the standard 
plan(up to 4%) and a decrease in the dose to the spinal cord. In our measurements, the doses measured by 
the TLD mostly increased from baseline. We did not measure an under-dosing in either PTV with the 
TLD as we saw in the treatment planning studies, however we suspect this was due to the TLD location 
and the increased heterogeneity within the PTVs.  The dose to the spinal cord TLD decreased in the low 
energy irradiation to the complex plan, which was similar to what we saw in the treatment planning 
studies. Otherwise, increases in the dose to the spinal cord up to 8% were observed in our measurements, 
which was not consistent with the treatment planning studies. There was a larger uncertainty in the spinal 
cord TLD measurements, however. The severity score of 3, resultant of the treatment planning studies, 
overall was reasonable. 
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Failure mode 2: Beam symmetry 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for beam 
symmetry changes of approximately 2%, 3.5%, and 10% are summarized for standard phantom plans in 
Table 41 - Table 43 and complex phantom plans in Table 44 - Table 46. All structure evaluation criteria 
had below a 2% change from baseline (in the direction used for scoring, decrease in PTV or increase in 
OAR) for all three symmetry errors. These values ranged from 0% to -0.19% in the PTVs of the standard 
plan with 2% symmetry errors and 0.29% to 0.36% in the maximum dose to the normal tissue. All spinal 
cord doses decreased this is plan at 2% symmetry, up to -1.15%. The standard plan PTV dose differences 
from baseline ranged from -0.1% to -0.76% and 0.26% to 0.49% in the normal tissue maximum dose. 
Again, the spinal cord maximum doses only decreased, up to -0.95%. In the standard plan with 10% 
symmetry errors, PTV under-dosing ranged from -0.02 % to -1.18% and  the normal tissue maximum 
dose increased up to 1.43% while the spinal cord maximum dose increased only with the bottom to top 
symmetry error, changing 0.54% from baseline. For the complex plan, PTV dose difference from baseline  
ranged from 0.06% to -0.63% with 2% symmetry errors and were at maximum 0.07% in the normal 
tissue. All spinal cord doses decreased this is plan at 2% symmetry, up to -1.63%. The complex plan PTV 
dose differences from baseline ranged from -0.04% to -0.81% and 0.22% in the normal tissue maximum 
dose. Again, the spinal cord maximum doses only decreased, up to -1.60% difference from baseline. In 
the complex plan with 10% symmetry errors, PTV under-dosing ranged from -0.01% to -1.62% and  the 
normal tissue maximum dose increased up to 1.34% while the spinal cord maximum dose increased only 
with the top to bottom symmetry error, changing 0.03% from baseline. Otherwise, the spinal cord 
maximum dose decreased up to -3.0%. Overall, these small errors resulted in a severity score of 1 for this 
failure mode. 
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Standard Phantom Treatment Plan 
Structure Evaluation criteria 
2% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% -0.09% -0.06% 0.06% 0.01% 
D99% 0.00% -0.01% 0.15% 0.02% 
Secondary PTV 
D95% -0.30% -0.43% -0.29% -0.07% 
D99% -0.38% -0.49% -0.39% -0.16% 
Spinal Cord Max Dose -1.15% -0.55% -0.81% -0.98% 
Normal Tissue Max Dose 0.29% 0.36% 0.27% 0.24% 
Table 41: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 2% for the standard 
phantom treatment plan. 
 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
3.5% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% 0.09% -0.15% 0.02% -0.02% 
D99% 0.15% -0.18% 0.01% -0.02% 
Secondary PTV 
D95% -0.01% -0.58% -0.29% -0.17% 
D99% 0.01% -0.76% -0.38% -0.17% 
Spinal Cord Max Dose -0.95% -0.19% -0.55% -0.62% 
Normal Tissue Max Dose 0.43% 0.26% 0.29% 0.29% 
Table 42: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 3.5% for the 
standard phantom treatment plan. 
 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
10% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% -0.17% -0.38% 0.01% -0.02% 
D99% -0.34% -0.62% 0.16% -0.03% 
Secondary PTV 
D95% -0.43% -1.18% -0.51% -0.16% 
D99% -0.56% -1.29% -0.58% -0.21% 
Spinal Cord Max Dose -1.80% 0.54% -0.93% -1.17% 
Normal Tissue Max Dose 1.43% 0.34% 0.51% 0.43% 
Table 43: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 10% for the 
standard phantom treatment plan. 
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Complex Phantom Treatment Plan 
Structure Evaluation criteria 
2% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% -0.35% -0.06% -0.23% -0.06% 
D99% -0.63% -0.32% -0.47% -0.32% 
Secondary PTV 
D95% -0.07% -0.34% -0.17% -0.34% 
D99% 0.33% -0.42% 0.03% -0.42% 
Spinal Cord Max Dose -0.76% -1.63% -1.31% -1.63% 
Normal Tissue Max Dose -0.43% 0.07% -0.13% 0.07% 
Table 44: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 2% for the complex 
phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
3.5% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% -0.44% -0.08% -0.18% -0.15% 
D99% -0.81% -0.34% -0.47% -0.30% 
Secondary PTV 
D95% -0.04% -0.38% -0.24% -0.22% 
D99% 0.35% -0.81% -0.42% -0.22% 
Spinal Cord Max Dose -0.36% -1.60% -1.11% -1.12% 
Normal Tissue Max Dose -0.39% 0.22% -0.20% -0.43% 
Table 45: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 3.5% for the 
complex phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
10% Symmetry 
Top to bottom Bottom to top Left to right Right to left 
Change from baseline 
Primary PTV 
D95% -0.94% 0.01% -0.31% -0.28% 
D99% -1.28% -0.01% -0.61% -0.67% 
Secondary PTV 
D95% -0.04% -0.91% -0.15% -0.14% 
D99% 0.40% -1.62% 0.03% 0.41% 
Spinal Cord Max Dose 0.30% -3.00% -0.90% -0.84% 
Normal Tissue Max Dose 0.48% 1.34% 0.07% -0.45% 
Table 46: Dosimetric changes from baseline used for severity scoring for beam symmetry changes of 10% for the complex 
phantom treatment plan. 
The DVHs for this failure mode in the standard phantom treatment plan are shown in Figure 57-
Figure 59. The DVHs for this failure mode in the complex phantom treatment plan are shown in Figure 
60-Figure 62. It was observed that all changes from baseline were very small for both plans. The largest 
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differences appeared to be a decrease in the spinal cord dose for each case, though these changes were 
very small. This agreed with the severity scoring changes summarized above. 
 
Figure 57: DVHs for phantom structures in the standard treatment plan with beam symmetry changes of 2%, with 
dashed lines showing baseline DVHs. 
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Figure 58: DVHs for phantom structures in the standard treatment plan with beam symmetry changes of 3.5%, with 
dashed lines showing baseline DVHs. 
 
Figure 59: DVHs for phantom structures in the standard treatment plan with beam symmetry changes of 10%, with 
dashed lines showing baseline DVHs. 
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Figure 60: DVHs for phantom structures in the complex treatment plan with beam symmetry changes of 2%, with dashed 
lines showing baseline DVHs. 
 
Figure 61: DVHs for phantom structures in the complex treatment plan with beam symmetry changes of 3.5%, with 
dashed lines showing baseline DVHs. 
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Figure 62: DVHs for phantom structures in the complex treatment plan with beam symmetry changes of 10%, with 
dashed lines showing baseline DVHs. 
Considering the geometry of the phantom and delivery set up, we expected in plane symmetry 
(top to bottom or bottom to top) to affect all of the structures in the superior-inferior, increasing the dose 
to one side and decreasing the other. This effect would compound with beams coming from different 
gantry angles. These effects may not be evident in the mean doses, but would be volumetrically visible, 
changing the structure coverages. Cross plane symmetry (right to left or left to right) was expected to 
affect the outer edges of the structures most, but would likely be washed out with multiple beam angles.  
Overall, only very minimal changes were seen the doses to phantom structures with beam symmetry 
changes up to 10% in either direction, which was likely due to the central location of the structures within 
the phantom along with the central location of the isocenter. Additionally, the maximum jaw setting for 
these treatment plans was less than 10 x 10 cm2, with the furthest jaw positon off-axis being 5.4 cm in the 
X direction in the complex plan. Since symmetry errors were defined in a 20 x 20 cm2 field, the symmetry 
errors in these smaller phantom fields were scaled down. The most prevalent changes were small 
decreases in the spinal cord doses, which likely were exaggerated because the cord structure extends 
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almost three times longer in the superior inferior direction than either of the PTVs. It also lies close to a 
steep dose gradient which increases the changes of small changes in the plan affecting the structure dose. 
Physical measurement results 
Beam symmetry adjustment and measurements: Irradiation set #1 
The differences in the doses measured to the phantom TLD for the irradiation with beam 
symmetry adjustments of 5% in-plane and 3% cross-plane from the baseline irradiation for the first 
irradiation set are shown in Table 47, where a positive difference indicates that the failure mode dose was 
higher than the baseline dose. When the in plane symmetry was adjusted by 5%, TLD doses differed very 
little from the baseline irradiation on average. The primary PTV TLD dose differed from baseline on 
average by 0.4%, the secondary PTV TLD dose differed on average by 0.8%, and the spinal cord TLD on 
average by -0.5%. When the cross plane symmetry was adjusted by 3%, the anterior primary PTV TLD 
doses decreased on average by -1.5% and the posterior TLD doses increased on average by 3.2%. Overall, 
the primary PTV TLD average difference was 0.85%. Secondary PTV TLD doses differed on average by 
-1.2% and the spinal cord TLD dose increased from baseline by 2.5%.  
The DTA between the primary PTV and OAR on the axial field was 0.2 mm higher and 0.9 mm 
lower for the irradiation with beam symmetry errors of 5% in-plane and 3% cross-plane, respectively. The 
absolute differences in the percent of pixels passing gamma analysis with 7%/4mm and 5%/3mm criteria 
are shown in Table 48, where a positive value indicates that the failure mode percent of pixels passing 
was higher than that for the baseline. For the in plane symmetry adjustment of 5%, the axial percent of 
pixels passing a 7%/4mm gamma analysis decreased from baseline 8.2% and on the sagittal film there 
was practically no change in the percent of pixels passing. When the cross plan symmetry was adjusted 
3%, the percent of pixels passing a gamma analysis with 7%/4mm criteria decreased 4.6% on the axial 
film and increased 3.6% on the sagittal film. 
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Structure TLD position 
In-plane Symmetry 5% Cross-plane Symmetry 3% 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 1.0% -2.5% 
Primary PTV Inferior Anterior 0.1% -0.5% 
Primary PTV Superior Posterior -1.4% 4.1% 
Primary PTV Inferior Posterior 1.9% 2.3% 
Secondary PTV Superior 0.2% -0.8% 
Secondary PTV Inferior 1.4% -1.6% 
Spinal Cord Superior -0.6% 2.3% 
Spinal Cord Inferior -0.4% 2.7% 
Table 47: TLD differences from baseline from the first irradiation set with beam symmetry adjustments of 5% in-plane 
and 3% cross-plane (separately). 
Film Criterion 
In-plane Symmetry 5% Cross-plane Symmetry 3% 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm -8.2% -4.6% 
5%/3mm -7.6% -5.3% 
Sagittal 
7%/4mm 0.3% 3.6% 
5%/3mm 9.0% 15.6% 
Table 48: Differences from baseline in gamma analysis results for axial and sagittal films within the phantom for the first 
irradiation set with beam symmetry adjustments of 5% in-plane and 3% cross-plane (separately). 
Beam symmetry adjustment and measurements: Irradiation set #2 
The differences in the doses measured to the phantom TLD for the three irradiations with a beam 
symmetry adjustments of 3.6% in-plane (angular steering), 3.8% in-plane (translational steering), and 
3.65% cross-plane symmetry (angular steering) each from the baseline irradiation for the second 
irradiation set are shown in Table 49 and Table 51 for standard and complex plans, respectively. A 
positive difference indicates that the failure mode dose was higher than the baseline dose, which was the 
case for all TLD for all symmetry adjustments with both plans. These increases did not seem to follow 
exactly the same trends for standard and complex plans. With the angular in plane symmetry of 3.6%, 
with the average differences in TLD doses  of 1.4% in the primary PTV, 3.1% in the secondary PTV, and 
1.8% in the spinal cord. For the complex plan with this symmetry adjustment, the primary PTV TLD dose 
increased from baseline an average of 2.6%, the secondary PTV TLD increased by an average of 2.8%, 
and the spinal cord TLD doses increased an average of 3.4%. When the beam was steered translationally 
to adjust the in plane symmetry by 3.8%, the primary PTV TLD doses in the standard plan increased more 
than the angular in plane steering, on average 4.1%. The secondary PTV TLD doses increased on average 
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the same as the angular in plane steering, 3.1%, and the spinal cord TLD doses increased just slightly on 
average from baseline by 0.6%. In the complex plan, the primary PTV TLD dose increased from baseline 
an average of 3.4%, the secondary PTV TLD increased by an average of 2.7%, and the spinal cord TLD 
doses increased an average of 1.2%.When the cross plane symmetry was adjusted angularly by 3.65%, the 
standard plan primary PTV TLD doses increased on average by 2.6% from baseline and 4.2% in the 
secondary PTV. Spinal cord TLD doses increased an average of 1.9% from baseline for these irradiations.  
With the cross plan symmetry adjustment, the complex plan TLD doses increased on average by 3.1% in 
the primary PTV, 3.6% in the secondary PTV, and 2.6% in the spinal cord.  
The average DTA between the primary PTV and OAR on the axial field for the standard plan for 
the 3.6% in-plane (angular steering) irradiation was 0.2 mm larger than the baseline irradiation, 0.2 mm 
larger for the 3.8% in-plane (translational steering) irradiation, and 0.3 mm smaller for the 3.65% cross-
plane symmetry (angular steering) irradiation. For the complex plan, the DTA for the 3.6% in-plane 
(angular steering) irradiation was 0.5 mm smaller than the baseline irradiation, 0.2 mm smaller for the 
3.8% in-plane (translational steering) irradiation, and 0.2 mm smaller for the 3.65% cross-plane symmetry 
(angular steering) irradiation.  
The differences in the percent of pixels passing gamma analysis with 7%/4mm and 5%/3mm 
criteria are shown in Table 50 and Table 52 for standard and complex plans, respectively. A positive 
value indicates that the failure mode percent of pixels passing was higher than that for the baseline. The 
corresponding gamma maps are shown in Figure 63 - Figure 68 for the standard treatment plan and Figure 
69 - Figure 74 for the complex plan. The in plane symmetry adjustments changed the percent of pixels 
passing the 7%/4mm gamma analysis on the standard plan axial film by 11.9% and -12.7% for angular 
and translational adjustments, respectively. Compared to the baseline axial film gamma maps, the angular 
in plane symmetry adjustment seemed to reduce failure on the anterior side of films 2 and 3 and slightly 
increased the failure on the posterior side. The positional in plane steering, on the other hand, increased 
failures on the axial films for the standard plan, particularly in the primary PTV and the right anterior 
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corner.  The standard plan sagittal films had changes in percent of pixels passing for the in plane 
symmetry irradiations of 15.1% and -13.9%. The distribution of failures on the standard sagittal film with 
the angular in plane symmetry adjustment was very similar to the baseline, with reduced failures 
primarily on the superior half of the film. For the translational adjustment of the in plane symmetry, the 
sagittal film gamma map showed strong failure throughout the PTV, with slightly greater concentration of 
failure in the inferior half of the film, though the baseline standard sagittal film seemed to have that trend 
as well. The complex plan with in plane symmetry adjustments had 17.6% and -11.6% increases on the 
axial film and 14.3% and -9.6% on the sagittal film with angular and translational steering, respectively. 
On the axial film gamma map from irradiations with angular adjustment to the symmetry, the failures 
throughout the PTVs seen in the baseline gamma maps reduced overall and there was a concentration of 
failure in a high dose region outside the primary PTV in the left posterior corner as well as the other 
corner of the primary PTV.  This angular in plane symmetry resulted in an overall reduction in the 
failures on the sagittal film, with not obvious pattern change compared to baseline. The translational 
steering of the in plane symmetry resulted in an overall increase in the failures on the complex plan axial 
film, which were distributed throughout the PTVs and in between them. There was not a change in the 
pattern of the failures from baseline. On the sagittal film, a similar overall increase in the failures was 
seen. For the cross symmetry angular adjustment of 3.65%, the standard plan had increases in percent of 
pixels passing the 7%/4mm gamma analysis of 17.4% on the axial film and 15.5% on the sagittal film. 
The failures on the standard plan axial film gamma map for the cross plane symmetry adjustment seemed 
to follow the same pattern as the baseline gamma map but had less failure overall and particularly in the 
left-anterior quadrant of the film. In the complex plan axial film, the failures were much less prevalent 
than in the baseline film but seemed to have increased in a concentrated spot where the primary PTV dose 
extended outside the structure in the left posterior corner. The sagittal film gamma map showed regions 
on failure along the superior and inferior edges of the PTV. The failures overall were less prevalent than 
the baseline irradiations, but it was difficult to determine whether the distribution of failures was very 
different since the distribution on the baseline films were rather dispersed throughout the PTV. In the 
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complex plan, the percent of pixels passing on the axial and sagittal films with a cross plane symmetry 
adjustment increased by 21.3% and 12.8%, respectively. On the axial film, the failures reduced 
throughout the PTVs and were concentrated in that higher dose region adjacent to the primary PTV in the 
left posterior corner as well as the other corner of the primary PTV and in a line along the outside of the 
secondary PTV. Similar to the standard plan sagittal film, the prevalence of failure was reduced on the 
film from the cross plane symmetry adjusted irradiations, but the pattern did not appear largely different 
than baseline with the exception of perhaps less failure in the inferior half of the film. 
We saw larger differences in the doses to TLD and changes in the dose distributions from 
baseline with our measurements than were seen in our treatment planning studies. Part of this could be 
accounted for by the changes in beam flatness with physical beam steering which was likely not the same 
as that in the beam model.  These differences in flatness would be difference since the physical 
measurements were made with an improper configuration of the beam (photon beam not properly incident 
on the flattening filter) versus the treatment planning study beams were made with proper beam 
configuration with an additional modifier (indecent properly on the flattening filter and on the physical 
wedge). The fact that differences were  all positive could potentially be explained for in the in plane 
symmetry adjustments, which would be expected to cause changes in the superior-inferior direction, by 
the fact that the isocenter was just superior of the axial cut in the phantom insert, adjacent to which the 
TLD lie. For the angularly steered in plane symmetry measurements, the superior PTV TLD doses 
changed more than the inferior PTV TLD doses, which would support that notion. These changes were 
also slightly visible on the sagittal film gamma maps for the standard plan, with differences from the 
baseline gamma maps primarily in the superior half and more failures in the inferior half. The opposite 
was mostly true for the translationally steered in plane symmetry error, but the superior/inferior 
differences weren’t as large. As mentioned, cross plane symmetry errors would be expected to 
approximately wash out when multiple beam angles are used, however this would depend on the beam 
weighting and the shapes created by the MLC segments. This would result in a decrease in the PTV dose 
122 
 
homogeneity may have been the cause of the measured changes that were seen with the cross plane 
symmetry adjusted.  
Standard Phantom Treatment Plan Irradiation – TLD Results 
Structure TLD position 
3.6% In-plane 3.8% In-plane 3.65% Cross-plane 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 1.8% 3.7% 2.0% 
Primary PTV Inferior Anterior 0.8% 3.6% 2.1% 
Primary PTV Superior Posterior 2.0% 3.8% 3.6% 
Primary PTV Inferior Posterior 0.9% 5.1% 2.7% 
Secondary PTV Superior 3.4% 2.7% 4.3% 
Secondary PTV Inferior 2.8% 3.4% 4.1% 
Spinal Cord Superior 1.6% 0.7% 1.8% 
Spinal Cord Inferior 1.9% 0.4% 2.0% 
Table 49: Average TLD differences from baseline from the second irradiation set with symmetry adjustments of 3.6% in-
plane (angular steering), 3.8% in-plane (translational steering), and 3.65% cross-plane symmetry (angular steering) for 
the standard plan. 
 
Standard Phantom Treatment Plan Irradiation – Gamma Analysis Results 
Film Criterion 
3.6% In-plane 3.8% In-plane 3.65% Cross-plane 
Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 11.9% -12.7% 17.4% 
5%/3mm -7.5% -39.6% 5.6% 
Sagittal 
7%/4mm 15.1% -13.9% 15.5% 
5%/3mm 2.3% -25.8% 2.3% 
Table 50: Average Differences from baseline in gamma analysis results for axial and sagittal films within the phantom for 
the first irradiation set with symmetry adjustments of 3.6% in-plane (angular steering), 3.8% in-plane (translational 
steering), and 3.65% cross-plane symmetry (angular steering) for the standard plan. 
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Complex Phantom Treatment Plan Irradiation – TLD Results 
Structure TLD position 
3.6% In-plane 3.8% In-plane 3.65% Cross-plane 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 2.1% 2.6% 2.7% 
Primary PTV Inferior Anterior 2.0% 2.9% 3.0% 
Primary PTV Superior Posterior 5.1% 3.7% 3.8% 
Primary PTV Inferior Posterior 1.3% 4.4% 2.7% 
Secondary PTV Superior 2.9% 2.5% 3.6% 
Secondary PTV Inferior 2.6% 2.8% 3.6% 
Spinal Cord Superior 1.9% 1.9% 2.8% 
Spinal Cord Inferior 4.9% 0.5% 2.4% 
Table 51: Average TLD differences from baseline from the second irradiation set with symmetry adjustments of 3.6% in-
plane (angular steering), 3.8% in-plane (translational steering), and 3.65% cross-plane symmetry (angular steering) for 
the complex plan. 
 
Complex Phantom Treatment Plan Irradiation – Gamma Analysis Results 
Film Criterion 
3.6% In-plane 3.8% In-plane 3.65% Cross-plane 
Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 16.6% -11.6% 21.3% 
5%/3mm -10.1% -37.2% -3.4% 
Sagittal 
7%/4mm 14.3% -9.6% 12.8% 
5%/3mm -2.5% -20.2% -1.3% 
Table 52: Average differences from baseline in gamma analysis results for axial and sagittal films within the phantom for 
the first irradiation set with symmetry adjustments of 3.6% in-plane (angular steering), 3.8% in-plane (translational 
steering), and 3.65% cross-plane symmetry (angular steering) for the complex plan. 
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Figure 63: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with in 
plane symmetry angular adjustment of 3.6% (bottom). 
 
Figure 64 Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with in 
plane symmetry angular adjustment of 3.6% (bottom). 
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Figure 65: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with in 
plane symmetry positional adjustment of 3.8% (bottom). 
 
Figure 66: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with in 
plane symmetry positional adjustment of 3.8% (bottom). 
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Figure 67: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
cross plane symmetry angular adjustment of 3.65% (bottom). 
 
Figure 68: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
cross plane symmetry angular adjustment of 3.65% (bottom). 
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Figure 69: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with in 
plane symmetry angular adjustment of 3.6% (bottom). 
 
 
Figure 70: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with in 
plane symmetry angular adjustment of 3.6% (bottom). 
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Figure 71: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with in 
plane symmetry positional adjustment of 3.8% (bottom). 
 
Figure 72: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with in 
plane symmetry positional adjustment of 3.8% (bottom). 
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Figure 73: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
cross plane symmetry angular adjustment of 3.65% (bottom). 
 
Figure 74: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
cross plane symmetry angular adjustment of 3.65% (bottom). 
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Beam symmetry phantom studies summary 
Changes in the beam symmetry in our treatment planning studies resulted in all small changes in 
the doses to the phantom structures, with the most prevalent difference from baseline being a small 
decrease in the dose to the spinal cord, especially with bottom-top (in plane) symmetry errors. In our 
measurements, the doses measured by the TLD all increased from baseline. We did not measure a 
decrease in the dose to the spinal cord but rather, an increase. The differences in treatment planning 
studies and measurements were likely due to both differences in the nature of the symmetry errors and the 
evaluations themselves, with TLD only capturing a small part of the full volumetric picture. The severity 
score of 1, resultant of the treatment planning studies, may be slightly low since differences were 
measured, however those differences were in the very sensitive spinal cord TLD or were increases in the 
PTV doses which are not considered for severity scoring according to our currently presented method. 
Failure mode 3: MLC position 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for systematic 
MLC positional errors in one bank of leaves (X1 or X2) of both 1 mm and 2mm are summarized for 
standard phantom plans in Table 53 and Table 54. As in the first two failure modes, the dose differences 
are color-coded to demonstrate severity score levels. Dosimetric changes ranging from about 0% to 20% 
were seen in the standard phantom treatment plan structures at the evaluation criteria. Moving either MLC 
bank out by 1 mm resulted in increases to the maximum dose of the spinal cord, by 3.7% for the X1 bank 
and 5.7% for the X2 bank. This change in the X1 bank also resulted in small reductions in the PTV 
coverage. Moving the MLC in the X1 bank out by 2 mm did not result in substantial errors in any of the 
structures. However, moving this bank in by 2 mm resulted in under-dosing 99% of the primary PTV 
volume by over 9% and 95% of the primary PTV volume by about 7.5% as well as decreasing D99% and 
D95% for the secondary PTV by almost 4% and 5%, respectively. Shifts of 2 mm in the X2 MLC bank 
resulted in even larger changes. When the X2 leaves were shifted out by 2 mm, the dose to the primary 
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PTV was decreased by almost 3% and the spinal cord dose increased by over 8%. When the X2 leaves 
were shifted in by 2 mm on the standard phantom treatment plan, 95% of the primary PTV volume was 
under-dosed by 16% and 99% of the primary PTV volume was under-dosed by almost 20%. The 
secondary PTV was also under-dosed by about 8% for the D99% and D95%. Based on these results from the 
standard phantom treatment plan, the severity scores for an MLC positional error of 1 mm was 4 and of 2 
mm was 8. With the collimator at 0°, the X1 and X2 banks of leaves are used to modulate the dose to the 
left or right side of the field from the BEV, respectively. As the gantry rotates around the patient, the 
structures blocked by either bank change. The differences seen in shifting the X1 bank or the X2 bank 
likely has to do with the amount of modulation either bank is responsible for, the beam and segment 
weighting, and where the edges of the fields are. Based on the fact that larger changes were seen with the 
X2 bank, we would expect those leaves to move within the fields slightly more and therefore shifts have a 
greater impact on the dose distribution. 
For complex plans, the resultant changes in the phantom structure doses used for severity scoring 
for systematic MLC positional errors in one bank of leaves (X1 or X2) of both 1 mm and 2mm are 
summarized in Table 55 and Table 56. All changes in the structure evaluation criteria for systematic MLC 
errors of 1 mm in the complex plan were under 2.5%, with the exception of moving the X2 bank out by 1 
mm which resulted in slightly over a 3% increase in the maximum dose to the spinal cord. When the 
MLC banks were shifted 2 mm, dosimetric changes up to over 8% were seen in the complex phantom 
treatment plan structures at the evaluation criteria. Under-dosing of the primary PTV by about 4-8% 
resulted from moving either the X1 or X2 MLC bank in by 2 mm. Additionally when the X1 leaves were 
shifted in by 2 mm on the complex phantom treatment plan, the spinal cord maximum dose increased by 
almost 5%. When the X2 leaves were shifted in by 2 mm, the maximum dose to the normal tissue 
structure increased by about 5%. When the X2 leaves were shifted 2 mm out, only small changes were 
seen in the PTV doses, but the spinal cord maximum dose increased by over 8%. Discrepancies between 
the results from shifts in the X1 and X2 banks were a result of the complex modulation as in the standard 
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phantom treatment plan. The discrepancies weren’t as large, which may indicate that since this plan was 
more complex, utilizing more segments and smaller segments, both banks were required  to participate 
heavily in the modulation. Overall, the worst error in the complex treatment plan would result in a 
severity score of 2 for an error of 1 mm and severity score of 6 for an error of 2 mm. Since worse errors 
were seen with the standard phantom treatment plan, the severity score of 8 determined by those results 
was assigned to this failure mode. 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
1 mm MLC positional errors 
X1 + 1mm X1 - 1mm X2 +1mm X2 - 1mm 
Change from baseline 
Primary PTV 
D95% -1.08% -0.01% 0.29% -0.50% 
D99% -1.26% -0.49% 0.42% -0.92% 
Secondary PTV 
D95% -1.37% 0.89% -0.42% 0.07% 
D99% -1.26% 0.55% -0.50% -0.36% 
Spinal Cord Max Dose 3.65% -2.40% 5.74% -5.06% 
Normal Tissue Max Dose -0.29% 1.32% 0.00% 0.34% 
Table 53: Dosimetric changes from baseline used for severity scoring for systematic MLC positional errors of 1 mm in 
one bank of leaves (X1 or X2) for the standard phantom treatment plan. 
 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
2 mm MLC positional errors 
X1 + 2mm X1 - 2mm X2 +2mm X2 - 2mm 
Change from baseline 
Primary PTV 
D95% 0.46% -7.45% -2.46% -16.08% 
D99% 0.47% -9.10% -2.83% -19.80% 
Secondary PTV 
D95% 0.51% -3.96% -1.03% -7.98% 
D99% 0.59% -4.80% -1.91% -8.63% 
Spinal Cord Max Dose 0.68% -8.64% 8.17% -24.17% 
Normal Tissue Max Dose 0.56% -2.99% 0.92% -7.95% 
Table 54: Dosimetric changes from baseline used for severity scoring for systematic MLC positional errors of 2 mm in 
one bank of leaves (X1 or X2) for the standard phantom treatment plan. 
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Complex Phantom Treatment Plan 
Structure Evaluation criteria 
1 mm MLC positional errors 
X1 + 1mm X1 - 1mm X2 +1mm X2 - 1mm 
Change from baseline 
Primary PTV 
D95% -1.26% 0.07% 0.61% -1.24% 
D99% -1.25% -0.16% 0.87% -1.95% 
Secondary PTV 
D95% -2.26% 2.18% 0.24% -0.64% 
D99% -1.62% 1.50% 0.41% -0.55% 
Spinal Cord Max Dose 0.86% 0.69% 3.15% -1.58% 
Normal Tissue Max Dose -0.73% 1.32% 0.53% 1.10% 
Table 55: Dosimetric changes from baseline used for severity scoring for systematic MLC positional errors of 1 mm in 
one bank of leaves (X1 or X2) for the complex phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
2 mm MLC positional errors 
X1 + 2mm X1 - 2mm X2 +2mm X2 - 2mm 
Change from baseline 
Primary PTV 
D95% -0.02% -5.64% -2.01% -4.39% 
D99% 0.53% -7.94% -2.44% -7.69% 
Secondary PTV 
D95% 0.06% 6.14% 2.06% 3.84% 
D99% 1.00% 4.77% 1.32% 3.35% 
Spinal Cord Max Dose -0.05% 4.97% 8.35% 1.49% 
Normal Tissue Max Dose 0.36% 0.22% 1.77% 5.07% 
Table 56: Dosimetric changes from baseline used for severity scoring for systematic MLC positional errors of 2mm in one 
bank of leaves (X1 or X2) for the complex phantom treatment plan. 
The DVHs for MLC positional errors of 1 mm and 2 mm are shown in Figure 75 and Figure 77 
and Figure 76 and Figure 78, respectively. Very small changes in the standard treatment plan PTV doses 
with a 1mm MLC positional error were seen, as was a spread in the dose to the spinal cord with moving 
the X2 bank out by 1 mm creating the largest increase. Changes in the complex plan spinal cord dose 
were similar and PTV dose changes were slightly larger than those in the standard plan. 
Target under-dosing was seen very clearly when the MLC banks were shifted 2 mm in the 
standard phantom treatment plan (Figure 76). In the complex phantom treatment plan, however, the dose 
to the secondary PTV was clearly increased and the primary PTV lost coverage but gained hotspots 
(Figure 78). There was also a large spread in the dose to the spinal cord dose for both the standard and 
complex plans, with only a 2 mm shift out of the X2 bank causing an increase in the spinal cord DVH.  
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Figure 75: DVHs for phantom structures in the standard treatment plan with systematic MLC positional errors in one 
bank of 1 mm, with dashed lines showing baseline DVHs. 
 
Figure 76: DVHs for phantom structures in the standard treatment plan with systematic MLC positional errors in one 
bank of 2 mm, with dashed lines showing baseline DVHs. 
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Figure 77: DVHs for phantom structures in the complex treatment plan with systematic MLC positional errors in one 
bank of 1 mm, with dashed lines showing baseline DVHs. 
 
 
Figure 78: DVHs for phantom structures in the complex treatment plan with systematic MLC positional errors in one 
bank of 2 mm, with dashed lines showing baseline DVHs. 
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The increase in differences with larger MLC positional errors was obvious. As one would expect, 
when the MLC moved inward (-1 mm or -2 mm), the doses to structures generally decreased and the 
when the MLC moved outward (+1 mm or +2 mm), the doses to structures generally increased. The fact 
that the dose to the normal tissue was least effected reflects the role of the MLC in IMRT to not only 
block along the edges of the structures, but to modulate the dose within them. The relationship between 
MLC positional errors and structures doses was therefore rather complex. One surprising result was that 
the dose to the secondary PTV increased for 2 mm shifts inward in the complex plan which would be 
expected to universally reduce the doses since the fields were smaller. An axial image of the phantom and 
dose distribution is shown in Figure 79, with the baseline plan on the left and the plan with the X2 bank 
of MLC systematically shifted inward. The primary PTV clearly lost coverage, however the dose to the 
secondary PTV increased. This demonstrated the complexity of the role of modulation well. 
 
Figure 79: Axial image of phantom with complex treatment plan dose distributions: Baseline plan (left) and X2 MLC 
systematically shifted inward by 2 mm (right). Isodose values are shown in the upper left corner. 
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Physical measurement results 
MLC positional error measurements: Irradiation set #1 
The differences in the doses measured to the phantom TLD for the irradiation with MLC 
positional errors of 1 mm out and 3 mm out in both banks from the baseline irradiation for the first 
irradiation set are shown in Table 57 where a positive difference indicates that the failure mode dose was 
higher than the baseline dose. On average, the dose to the primary PTV TLD increased from baseline by 
14.2% with the MLC shifted out 1 mm. With this MLC shift, the dose to the secondary PTV and spinal 
cord TLD also increased, on average by 7.7% and 18.8%, respectively. With the MLC shifted out 3 mm, 
the dose to the primary PTV TLD increased from baseline by 36.6% on average. In the secondary PTV, 
the dose to the TLD increased on average by 22.3% and in the spinal cord the dose was close to doubling, 
increasing by 91.2% on average. The DTA between the primary PTV and OAR on the axial film was 0.7 
mm lower than the baseline irradiation for the irradiation with a systematic MLC positional error of 1 mm 
out and 3 mm out, respectively. The absolute differences in the percent of pixels passing gamma analysis 
with 7%/4mm and 5%/3mm criteria are shown in Table 58.  
Structure TLD position 
MLC 1 mm out MLC 3 mm out 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 12.5% 35.3% 
Primary PTV Inferior Anterior 11.6% 38.5% 
Primary PTV Superior Posterior 17.6% 38.2% 
Primary PTV Inferior Posterior 15.0% 34.4% 
Secondary PTV Superior 8.9% 25.6% 
Secondary PTV Inferior 6.5% 19.0% 
Spinal Cord Superior 22.5% 92.7% 
Spinal Cord Inferior 15.1% 89.7% 
Table 57: TLD differences from baseline from the first irradiation set with systematic MLC positional errors of 1 mm and 
3 mm in both banks. 
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Film Criterion 
MLC 1 mm out MLC 3 mm out 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 23.2% -34.5% 
5%/3mm 35.9% -15.9% 
Sagittal 
7%/4mm 7.7% -34.5% 
5%/3mm 22.3% -15.9% 
Table 58: Absolute differences from baseline in gamma analysis results for axial and sagittal films within the phantom for 
the first irradiation set with systematic MLC positional errors of 1 mm and 3 mm in both banks. 
MLC positional error measurements: Irradiation set #2 
The differences in the doses measured to the phantom TLD for the irradiations with MLC 
positional errors of 2 mm out in one bank of leaves from the baseline irradiation for the second irradiation 
set are shown in Table 59 for standard and complex plans where a positive difference indicates that the 
failure mode dose was higher than the baseline dose. On average, the primary PTV TLD dose increased 
by 1.5% in the standard plan with the 2 mm shift outward. The secondary PTV and spinal cord TLD 
doses also increased from baseline, by 1.3% and 6.4% on average, respectively. In the complex plan, the 
primary PTV TLD dose increased by 2.3% on average, the secondary PTV TLD dose increased by 1.8% 
on average, and the spinal cord dose increased by 6.3% on average.  
The DTA between the primary PTV and OAR on the axial field was 0.9 mm lower than the 
baseline irradiation for the irradiation for the standard plan and 0.9 mm lower for the complex plan. The 
differences in the percent of pixels passing gamma analysis with 7%/4mm and 5%/3mm criteria are 
shown in Table 60 for standard and complex plans. The corresponding gamma maps are shown in Figure 
80 and Figure 81 for the standard plan and Figure 82 and Figure 83 for the complex plan. In the standard 
plan, the percent of pixels passing a 7%/4mm gamma analysis increased by 18% on the axial film and 
11.3% on the sagittal film. On the axial films, there was a clear reduction in points failing compared to the 
baseline which was not expected with improper MLC positioning, however this must have been due to an 
error in the original baseline delivery. The distribution of failure was similar between the two sets of 
irradiations, though it appeared that there were fewer failures outside of the PTV regions. On the sagittal 
films, the failures were mostly along the superior and inferior edges of the PTV, as opposed to spread 
within the PTV like the baseline films.  For the complex plan with 2 mm shifts outward, the axial film 
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gamma analysis with 7%/4mm criteria resulted in 17.9% more pixels passing than the baseline plan, 
while on the sagittal film the percent of pixels passing increased by 8.7%. These increases were similar in 
magnitude to those from the standard plan. On the axial films gamma maps, the failures within the PTVs 
decreased and on two of the three films there were concentrated spots of failure in the left posterior corner 
and the right anterior corner. On the sagittal film gamma maps, the distribution of failure was very similar 
to baseline just with an overall decrease in the amount of failure. 
Structure TLD position 
Standard Plan Irradiation Complex Plan Irradiation 
MLC 2 mm out, one bank 
Difference in Dose from Baseline 
Primary PTV Superior Anterior 1.7% 2.8% 
Primary PTV Inferior Anterior 2.0% 3.2% 
Primary PTV Superior Posterior 0.8% 2.2% 
Primary PTV Inferior Posterior 1.3% 1.0% 
Secondary PTV Superior 0.8% 2.3% 
Secondary PTV Inferior 1.7% 1.3% 
Spinal Cord Superior 6.8% 5.3% 
Spinal Cord Inferior 6.0% 7.2% 
Table 59: Average TLD differences from baseline from the second irradiation set with systematic MLC positional errors 
of 2 mm in one bank for standard and complex plans. 
 
Film Criterion 
Standard Plan Irradiation Complex Plan Irradiation 
MLC 2 mm out, one bank 
Differences in Pixels Passing from Baseline 
Axial 
7%/4mm 18.0% 17.9% 
5%/3mm -6.0% -9.2% 
Sagittal 
7%/4mm 11.3% 8.7% 
5%/3mm -4.1% -6.9% 
Table 60: Average absolute differences from baseline in gamma analysis results for axial and sagittal films within the 
phantom for the second irradiation set with systematic MLC positional errors of 2 mm in one bank for standard and 
complex plans. 
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Figure 80: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the MLC shifted out 2 mm in one bank(bottom). 
 
Figure 81: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the MLC shifted out 2 mm in one bank (bottom). 
141 
 
 
Figure 82: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
the MLC shifted out 2 mm in one bank (bottom). 
 
Figure 83: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the complex treatment plan with 
the MLC shifted out 2 mm in one bank (bottom). 
The differences seen in this second set of MLC positional error measurement should have 
corresponded well to the treatment planning studies since the treatment plan used was the same and the 
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errors simulated were the same. However, we did not see quite as large of differences in our measured 
doses as we did in the treatment planning studies, particularly in the PTVs. Outward motion of the leaves 
did not affect the PTVs as extremely as inward motion in the treatment planning studies, and so our 
ability to see those PTV changes were limited since we only performed measurements with outward 
motion. Differences between our treatment planning studies and measurements may also have been due to 
the fact that the TLD only measured the dose to a small volume and therefore were unable to capture the 
volumetric effects of this failure mode. The differences seen in the film were large, but the role of the 
MLC shift was not immediately obvious. That was likely due to the modulation effects discussed. 
MLC position phantom studies summary 
Systematic changes in the MLC positions in our treatment planning studies primarily showed 
changes in the dose to the spinal cord, with the maximum dose increasing with outward (positive) leaf 
displacement up to 8%. Inward displacement of one bank of leaves reduced structure doses as would be 
expected, with under-dosing of the PTVs up to 20% in the standard treatment plan. One may have 
expected the complex plan to have larger errors since there were more segments and therefore more MLC 
positions to change, but it may have been the case that there was more wash out of these errors with the 
more complex plan. Our measurements were limited to outward displacement of the leaves, and with 2 
mm systematic shifts in one bank, the increased dose to the spinal cord as measured by the TLD was 
about 5-7%, which is comparable to what we saw in the treatment planning studies. The severity score of 
8 is supported by both treatment planning studies and measurements with up to 2 mm systematic 
displacement in one bank of leaves. 
Failure mode 4: Gantry Angle 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring from 2° changes in 
the gantry angle are summarized in Table 61 and Table 62 for standard and complex phantom plans, 
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respectively. In the standard phantom treatment plan, a positive 2° change in the gantry angle only 
resulted in up almost 1% decrease PTV coverage, while a negative 2° change increased the maximum 
dose to the spinal cord by almost 12%. In the complex treatment plan, a positive 2° change in the gantry 
angle resulted in an increase in the spinal cord maximum dose of almost 8.5%, while a negative 2° change 
resulted in a decrease in D99% for the primary PTV of about 2.5%. As a result of the increase in the 
maximum spinal cord dose in the standard treatment plan with a negative 2° change in gantry angle, the 
severity score for this failure mode is 7. 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees -2 degrees 
Change from baseline 
Primary PTV 
D95% -0.27% -0.04% 
D99% -0.93% 0.02% 
Secondary PTV 
D95% 0.08% -0.09% 
D99% 0.02% -0.19% 
Spinal Cord Max Dose -5.91% 11.69% 
Normal Tissue Max Dose 0.11% 0.14% 
Table 61: Dosimetric changes from baseline used for severity scoring for gantry angle changes of +2° and -2° for the 
standard phantom treatment plan. 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees -2 degrees 
Change from baseline 
Primary PTV 
D95% -0.29% -0.44% 
D99% -1.32% -2.39% 
Secondary PTV 
D95% 0.17% 0.18% 
D99% 0.79% 0.78% 
Spinal Cord Max Dose 8.43% -3.22% 
Normal Tissue Max Dose -0.79% 0.00% 
Table 62: Dosimetric changes from baseline used for severity scoring for gantry angle changes of +2° and -2° for the 
complex phantom treatment plan. 
The DVHs for gantry angle errors of 2° are shown in Figure 84 and Figure 85 for standard and 
complex phantom treatment plans, respectively. The spinal cord dose is the primary structure affected by 
this failure mode, with increases in the overall dose then the gantry was rotated +2° in the standard plan 
and decreases in the overall dose when the gantry was rotated -2° in the standard plan. In the complex 
plan, the -2° rotation of the gantry had minimal effects on the spinal cord dose, but the +2° rotation 
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increased the overall cord dose. These spinal cord dose changes were supportive of the dosimetric 
changes seen at our evaluation criteria. 
 
Figure 84: DVHs for phantom structures in the standard treatment plan with gantry angle errors of 2°, with dashed lines 
showing baseline DVHs. 
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Figure 85: DVHs for phantom structures in the complex treatment plan with gantry angle errors of 2°, with dashed lines 
showing baseline DVHs. 
Gantry angle changes slightly moved all of the structures we investigated, but since the spinal 
cord is located near a steep dose gradient, changes were most evident there. In the case of the standard 
plan, the shape of dose distribution around the spinal cord, gantry rotation in the positive direction 
resulted in the cord entering the steep dose gradient between it and the primary PTV. The other side of the 
spinal cord had more room to spare before entering the steep dose gradient, which was why the dose 
decreased with the negative gantry rotation. This is demonstrated in Figure 86. The complex plan had a 
similar effect with the positive gantry rotation, but due to the shape of the dose distribution in the sparing 
region, the negative rotation only managed to maintain the cord position within the sparing region and not 
move it away further from the gradient, therefore keeping the dose about the same. 
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Figure 86: Axial image of phantom primary PTV (red) and spinal cord OAR (blue) with standard treatment plan dose 
distributions: Gantry angle -2° (left), baseline plan (center) and gantry angle +2° (right). Isodose values are shown in the 
upper left corner. 
Physical measurement results 
Gantry angle error measurements: Irradiation set #3 
The average differences in the doses measured to the phantom TLD for the three irradiations with 
gantry errors of +2° for each beam from the baseline irradiation for the third irradiation set are shown in 
Table 63 where a positive difference indicates that the failure mode dose was higher than the baseline 
dose. On average, the primary PTV TLD doses decreased from baseline by -2.6%. The secondary PTV 
TLD did not change much from baseline, decreasing only -0.4%. Similarly, the spinal cord TLD dose 
barely changed from baseline, with an average of 0.1%.  
There was no difference in the DTA between the primary PTV and OAR on the axial film. The 
differences in the percent of pixels passing gamma analysis with 7%/4mm and 5%/3mm criteria are 
shown in Table 64. The corresponding gamma maps are shown in Figure 87 and Figure 88 with the 
5%/3mm criteria to accentuate failure regions. The percent of pixels passing a 7%/4mm gamma analysis 
on the axial film decreased -10.2% from baseline and on the sagittal film it decreased -8.7%. The failures 
on the gamma maps with gantry angle errors were most in the PTV regions and appeared to have a similar 
shape to the failures on the gamma maps of the baseline plan for this irradiation set which included a line 
of less failure where the dose to the primary PTV dropped off to the dose of the secondary PTV. The 
sagittal films showed increased failure focused in the PTV and distributed more throughout the PTV than 
-2° +2° Baseline 
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in the baseline sagittal films for this irradiation set, which had failures along the superior and inferior 
edges of the PTV.  
Structure TLD position 
+2° Gantry Angle 
Difference in Dose from Baseline 
Primary PTV Superior Anterior -2.2% 
Primary PTV Inferior Anterior -1.8% 
Primary PTV Superior Posterior -2.3% 
Primary PTV Inferior Posterior -3.9% 
Secondary PTV Superior -0.8% 
Secondary PTV Inferior -0.0% 
Spinal Cord Superior -0.3% 
Spinal Cord Inferior 0.4% 
Table 63: Average TLD differences from baseline from the third irradiation set with gantry angle errors of +2°. 
Film Criterion 
+2° 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm -10.2% 
5%/3mm -24.0% 
Sagittal 
7%/4mm -8.7% 
5%/3mm -19.6% 
Table 64: Average absolute differences from baseline in gamma analysis results for axial and sagittal films within the 
phantom for the third irradiation set with gantry angle errors of +2°. 
 
Figure 87: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the gantry rotated +2° (bottom). 
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Figure 88: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the gantry  rotated +2° (bottom). 
 
Overall, the doses to the TLDs with +2° rotation of the gantry were decreased from baseline. 
Based on the treatment planning studies, we expected an increase in the spinal cord dose but this was not 
the case. This was likely due to the central location of the TLD within the spinal cord structure. The 
changes in dose to the spinal cord dose mostly occurred along the left edge when it entered the steep dose 
gradient or moved away from it in the treatment planning studies. The decrease in the primary PTV TLD 
doses was due to slight overall changes in the dose distribution from the gantry rotation and corresponded 
to very small losses in coverage of the targets in the treatment planning studies. These changes were well 
demonstrated on the axial film gamma maps, which showed failure concentrated in the PTVs. We would 
perhaps expect to see increasing failure with off-axis distance on the axial film since that would 
correspond to a larger displacement when the gantry was rotated. This was not evident on the axial film 
gamma maps, which captured such a small region that was dominated by high doses. The doses further 
off-axis rapidly fell off to more homogeneous low doses that were not as affected by the gantry rotation. 
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Gantry angle phantom studies summary 
Systematic changes in the gantry angles in our treatment planning studies primarily showed 
changes to the spinal cord dose with an increase in the standard plan maximum cord dose of 12% with -2° 
gantry angle error and the complex plan maximum cord dose of 8% with +2° gantry angle error. There 
was also a slight reduction in primary PTV coverage with the +2° gantry angle error.  Reduced dose to the 
primary PTV of up to 4% was the largest change observed in our measurements. Other TLD doses 
changed very little from baseline, including the spinal cord doses which the treatment planning studies 
showed to have large positive differences. The severity score of 7, resultant of the treatment planning 
studies, was higher than expected based on absolute dose measurements, however it was likely that the 
maximum spinal cord dose had a large change closer to the primary PTV where the dose is changing 
quickly as opposed to at the center of the cord where the TLD are located. This reflects the potential 
advantages of volumetric data when assessing these changes. Overall the treatment planning studies and 
measurements generally agree.  
Failure mode 5: Collimator Angle 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring from 2° changes in 
the collimator angle are summarized in Table 65 and Table 66 for standard and complex phantom plans, 
respectively. All structure evaluation criteria had below a 2% change from baseline for the standard 
phantom treatment plan, with all changes being negative with the exception of normal tissue maximum 
dose. The largest change in the standard plan with +2° collimator rotation was 1.46% increase in the 
maximum dose to the normal tissue. The largest change in the standard plan with -2° collimator rotation 
was 1.51% decrease in the dose to 99% of the secondary PTV.  In the complex treatment plan, a positive 
2° change in the collimator angle resulted in an increase in the spinal cord maximum dose of almost 
7.5%. Other changes were all less than 2% for this collimator rotation in the complex plan with small 
decreases in the primary PTV coverage and increases in the secondary PTV coverage. A negative 2° 
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change in the collimator angle resulted in an under-dose to 99% of the secondary PTV of the complex 
plan of almost 3%. The coverage of the secondary PTV also decreased, up to -1.2%, and the dose to the 
spinal cord decreased over 3%. As a result of the increase in the maximum spinal cord dose in the 
complex plan with +2° collimator rotation, the severity score for this failure mode was 5. 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees - 2 degrees 
Change from baseline 
Primary PTV 
D95% -0.33% -0.22% 
D99% -0.32% -0.64% 
Secondary PTV 
D95% -0.37% -0.51% 
D99% -0.54% -1.51% 
Spinal Cord Max Dose -0.33% -0.27% 
Normal Tissue Max Dose 1.46% 0.56% 
Table 65: Dosimetric changes from baseline used for severity scoring for collimator angle changes of +2° and -2° for the 
standard phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees - 2 degrees 
Change from baseline 
Primary PTV 
D95% -0.59% -0.91% 
D99% -1.13% -2.87% 
Secondary PTV 
D95% 0.81% -1.15% 
D99% 1.46% -1.20% 
Spinal Cord Max Dose 7.44% -3.33% 
Normal Tissue Max Dose 1.60% 1.26% 
Table 66: Dosimetric changes from baseline used for severity scoring for collimator angle changes of +2° and -2° for the 
complex phantom treatment plan. 
The DVHs for collimator angle errors of 2° are shown in Figure 89 and Figure 90 for standard 
and complex phantom treatment plans, respectively. DVHs for the standard phantom treatment showed 
little to no change from baseline. The spinal cord dose increase in the complex treatment plan with +2° 
collimator rotation was evident, as was some slight loss of coverage in the PTVs. There also appeared to 
be an increase in the spinal cord dose for the complex plan with -2° collimator rotation, which was not 
what we observed in our dosimetric evaluation criteria, however the DVH for the spinal cord with  -2° 
collimator rotation is slightly more steep and therefore didn’t result in an increase in the maximum spinal 
cord dose.  
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Figure 89: DVHs for phantom structures in the standard treatment plan with collimator angle errors of 2°, with dashed 
lines showing baseline DVHs. 
 
Figure 90: DVHs for phantom structures in the complex treatment plan with collimator angle errors of 2°, with dashed 
lines showing baseline DVHs. 
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Rotating the collimator by 2° did not result in very large changes in the dose to the phantom 
structures or the overall dose distribution. Small systematic rotational errors in the collimator would be 
expected to smear the dose distribution since opposing beams would have be rotated opposite each other. 
The maximum change of 7.4% increase in the maximum spinal cord dose in the complex plan was a 
result of the spinal cord coming just close enough to the steep dose gradient between it and the primary 
PTV that the maximum dose increased from around 425 cGy to almost 460 cGy, just outside of the 
tolerance criteria. This maximum dose was only over a very small volume and is difficult to see in the 
treatment plan. This emphasized that even very small changes that were not immediately obvious had the 
potential to threaten our goals, specifically critical structure sparing when they were immediately adjacent 
to our targets.  
Physical measurement results 
Collimator angle error measurements: Irradiation set #3 
The average differences in the doses measured to the phantom TLD for the three irradiations with 
collimator angle errors of +2° for each beam from the baseline irradiation for the third irradiation set are 
shown in Table 63 where a positive difference indicates that the failure mode dose was higher than the 
baseline dose. Differences from the baseline were mostly negative, with a decrease in the primary PTV 
TLD of -1.4% on average. The dose to the TLD in the secondary PTV decreased by -0.3% on average and 
the dose to the spinal cord TLD decreased by -1.2% on average. The average DTA between the primary 
PTV and OAR on the axial film was 0.3 mm larger for the irradiations with the collimator angle adjusted 
by +2°.  
The differences in the percent of pixels passing gamma analysis with 7%/4mm and 5%/3mm 
criteria are shown in Table 64. The corresponding gamma maps with are shown in Figure 91 and Figure 
92, with 5%/3mm criteria to make failures more visible. The percent of pixels passing the gamma analysis 
changed very little from baseline, with a decrease of only -0.3% on the axial film and -1.8% on the 
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sagittal film, both with 7%/4mm criteria. Distribution of failure on the axial film gamma maps followed a 
similar pattern to the baseline measurements for this irradiation set, with failures mostly in the PTVs and 
along the posterior edge of the film. On the sagittal films, the failure was focused along the superior and 
inferior edges of the PTV as in the baseline, but were greater and more dense.  
Structure TLD position 
+2° Collimator Angle 
Difference in Dose from Baseline 
Primary PTV Superior Anterior -0.1% 
Primary PTV Inferior Anterior 0.3% 
Primary PTV Superior Posterior -0.5% 
Primary PTV Inferior Posterior -1.1% 
Secondary PTV Superior -0.6% 
Secondary PTV Inferior -0.0% 
Spinal Cord Superior -1.1% 
Spinal Cord Inferior -1.3% 
Table 67: Average TLD differences from baseline from the third irradiation set with collimator angle errors of +2°. 
 
Film Criterion 
+2° Collimator Angle 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm -0.3% 
5%/3mm -0.7% 
Sagittal 
7%/4mm -1.8% 
5%/3mm -4.7% 
Table 68: Average absolute differences from baseline in gamma analysis results for axial and sagittal films within the 
phantom for the third irradiation set with collimator angle errors of +2°. 
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Figure 91: Axial film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the collimator rotated +2° (bottom). 
 
Figure 92: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the collimator rotated +2° (bottom). 
We saw very small changes in the doses to the TLD for our measurements with systematic 
collimator angle rotations of +2°. This was consistent with our treatment planning studies for a standard 
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phantom treatment plan. As shown on the gamma maps, there were some changes to the doses within the 
PTVs on the axial films, but since this plane was very close to isocenter and is always perpendicular to 
the plane of the collimator, a small rotation of the collimator would not be expected to affect the dose 
much. Most notably we saw an increase in failure along the superior and inferior edges of the PTV on the 
sagittal films. These failures were caused by the collimator rotation because the sagittal plane was parallel 
to the collimator for some gantry angles and these edges were collimated by the jaw. Similar changes 
along the anterior and posterior edges of the PTV on this film were not seen because the MLC were 
responsible for the collimation and with modulation the dose errors were smeared. 
Collimator angle phantom studies summary 
Systematic changes in the collimator angles in our treatment planning studies primarily showed 
changes in the complex treatment plan, with an increase in the spinal cord maximum dose of almost 3% 
with -2° collimator angle error and over 7% with +2° gantry angle error. There was also a small reduction 
in PTV coverage, more so with the -2° gantry angle error.  Small reductions in the primary PTV doses 
were observed in our measurements, as were small reductions in the dose to the spinal cord. The 
measurements were performed using a standard treatment plan and were consistent with the results of the 
treatment planning studies on the standard treatment plan. The changes to the dose distributions measured 
by the film were small but consistent with the effects expected of small collimator rotations. The severity 
score of 5 from the complex plan treatment planning study represented a more conservative estimate of 
failure mode consequences than we saw in the measurements which was appropriate since the treatment 
planning studies included different plans that were affected in different ways.  
Failure mode 6: Couch Angle 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring from 2° changes in 
the couch angle are summarized in Table 69 and Table 70 for standard and complex phantom plans, 
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respectively. All structure evaluation criteria had below a 2.5% change from baseline for the standard 
phantom treatment plan, with the largest changes being increases of 2.4% and 1.6% in the spinal cord 
maximum dose for couch rotations of +2° and -2°, respectively. Changes in the PTVs for the standard 
plan with couch angle errors were al less than 0.2%. In the complex treatment plan, a positive 2° change 
in the couch angle resulted in an under-dose to 99% of the secondary PTV of almost 6% and an increase 
in the spinal cord maximum dose of over 6%. A negative 2° change in the couch angle resulted in an 
under-dose to 99% of the primary PTV of almost 6%. Other changes in the complex plan were all less 
than 1.5%. As a result of these under-doses and the increase in spinal cord maximum dose, the severity 
score for this failure mode was 4. 
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees - 2 degrees 
Change from baseline 
Primary PTV 
D95% -0.06% -0.06% 
D99% 0.03% -0.16% 
Secondary PTV 
D95% 0.06% -0.06% 
D99% 0.04% -0.17% 
Spinal Cord Max Dose 2.43% 1.56% 
Normal Tissue Max Dose 0.24% -0.02% 
Table 69: Dosimetric changes from baseline used for severity scoring for couch angle changes of +2° and -2° for the 
standard phantom treatment plan. 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
+ 2 degrees - 2 degrees 
Change from baseline 
Primary PTV 
D95% 0.11% -0.54% 
D99% 0.00% -5.91% 
Secondary PTV 
D95% 0.09% 0.26% 
D99% -5.94% 1.11% 
Spinal Cord Max Dose 6.35% -1.36% 
Normal Tissue Max Dose -0.07% -0.03% 
Table 70: Dosimetric changes from baseline used for severity scoring for couch angle changes of +2° and -2° for the 
complex phantom treatment plan. 
The DVHs for couch angle errors of 2° are shown in Figure 93 and Figure 94 for standard and 
complex phantom treatment plans, respectively. There were very minimal changes in the structure doses 
in the standard phantom treatment plan. An increase in the dose to the spinal cord and small dips in the 
PTV coverage were evident in the complex plan DVHs. 
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Figure 93: DVHs for phantom structures in the standard treatment plan with couch angle errors of 2°, with dashed lines 
showing baseline DVHs. 
 
Figure 94: DVHs for phantom structures in the complex treatment plan with couch angle errors of 2°, with dashed lines 
showing baseline DVHs. 
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Overall, changing the couch angle by 2° primarily showed changes in the dose to the spinal cord. 
This was similar to the gantry angle and collimator angle failure modes, which all resulted in slight 
movement of the spinal cord with respect to the steep dose gradient required to spare it from the adjacent 
primary PTV dose. There was also some loss of coverage in the secondary PTV with the +2° rotation, 
which was a result of the orientation of dose distribution on the targets being just slightly different such as 
in Figure 95. Similarly with the -2° rotation, a slight decrease in primary PTV coverage occurred. 
 
Figure 95: Axial images of the phantom with the complex treatment plan dose distribution: baseline (left) and with the 
couch rotated +2°. 
Physical measurement results 
Couch angle error measurements: Irradiation set #3 
The average differences in the doses measured to the phantom TLD for the three irradiations with 
couch angle errors of +2° for each beam from the baseline irradiation for the third irradiation set are 
shown in Table 71 where a positive difference indicates that the failure mode dose was higher than the 
baseline dose. On average, the dose to the primary PTV TLD changed from baseline by -0.35%. The 
secondary PTV TLD doses also had minimal changes, on average -0.3%. The dose to the spinal cord TLD 
decreased from baseline by -1.2% on average. There was no difference in the DTA between the primary 
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PTV and OAR on the axial film. The absolute differences in the percent of pixels passing gamma analysis 
with 7%/4mm and 5%/3mm criteria are shown in Table 72. The corresponding gamma maps are shown in 
Figure 96 and Figure 97. The percent of pixels passing gamma analysis with 7%/4mm criteria changed 
less than 1% on the axial film and reduced -3.4% from baseline on the sagittal film. The axial film gamma 
maps had failures mostly in the PTVs, though the distributions, especially on films 2 and 3, were different 
that those from the baseline gamma maps with less failure overall and more failure on the anterior side of 
the film. Failures on the sagittal films were distributed throughout the PTV and were more concentrated 
on the inferior edge of the PTV.  
Structure TLD position 
+2° Couch Angle 
Difference in Dose from Baseline 
Primary PTV Superior Anterior -0.1% 
Primary PTV Inferior Anterior 0.3% 
Primary PTV Superior Posterior -0.5% 
Primary PTV Inferior Posterior -1.1% 
Secondary PTV Superior -0.6% 
Secondary PTV Inferior -0.0% 
Spinal Cord Superior -1.1% 
Spinal Cord Inferior -1.3% 
Table 71: Average TLD differences from baseline from the third irradiation set with couch angle errors of +2°. 
 
Film Criterion 
+2° Couch Angle 
Absolute Difference in Pixels Passing from Baseline 
Axial 
7%/4mm 0.8% 
5%/3mm 3.9% 
Sagittal 
7%/4mm -3.4% 
5%/3mm -9.2% 
Table 72: Average absolute differences from baseline in gamma analysis results for axial and sagittal films within the 
phantom for the third irradiation set with couch angle errors of +2°. 
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Figure 96: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the couch rotated +2° (bottom). 
 
 
Figure 97: Sagittal film dose distributions from the TPS (upper left), film from one irradiation (upper right), and the 
gamma maps (5%/3mm) from this film for the three irradiations of the phantom with the standard treatment plan with 
the collimator rotated +2° (bottom). 
The TLD dose differences from baseline did not reflect the changes we saw in the maximum dose 
to the spinal cord in our standard plan treatment planning studies. As with the other angular failure 
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modes, the lack of increase in the spinal cord was likely due to the central positon of the TLD and the 
change in maximum spinal cord dose occurring on the edges near the steep dose gradient. The slight 
decreases in PTV coverage that we saw in the treatment planning studies were in the complex treatment 
plan and so they were not expected in the measurements and the changes we saw in the PTV TLD were 
very small. Similar to the collimator rotation, we expected small a rotation of the couch to effect the dose 
distribution on the axial films very little. Although there were slight changes to the distribution of the 
failures, this was likely within the uncertainty of the measurement. On the sagittal film, the change in the 
failures along the superior and inferior edge of the PTV was consistent with a small couch rotation. 
Couch angle phantom studies summary 
Systematic changes in the couch angles in our treatment planning studies primarily showed 
changes in the complex treatment plan, with a decrease in the secondary PTV coverage and an increase in 
the spinal cord maximum dose of almost 6% with +2° couch angle error and a decrease in primary PTV 
coverage of almost 6% with -2° couch angle error.  The dose to the spinal cord in the standard plan 
increased slightly with either displacement of the couch angle.  The measurements showed the opposite, 
with small decreases in the cord dose and primary PTV dose which was likely due to the location of the 
TLD. The changes seen in the standard treatment plan both through the treatment planning studies and the 
measurements were both comparably small overall, especially considering the uncertainty in the spinal 
cord TLD.  The severity score of 4 from the complex plan treatment planning study was an appropriately 
conservative score considering the information we have. 
Failure mode 7: MU linearity 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for the MU 
linearity error scenarios described in Table 13 are summarized in Table 73 and Table 74 for both standard 
and complex phantom plans, respectively. All structure evaluation criteria had below a 1% change from 
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baseline in the standard phantom treatment plan, with the maximum change from baseline of 0.56% 
occurring with the 3B scenario (-6% change in all MU ≤5) in the normal tissue maximum dose. That 
scenario had the largest changes in all dosimetric evaluation criteria of the 6 MU linearity scenarios. All 
structure evaluation criteria had below a 1.5% in the complex phantom treatment plan, with the largest 
difference from baseline being in the secondary PTV with the 3A scenario (+6% change is all MU ≤5). IN 
the complex plan, this scenario had the largest changes from baseline for all dosimetric evaluation 
criteria. With these overall small errors, this failure mode was assigned a severity score of 1.  
Standard Phantom Treatment Plan 
Structure 
Evaluation 
criteria 
1A 1B 2A 2B 3A 3B 
Change from baseline 
Primary PTV 
D95% 0.06% 0.00% 0.06% 0.00% 0.11% 0.33% 
D99% 0.15% 0.00% 0.15% 0.00% 0.13% 0.32% 
Secondary PTV 
D95% 0.11% -0.01% 0.17% -0.01% 0.27% 0.33% 
D99% 0.06% 0.01% 0.21% 0.02% 0.20% 0.40% 
Spinal Cord Max Dose 0.15% -0.01% 0.17% -0.01% 0.40% 0.42% 
Normal Tissue Max Dose 0.09% 0.00% 0.13% -0.01% 0.17% 0.56% 
Table 73: Dosimetric changes from baseline used for severity scoring for six MU linearity error scenarios for the standard 
phantom treatment plan. 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
1A 1B 2A 2B 3A 3B 
Change from baseline 
Primary PTV 
D95% 0.21% -0.23% 0.17% -0.19% 0.74% 0.03% 
D99% 0.11% -0.34% 0.14% -0.15% 0.60% -0.02% 
Secondary PTV 
D95% 0.34% -0.34% 0.36% -0.31% 1.14% -0.05% 
D99% 0.35% -0.17% 0.37% -0.20% 1.11% 0.02% 
Spinal Cord Max Dose 0.26% -0.29% 0.28% -0.30% 0.79% 0.05% 
Normal Tissue Max Dose 0.15% -0.17% 0.11% -0.08% 0.60% 0.02% 
Table 74: Dosimetric changes from baseline used for severity scoring for six MU linearity error scenarios for the complex 
phantom treatment plan. 
The DVHs for the MU linearity errors are shown in Figure 98 and Figure 99 for standard and 
complex phantom treatment plans, respectively. Both sets of DVHs demonstrated that this failure mode 
only induced very small changes in the phantom plans by showing little to no changes from baseline.  
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Figure 98: DVHs for phantom structures in the standard treatment plan with MU linearity errors, with dashed lines 
showing baseline DVHs. 
 
Figure 99: DVHs for phantom structures in the complex treatment plan with MU linearity errors, with dashed lines 
showing baseline DVHs. 
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Although 36% of the segments had less than or equal to 5 MU for the complex plan, which had 
just slightly larger changes than the standard plan, and were therefore either increased or decreased for 
this study, the largest change to the MU for any one segment was only 0.3 MU (Scenario 2, 1 or 2 MU 
segments, or Scenario 3, 5 MU). Even if all 36% of the segments with 5 MU or less were adjusted by 0.3 
MU, that would only add up to 23.7 MU compared to the total MU of 3189 in the complex plan (an 
increase or decrease of 0.7% MU). The distribution of low MU segments throughout the beams had 
potential for creating errors, for example if one beam had all small MU segments with large adjustments, 
that beams’s contribution to the overall dose distribution would change. Even so, the resultant changes in 
a complex IMRT plan wash out from these relatively small changes in MU. Overall, the severity score of 
1 for this failure mode was reasonable. 
Failure mode 8: MLC transmission and leakage 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for changes in 
beam modeling of the MLC transmission and leakage are summarized in Table 75 and Table 76 for both 
standard and complex phantom plans, respectively. The maximum change from baseline in all structure 
evaluation criteria for the standard phantom treatment plan was a 2% increase in the maximum spinal 
cord dose from baseline. All other changes in evaluation criteria for both the standard and complex 
phantom plan were less than 1%. PTV doses decreased very slightly with either an increase or decrease in 
interleaf leakage transmission, at maximum -0.48% in the standard plan and -0.84% in the complex plan. 
The maximum dose to the spinal cord with 0% interleaf leakage transmission decreased for both plans, 
and as mentioned, with 10% interleaf leakage transmission increased by 2% in the standard plan but only 
0.48% in the complex plan. Overall, this failure mode was assigned a severity score of 1. 
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Standard Phantom Treatment Plan 
Structure Evaluation criteria 
Interleaf leakage 
transmission = 0 
Interleaf leakage 
transmission = 0.1 
Change from baseline 
Primary PTV 
D95% -0.07% -0.23% 
D99% -0.04% -0.48% 
Secondary PTV 
D95% -0.14% -0.05% 
D99% -0.21% -0.15% 
Spinal Cord Max Dose -0.56% 2.04% 
Normal Tissue Max Dose 0.12% -0.49% 
Table 75: Dosimetric changes from baseline used for severity scoring for MLC leakage and transmission modeling values 
of 0% and 10% for the standard phantom treatment plan. 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
Interleaf leakage 
transmission = 0 
Interleaf leakage 
transmission = 0.1 
Change from baseline 
Primary PTV 
D95% -0.10% -0.46% 
D99% -0.45% -0.67% 
Secondary PTV 
D95% -0.15% -0.84% 
D99% 0.19% -0.60% 
Spinal Cord Max Dose -0.40% 0.48% 
Normal Tissue Max Dose -0.47% 0.53% 
Table 76: Dosimetric changes from baseline used for severity scoring for MLC leakage and transmission modeling values 
of 0% and 10% for the complex phantom treatment plan. 
The DVHs for the MLC leakage and transmission modeling errors are shown in Figure 100 and 
Figure 101 for standard and complex phantom treatment plans, respectively. Both sets of DVHs 
demonstrate that this failure mode induced mostly very small changes in the phantom plans. The figures 
show that in both plans the increase in leakage transmission from baseline to a value of 10% resulted in 
an increase in the dose to the spinal cord, which was minimally reflected in the spinal cord for the 
complex plan with an increase in the maximum dose increase of only 0.48%, but was more obviously 
reflected in the spinal cord for the standard plan with an increase of 2.04%. 
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Figure 100: DVHs for phantom structures in the standard treatment plan with MLC leakage and transmission modeling 
errors, with dashed lines showing baseline DVHs. 
 
Figure 101: DVHs for phantom structures in the complex treatment plan with MLC leakage and transmission modeling 
errors, with dashed lines showing baseline DVHs. 
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The increased doses to the spinal cord seen in the DVHs for both the standard and complex 
treatment plans with increases in the interleaf leakage and transmission occurred because the MLC were 
used to block that structure and therefore it was subject to increased dose as a result of the increased 
leakage and transmission. Since greater changes occurred in the overall dose to the spinal cord volume as 
a whole than were captured by the increase in the maximum doses, this low severity score may have been 
an underestimation of the effects of changes in the MLC interleaf leakage and transmission on structures 
being blocked by the MLC, however we maintained our scoring system and this failure mode resulted in a 
severity score of 1. 
Failure mode 9: MLC tongue-and-groove effect 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for changes in 
beam modeling of the MLC tongue-and-groove effect are summarized in Table 77 and Table 78 for both 
standard and complex phantom plans, respectively. All structure evaluation criteria in the standard 
treatment plan had below a 1% change from baseline with the exception of the maximum dose to the 
spinal cord, which was increased by 3.6% when the tongue-and-groove width of 0.200 cm was used. 
When the tongue-and-groove width was decreased, the maximum spinal cord dose decreased by -0.31%. 
All PTV doses increased a very small amount (under 0.20% with the decreased width and 0.65% with the 
increased) in the standard phantom plan with either change in the tongue-and-groove width, with the 
exception of the dose to 99% of the secondary PTV which decreased only -0.01%.. In the complex 
treatment plan, all evaluation criteria had below a 3% change. Similar to the standard phantom plan, the 
largest change in the complex plan was an increase of 2.97% in the maximum dose to the spinal cord with 
an increase of in the tongue-and-groove width. PTV coverage decreased less than 0.4% with the 
decreased tongue-and-groove width and overall increased with the increased width, up to 0.68%. The 
resulting severity score for this failure mode was 2. 
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Standard Phantom Treatment Plan 
Structure Evaluation criteria 
Tongue-and-groove 
width = 0.005 cm 
Tongue-and-groove 
width = 0.200 cm 
Change from baseline 
Primary PTV 
D95% 0.05% 0.13% 
D99% 0.16% 0.15% 
Secondary PTV 
D95% 0.05% 0.58% 
D99% -0.01% 0.61% 
Spinal Cord Max Dose -0.31% 3.62% 
Normal Tissue Max Dose 0.18% -0.76% 
Table 77: Dosimetric changes from baseline used for MLC tongue-and-groove effect modeling with width values of 0.005 
cm and 0.200 cm for the standard phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
Tongue-and-groove 
width = 0.005 cm 
Tongue-and-groove 
width = 0.200 cm 
Change from baseline 
Primary PTV 
D95% -0.15% 0.17% 
D99% -0.32% 0.12% 
Secondary PTV 
D95% -0.15% 0.68% 
D99% -0.05% -0.04% 
Spinal Cord Max Dose -1.26% 2.97% 
Normal Tissue Max Dose -0.56% -0.76% 
Table 78: Dosimetric changes from baseline used for MLC tongue-and-groove effect modeling with width values of 0.005 
cm and 0.200 cm for the complex phantom treatment plan. 
The DVHs for the MLC leakage and transmission modeling errors are shown in Figure 102 and 
Figure 103 for standard and complex phantom treatment plans, respectively. Very small changes in the 
dose to the spinal cord were visible in both sets of DVHs. There was also a change in the shape of the 
secondary PTV DVH in the complex treatment plan with increased tongue-and-groove width, indicating 
smaller or less severe hotspots. All other changes were very small in the DVHs. 
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Figure 102: DVHs for phantom structures in the standard treatment plan with MLC tongue-and-groove modeling errors, 
with dashed lines showing baseline DVHs. 
 
Figure 103: DVHs for phantom structures in the complex treatment plan with MLC tongue-and-groove modeling errors, 
with dashed lines showing baseline DVHs. 
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The tongue-and-groove design of the MLC reduces interleaf transmission, but can result in under 
dosing between leaves and affects the width of the penumbra. The small changes in the dose to the spinal 
cord for both the standard and complex treatment plans likely resulted from the MLC crossing over the 
spinal cord in the X direction to block it as well as to modulate the overall dose. The reduction in 
secondary PTV hotspots seen in the complex plan with the 0.2 cm wide tongue-and-groove was a result of 
decreased hotspots along the inferior edge of that PTV. This could have resulted from the under-dosing 
tongue-and-groove effect or it could have resulted from the widened penumbra. Overall, the effects were 
most prominent along field edges, but were mostly small. 
Failure mode 10: MLC leaf end effects 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for changes in 
beam modeling of the MLC rounded leaf ends are summarized in Table 79 and Table 80 for both standard 
and complex phantom plans, respectively. An increase in the maximum dose to the spinal cord was seen 
in both the standard and complex plans when modeling the rounded MLC leaf ends using a 4 cm radius 
with magnitudes of over 7% and 6%, respectively. With this leaf end radius, changes in the PTVs were all 
under 1%, with the maximum decrease in the standard plan being -0.87% and in the complex plan -.81%. 
There was also some loss of coverage in the primary PTV for modeling radius values of 20 cm and 15 
cm, up to -1.63% in the dose to 99% of the primary PTV in the complex plan. With these increased leaf 
end radii, the spinal cord maximum doses decreased, up to -6.45% in the standard plan and -4.93% in the 
complex plan. The largest error was the 7.4% increase in maximum spinal cord dose in the standard 
treatment plan, resulting in a severity score of 5.  
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Standard Phantom Treatment Plan 
Structure Evaluation criteria 
Leaf end 
radius = 4 cm 
Leaf end 
radius = 20 cm 
Leaf end 
radius = 15 cm 
Change from baseline 
Primary PTV 
D95% -0.01% -0.53% -0.41% 
D99% 0.34% -0.81% -0.61% 
Secondary PTV 
D95% -0.85% 0.40% 0.28% 
D99% -0.87% 0.43% 0.17% 
Spinal Cord Max Dose 7.39% -6.45% -4.77% 
Normal Tissue Max Dose -2.18% 1.16% 0.86% 
Table 79: Dosimetric changes from baseline used for severity scoring for MLC rounded leaf end modeling with radius 
values of 4 cm, 15 cm, and 20 cm for the standard phantom treatment plan. 
 
Complex Phantom Treatment Plan 
Structure Evaluation criteria 
Leaf end 
radius = 4 cm 
Leaf end 
radius = 20 cm 
Leaf end 
radius = 15 cm 
Change from baseline 
Primary PTV 
D95% 0.27% -0.83% -0.60% 
D99% 0.41% -1.63% -1.30% 
Secondary PTV 
D95% -0.81% 0.39% 0.28% 
D99% -0.22% -0.22% 0.00% 
Spinal Cord Max Dose 6.38% -4.93% -3.85% 
Normal Tissue Max Dose -2.83% 1.87% 1.25% 
Table 80: Dosimetric changes from baseline used for severity scoring for MLC rounded leaf end modeling with radius 
values of 4 cm, 15 cm, and 20 cm for the complex phantom treatment plan. 
The DVHs for the MLC leakage and transmission modeling errors are shown in Figure 104 and 
Figure 105 for standard and complex phantom treatment plans, respectively. An increase in the spinal 
cord dose for each case with a smaller rounded leaf end modeling radius of 4 cm was clear, as well as a 
decrease in the spinal cord doses with an increase in the radius. The dose to the secondary PTV also 
changed for both standard and complex plans, most visibly decreasing in the secondary PTV with the leaf 
end radius of 4 cm.  
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Figure 104: DVHs for phantom structures in the standard treatment plan with MLC leaf end modeling errors, with 
dashed lines showing baseline DVHs. 
 
Figure 105: DVHs for phantom structures in the complex treatment plan with MLC leaf end modeling errors, with 
dashed lines showing baseline DVHs. 
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Decreasing the radius of the leaf end resulted in increased spinal cord doses, both the maximum 
and those seen on the DVHs. This was due to the increase in penumbra width along the end of the MLC 
that results from decreasing the leaf radius since the beam can then penetrate at greater angles through the 
leaf ends. Since the spinal cord is adjacent to a steep dose gradient and is blocked by the MLC, changes to 
the penumbra directly affect the dose. Decreases in the secondary PTV dose were also likely due to the 
increased penumbra width but were much smaller in magnitude. This would have depended on the way 
the field were modulated and how extensively the leaf ends stopped within the PTVs. 
Failure mode 11: CT Table 
Treatment planning study results 
The resultant changes in the phantom structure doses used for severity scoring for changing the 
electron density to CT number table are summarized in Table 81 and Table 82 for both standard and 
complex phantom plans, respectively. All structure evaluation criteria in both the standard and complex 
phantom treatment plans had below a 0.50% change. Since the changes were so small, it was difficult to 
identify any trends. This failure mode was assigned a severity score of 1.  
Standard Phantom Treatment Plan 
Structure Evaluation criteria 
+2% -2% PET CT 
Change from baseline 
Primary PTV 
D95% -0.02% 0.03% 0.05% 
D99% 0.01% 0.03% 0.18% 
Secondary PTV 
D95% 0.02% 0.04% -0.04% 
D99% -0.02% 0.00% 0.06% 
Spinal Cord Max Dose 0.11% 0.01% 0.03% 
Normal Tissue Max Dose 0.04% 0.05% -0.05% 
Table 81: Dosimetric changes from baseline used for severity scoring for differences in the CT table used for the standard 
phantom treatment plan. 
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Complex Phantom Treatment Plan 
Structure Evaluation criteria 
+2% -2% PET CT 
Change from baseline 
Primary PTV 
D95% -0.18% 0.00% -0.07% 
D99% -0.35% 0.01% -0.18% 
Secondary PTV 
D95% 0.01% 0.00% -0.08% 
D99% 0.15% 0.23% 0.00% 
Spinal Cord Max Dose -0.26% 0.00% -0.27% 
Normal Tissue Max Dose 0.09% -0.07% -0.33% 
Table 82: Dosimetric changes from baseline used for severity scoring for differences in the CT table used for the complex 
phantom treatment plan. 
The DVHs for the MLC leakage and transmission modeling errors are shown in Figure 106 and 
Figure 107 for standard and complex phantom treatment plans, respectively. There appeared to be no 
changes to the DVHs with changes in the CT table.  
 
Figure 106: DVHs for phantom structures in the s treatment plan with CT Table errors, with dashed lines showing 
baseline DVHs. 
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Figure 107: DVHs for phantom structures in the complex treatment plan with CT Table errors, with dashed lines 
showing baseline DVHs. 
The phantom is overall rather homogeneous, containing no high-Z materials. The materials that 
would be changed the most by any of these CT table changes were not a part of the phantom, so it is 
therefore not surprising that this failure mode had minimal effect on the dose distribution. This may have 
resulted in and underestimate of the severity for this failure mode, since head and neck patients were 
likely to have high-Z materials within the field such as dental fillings, however the phantom did not 
enable us to further investigate these effects.  
Phantom severity scoring summary 
The severity scores resulting from the largest deviations from the baseline plans in our phantom 
structure evaluation criteria for the standard and complex plans are summarized in Table 83. Scores of 1-8 
were assigned for our failure modes, with over half (6) of the failure modes having a severity score of 3 or 
lower.  Beam symmetry, MU linearity, MLC leakage and transmission, and CT table failure modes 
resulted in a severity score of 1. Three of the failure modes, collimator angle, couch angle, and MLC leaf 
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end modeling, were of mid-range severity with scores of 4 and 5. Two failure modes, MLC position and 
gantry angle, had mid-high severity with scores of 8 and 7, respectively.  
Failure Mode 
Standard Plan 
Severity Score 
Complex Plan 
Severity Score 
Overall Severity Score 
1. Beam Energy 3 1 3 
2. Beam Symmetry 1 1 1 
3. MLC Position    (1 mm) 4 2 
8                                 (2 mm) 8 5 
4. Gantry Angle 7 5 7 
5. Collimator Angle 1 5 5 
6. Couch Angle 1 4 4 
7. MU Linearity 1 1 1 
8. MLC Leakage & Transmission 1 1 1 
9. MLC Tongue & Groove 2 1 2 
10. MLC Leaf End 5 4 5 
11. CT Table 1 1 1 
Table 83: Summary of the phantom severity scores based on structure evaluation criteria and our severity scoring scale 
for standard and complex treatment plans. The overall severity score assigned for each failure mode represents the 
maximum severity. 
3.1.3 Comparison of qualitative and quantitative scores 
A comparison of the overall survey severity scores and those from our treatment planning studies 
is shown in Figure 108. Failure mode 1 (beam energy) is the only failure mode upon which the survey 
average and median agree with the more conservative of our phantom treatment planning study severity 
scores. The median survey severity score and more conservative phantom treatment planning study 
severity score also match for failure mode 6 (couch angle). For these two failure modes, the qualitative 
and quantitative severity scores were the same when compared directly. The severity scores from the 
complex phantom treatment planning studies also match the average and median survey severity scores 
for failure mode 3 and 10, however the severity scores for these failure modes resulting from the standard 
phantom treatment plan were more conservative and so in these cases the quantitative severity scores 
were higher than those from the qualitative assessment. Severity scores for failure modes 4 and 5 were 
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also higher for the quantitative assessment. For failure modes 2, 6, 7, 8, 9, and 11, the qualitative 
assessment predicted higher severity scores than the treatment planning studies quantitative scores. 
 
Figure 108: Summary of severity scores for survey (N=184) including the average scores, median scores (lines between 3rd 
and 2nd quartile boxes), and outliers and for standard and complex phantom treatment planning studies. 
The results of one-sample Wilcoxon Signed Rank Tests used to more strictly compare the 
qualitative and quantitative severity scores for our IMRT H&N physical failure modes are presented in 
Table 84. This test evaluated whether the median qualitative severity score equaled the quantitative 
severity score for each failure mode, with the null hypothesis that they were equal. P-values under 0.05 
indicated that the scores were significantly different and are highlighted in the table in red. P-values 
indicating that the severity scores were the same from qualitative and quantitative methods are 
highlighted in green. The median qualitative severity score and the 95% confidence interval of the median 
are shown for each failure mode.  In this case, the 95% confidence intervals of the median severity scores 
only contained one possible severity score for each failure mode. The conclusions from this analysis were 
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that failure modes 1 and 6 were given the same severity score by both methods, while all others received 
different scores from each method, are the same as those we could draw from Figure 108.  
Failure Mode 
Qualitative Severity Score 
95% Confidence Interval of the Median Quantitative 
Severity Score 
Wilcoxon Signed 
Rank 
p-value 
Lower 
Bound 
Median 
Upper 
Bound 
1. Beam Energy 2.74 3 3.26 3 0.889 
2. Beam Symmetry 3.78 4 4.22 1 0.000 
3. MLC Position   4.67 5 5.33 8 0.000 
4. Gantry Angle 3.72 4 4.28 7 0.000 
5. Collimator Angle 3.73 4 4.27 5 0.000 
6. Couch Angle 3.72 4 4.29 4 0.153 
7. MU Linearity 3.72 4 4.28 1 0.000 
8. MLC Leakage & 
Transmission 
3.73 4 4.27 1 0.000 
9. MLC Tongue & 
Groove 
3.74 4 4.26 2 0.000 
10. MLC Leaf End 3.75 4 4.26 5 0.000 
11. CT Table 2.73 3 3.27 1 0.000 
Table 84: For each failure mode: 95% confidence interval of the median of the qualitative severity scores, the quantitative 
severity scores and results of one-sample Wilcoxon Signed Rank Test, with significance level p<0.05 indicated in red. P-
values greater than significance level highlighted in green.  
Overall, only two of the ten severity scores were the same following qualitative and quantitatively 
methods. In this analysis, qualitative and quantitative severity scores were considered significantly 
different if they were not exactly the same. Two of the ten failure modes, failure mode 5 (collimator 
angle) and failure mode 10 (MLC leaf end), had severity scores from qualitative and quantitative methods 
within one score. For every failure mode, the maximum severity score from the survey responses was 
greater than the severity score from either of the phantom treatment planning studies (as shown in Figure 
108).  
To better understand the effects of applying the scoring scale and the lack of a quantitative 
component in the severity scoring scale on the assessment of the consequences of these failure modes, we 
also looked at the distribution of the percent dose errors estimated in the survey compared to the 
maximum dose deviations from baseline seen in the standard and complex phantom treatment planning 
studies. A summary of this comparison can be seen in Figure 109. The range of estimated percent dose 
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errors when outliers were included far exceeded those resulting from our treatment planning studies. Only 
for failure mode 8 were the qualitative and quantitative percent dose errors approximately the same. The 
results of the two approaches tended to follow a similar trend, but the median survey estimate was up to a 
factor of four off from our maximum phantom treatment planning study results. 
 
Figure 109: Summary of estimated percent dose errors for survey (N=184) including the averages, medians (lines between 
3rd and 2nd quartile boxes), and outliers and maximum percent dose errors seen in phantom structures for standard and 
complex phantom treatment planning studies. 
 
3.2 Specific Aim 2 
3.2.1 Patient treatment planning study results – true severity 
The results from our treatment planning studies on ten oropharyngeal patients are presented by 
failure mode. The dose differences from baseline for all structures evaluated and the evaluation criteria 
are tabulated for all ten patients for all eleven failure modes in Appendix B. Additionally, the DVHs 
corresponding to these structures for each of the patients are in Appendix C. 
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Failure mode 1: Beam energy true severity 
As with the phantom treatment planning studies, our beam models with +10% and -10% energy 
were used to assess the true severity of this failure mode using clinical patient treatment plans. The 
resultant severity scores are shown in Table 85. The overall severity scores based on the maximum dose 
deviation from the baseline plan structure doses at the evaluation criteria ranged from 2 to 9, with patient 
7 being the only one with a severity score less than 7 for this failure mode. All of the overall severity 
scores were based on the OARs and all patients except patient 2 had higher severity scores for the +10% 
energy adjustment.  
In six of the ten patients, the dose to 100% of the brainstem increased largely and resulted in the 
high severity score. This effect could have been exaggerated because the dose to the 100% of the 
brainstem was only a couple hundred cGy over the course of the treatment, so an increase of only 20 cGy 
could result in a 10% dose difference from the baseline. In patients 2 and 3, the dose to 50% of the parotid 
glands increased enough to result in a severity score of 9. In both cases, the left parotid gland was right up 
against the primary PTV but this was not uncommon in this group of patients. In patients 7 and 10, the 
maximum doses to the orbits and lens increased substantially with the increase in the energy. These 
structures were very small and were out of the fields so they were receiving overall low doses.  These 
factors were likely exaggerating the effect of beam energy changes on the dose.  It was very likely that the 
changes in the shoulders of the dose profiles with changes in energy were the cause of these errors in 
structures out of the field and far from isocenter, since these patients all had isocenter on the neck, just 
inferior to the chin, which allowed for the upper IMRT fields to be matched to the supraclavicular fields.  
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Patient 
Energy -10% Energy +10% 
Overall 
PTVs OARs Total PTVs OARs Total 
1 5 3 5 6 7 7 7 
2 4 9 9 4 9 9 9 
3 4 7 7 4 8 8 8 
4 1 1 1 1 7 7 7 
5 1 1 1 1 8 8 8 
6 1 4 4 1 9 9 9 
7 1 1 1 1 2 2 2 
8 1 3 3 1 8 8 8 
9 1 3 3 1 9 9 9 
10 1 4 4 1 9 9 9 
Table 85: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with -10% and +10% 
beam energy adjustments. 
Failure mode 2: Beam symmetry true severity 
As with the phantom treatment planning studies, physical wedges with approximately 2%, 3.5%, 
and 10% symmetry were used to assess the true severity of this failure mode using clinical patient 
treatment plans. The resultant severity scores are shown in Table 86, Table 87, and Table 88. The severity 
scores for beam symmetry errors of 2% and 3.5% were 1 for all patients with the exception of patient 10, 
which had a severity score resulting from differences in the OAR dose, assigning a severity score of 9. A 
similar trend was seen with symmetry errors of 10%, however the severity scores ranged from 1 to 5 for 
patients 1-9. The severity scores of 9 for patient 10 all came from optic nerves and orbits, which had 
small volumes and low doses. This combined with the fact that the isocenter was far from these structures 
and therefore the differences in the dose caused by symmetry errors were larger resulted in an 
exaggeration of the severity similar to that seen in the beam energy true severity results. Without 
considering the optic nerves and orbits, the severity score for patient 10 would be 6 from the dose to 
100% of the brainstem increasing. If we eliminated all of the mentioned low dose evaluations and small 
volume structures, the severity score for patient 10 would be 1. Other severity scores greater than 1 were 
largely, but not solely, the result of increases to the cochlear doses. While these doses were not as low in 
all cases, they were still relatively low and had a volume less than 1 cc, which may have contributed to 
the severity scores as in the other cases. 
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2 1 1 1 1 1 1 1 1 1 1 1 1 1 
3 1 1 1 1 1 1 1 1 1 1 1 1 1 
4 1 1 1 1 1 1 1 1 1 1 1 1 1 
5 1 1 1 1 1 1 1 1 1 1 1 1 1 
6 1 1 1 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 1 1 1 
8 1 1 1 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 1 1 1 1 1 1 
10 1 9 9 1 9 9 1 9 9 1 9 9 9 
Table 86: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with 2% beam symmetry 
errors. 
Patient 
3.5% Beam Symmetry 
Top to bottom Bottom to top Left to right Right to left 
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1 1 1 1 1 1 1 1 1 1 1 1 1 1 
2 1 1 1 1 1 1 1 1 1 1 1 1 1 
3 1 1 1 1 1 1 1 1 1 1 1 1 1 
4 1 1 1 1 1 1 1 1 1 1 1 1 1 
5 1 1 1 1 1 1 1 1 1 1 1 1 1 
6 1 1 1 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 1 1 1 
8 1 1 1 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 1 1 1 1 1 1 
10 1 9 9 1 9 9 1 9 9 1 9 9 9 
Table 87: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with 3.5% beam 
symmetry errors. 
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Patient 
10% Beam Symmetry 
Top to bottom Bottom to top Left to right Right to left 
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1 1 1 1 1 1 1 1 2 2 1 1 1 2 
2 1 1 1 1 1 1 1 3 3 1 1 1 3 
3 1 1 1 1 1 1 2 2 2 1 1 1 2 
4 1 2 2 1 2 2 1 4 4 1 1 1 4 
5 1 4 4 1 3 3 1 2 2 1 2 2 4 
6 1 1 1 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 2 2 2 
8 1 1 1 1 1 1 1 2 2 1 1 1 2 
9 1 2 2 1 2 2 2 5 5 1 1 1 5 
10 1 9 9 1 9 9 1 9 9 1 9 9 9 
Table 88: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with 10% beam 
symmetry errors. 
Failure mode 3: MLC position true severity 
Systematic MLC shifts of 1 mm and 2 mm in one bank were applied to our ten clinical patients as 
in the phantom treatment planning studies. The resultant severity scores are shown in Table 89 and Table 
90 for 1 mm and 2 mm shifts, respectively. For 1 mm errors, the overall severity scores ranged from 3 to 
10. For 2 mm errors, they ranged from 7 to 10. The causes of these severity scores were all OAR dose 
increases, though PTV coverage was decreased in several cases. The severity scores of 10 in patient 9 
were from an increase in the dose to the larynx with shifts of the X1 MLC out, which also resulted in 
severity scores of 9 from an increase in the dose to the parotid glands. The highest severity scores were 
seen in patient 10 for this failure mode, which had a severity score of 9 and 10 for all of the eye-related 
structures. There were also severity scores of 9 from increases to the left parotid gland dose, increases in 
the brainstem and cord doses (S=4-8) and loss of coverage of the tertiary PTV (PTV3 with 54 Gy) for all 
of the different MLC positional errors. 
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Patient 
1 mm MLC Positional Errors 
X1 -1mm X1 +1mm X2 -1mm X2 +1mm 
Overall 
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1 1 1 1 1 1 1 1 1 1 1 7 7 7 
2 1 1 1 1 1 1 1 1 1 1 2 2 2 
3 1 1 1 1 1 1 1 1 1 1 5 5 5 
4 1 1 1 1 1 1 1 1 1 1 5 5 5 
5 1 3 3 1 9 9 1 9 9 1 9 9 9 
6 1 1 1 1 9 9 1 9 9 1 9 9 9 
7 1 1 1 1 4 4 1 1 1 1 4 4 4 
8 1 1 1 1 1 1 1 1 1 1 7 7 7 
9 1 9 9 1 10 10 1 1 1 1 6 6 10 
10 3 10 10 2 10 10 3 10 10 3 10 10 10 
Table 89: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with 1 mm systematic 
MLC shifts in one bank (X1 or X2). 
Patient 
2 mm MLC Positional Errors 
X1 -2mm X1 +2mm X2 -2mm X2 +2mm 
Overall 
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1 6 1 6 1 2 2 1 1 1 1 9 9 9 
2 1 1 1 1 5 5 1 1 1 1 5 5 5 
3 1 1 1 1 5 5 1 1 1 1 7 7 7 
4 3 1 3 1 1 1 3 1 3 1 8 8 8 
5 4 3 4 1 9 9 3 3 3 1 9 9 9 
6 1 1 1 1 9 9 2 9 9 1 9 9 9 
7 1 1 1 1 7 7 7 1 7 1 7 7 7 
8 4 1 4 1 1 1 2 1 2 1 9 9 9 
9 3 9 9 1 10 10 1 1 1 1 9 9 10 
10 4 10 10 2 10 10 3 10 10 3 10 10 10 
Table 90: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with 2 mm systematic 
MLC shifts in one bank (X1 or X2). 
Failure mode 4: Gantry angle true severity 
Systematic gantry angle errors of -2° and +2° were introduced into our ten patient plans as done 
with the phantom treatment planning studies. The resultant severity scores are shown in Table 91. The 
overall severity scores for this failure mode ranged from 1 to 7, with most being either 4 or 5. The 
maximum overall severity score of 7 in patient 5 came from the gantry angle changing -2°, resulting in an 
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increase in the dose to the left parotid gland. Moving the gantry the opposite direction for this patient 
resulted in a lesser increase in the right parotid gland dose. The parotid glands were affected in this same 
orientation in most patients, which made sense since they all utilize the same gantry angle protocol. 
Patient 
Gantry Angle Errors 
-2° +2° 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 4 4 1 1 1 4 
2 1 4 4 1 4 4 4 
3 1 1 1 1 1 1 1 
4 1 4 4 1 1 1 4 
5 1 7 7 1 5 5 7 
6 1 5 5 1 4 4 5 
7 1 1 1 1 5 5 5 
8 1 2 2 1 2 2 2 
9 1 3 3 1 4 4 4 
10 1 4 4 1 5 5 5 
Table 91: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with -2° and +2° gantry 
angle errors. 
Failure mode 5: Collimator angle true severity 
Systematic collimator angle errors of -2° and +2° were introduced into our ten patient plans as 
done with the phantom treatment planning studies. The resultant severity scores are shown in Table 92. 
The overall severity scores for collimator angle errors ranged from 4 to 9 for this set of patients. As with 
most of the other failure modes, the severity scores were largely from increases in OAR doses. The 
severity scores of 9 all came from cochlear dose increases, with patient 8 also having a severity score of 9 
from the right parotid gland dose increasing with a +2° error. 
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Patient 
Collimator Angle Errors 
-2° -2° 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 9 9 2 9 9 9 
2 2 4 7 1 5 5 7 
3 1 5 7 4 7 7 7 
4 1 4 9 2 8 8 9 
5 1 4 7 1 7 7 7 
6 1 7 3 4 4 4 4 
7 2 9 7 4 9 9 9 
8 1 4 7 5 9 9 9 
9 3 7 7 4 5 5 7 
10 1 4 2 1 9 9 9 
Table 92: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with -2° and +2° 
collimator angle errors. 
Failure mode 6: Couch angle true severity 
Systematic couch angle errors of -2° and +2° were introduced into our ten patient plans as done 
with the phantom treatment planning studies. The resultant severity scores are shown in Table 93. The 
overall severity scores for couch angle errors ranged from 2 to 9, with half of the patients having a score 
of 7. All of the severity scores were a result of increases in the OAR doses. Similar to the collimator angle 
errors, the severity scores of 9 came from cochlea dose increase and, in patient 8, an increase in the dose 
to the right parotid gland.  
Patient 
Couch Angle Errors 
-2° -2° 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 9 9 1 2 2 9 
2 1 7 7 1 5 5 7 
3 1 7 7 1 1 1 7 
4 1 9 9 1 4 4 9 
5 1 7 7 1 5 5 7 
6 1 3 3 1 2 2 3 
7 1 7 7 1 7 7 7 
8 4 7 7 1 9 9 9 
9 1 7 7 1 7 7 7 
10 1 2 2 1 2 2 2 
Table 93: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with -2° and +2° couch 
angle errors. 
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Failure mode 7: MU linearity true severity 
As in the phantom treatment planning studies, three MU linearity error scenarios were applied to 
ten clinical patient treatment plans.  The resultant severity scores are shown in Table 94. All patients had 
an overall severity score of 1. These results were interesting in the same manner as the phantom results 
since there are a large number of segments with few MU in the patient plans which would be affected by 
these linearity errors. The distribution of the MU/segment for the ten patients is shown in Figure 110. 
However, these changes were so small overall that they did not substantially affect the dose to any of the 
structures. 
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1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
5 1 1  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Table 94: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with MU linearity errors. 
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Figure 110: The distribution of segments with few MU which would be affected my MU linearity errors for each of our 
ten patients. 
Failure mode 8: MLC leakage and transmission modeling true severity 
As in the phantom treatment planning studies, beam models with errors in the interleaf leakage 
transmission were applied to ten clinical patient treatment plans to assess the severity of this failure mode.  
The resultant severity scores are shown in Table 95resulting from an increase in the MLC interleaf 
leakage transmission. Overall severity scores all resulted from cochlea and parotid gland increased doses. 
There were also some small increases in brainstem and spinal cord doses for some patients, but the errors 
with this failure mode were dominated by the cochlear and parotids. This was likely due to the small 
volume and lower doses associated with the cochlea and the large amount of MLC blocking required for 
parotid glands immediately adjacent to targets. 
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Patient 
MLC Leakage and Transmission Modeling Errors 
Interleaf leakage transmission = 0% Interleaf leakage transmission = 10% 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 1 1 1 7 7 7 
2 1 1 1 1 7 7 7 
3 1 1 1 1 5 5 5 
4 1 1 1 1 8 8 8 
5 1 3 3 1 7 7 7 
6 1 1 1 1 6 6 6 
7 1 1 1 1 7 7 7 
8 1 1 1 1 5 5 5 
9 1 1 1 1 8 8 8 
10 1 1 1 1 7 7 7 
Table 95: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with MLC leakage and 
transmission errors. 
Failure mode 9: MLC tongue-and-groove modeling true severity 
As in the phantom treatment planning studies, beam models with errors in MLC tongue-and-
groove width were applied to ten clinical patient treatment plans to assess the severity of this failure 
mode.  The resultant severity scores are shown in  
Patient 
MLC Tongue-and-Groove Modeling Errors 
Tongue-and-groove width = 0.005 cm Tongue-and-groove width = 0.200 cm 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 1 1 1 2 2 2 
2 1 1 1 1 2 2 2 
3 1 1 1 1 1 1 1 
4 1 1 1 1 4 4 4 
5 1 4 4 1 3 3 4 
6 1 1 1 1 1 1 1 
7 1 1 1 1 2 2 2 
8 1 1 1 1 2 2 2 
9 1 1 1 1 4 4 4 
10 1 1 1 1 3 3 3 
Table 96. The overall severity scores for this failure mode ranged from 1 to 4. Only for patient 5 
did a decrease in the tongue width result in a higher severity score than an increase which was a result of 
an increase in the dose to the spinal cord with either tongue width. 
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Patient 
MLC Tongue-and-Groove Modeling Errors 
Tongue-and-groove width = 0.005 cm Tongue-and-groove width = 0.200 cm 
Overall 
PTVs OARs Total PTVs OARs Total 
1 1 1 1 1 2 2 2 
2 1 1 1 1 2 2 2 
3 1 1 1 1 1 1 1 
4 1 1 1 1 4 4 4 
5 1 4 4 1 3 3 4 
6 1 1 1 1 1 1 1 
7 1 1 1 1 2 2 2 
8 1 1 1 1 2 2 2 
9 1 1 1 1 4 4 4 
10 1 1 1 1 3 3 3 
Table 96: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with MLC tongue-and-
groove modeling errors. 
Failure mode 10: MLC leaf end modeling true severity 
As in the phantom treatment planning studies, beam models with errors in MLC leaf end 
modeling radius were applied to ten clinical patient treatment plans to assess the severity of this failure 
mode.  The resultant severity scores are shown in Table 97. Overall severity scores for changes in the 
rounded leaf end modeling radius ranged from 5 to 9 and were all a result of decreasing this radius to 4 
cm, making the ends more round. Again, parotid gland dose increases were largely the cause of these 
severity scores, as well as increases in the cochlear doses. 
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Patient 
MLC Leaf End Modeling Errors 
Leaf end radius = 4 cm Leaf end radius = 20 cm Leaf end radius = 15 cm 
Overall 
PTVs OARs Total PTVs OARs Total PTVs OARs Total 
1 1 8 8 1 1 1 1 1 1 8 
2 1 8 8 1 1 1 1 1 1 8 
3 1 5 5 1 1 1 1 1 1 5 
4 1 9 9 1 1 1 1 1 1 9 
5 1 7 7 3 1 3 2 2 2 7 
6 1 5 5 1 1 1 1 1 1 5 
7 1 9 9 1 1 1 1 1 1 9 
8 1 7 7 1 1 1 1 1 1 7 
9 1 8 8 1 1 1 1 1 1 8 
10 1 7 7 1 1 1 1 1 1 7 
Table 97: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with MLC leaf end 
modeling errors. 
Failure mode 11: CT table true severity 
As in the phantom treatment planning studies, beam models with errors in the CT table used for 
heterogeneity corrections in the treatment planning system were applied to ten clinical patient treatment 
plans to assess the severity of this failure mode.  The resultant severity scores are shown in Table 98. The 
overall severity scores for this failure mode ranged from 1 to 3. Patient 2 had changes in the dose to the 
spinal cord with when the PET CT table was used, which had large differences in the more dense 
materials. Patient 5 had increases to the spinal cord maximum dose for all three CT tables evaluated. It 
seemed that the spinal cord of patient 5 was in a particularly steep dose gradient so that any little change 
could result in a substantial change in the maximum dose to the cord, because it had increases in dose of 
some magnitude resulting in a severity score greater than one for all failure modes except failure mode 1. 
Other patients’ spinal cords weren’t necessarily this sensitive, for example patient one only had 
substantial increases in spinal cord maximum doses in 5/11 failure modes. 
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Patient 
CT Table Errors 
2% high PET CT 2% low 
Overall 
PTVs OARs Total PTVs OARs Total PTVs OARs Total 
1 1 1 1 1 1 1 1 1 1 1 
2 1 1 1 1 2 2 1 1 1 2 
3 1 1 1 1 1 1 1 1 1 1 
4 1 1 1 1 1 1 1 1 1 1 
5 1 3 3 1 3 3 1 3 3 3 
6 1 1 1 1 1 1 1 1 1 1 
7 1 1 1 1 1 1 1 1 1 1 
8 1 1 1 1 1 1 1 1 1 1 
9 1 1 1 1 1 1 1 1 1 1 
10 1 1 1 1 1 1 1 1 1 1 
Table 98: Severity scores from PTVs, OARs, and overall for ten clinical oropharyngeal patients with CT table errors. 
Summary of true severity scores  
A summary of the overall severity scores for all failure modes for each patient is tabulated in 
Table 99, which includes symmetry errors of 2% and MLC positional errors of 2 mm. Several factors may 
have played a role in exaggerating the severity of some failure modes including structures or constraints 
with low doses or small volumes. Not all patients had these structures, such as cochlea, orbits, lenses, and 
optic nerves, so we reassessed the severity scores for all failure modes using only the four OARs that each 
patient had, which were: brainstem, spinal cord, and left and right parotid glands. We used the difference 
from baseline in the maximum dose to the brainstem and cord and the mean dose to the parotid glands. 
The results of this reevaluation are shown in Table 100. This resulted in generally lower severity scores, 
but not in every case. Patients 1, 4, 8, and 10 were especially affected by this since those challenging 
structures were a part of the evaluation of these patients.  A side-by-side comparison of the overall true 
severity scores from these to OAR evaluation criteria is shown in Table 101.  
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True Severity Scores 
PTVs and All OARs 
Failure Mode 
Patient Number 
1 2 3 4 5 6 7 8 9 10 
1 7 9 8 7 8 9 2 8 9 9 
2 1 1 1 1 1 1 1 1 1 9 
3 9 5 7 8 9 9 7 9 10 10 
4 4 4 1 4 7 5 5 2 4 5 
5 9 7 7 9 7 4 9 9 7 9 
6 9 7 7 9 7 3 7 9 7 2 
7 1 1 1 1 1 1 1 1 1 1 
8 7 7 5 8 7 6 7 5 8 7 
9 2 2 1 4 4 1 2 2 4 3 
10 8 8 5 9 7 5 9 7 8 7 
11 1 2 1 1 3 1 1 1 1 1 
Table 99: True severity scores based on PTV coverage (D95%) and QUANTEC criteria of OARs for ten clinical 
oropharyngeal patients for 11 IMRT physical failure modes near tolerance criteria levels. 
True Severity Scores 
PTVs and 4 Common OARs 
Failure Mode 
Patient Number 
1 2 3 4 5 6 7 8 9 10 
1 7 9 8 7 8 9 2 8 9 3 
2 1 1 1 1 1 1 1 1 1 2 
3 5 5 7 6 9 9 7 5 4 9 
4 4 4 1 4 7 5 5 1 4 5 
5 7 5 7 2 7 7 5 5 7 7 
6 5 7 7 4 7 3 4 8 7 2 
7 1 1 1 1 1 1 1 1 1 1 
8 7 7 5 5 7 6 7 5 8 7 
9 1 2 1 1 4 1 1 1 4 3 
10 4 8 4 3 7 5 4 1 4 7 
11 1 2 1 1 3 1 1 1 1 1 
Table 100: True severity scores based on PTV coverage (D95%) and QUANTEC criteria of four common OARs for ten 
clinical oropharyngeal patients for 11 IMRT physical failure modes near tolerance criteria levels. 
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Failure Mode 
True Severity Score Comparison 
PTVs & All OARs PTVs & 4 Common OARs 
Median Average Std Dev Median Average Std Dev 
1 8 7.6 2.12 8 7 2.49 
2 1 1.8 2.53 1 1.1 0.32 
3 9 8.8 1.14 7 7.1 2.08 
4 4 4.1 1.66 4 4 1.83 
5 8 7.7 1.64 7 5.9 1.66 
6 7 6.7 2.41 6 5.4 2.07 
7 1 1 0 1 1 0 
8 7 6.7 1.06 7 6.4 1.07 
9 2 2.5 1.18 1 1.9 1.29 
10 7.5 7.3 1.42 4 4.7 2.11 
11 1 1.3 0.67 1 1.3 0.67 
Table 101: A comparison of the overall true severity scores from 10 patients with two different OAR criteria evaluated. 
The set of severity scores found using the four common OARs was less conservative, but may 
have been more reasonable. This problem highlighted the limitation of using our straight-forward and 
simplified quantitative approach to assigning severity scores. The simple approach allowed us to assess 
severity in a straight forward manner which was easily relatable to physics measurements, goals, and 
tolerances. However, the complicated nature of tissue response and the balancing act of achieving 
coverage while sparing normal tissues was over-simplified with this approach. The true severity was 
extremely challenging to identify for any given patient, none the less an entire patient population. Our 
approach simplified this problem and enabled us to still provide meaningful information with respect to 
the severity of the consequences of these failure modes and make comparisons. 
3.2.2 Comparison of qualitative and quantitative severity scores ability to predict true severity 
scores 
An overall comparison of the survey results (qualitative severity scores), phantom treatment 
planning studies on standard and complex plans (quantitative severity scores), and treatment planning 
studies using ten clinical oropharyngeal patients (true severity scores) using the evaluation of the PTVs 
and four common OARs is shown in Figure 111. The spread in the true severities seemed to exceed that 
in both our qualitative and quantitative severity scores for many of the eleven failure modes.  
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For failure mode 1 (beam energy), eight of the ten true severity scores were larger than both the 
qualitative and quantitative severity scores we predicted. Qualitative and quantitative severity scores for 
this failure mode agreed only with patient 10. The lack of agreement between quantitative and true 
severity here is likely due to the fact that in the phantom isocenter was at the center of the patient, 
between PTVs, and all structures were fairly central, while in the patient plans isocenter was below the 
chin, with field edges further off axis covering PTVs and OARs. This meant that the changes in the off 
axis dose due to energy changes that were more pronounced further off-axis had a greater effect on the 
patient plans.  
For failure mode 2 (beam symmetry 2%), the true severity scores were all lower than the survey 
predicted and agreed well with the quantitative phantom scores. Patient 10 had a higher severity for 
failure mode 2 than the quantitative phantom scores predicted, indicating that the quantitative scores may 
not have been sufficiently conservative for all oropharyngeal patients with this failure mode.  This made 
sense since we would expect the effects of symmetry errors to affect the patients with larger field sizes 
and non-central isocenters more than the phantom.  
For failure mode 3 (MLC position 2 mm), the true severity scores were high, up to 10 for one 
patient. The qualitative severity scores underestimated this as did the quantitative scores, however the 
overall quantitative score of 8 appeared to be a better estimate than the median qualitative score of 5. In 
the literature the reported severity of this failure mode was lower, with Mu et al. showing up to 13% 
changes in parotid dose for a H&N patient with 1 mm systematic errors which would correspond to a 
severity score of 7 on our scale48. Our high true severity score for this failure mode resulted from parotid 
and eye-related structure dose increases in patient 10 for both 1 mm and 2 mm shifts. With a comparable 
set up to the study be Mu, et al. we saw up to a 33% increase in the mean dose to the left parotid gland 
with 1 mm systematic shifts (S=9). This difference first demonstrated that it was difficult to fully capture 
patient variability with just one severity score. This comparison also demonstrated that our quantitative 
severity score provided a better estimate of the severity in our study and the literature.  
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For failure mode 4 (gantry angle 2°), the phantom and patient plans both fell within the whiskers 
of the survey. The overall quantitative severity score matched the highest true severity score of this failure 
mode (S=7) while the median qualitative score was low (S=4). The steep dose gradient in the phantom 
near a critical structure, which was cause of the phantom severity score, conservatively represented the 
potential failures in true clinical patients. Severity of gantry angle errors were reported to be high in the 
literature, up to 40% dose errors 10 cm from isocenter in a pelvic IMRT case with 2° systematic 
rotation74. Our patient plans included doses delivered up to 13.4 cm from the isocenter, but the patient 
structures at the evaluation criteria did not capture errors that large. This comparison again highlighted the 
complexity of comparing patient-specific dose distributions as well as the challenge of capturing the 
magnitude of errors in a clinically meaningful manner.  
For failure mode 5 (collimator angle 2°), quantitative and true severity scores again fell within the 
whiskers of the survey results, but both the median qualitative and overall quantitative severity scores, 
S=4 and S=5 respectively, were low compared to the maximum true severity score of 7. Unlike for failure 
mode 4, the phantom for this failure mode did not provide a conservative representation of true clinical 
patients, likely due to the patients OARs further off-axis than those in the phantom that experienced a 
greater displacement in the dose as a result of the collimator rotation. An IMRT pelvic plan in the 
literature reported up to 20% dose errors with 2° collimator rotation, which was slightly higher than the 
errors we saw in our H&N patient population 74. 
For failure mode 6 (couch angle 2°), qualitative and quantitative severity scores were again lower 
than the true severity score, though there was a relatively large spread in the patient results. The highest 
true severity score of 8 was completely outside of the range of survey responses, while both quantitative 
and qualitative severity scores predicted S=4. The sensitivity of off-axis OARs to couch angle rotations 
was much greater in the large field patients than in our smaller field phantom. As reported in the 
literature, errors in the couch angle had the potential to cause errors comparable in magnitude to 
collimator and gantry angular misalignments 75. 
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For failure mode 7 (MU linearity), the quantitative severity scores matched all true severity 
scores at S = 1, but the qualitative severity scores were high. This was not surprising since MU linearity at 
low MU has been published on extensively, one would expect this failure mode to have an effect on the 
true severity. This, however, was not the case in our study.  
For failure mode 8 (MLC leakage and transmission modeling), the qualitative (S=4) and 
especially quantitative (S=1) severity scores underestimated the true severity scores, the maximum of 
which was 7. The fields in the patient treatment plans were larger than those in the phantom treatment 
plans because the targets were much larger and extended to include many more nodes. As a result, the 
MLC were used more extensively for blocking and therefore the effects of interleaf leakage and 
transmission were greater.  
For failure mode 9 (MLC tongue-and-groove modeling) the median qualitative severity score 
predicted the highest true severity score of 4, while the overall quantitative score was within the spread of 
the true severity scores but low (S=2). The larger patient fields would also be affected more greatly by 
tongue-and-groove effects than the smaller phantom fields, which may explain this discrepancy. The 
magnitude of errors seen in our patient studies was comparable to the 5% dose error reported in the 
literature84. 
For failure mode 10 (MLC leaf end modeling), there was a relatively large spread in the true 
severity scores and both median qualitative and overall quantitative underestimated the maximum true 
severity (S=8), but lay around the average true severity score (S=4.7). This phantom has been known to 
respond to errors in rounded leaf end modeling as demonstrated by Cadman, et al. an increase in the 
spinal cord TLD doses and DTA in the high dose gradient region were seen when the leaf offset used to 
account for transmission were not accounted for. Although this was a different component of MLC leaf 
end modeling, the effects on the phantom results were seen in in similar regions in the phantom89. Most 
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likely, the changes in penumbra resultant from changes in the leaf end modeling effected patient treatment 
plans more than phantom plans since there were larger fields in which more MLC leaf ends were exposed.  
Finally, for failure mode 11 (CT table), the median qualitative severity score predicted the 
maximum true score, while the quantitative score agreed with most of the true scores at S=1.  The 
phantom was made of a rather homogenous medium and therefore was not affected by the change in CT 
table, while there were some small changes in some of the patient treatment plans. Small changes that 
would not have increased the severity score from 1 were reported in the literature for conformal radiation 
treatments with errors in the CT table comparable to our study88. Patient-specific anatomy played a large 
role in the severity of this failure mode. 
As was done to compare the qualitative and quantitative severity scores, we performed Wilcoxon 
Signed Rank tests to compare the quantitative (one-sample) and qualitative severity scores (independent 
samples) to the true severity scores.  The results of this comparison are shown in Table 102 and in 
addition to the significance values for these tests, this table includes the 95% confidence intervals of the 
median true severity scores, the overall quantitative severity scores, and the median qualitative severity 
scores. Based on this assessment, neither method perfectly predicted the true severity scores but the 
quantitative assessment performed better than the qualitative with eight of the eleven failure mode 
severity scores not having significant differences from the median true severity score for the quantitative 
scores compared to six of the eight of the qualitative scores. If we performed this same analysis with the 
true severity scores from all of the OARs instead of just the four common OARs, the ability of both the 
quantitative and qualitative severity scores to predict the true severity scores were reduced, with five of 
the eleven failure mode quantitative severity scores not significantly different than the true median 
severity score and three of the eleven qualitative severity scores. This analysis is shown in Table 103. In 
either case, the quantitative severity scores matched the median true severity scores better, technically 
proving our hypothesis to be true. In addition to this analysis, we compared the maximum severity scores 
for each the qualitative, quantitative, and true, since we were most concerned with the maximum 
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consequences of our IMRT H&N physical failure modes. This comparison is shown in Table 104. Based 
on the maximum true severity scores, the maximum qualitative severity scores better predicted the true 
severity, with two of the qualitative severity scores matching perfectly and 3 matching within one score. 
The maximum quantitative severity scores (used as the overall quantitative severity score), median 
qualitative, and maximum qualitative severity scores all directly matched two of the failure mode 
maximum true severity scores. In each case, these two matches were for different failure modes. 
Additionally, the quantitative severity score was within one score for one failure mode and the maximum 
qualitative severity score was within one score for two failure modes. This told us that when considering 
the overall maximum severity scores, the qualitative approach performed slightly better, by predicting 
two additional failure mode severity scores within one score than the quantitative, though both 
approaches matched the same number of severity scores directly. 
In the end, neither the qualitative or quantitative approach to providing severity scores for our 
step and shoot IMRT H&N physical failure modes fully captured the true severities that we observed in 
ten clinical patients. These true severity scores were highly variable amongst patients for many of the 
failure modes, indicating that patient-specific components play a large role in the severity of 
consequences from a particular failure mode. This was well-reflected in the variability of severity scoring 
amongst survey responses from members of the medical physics community however the qualitative 
scores obtained did not always reflect the true severity. The IROC-H IMRT H&N phantom designed to 
mimic an oropharyngeal patient and assess an institution’s ability to properly deliver a complex IMRT 
treatment, represented the effects of many of the failure modes in a true patient moderately well. The 
phantom was limited in its representation of true patients, particularly in the field sizes used and the 
presence of structures far off-axis, and therefore did not always capture the maximum true severity. When 
considering maximum true severity scores, each approach to scoring matched the true severity for 
different failure modes, demonstrating that overall, these methods are imperfect along but have the 
potential to provide complementary information.
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Figure 111: Summary of severity scores obtained from survey, phantom treatment planning studies on standard and complex plans, and ten oropharyngeal clinical 
patients for our 11 IMRT physical failure modes. 
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Failure Mode 
True Severity Score 
95% Confidence Interval of the Median 
Quantitative 
Severity 
Score 
Sig. 
Qualitative 
Severity 
Score 
Sig. 
Lower 
Bound 
Median 
Upper 
Bound 
1. Beam Energy 6.02 8 9.98 3 0.010 3 0.026 
2. Beam 
Symmetry 
0.75 1 1.25 1 0.317 4 0.233 
3. MLC Position   5.35 7 8.65 8 0.215 5 0.061 
4. Gantry Angle 2.55 4 5.45 7 0.007 4 0.746 
5. Collimator 
Angle 
5.68 7 8.32 5 0.206 4 0.001 
6. Couch Angle 4.36 6 7.64 4 0.055 4 0.068 
7. MU Linearity 1.0 1 1.0 1 1.000 4 0.020 
8. MLC Leakage & 
Transmission 
6.15 7 7.85 1 0.004 4 0.000 
9. MLC Tongue & 
Groove 
0 1 2.02 2 0.851 4 0.168 
10. MLC Leaf End 2.33 4 5.67 5 0.764 4 0.890 
11. CT Table 0.46 1 1.54 1 0.180 3 0.017 
Table 102: Comparison of median qualitative severity scores from the survey (N=184) and the overall quantitative 
severity scores from standard and complex phantom treatment planning studies to the 95% confidence interval of the 
median true severity score based on the evaluation of PTVs and four common OARs in ten oropharyngeal patient 
treatment plans. Red indicates that the score does not lie within the 95% CI and green indicates it does.  
Failure Mode 
True Severity Score 
95% Confidence Interval of the Median 
Quantitative 
Severity 
Score 
Sig. 
Qualitative 
Severity 
Score 
Sig. 
Lower 
Bound 
Median 
Upper 
Bound 
1. Beam Energy 6.32 8 9.68 3 0.006 3 0.004 
2. Beam 
Symmetry 
0 1 3.01 1 0.317 4 0.679 
3. MLC Position   8.10 9 9.90 8 0.057 5 0.000 
4. Gantry Angle 2.68 4 5.32 7 0.007 4 0.746 
5. Collimator 
Angle 
6.70 8 9.30 5 0.006 4 0.001 
6. Couch Angle 5.09 7 8.91 4 0.011 4 0.002 
7. MU Linearity 1.0 1 1.0 1 1.000 4 0.020 
8. MLC Leakage & 
Transmission 
6.16 7 7.84 1 0.004 4 0.000 
9. MLC Tongue & 
Groove 
1.7 2 2.93 2 0.163 4 0.168 
10. MLC Leaf End 6.38 7.5 8.62 5 0.011 4 0.000 
11. CT Table 0.46 1 1.54 1 0.180 3 0.017 
Table 103: Comparison of median qualitative severity scores from the survey (N=184) and the overall quantitative 
severity scores from standard and complex phantom treatment planning studies to the 95% confidence interval of the 
median true severity score based on the evaluation of PTVs and all OARs in ten oropharyngeal patient treatment plans. 
Red indicates that the score does not lie within the 95% CI and green indicates it does.  
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Failure Mode 
Severity Scores 
True Quantitative Qualitative 
Maximum  Maximum  Median  Maximum  
1 9 3 3 9 
2 2 1 4 7 
3 10 8 5 9 
4 7 7 4 9 
5 7 5 4 8 
6 8 4 4 8 
7 1 1 4 9 
8 8 1 4 9 
9 4 2 4 8 
10 8 5 4 10 
11 3 1 3 9 
Table 104: Comparison of maximum true severity scores from the evaluation of PTVs and four common OARs in ten 
oropharyngeal patient treatment plans to maximum quantitative severity scores from standard and complex phantom 
treatment planning studies and median and maximum qualitative severity scores from the survey (N=184). Green 
indicates matching exactly with maximum true severity, yellow indicates matching within 1 score. 
Failure Mode 
Severity Scores 
True Quantitative Qualitative 
Maximum  Maximum  Median  Maximum  
1 9 3 3 9 
2 9 1 4 7 
3 10 8 5 9 
4 7 7 4 9 
5 9 5 4 8 
6 9 4 4 8 
7 1 1 4 9 
8 8 1 4 9 
9 4 2 4 8 
10 9 5 4 10 
11 3 1 3 9 
Table 105: Comparison of maximum true severity scores from the evaluation of PTVs and all OARs in ten oropharyngeal 
patient treatment plans to maximum quantitative severity scores from standard and complex phantom treatment 
planning studies and median and maximum qualitative severity scores from the survey (N=184). Green indicates 
matching exactly with maximum true severity, yellow indicates matching within 1 score. 
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Chapter 4: Conclusions 
4.1 Specific Aim 1 Conclusions 
The objective of this specific aim was to obtain and compare qualitative and quantitative FMEA 
severity scores for the identified critical IMRT H&N physical dose delivery failure modes. The working 
hypothesis of this specific aim was that subjective qualitative severity scores obtained through a 
conventional FMEA were significantly different than quantitative severity scores generated from 
computed and measured data. Based on our comparison using the one-sample Wilcoxon Signed Rank 
Test, our hypothesis was true for nine of the eleven failure modes.  Large variability was observed in the 
qualitative severity scores for our failure modes obtained through an online survey of medical physicists, 
though no universal trends in the scores with demographics were identified.  Treatment planning studies 
with the IROC-H IMRT H&N phantom using standard and complex treatment plans often resulted in 
different severity scores, providing insight to the potential variability amongst patients. Physical 
measurements with the phantom generally demonstrated agreement with the treatment planning studies, 
though the sensitivity of the phantom to the failure modes was lower, particularly the absolute dose 
measurements with TLD because of the higher uncertainty associated with the TLD compared to ion 
chamber measurements.  
4.2 Specific Aim 2 Conclusions 
The objective of this specific aim was to compare the validity of the quantitative and qualitative 
scores by evaluating the true severity for each failure mode in clinical H&N patients. The working 
hypothesis of this specific aim was that quantitative severity scores were significantly more likely than 
qualitative subjective scores to describe true clinical consequences. Based on our comparison of the 
median qualitative and maximum quantitative severity scores to the true severity scores from patient plans 
using independent sample and one sample Wilcoxon Signed Rank Tests, respectively, our hypothesis was 
true with quantitative severity scores matching the median true severity for eight of the eleven failure 
modes and median qualitative severity scores matching the median true severity for six of the eleven 
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failure modes. Patient treatment plans demonstrated sensitivity to failure modes primarily in OARs  and 
overall severity scores for each failure mode  had large variability amongst patients. OAR structures with 
small volumes and relatively small doses proved to be extremely sensitive in some cases when using our 
severity scoring scale (Table 7).  
4.3 Overall Conclusions 
FMEA has been gaining popularity in radiation therapy in response to both 1) catastrophic errors 
which highlight our need for comprehensive process quality management and 2) the ever-increasing work 
load required to keep up with the advancing technologies and techniques in today’s busy clinics. Many 
advantages and disadvantages of the application of FMEA to radiation therapy processes have been 
discussed7,37-41. Our goal was to draw on some of the disadvantages to expand the utility of FMEA for 
radiation therapy and improve the results of these analyses. Based on our comparison of qualitative and 
quantitative severity scores to true clinical severity scores, we concluded that quantitative severity scores 
better predicted true severity scores for our step and shoot IMRT H&N physical failure modes, indicating 
that using a quantitative approach to severity scoring is a valuable and needed improvement over the 
subjective traditional qualitative approach for physics specific components of radiation therapy processes.  
From this work, a few observations on step and shoot H&N IMRT QA procedures for specific 
failure modes can be made. First, beam energy had a greater potential for inducing high severity errors in 
patient plans than expected in our survey or phantom studies. These errors appeared to be primarily a 
result of the off-axis changes caused by energy changes as opposed to the commonly measured PDD 
changes. Gao, et al. has recommended measuring diagonal profiles to monitor beam energy and our 
results support that idea63. What was also observed during the phantom measurements using clinically 
decommissioned linacs, was that the safeguards currently in place with modern linacs do not allow for 
any significant energy changes that would exceed current AAPM TG-40’s QA 2% acceptability criteria 
and possibly the TG-142’s criteria of 1% from baseline60,90. Second, the MLC tolerance recommended for 
IMRT by AAPM TG-142 of ±1 mm is critical. We saw the potential for severe consequences in our 
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studies with systematic MLC offsets of 2 mm and even offsets of 1 mm had the potential for introducing 
dose delivery errors to normal tissues. These failure modes were determined to be the most critical in our 
analysis. Our study also indicated that angular misalignments and MLC modeling failures can be serious, 
but not to the same degree as the energy and MLC offset failures. Alternatively, we saw that MU linearity 
errors for segments with less than 5 MU did not have a substantial impact on H&N patient treatment 
plans. More recent machines are not as susceptible to the over-shoot effect and it is becoming more 
common to set lower limits on the number of MU/segment allowed in the TPS, which both serve to 
eliminate this failure mode.  We do not have sufficient data to recommend completely removing this QA 
test, however these factors along with our results indicate that this failure mode is of low priority.  
Regarding FMEA in radiation therapy, we can conclude that quantitative data can provide insight 
into the effects of tolerance criteria level failures that can be underestimated within the perception the 
medical physics community. However, the qualitative severity scores provided useful information as well 
and the more important conclusion of this project was that while this process is very complicated the 
more information available to inform scoring decisions, the more reliable and accurate the severity 
scoring will be. The benefit of generating a more comprehensive understanding of the entire process by 
the full participating team is clear and can only improved by utilizing quantitative data that solidify the 
understanding of the risks these failure modes present. Moving forward, FMEA and other risk-based 
prospective quality improvement methods will continue  to become more widely implemented due to the 
publication of AAPM TG-100, the progression of radiation therapy advancements and required quality 
management, and the continued mentality of “one error is an error too many.” Based on the results of this 
study, we recommend further quantitative investigation into the severity of physical failure modes in 
additional treatment sites to fully utilize the FMEA process for the improvement of physics-specific 
components to the radiation therapy process. An FMEA as conventionally proposed already requires a 
significant allocation of time and resources, so adding a quantitative component to the analysis for each 
clinic is not necessarily feasible. A robust yet generalized investigation of failure mode effects on various 
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treatment sites such as that performed in this study and expanded to include other common treatment 
equipment and techniques would be valuable for guiding individual clinics attempting to improve their 
physics quality management through FMEA. Since we have shown that the effect of these failure modes 
are very patient specific, a study of the impacts on different treatment sites would allow for the 
identification of the most conservative severity estimates for certain radiation therapy processes as whole 
enabling clinics treating multiple sites to maintain a conservative approach. In order to integrate this 
quantitative approach, we also recommend the formulation of a severity scoring scale and method that 
includes a quantitative component as ours did. This scoring scale and method should be physician driven 
to ensure that our clinical objectives remain forefront in these efforts. Following these steps, the FMEA 
process, particularly for the improvement of physics quality management, has the potential for being 
extremely useful in not only increasing our appreciation for radiation therapy processes as a whole but in 
allowing us to understand and effectively mitigate risks.  
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Appendix A: Surveys for qualitative severity scoring 
A.1 Pilot Survey 
2013 IMRT FMEA Survey 
Failure Modes and Effects Analysis (FMEA) is a risk analysis tool recommended in the upcoming AAPM 
TG-100 report. FMEA provides a prospective end-to-end risk evaluation of radiotherapy processes by 
means of a subjective qualitative scoring system. Several institutions are already beginning to 
implement FMEA, though its proper place in radiotherapy quality management is currently unclear. 
 
Objective: This survey is being conducted to evaluate the subjective nature of FMEA in radiotherapy. We 
are examining dose calculation and linac delivery failures near tolerance criteria levels. Data will be used 
for a dissertation project. 
  
Instructions:  Please answer the questions to the best of your ability based on your knowledge and 
experience. Please only complete this survey once. If you have any questions or comments, please fill in 
the blank comment section at the end and feel free to contact Jackie Tonigan at 
JRTonigan@mdanderson.org.  
 
General Information: 
 
1. How many years of clinical physics experience do you have? 
     
 
 
2. Are you currently ABR certified? Check one. 
 
Yes   
No 
 
3. Approximately what percentage of your time is dedicated to clinical work? 
 
 
Consider a head and neck IMRT treatment delivery (not VMAT). 
For this type of treatment in your current practice: 
 
4. What linear accelerator manufacturer do you primarily use? Check one. 
 
Varian 
Elekta 
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Siemens 
Other  
 
5. What treatment planning system do you primarily use? Check one. 
 
Eclipse 
Pinnacle 
Other  
 
6. What technique do you primarily use? Check one. 
 
Step and shoot/Segmental MLC 
Sliding window/Dynamic MLC 
Other  
 
Failure Mode Scoring 
  
Failure Modes and Effects Analysis (FMEA) is a prospective quality tool. It is used to rank potential 
failures of a process (failure modes) in order of the risk they present. To rank the failures, three scores 
are assigned for each failure mode by a team of experts: the likelihood of occurrence (O), severity (S), 
and lack of detectability (D).7,45 
7. How familiar are you with Failure Modes and Effects Analysis? Circle one. 
 
Very familiar 
Somewhat familiar 
Slightly familiar 
Not familiar 
 
  
209 
 
Consider a head and neck IMRT treatment delivery (not VMAT) in your current practice. For each of the 
12 planning and delivery failures in Table 1*, think about the failure propagating through the treatment 
process to the patient for the whole treatment course. You will evaluate the risk associated with each 
failure.  
 
Estimating Percent Dose Error 
In Table 1*, column 2, fill in your best estimate of the percent dose error for patient target structures for 
each failure. Imagine the worst case scenario. Consider each failure independently. 
 
Estimating Failure Mode Scores 
In columns 3-5 of Table 1*, use Table A (provided on each of the following sheets) to fill in your best 
estimate of the following scores: 
O = Occurrence. The likelihood the failure would occur. (1-10) 
D = Detectability. The likelihood the failure would go undetected. (1-10) 
S = Severity. The severity of the consequences of the failure. (1-10) 
Note that risk increases for each score from 1 to 10, with 10 being the most risky. 
Again, imagine the worst case scenario. Consider each failure independently.  
 
*Table 1 is on pages 3 and 4 
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Table A: FMEA Score Scales 
Table 1: Failure Mode Scoring 
Please fill in this table using Table A above for columns 3-5 as instructed. 
Failure % dose error 
O 
Occurrence 
(1-10) 
D 
Detectability 
(1-10) 
S 
Severity 
(1-10) 
Delivery Failures 
1 
Beam energy differs from baseline by 1% 
(TMR or PDD ratio)         
 
          
2 
Beam symmetry differs from baseline by 
2%         
            
3 
MLC systematically differs in one bank by 
2 mm         
            
4 
Gantry angle systematically differs from 
baseline by 2.0°         
            
5 
Collimator angle systematically differs 
from baseline by 2.0°         
            
6 
Couch angle systematically differs from 
baseline by 2.0°         
Table A: FMEA Score Scales 
Rank Occurrence (O) Detectability (D) Severity (S) 
 Qualitative Frequency Qualitative Estimated probability of 
failure going undetected 
Qualitative Categorization 
1 Failure Unlikely 0.01% Never undetected 0.01% No effect  
2  0.02% Very low likelihood 
undetected 
0.2% Inconvenience Inconvenience 
3 Relatively few failures 0.05%  0.5%   
4  0.1% Low likelihood 
undetected 
1% Minor dosimetric error Suboptimal plan or 
treatment 
5  < 0.2%  2% Limited toxicity or tumor 
underdose 
Wrong dose, dose 
distribution, location 
or volume 
6 Occasional failures < 0.5%  5%   
7  < 1% Moderate likelihood 
undetected 
10% Recordable event, Potentially 
serious toxicity or tumor 
underdose 
 
8 Repeated failures < 2%  15%   
9  <5% High likelihood 
undetected 
20% Reportable event, Possible very 
serious toxicity or tumor 
underdose 
Very wrong dose, dose 
distribution, location 
or volume 
10 Failures inevitable > 5% Always undetected > 20% Catastrophic  
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Table 1: Failure Mode Scoring Continued… 
Please fill in this table using Table A above for columns 3-5 as instructed. 
Failure % dose error 
O 
Occurrence 
(1-10) 
D 
Detectability 
(1-10) 
S 
Severity 
(1-10) 
 
7 
Patient setup systematically differs from 
baseline by 3 mm in one direction         
 
8 
MU linearity for < 5 MU systematically 
differs from baseline by 6%         
Dose Calculation Failures 
9 
MLC transmission and leakage modeling is 
off by 0.5%         
            
10 
MLC tongue-and-groove modeling is off 
by 0.5%         
            
11 MLC leaf end modeling is off by 0.5% 
        
            
12 
CT number to electron density table 
systematically is off by 2%         
       
 
Questions or Comments: 
Rank Occurrence (O) Detectability (D) Severity (S) 
 Qualitative Frequency Qualitative Estimated probability of failure 
going undetected 
Qualitative Categorization 
1 Failure Unlikely 0.01% Never undetected 0.01% No effect  
2  0.02% Very low likelihood 
undetected 
0.2% Inconvenience Inconvenience 
3 Relatively few failures 0.05%  0.5%   
4  0.1% Low likelihood 
undetected 
1% Minor dosimetric error Suboptimal plan or 
treatment 
5  < 0.2%  2% Limited toxicity or tumor 
underdose 
Wrong dose, dose 
distribution, location or 
volume 
6 Occasional failures < 0.5%  5%   
7  < 1% Moderate likelihood 
undetected 
10% Recordable event, 
Potentially serious toxicity 
or tumor underdose 
 
8 Repeated failures < 2%  15%   
9  <5% High likelihood 
undetected 
20% Reportable event, Possible 
very serious toxicity or 
tumor underdose 
Very wrong dose, dose 
distribution, location or 
volume 
10 Failures inevitable > 5% Always undetected > 20% Catastrophic  
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Thank you for your time! 
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A.2 Full Survey 
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Appendix B: Patient Failure Mode Dose Deviations 
 
Patient 1 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy)) 
Failure Mode 1: 
Beam Energy 
Failure Mode 2: Beam Symmetry 
+10% -10% 
2 degrees 3.5 degrees 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
PTVs 
PTV 66 D95% 6813.93 -3.08% -2.96% 0.05% 0.16% 0.27% 0.06% 0.16% 0.21% 0.12% -0.08% 
PTV 63 D95% 6555.78 -9.82% -8.56% -0.08% -0.03% 0.08% -0.30% 0.10% 0.06% -0.28% -0.44% 
PTV 60 D95% 6227.13 -8.58% -7.45% -0.19% -0.07% 0.19% -0.47% -0.01% -0.01% -0.05% -0.54% 
PTV 54 D95% 5592.63 -8.32% -7.37% -0.05% 0.10% 0.30% -0.22% 0.10% 0.25% 0.06% -0.28% 
OARs 
Brainstem Max to 1 cc 3574.97 -3.20% -2.96% -1.42% -1.34% -0.28% -2.31% -1.24% -1.15% 0.63% -2.03% 
 
D100% 232.00 10.34% -3.88% -13.36% -13.36% -12.93% -13.79% -10.34% -10.34% -9.48% -11.21% 
Cord Max 3616.88 5.59% 4.26% -0.97% -0.83% -0.25% -1.41% -0.85% -0.59% 0.35% -1.44% 
 
Max to 0.3 cc 3562.91 4.93% 3.61% -0.71% -0.63% -0.04% -1.05% -0.49% -0.21% 0.47% -1.08% 
L parotid Mean 1603.28 -0.87% -5.59% -3.62% -3.40% -2.86% -3.98% -2.81% -2.45% -2.01% -3.43% 
 
D50% 1064.86 0.26% -9.08% -7.02% -6.95% -6.18% -7.72% -5.67% -5.49% -4.38% -6.51% 
R parotid Mean 3097.12 -3.05% -3.46% -2.24% -2.06% -1.50% -2.68% -1.71% -1.57% -0.94% -2.30% 
 
D50% 5876.52 -0.27% -0.77% 0.07% 0.19% 0.28% 0.30% 0.23% 0.42% 0.02% 0.12% 
L cochlea Mean 1245.11 -18.43% -19.85% -3.44% -3.47% -2.12% -4.67% -3.26% -3.32% -1.04% -4.62% 
 
D05% 1763.35 -15.26% -15.44% -2.15% -2.21% -0.74% -3.40% -1.76% -1.88% 0.45% -3.18% 
R cochlea Mean 2045.89 -11.42% -10.88% -3.20% -2.91% -1.50% -4.24% -2.63% -2.44% -0.22% -3.81% 
 
D05% 2851.25 -7.19% -5.54% -1.99% -1.99% -0.55% -3.29% -1.60% -1.78% 0.68% -2.94% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right 
to left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95% 6813.93 0.07% 0.00% -0.33% -0.24% 0.11% 0.03% 0.08% -0.02% 0.80% -0.47% 0.70% -0.69% 
PTV 63 D95% 6555.78 -0.65% -0.65% -1.90% -1.19% -0.24% -1.18% 0.02% -0.32% 0.05% -8.86% 0.57% -1.54% 
PTV 60 D95% 6227.13 -0.03% -0.10% -0.90% -1.67% -0.23% -0.42% 0.28% -0.39% 0.10% -6.49% 1.03% -1.44% 
PTV 54 D95% 5592.63 -0.11% 0.02% -0.57% -1.08% 0.22% -0.17% 0.59% -0.54% 0.63% -2.13% 1.34% -1.80% 
OARs 
Brainstem 
Max 
 to 1 cc 3574.97 0.52% 0.86% 2.73% -4.07% 0.96% -0.46% 1.06% -0.86% 2.37% -1.53% 2.54% -2.28% 
 
D100% 232.00 -10.78% -10.78% -9.48% -13.36% 0.43% 0.43% 3.88% -3.02% 0.86% 0.00% 7.76% -7.33% 
Cord Max 3616.88 0.20% 0.84% 1.51% -2.63% 1.07% 0.24% 0.34% 0.23% 3.56% -0.41% 1.20% -0.21% 
 
Max 
to 0.3 cc 3562.91 0.24% 0.85% 1.35% -2.31% 1.42% 0.35% 0.70% 0.66% 3.97% -0.54% -3.05% -0.03% 
L parotid Mean 1603.28 -2.50% -1.81% -0.99% -4.01% 0.61% -0.02% 4.38% -3.81% 1.52% -0.73% 9.27% -8.02% 
 
D50% 1064.86 -5.40% -5.13% -3.55% -8.33% 1.36% -0.96% 1.87% -1.60% 3.17% -2.41% 4.42% -3.74% 
R parotid Mean 3097.12 -0.72% -0.62% 1.00% -50.31% -0.29% 0.26% 3.42% -50.21% 0.23% 0.17% 7.77% -7.14% 
 
D50% 5876.52 -0.27% 0.05% -0.31% 0.34% 0.26% 0.22% 0.33% 0.16% 0.76% -0.15% 0.91% -0.31% 
L cochlea Mean 1245.11 0.99% 0.82% 3.77% -4.57% -0.11% 0.12% 11.84% -10.26% 0.33% -0.30% 27.09% -18.80% 
 
D05% 1763.35 1.70% 1.30% 4.47% -4.03% 0.22% 0.56% 12.45% -11.34% 0.83% 0.28% 29.10% -21.54% 
R cochlea Mean 2045.89 -0.14% 0.40% 3.42% -5.27% -0.31% 0.42% 10.26% -9.14% -0.08% 0.02% 21.86% -17.38% 
 
D05% 2851.25 1.03% 0.46% 4.01% -4.66% 0.32% -0.31% 12.41% -11.70% 0.86% -0.72% 26.98% -21.55% 
 
 
 
 
232 
 
Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2° -2° + 2° -2° + 2° -2° 1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95% 6813.93 -0.30% -0.25% -0.56% -1.30% -0.60% -0.32% 0.01% 0.00% 0.06% -0.03% 0.06% -0.13% 
PTV 63 D95% 6555.78 -0.34% -0.10% -2.62% -3.94% -1.61% -0.78% 0.01% 0.00% 0.05% -0.03% 0.00% -0.08% 
PTV 60 D95% 6227.13 0.21% -0.47% -0.61% -3.74% -2.22% -0.84% 0.07% 0.00% 0.14% -0.03% 0.08% -0.07% 
PTV 54 D95% 5592.63 -0.31% -0.12% -1.98% -1.08% 0.11% -1.39% 0.11% -0.01% 0.19% -0.03% 0.29% -0.14% 
OARs 
Brainstem 
Max  
to 1 cc 3574.97 0.00% -0.07% 6.10% -0.59% 1.50% 0.71% 0.05% -0.01% -0.18% -0.03% 0.20% -0.11% 
 
D100% 232.00 0.43% 0.43% -0.43% -2.59% -0.43% 0.00% 0.00% 0.00% 0.00% 0.00% 0.43% 0.00% 
Cord Max 3616.88 1.29% -0.68% 13.54% 9.81% 7.36% -0.27% 0.20% -0.02% 0.06% -0.04% 0.79% -0.27% 
 
Max  
to 0.3 cc 3562.91 1.16% -0.22% 10.96% 3.74% 5.45% -0.71% 0.59% 0.37% 0.47% 0.31% 1.15% 0.06% 
L parotid Mean 1603.28 6.56% -3.94% -5.16% 13.58% 3.98% 1.09% -0.09% 0.00% 0.00% -0.02% 0.15% -0.24% 
 
D50% 1064.86 0.20% 1.54% -0.97% 13.74% 8.77% -4.53% 0.06% -0.01% 0.06% -0.02% 0.76% -0.35% 
R parotid Mean 3097.12 -0.41% 1.86% 6.26% -0.73% 0.01% 3.62% -0.20% 0.00% -0.19% -0.01% -0.29% -0.14% 
 
D50% 5876.52 -0.14% 0.10% -0.29% 0.74% 0.38% -0.35% 0.08% -0.01% 0.18% -0.03% 0.30% -0.18% 
L cochlea Mean 1245.11 1.40% -0.34% 20.78% -10.44% 7.19% -0.31% 0.13% -0.01% -0.02% -0.02% 0.55% -0.17% 
 
D05% 1763.35 1.89% 1.03% 35.83% -6.87% 9.21% 11.66% 0.12% 0.00% 0.00% 0.00% 0.51% -0.12% 
R cochlea Mean 2045.89 3.81% -2.98% 1.95% 28.05% 23.22% -3.63% 0.13% -0.01% 0.24% -0.03% 0.15% -0.05% 
 
D05% 2851.25 2.99% -1.23% -28.83% 35.79% 20.06% 11.05% 0.18% 0.00% 0.42% -0.04% 0.25% -0.07% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 15 
cm 
radius = 20 
cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95% 6813.93 -0.10% 0.06% -0.13% 0.14% 0.49% -0.34% -0.48% 0.34% 0.09% 0.09% 
PTV 63 D95% 6555.78 -0.14% 0.17% -0.09% 0.08% 0.27% -0.15% -0.14% 0.31% 0.11% 0.11% 
PTV 60 D95% 6227.13 -0.14% 0.40% -0.07% 0.20% 1.17% -0.42% -0.32% 0.31% 0.14% 0.14% 
PTV 54 D95% 5592.63 -0.07% 0.84% -0.13% 0.09% 0.96% -0.75% -0.93% 0.52% 0.07% 0.07% 
OARs 
Brainstem 
Max  
to 1 cc 3574.97 -0.39% 2.71% -0.34% 1.43% 2.07% -1.65% -0.76% 0.35% 0.28% 0.28% 
 
D100% 232.00 0.00% 0.86% 0.00% 1.29% 0.86% -0.43% 0.00% 1.72% -0.86% -0.86% 
Cord Max 3616.88 -0.43% 2.67% -0.32% 0.99% 1.83% -0.31% -0.32% 0.45% -0.68% 0.06% 
 
Max  
to 0.3 cc 3562.91 -0.05% 2.07% 0.07% 0.02% 1.94% -0.11% -0.32% 0.92% 0.52% 0.52% 
L parotid Mean 1603.28 -0.96% 10.61% -0.67% 1.99% 6.04% -3.37% -4.26% 0.94% 0.11% -0.25% 
 
D50% 1064.86 -1.66% 17.99% -1.32% 5.32% 5.57% -2.25% -2.27% 0.83% -0.27% -0.27% 
R parotid Mean 3097.12 -0.59% 4.42% -0.28% 0.21% 4.65% -2.74% -3.77% 0.53% -0.18% -0.25% 
 
D50% 5876.52 -0.03% 0.69% -0.18% 0.39% 0.55% -0.04% 0.02% 0.65% 0.03% 0.03% 
L cochlea Mean 1245.11 -0.86% 7.75% -0.69% 3.32% 16.18% -9.10% -8.03% 0.33% -2.41% 0.22% 
 
D05% 1763.35 -0.79% 6.82% -0.52% 2.78% 16.31% -9.70% -8.55% 0.33% 0.39% 0.39% 
R cochlea Mean 2045.89 -0.70% 5.76% -0.74% 3.50% 11.52% -6.62% -5.55% 0.40% -2.46% 0.46% 
 
D05% 2851.25 -0.67% 5.66% -0.98% 4.63% 14.39% -8.21% -6.87% 0.17% 0.53% 0.53% 
Table 106: Patient 1 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 2 
Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
Failure Mode 1: Beam 
Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
PTVs 
PTV 70 D95% 6854.12 -3.42% -3.25% -0.45% -0.57% -0.03% -0.76% -0.45% -0.22% -0.22% -0.72% 
PTV 63 D95% 6163.19 -4.62% -5.76% -0.27% -0.59% -0.63% -0.36% -0.27% -0.72% -0.72% -0.40% 
PTV 57 D95% 5545.40 -5.68% -4.88% -0.34% -0.55% -0.32% -0.54% -0.34% -0.46% -0.46% -0.43% 
OARs 
Brainstem 
Max  
to 1 cc 3863.71 -1.58% -0.59% -1.15% -1.02% 0.96% -2.14% -1.15% 0.33% 0.33% -1.77% 
 
D100% 1167.00 6.43% 4.88% -3.17% -3.68% 0.51% -4.71% -3.17% -1.29% -1.29% -4.37% 
Cord Max 4082.86 21.30% 22.05% -1.16% -1.09% -0.56% -1.23% -0.87% -0.57% -0.57% -0.96% 
 
Max  
to 0.3 cc 4038.64 18.35% 18.86% -3.35% -1.41% -0.66% -4.21% -3.35% -1.74% -1.74% -1.85% 
L Parotid Mean 2026.93 6.04% 3.63% -3.88% -3.48% -3.09% -3.67% -3.03% -2.37% -2.37% -3.26% 
 
D50% 1392.89 35.43% 29.83% -5.18% -6.44% -4.42% -6.44% -5.18% -4.69% -4.69% -5.83% 
R Parotid Mean 1544.70 9.12% 5.70% -3.70% -3.76% -2.89% -3.73% -2.67% -2.35% -2.35% -3.18% 
 
D50% 1021.88 26.60% 19.72% -5.62% -7.25% -4.97% -7.25% -5.62% -4.88% -4.88% -6.29% 
L Cochlea Mean 2689.28 1.82% 4.14% -2.09% -2.29% -1.07% -3.60% -1.82% -0.11% -0.11% -3.06% 
 
D05% 3192.78 2.43% 5.32% -1.44% -1.69% 0.88% -3.01% -16.98% 0.50% 0.50% -2.66% 
Mandible Max 7220.01 4.00% 4.66% -0.69% -0.58% 0.10% -0.21% -0.48% -0.25% -0.25% -0.34% 
Brain Max 5007.83 -3.34% -0.79% 0.06% -0.05% 1.32% -0.85% -0.01% 1.36% 1.36% -0.61% 
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Structure
s 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 70 D95% 6854.12 -0.03% 0.15% -0.41% -1.31% -0.02% -0.79% 0.02% -0.79% -0.10% -1.81% 0.01% -0.83% 
PTV 63 D95% 6163.19 -0.63% -0.54% -1.50% -0.74% 0.00% -0.80% 0.33% -1.29% 0.15% -2.86% 0.65% -1.91% 
PTV 57 D95% 5545.40 -0.32% -0.07% -0.55% -0.96% 0.10% -0.91% 0.45% -1.33% 0.14% -2.74% 0.79% -1.96% 
OARs 
Brainstem 
Max 
 to 1 cc 3863.71 0.96% 1.18% 2.70% -3.47% 1.56% -1.69% 1.31% -1.71% 2.69% -2.68% 2.23% -2.44% 
 
D100% 1167.00 0.51% -0.77% 2.49% -5.48% 0.00% -8.51% -2.77% -8.13% 8.11% -9.97% -0.99% 3.70% 
Cord Max 4082.86 -0.35% -0.28% -0.43% -1.80% 0.88% -0.55% 0.64% -0.51% 1.74% -0.49% 2.15% -0.39% 
 
Max 
 to 0.3 cc 4038.64 -0.66% -0.55% -0.61% -1.75% -0.51% -3.09% -0.59% -2.95% 0.82% -3.40% 0.50% -0.15% 
L Parotid Mean 2026.93 -2.75% -1.40% -1.28% -3.18% -0.64% -0.14% 1.03% -1.70% -0.75% 0.09% 2.69% -2.87% 
 
D50% 1392.89 -4.42% -4.07% -3.45% -5.72% -0.62% 0.02% 0.48% -0.94% -0.57% 0.21% 1.69% -1.45% 
R Parotid Mean 1544.70 -1.72% -1.95% -0.70% -3.60% -0.20% -0.05% 3.84% -3.89% -0.39% 0.18% 7.81% -7.28% 
 
D50% 1021.88 -4.97% -4.69% -3.64% -7.06% -0.15% -0.09% 1.65% -1.77% 0.08% -0.08% 3.64% -2.13% 
L Cochlea Mean 2689.28 0.65% 0.11% 2.83% -4.60% 0.78% -1.14% 1.18% -1.87% 1.93% -1.04% 2.77% -2.77% 
 
D05% 3192.78 0.88% 0.81% 3.29% -3.95% 1.48% -0.85% 1.87% -1.50% 2.70% -0.65% 2.76% -1.44% 
Mandible Max 7220.01 -0.03% 0.30% 0.68% -0.28% 0.13% -0.28% -0.01% -0.12% -0.10% 0.06% -0.25% 0.40% 
Brain Max 5007.83 2.72% 2.31% 4.57% -2.40% 0.92% -0.25% 2.68% -1.27% 1.71% -0.17% 3.85% -1.26% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
Failure Mode 4: Gantry Angle 
Failure Mode 5: Collimator 
Angle 
Failure Mode 6: Couch 
Angle 
Failure Mode 7: MU 
Linearity 
+ 2° -2° + 2° -2° + 2° -2° 1A 1B 2A 2B 3A 3B 
PTVs 
PTV 70 D95% 6854.12 -0.22% -0.35% -0.38% 0.00% -0.49% -1.08% -0.02% 0.00% 0.04% 0.00% -0.08% 0.04% 
PTV 63 D95% 6163.19 0.02% -0.88% -3.12% 0.00% -1.28% -0.17% 0.04% 0.00% 0.15% -0.01% 0.11% 0.01% 
PTV 57 D95% 5545.40 -0.49% -0.71% -1.51% 0.00% -1.26% -0.45% -0.02% 0.00% 0.07% -0.01% -0.07% 0.05% 
OARs 
Brainstem 
Max  
to 1 cc 3863.71 -0.05% 0.01% 3.07% 0.00% -0.92% 2.41% 0.07% 0.00% 0.26% -0.01% 0.15% 0.06% 
 
D100% 1167.00 0.09% 0.43% 3.34% 0.00% 0.26% 1.37% 0.00% 0.00% -0.09% 0.00% -0.09% 0.09% 
Cord Max 4082.86 0.75% 0.69% 1.98% 0.23% 0.95% 1.16% 0.15% -0.01% 0.38% -0.02% 0.22% 0.03% 
 
Max  
to 0.3 cc 4038.64 0.16% 0.63% 1.27% -0.28% -1.09% 1.10% 0.09% -0.03% 0.13% -0.03% 0.25% 0.01% 
L Parotid Mean 2026.93 5.16% -4.01% -4.38% 7.76% 11.96% -9.43% 0.23% -0.01% 0.20% -0.01% 0.85% -0.14% 
 
D50% 1392.89 3.79% -2.09% -1.26% 0.00% 8.34% -6.02% 0.58% -0.24% 0.47% -0.24% 0.91% -0.43% 
R Parotid Mean 1544.70 -4.10% 5.96% 5.16% -0.99% -4.13% 7.36% 0.04% -0.01% 0.04% -0.01% 0.42% -0.05% 
 
D50% 1021.88 -0.50% 2.13% 3.28% 0.00% -2.48% 4.64% 0.37% -0.02% 0.41% -0.02% 1.35% -0.21% 
L Cochlea Mean 2689.28 -2.27% 3.44% 6.15% 6.00% 10.55% -2.79% -0.05% 0.01% -0.03% 0.01% 0.05% 0.03% 
 
D05% 3192.78 -2.25% 5.11% 7.41% 0.00% 6.83% 1.96% -0.03% 0.00% -0.03% 0.00% 0.25% 0.00% 
Mandible Max 7220.01 -0.67% 0.01% 1.75% 1.05% 0.06% -0.03% -0.11% 0.01% -0.15% 0.01% -0.24% 0.08% 
Brain Max 5007.83 0.67% 0.08% 6.62% 5.18% 4.29% 0.52% -0.13% 0.01% -0.08% 0.00% -0.17% 0.10% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
MLC Modeling 
Failure Mode 11: CT 
Table 
Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 70 D95% 6854.12 -0.10% 0.02% -0.10% -0.18% 0.45% -0.70% -0.63% -0.64% -0.77% -0.17% 
PTV 63 D95% 6163.19 -0.10% 0.49% -0.11% -0.18% 0.69% -0.89% -0.84% -0.67% -0.97% -0.28% 
PTV 57 D95% 5545.40 -0.11% 0.92% -0.14% -0.10% 0.91% -1.24% -1.04% -1.04% -1.08% -0.28% 
OARs 
Brainstem 
Max  
to 1 cc 3863.71 -0.13% 2.44% -0.12% -0.11% 3.51% -2.11% -2.93% -0.52% -0.45% 0.32% 
 
D100% 1167.00 -0.86% 7.46% -0.69% 3.17% 19.79% -7.88% -7.54% 1.46% 2.06% 0.26% 
Cord Max 4082.86 -0.11% 2.45% -0.21% 0.86% 0.86% -0.12% -0.11% -1.50% -1.00% 0.13% 
 
Max 
 to 0.3 cc 4038.64 -0.37% 2.13% -0.17% 0.20% 1.13% -0.59% -0.43% -2.13% -1.14% -0.10% 
L Parotid Mean 2026.93 -0.77% 6.82% -0.07% -0.66% 1.99% -1.10% -0.88% 2.42% 3.02% -0.79% 
 
D50% 1392.89 -1.51% 9.76% -1.00% 3.02% 2.00% -3.94% -1.32% -9.04% 3.81% -1.75% 
R Parotid Mean 1544.70 -0.93% 10.75% -0.68% 2.95% 5.74% -3.69% -2.74% -1.89% -1.50% -0.46% 
 
D50% 1021.88 -1.57% 18.03% -1.14% 6.04% 5.57% -1.36% -1.15% -0.06% 0.54% -0.76% 
L Cochlea Mean 2689.28 -0.41% 4.52% -0.25% 1.10% 9.67% -1.90% -2.55% 1.47% -1.96% 0.39% 
 
D05% 3192.78 -0.22% 3.32% -0.15% 1.51% 8.21% -1.25% -1.94% 1.46% -2.04% 0.50% 
Mandible Max 7220.01 -0.11% -0.15% 0.17% -0.31% -0.10% 0.39% 0.47% -1.26% -1.54% -0.11% 
Brain Max 5007.83 0.09% 1.21% -0.17% 1.33% 1.55% -0.99% -1.77% -2.71% -3.57% 0.19% 
Table 107: Patient 2 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 3 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: 
Beam Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
PTVs 
PTV 66 D95% 6484.89 -3.34% -3.64% -0.08% -0.03% 0.15% -0.85% -0.20% -0.13% 0.08% -0.51% 
PTV 63 D95% 6308.66 -2.96% -6.56% 0.38% 0.36% -0.27% 1.25% 0.57% 0.54% -0.79% 1.35% 
PTV 60 D95% 5927.20 -5.43% -5.58% -0.08% 0.07% 0.03% -0.50% -0.03% 0.09% -0.14% -0.21% 
PTV 54 D95% 5231.74 -4.89% -5.56% -0.12% -0.08% 0.14% -0.95% -0.29% -0.24% 0.20% -0.58% 
OARs 
Brainstem Max 4687.22 3.01% 3.80% -0.10% -0.07% 0.33% -1.25% -0.58% -0.53% 0.75% -0.86% 
 
D100% 306.00 15.36% 6.21% -15.36% -15.36% -14.38% -16.34% -12.42% -12.09% -10.46% -12.75% 
Spinal Cord Max 4408.54 10.25% 10.84% 0.09% 0.11% 0.40% -0.83% -0.37% -0.35% 0.32% -0.62% 
 
Max 
 to 0.3 cc 4250.74 10.22% 10.52% -1.53% -1.48% -1.18% -2.42% -1.90% -1.86% -1.22% -2.16% 
L Parotid Mean 2457.69 5.92% 4.76% -2.66% -2.68% -2.30% -3.29% -2.09% -2.16% -1.53% -2.53% 
 
D50% 
1493.25 21.94% 17.74% -5.61% -5.76% -5.13% -6.61% -4.83% -5.05% -3.77% -5.43% 
R Parotid Mean 2202.19 7.19% 5.96% -1.81% -1.75% -1.51% -2.16% -1.45% -1.36% -1.18% -1.45% 
 
D50% 
1149.00 43.29% 37.90% -5.57% -5.37% -5.13% -6.18% -5.21% -4.96% -4.43% -5.28% 
L Cochlea Mean 3054.16 2.51% 5.78% -1.45% -1.73% -0.06% -3.32% -1.44% -1.81% 0.98% -2.73% 
 
D05% 4375.51 -1.73% 2.18% -3.53% -3.92% -2.25% -5.54% -3.71% -4.13% -1.27% -4.97% 
Mandible Max 7128.23 -0.41% 2.29% -0.16% -0.19% 0.58% -1.02% -0.22% -0.48% 0.60% -0.82% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95% 6484.89 -0.14% -0.09% -1.08% -1.76% 0.12% -0.23% 0.62% -0.28% -0.11% -0.77% -0.10% -1.39% 
PTV 63 D95% 6308.66 -1.22% -1.32% -3.14% 2.40% 0.04% 0.07% 0.07% 0.51% -0.67% -0.42% -0.96% 0.43% 
PTV 60 D95% 5927.20 -0.51% -0.27% -1.47% -1.22% 0.03% 0.08% 0.69% -0.75% -0.81% 0.07% -0.18% -2.29% 
PTV 54 D95% 5231.74 0.08% 0.18% -0.78% -2.28% 0.16% -0.25% 0.96% -0.47% 0.20% -0.83% 0.57% -1.72% 
OARs 
Brainstem Max 4687.22 1.19% 1.46% 2.28% -2.66% 0.93% -0.18% 0.92% 0.36% 1.13% -0.82% 0.44% -0.39% 
 
D100% 306.00 -12.42% -12.09% -10.13% -15.69% 0.98% -1.96% 7.19% -5.56% 7.19% -2.61% 12.09% -9.80% 
Spinal Cord Max 4408.54 1.33% 1.53% 1.79% -1.67% 0.13% 0.05% 0.28% 0.74% 0.25% -0.69% -0.63% 0.63% 
 
Max  
to 0.3 cc 4250.74 -0.35% 0.06% 0.88% -3.12% -1.74% -3.83% -1.15% -1.16% -3.22% -6.88% -1.68% -3.15% 
L Parotid Mean 2457.69 -1.41% -1.51% -0.22% -2.91% 0.10% 0.18% 4.25% -3.54% -0.48% 0.32% 7.49% -7.48% 
 
D50% 1493.25 -3.63% -1.82% -5.66% -8.27% 0.12% 0.08% 7.81% -5.60% 0.09% 0.06% 15.80% -11.17% 
R Parotid Mean 2202.19 -0.94% -0.73% -0.37% -1.49% 0.03% 0.21% 4.63% -3.48% 0.20% -0.20% 7.98% -7.58% 
 
D50% 1149.00 0.99% 0.44% 0.65% 1.03% 0.04% -0.19% 5.72% -3.57% 1.24% -0.52% 11.54% -6.78% 
L Cochlea Mean 3054.16 0.26% -0.68% 3.56% -5.54% 0.07% -0.18% 2.65% -2.18% 0.21% -0.64% 4.88% -4.97% 
 
D05% 4375.51 -1.87% -2.95% 2.40% -8.74% -3.43% -3.86% -0.40% -5.10% -1.69% -4.23% 1.04% -8.20% 
Mandible Max 7128.23 0.99% 0.49% 2.32% -0.85% 0.03% -0.67% 0.32% 0.22% 0.20% -0.78% -0.46% 0.04% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95 6484.89 -0.37% -0.33% -1.37% -2.93% -0.51% -0.33% -0.27% 0.00% -0.22% -0.01% -0.25% 0.02% 
PTV 63 D95 6308.66 -0.15% 0.15% -0.90% 0.68% -0.22% 0.15% -0.11% -0.01% 0.12% -0.03% -0.06% 0.01% 
PTV 60 D95 5927.20 -0.93% 0.76% -0.52% -1.34% -1.46% 0.76% -0.29% -0.01% -0.16% -0.02% -0.21% 0.00% 
PTV 54 D95 5231.74 -0.06% -0.96% -2.08% -5.55% -0.18% -0.96% -0.17% -0.01% -0.09% -0.01% -0.12% 0.00% 
OARs 
Brainstem Max 4687.22 0.33% -0.81% 0.10% 5.89% 3.35% -0.81% -0.07% -0.01% 0.07% -0.02% 0.02% -0.01% 
 
D100 306.00 0.00% 1.31% -3.27% 2.94% -0.65% 1.31% -0.33% 0.00% -0.33% 0.00% -0.33% 0.00% 
Spinal Cord Max 4408.54 0.46% -0.93% -4.28% 10.48% 1.25% -0.93% -0.06% -0.01% 0.10% -0.02% 0.05% -0.01% 
 
Max 
 to 0.3 cc 4250.74 0.51% 0.04% -3.83% 11.52% 1.35% 0.04% -2.16% -1.90% -2.02% -1.93% -2.01% -1.93% 
L Parotid Mean 2457.69 0.50% -5.77% 2.03% 6.64% 11.08% -5.77% -0.29% 0.00% -0.22% -0.01% -0.30% 0.03% 
 
D50% 1493.25 1.88% -9.63% 28.71% -9.63% 14.96% 19.45% -0.23% 0.00% -0.14% 0.00% -0.01% 0.00% 
R Parotid Mean 2202.19 -1.81% 2.02% 2.74% 2.22% 0.56% 2.02% -0.04% -0.01% 0.01% -0.01% 0.07% 0.00% 
 
D50% 1149.00 -0.54% 9.67% -0.58% 9.67% 5.44% 16.56% 0.02% -0.06% 0.15% -0.06% 0.31% -0.09% 
L Cochlea Mean 3054.16 -2.09% -12.84% 8.00% -4.03% 12.67% -12.84% -0.43% 0.00% -0.53% 0.01% -0.32% -0.02% 
 
D05% 4375.51 -6.58% -21.99% 6.20% -14.38% 14.68% -21.99% -4.38% -3.86% -4.51% -3.86% -4.30% -3.89% 
Mandible Max 7128.23 0.32% -1.22% 0.15% 2.49% 0.89% -1.22% -0.39% 0.00% -0.38% 0.00% -0.44% 0.03% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95 6484.89 -0.04% 0.42% -0.08% -0.19% 0.39% -0.81% -0.87% 0.00% 0.00% 0.00% 
PTV 63 D95 6308.66 -0.05% 0.58% -0.19% 0.41% -0.52% 0.59% 0.64% 0.00% 0.00% 0.00% 
PTV 60 D95 5927.20 -0.04% 0.81% -0.11% -0.23% 0.02% -0.39% -0.48% 0.00% 0.00% 0.00% 
PTV 54 D95 5231.74 -0.06% 1.25% -0.01% -0.25% 1.16% -0.96% -0.98% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 4687.22 -0.16% 1.70% -0.08% 0.66% 1.17% -0.18% -0.57% 0.00% 0.00% 0.00% 
 
D100 306.00 0.00% 1.96% 0.00% 1.31% 4.90% -0.33% -0.98% 0.00% 0.00% 0.00% 
Spinal Cord Max 4408.54 -0.23% 1.96% -0.09% 0.59% 1.01% -0.08% -0.18% 0.00% 0.00% 0.00% 
 
Max 
 to 0.3 cc 4250.74 -2.16% -1.32% -1.90% -3.86% -1.48% -5.77% -6.14% -1.90% -1.90% -1.90% 
L Parotid Mean 2457.69 -0.65% 6.45% -0.33% 0.57% 5.50% -3.67% -3.25% 0.00% 0.00% 0.00% 
 
D50% 1493.25 -1.28% 13.48% -0.44% 3.01% 14.38% -6.40% -6.27% 0.00% 0.00% 0.00% 
R Parotid Mean 2202.19 -0.60% 7.82% -0.66% 2.75% 5.76% -3.86% -2.98% 0.00% 0.00% 0.00% 
 
D50% 1149.00 -1.56% 18.73% -1.42% 6.79% 16.56% -5.21% -4.83% 0.00% 0.00% 0.00% 
L Cochlea Mean 3054.16 -0.45% 3.47% -0.44% 0.69% 8.60% -1.34% -1.93% 0.00% 0.00% 0.00% 
 
D05% 4375.51 -4.09% -2.45% -4.32% -4.87% 2.74% -5.51% -5.78% -3.86% -3.86% -3.86% 
Mandible Max 7128.23 0.01% 0.15% -0.05% -0.48% 0.31% -0.45% -0.72% 0.00% 0.00% 0.00% 
Table 108: Patient 3 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 4 
Structures 
Evaluation 
Criteria 
Baseline Dose 
(cGy) 
Failure Mode 1: Beam 
Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to 
left 
PTVs 
PTV 66 D95% 6503.93 -0.21% -0.07% 0.08% 0.02% 0.05% -0.17% 0.16% 0.10% -0.17% 0.08% 
PTV 60 D95% 5825.80 -0.15% -0.77% -0.02% -0.13% 0.18% -0.70% -0.05% -0.17% 0.19% -0.41% 
PTV 54 D95% 5233.56 -0.14% -1.82% 0.16% 0.09% 0.47% -0.86% 0.04% -0.04% 0.65% -0.69% 
OARs 
Brainstem Max 3531.81 -1.21% -1.90% -0.84% -0.86% -0.26% -2.12% -0.75% -0.77% 0.55% -1.61% 
 
Max 
 to 1 cc 2945.23 -0.68% -1.40% -1.47% -1.47% -0.71% -2.88% -1.33% -1.30% 0.33% -2.25% 
Spinal Cord Max 3331.31 0.43% 0.64% -0.23% -1.88% -1.79% -1.33% 0.05% -1.57% -0.72% 0.54% 
 
Max  
to 0.03 cc 3291.92 0.44% 0.47% -0.18% -1.82% -1.73% -1.24% 0.15% -1.52% -0.67% 0.58% 
L Parotid Mean 2090.86 -2.81% -1.26% -2.30% -2.34% -1.85% -3.21% -1.74% -1.80% -1.30% -2.53% 
 
D50% 1489.64 -5.19% -1.68% -4.35% -4.48% -3.63% -5.56% -3.43% -3.57% -2.86% -4.40% 
R Parotid Mean 3805.94 -1.21% -2.63% -1.29% -1.36% -0.63% -2.01% -0.98% -1.02% -0.26% -1.55% 
 
D50% 3210.12 -2.57% -3.94% -1.21% -1.06% -0.31% -2.57% -1.27% -1.14% -1.31% -1.90% 
L Cochlea Mean 1044.82 -8.57% -6.90% -1.38% -1.70% -0.43% -3.26% -2.23% -2.52% -0.54% -3.50% 
 
D05% 1322.08 -7.17% -6.35% -0.76% -1.19% 0.15% -2.70% -1.72% -1.97% 0.08% -2.87% 
R Cochlea Mean 1639.80 -3.33% -4.74% -2.42% -2.45% -1.09% -4.05% -2.30% -2.33% 0.14% -3.22% 
 
D05% 2074.80 -3.28% -3.96% -1.83% -1.91% -0.53% -3.50% -1.71% -1.83% 0.66% -2.75% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95% 6503.93 -0.36% -0.24% -0.80% -0.32% -0.13% 0.10% -0.42% 0.34% -0.76% 0.05% -1.25% 0.45% 
PTV 60 D95% 5825.80 0.26% 0.16% 0.39% -1.19% -0.42% 0.23% -1.10% 0.99% -4.15% 0.36% -2.86% 1.74% 
PTV 54 D95% 5233.56 0.85% 0.95% 1.39% -1.67% -0.48% 0.62% -1.64% 1.36% -3.76% 0.98% -4.35% 2.19% 
OARs 
Brainstem Max 3531.81 0.68% 0.90% 2.49% -3.32% -2.68% 2.82% -2.50% 2.01% -6.07% 4.81% -5.96% 4.31% 
 
Max  
to 1 cc 2945.23 0.09% 0.62% 2.46% -4.39% -2.16% 2.53% -2.64% 2.76% -4.76% 4.88% -5.62% 5.21% 
Spinal Cord Max 3331.31 2.14% -2.92% -4.01% -0.42% -1.52% 0.01% -2.37% 4.18% -2.48% 0.78% -2.91% 6.51% 
 
Max 
 to 0.03 cc 3291.92 2.28% -2.97% -3.93% -0.30% -1.38% 0.11% -3.60% 4.30% -3.80% -58.21% -5.11% 6.73% 
L Parotid Mean 2090.86 -1.43% -1.28% -0.32% -3.29% -0.05% 0.64% -2.08% 2.71% -0.55% 1.02% -4.24% 5.37% 
 
D50% 1489.64 -2.99% -3.12% -1.66% -5.63% -0.51% 0.95% -1.68% 2.08% -1.54% 1.81% -3.45% 4.16% 
R Parotid Mean 3805.94 0.04% 0.06% 1.52% -2.23% 0.07% 0.25% -1.93% 2.11% -0.49% 0.46% -4.14% 4.21% 
 
D50% 3210.12 -1.72% -0.12% 2.20% -2.45% -1.61% -0.25% -2.94% 2.32% -1.40% -1.09% -7.17% 7.54% 
L Cochlea Mean 1044.82 3.69% 3.42% 6.25% -1.91% -0.81% 0.26% -6.87% 7.82% -2.81% 0.50% -13.37% 17.99% 
 
D05% 1322.08 6.27% 5.74% 6.28% 0.33% -1.02% 0.39% -6.49% 9.26% -4.35% 0.85% -13.24% 21.09% 
R Cochlea Mean 1639.80 1.73% 1.79% 4.87% -4.07% 0.74% -0.14% -9.94% 8.45% 0.51% -0.60% -20.77% 18.63% 
 
D05% 2074.80 1.86% 1.47% 4.82% -4.09% 0.94% -0.10% -9.00% 8.55% 0.72% -0.63% -17.71% 21.47% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95% 6503.93 -0.13% -0.11% -0.23% -0.43% -0.89% -1.35% -0.16% -0.02% -0.08% -0.03% -0.10% 0.05% 
PTV 60 D95% 5825.80 -0.80% 0.16% -0.06% -1.61% -0.09% -3.68% -0.30% -0.02% -0.28% -0.03% -0.45% 0.08% 
PTV 54 D95% 5233.56 -0.28% -0.48% -1.49% -1.64% -2.56% -3.41% -0.19% -0.02% -0.24% -0.02% -0.34% 0.20% 
OARs 
Brainstem Max 3531.81 -2.61% 3.03% 6.31% 5.35% 3.90% -4.44% -0.45% -0.01% -0.53% 0.00% -0.98% 0.31% 
 
Max  
to 1 cc 2945.23 -0.21% 0.43% 1.59% 0.10% 8.77% -3.99% -0.27% 0.00% -0.19% 0.00% -0.72% 0.31% 
Spinal Cord Max 3331.31 3.54% 1.14% 2.07% 0.29% 0.07% 0.36% -0.01% 0.00% -0.01% 0.00% -0.01% 0.00% 
 
Max 
 to 0.03 cc 3291.92 0.30% 0.58% 0.77% -0.03% -0.11% 0.07% -0.03% 0.00% -0.03% 0.00% 0.06% 0.00% 
L Parotid Mean 2090.86 5.64% -4.53% 6.59% -3.92% -0.11% 3.15% 0.11% -0.03% 0.10% -0.04% 0.46% 0.13% 
 
D50% 1489.64 4.85% -2.87% 7.78% -5.06% -2.60% 6.87% 0.39% -0.06% 0.47% -0.07% 1.22% -0.22% 
R Parotid Mean 3805.94 -2.22% 2.49% -3.74% 5.59% 3.33% -1.34% -0.30% -0.02% -0.22% -0.03% -0.34% -0.02% 
 
D50% 3210.12 -4.02% 9.89% -6.62% 14.85% 12.79% -3.71% -0.05% -0.02% -0.05% -0.05% -0.52% 0.30% 
L Cochlea Mean 1044.82 -0.69% 1.22% -0.88% 1.96% 5.50% -4.56% -0.44% -0.02% -0.34% -0.03% -0.39% 0.16% 
 
D05% 1322.08 -0.41% 2.49% 2.54% 1.59% 6.05% -4.39% -0.45% 0.00% -0.19% 0.00% -0.74% 0.23% 
R Cochlea Mean 1639.80 3.66% -3.46% 23.88% -8.44% -2.56% 17.09% -0.18% -0.02% -0.26% -0.01% -0.35% -0.06% 
 
D05% 2074.80 4.90% -4.40% 29.46% 1.58% 7.44% 23.74% -0.38% 0.00% -0.47% 0.00% -0.88% -0.05% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose (cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 
4 cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95% 6503.93 0.03% -0.26% -0.04% 0.27% 0.60% -0.79% -0.29% 0.00% 0.00% 0.00% 
PTV 60 D95% 5825.80 0.12% -1.02% -0.11% 0.63% 1.53% -1.86% -1.06% 0.00% 0.00% 0.00% 
PTV 54 D95% 5233.56 0.08% -0.95% -0.02% 1.19% 1.78% -2.40% -1.87% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 3531.81 -0.01% -0.20% -0.23% 3.30% 3.17% -5.60% -3.97% 0.00% 0.00% 0.00% 
 
Max 
 to 1 cc 2945.23 -0.32% 1.38% -0.34% 4.84% 3.94% -4.70% -4.46% 0.00% 0.00% 0.00% 
Spinal Cord Max 3331.31 -0.12% 0.24% -0.14% 1.58% 1.54% -1.76% -1.28% 0.00% 0.00% 0.00% 
 
Max 
to 0.03 cc 3291.92 -0.15% 0.24% -0.15% 1.49% 1.64% -1.75% -1.23% 0.00% 0.00% 0.00% 
L Parotid Mean 2090.86 -0.02% 0.27% -0.50% 7.31% 4.25% -2.82% -1.87% 0.00% 0.00% 0.00% 
 
D50% 1489.64 -0.46% 2.14% -1.10% 11.80% 4.84% -2.93% -2.12% 0.00% 0.00% 0.00% 
R Parotid Mean 3805.94 -0.14% 0.40% -0.42% 3.06% 2.67% -2.67% -1.68% 0.00% 0.00% 0.00% 
 
D50% 3210.12 -0.17% 0.00% -0.28% 4.45% 5.05% -3.86% -2.75% 0.00% 0.00% -3.11% 
L Cochlea Mean 1044.82 -1.29% 6.32% -1.49% 16.00% 21.51% -7.45% -8.40% 0.00% 0.00% 0.00% 
 
D05% 1322.08 0.38% 7.43% -1.49% 15.11% 23.44% -8.74% -10.06% 0.00% 0.00% 0.00% 
R Cochlea Mean 1639.80 -0.89% 4.04% -0.99% 8.64% 12.48% -7.28% -7.93% 0.00% 0.00% 0.00% 
 
D05% 2074.80 -1.00% 4.77% -0.94% 6.09% 11.98% -8.39% -9.23% 0.00% 0.00% 0.00% 
Table 109: Patient 4 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 5 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: Beam 
Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
PTVs 
PTV 70 D95% 6750.39 -0.40% -0.51% 0.03% 0.09% 0.15% 0.17% -0.03% 0.22% -0.16% -0.11% 
PTV 60 D95% 6021.80 -0.38% -1.89% -0.11% 0.33% 0.29% 0.19% -0.17% 0.45% 0.07% -0.04% 
PTV 56 D95% 5670.80 -1.50% -1.94% -0.39% 0.06% 0.15% 0.10% -0.46% 0.21% -0.19% -0.25% 
OARs 
Brainstem Max 4732.41 -0.30% -2.28% -1.36% 0.09% -0.39% -0.43% -1.18% 0.76% -0.63% -0.77% 
 
Max  
to 1 cc 4278.49 0.48% -1.86% -1.48% -0.18% -0.26% -0.41% -1.25% 1.02% -0.42% -0.60% 
Spinal Cord Max 3982.58 -0.08% 2.04% -0.62% -0.38% -0.24% -0.26% -0.41% 0.17% -0.28% -0.43% 
 
Max 
 to 0.3 cc 3864.34 0.17% 2.27% -9.27% -28.66% 0.20% -0.80% 0.12% 0.15% 0.43% 0.35% 
L Parotid Mean 1803.35 -9.04% -6.09% -2.40% -1.95% -2.10% -1.93% -2.11% -1.24% -1.99% -1.73% 
 
D50% 1232.46 -11.20% -5.17% -2.48% -1.91% -2.13% -1.96% -1.69% -0.59% -1.50% -1.32% 
R Parotid Mean 2371.41 -3.71% -2.22% -1.88% -1.45% -1.52% -1.67% -1.67% -0.90% -1.37% -1.55% 
 
D50% 1686.91 -3.44% 0.54% -0.45% 0.25% 0.02% 0.06% -0.03% 1.24% 0.32% 0.39% 
Mandible Max 7408.85 1.64% -1.20% -0.29% 0.87% 0.50% 0.35% -0.42% 0.77% 0.23% 0.01% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 70 D95% 6750.39 -0.57% -0.08% -0.06% 0.06% -1.00% 0.73% 3.19% 0.26% -2.36% 0.93% -1.40% 3.54% 
PTV 60 D95% 6021.80 -1.17% 0.14% 0.11% 0.07% -1.53% 0.83% 2.93% 0.46% -3.82% 1.03% -2.85% 4.10% 
PTV 56 D95% 5670.80 -2.58% -1.60% -1.12% -1.30% -2.53% -0.44% -2.14% -0.80% -5.68% -0.52% -4.02% -0.23% 
OARs 
Brainstem Max 4732.41 -2.53% 2.81% 1.20% 1.22% -1.45% 1.62% 1.75% 1.62% -2.21% 2.71% 0.33% 2.94% 
 
Max 
 to 1 cc 4278.49 -2.52% 3.51% 1.89% 1.34% 1.11% 0.12% 2.29% 0.53% 1.48% -0.32% 1.10% 1.99% 
Spinal Cord Max 3982.58 6.55% 2.55% 2.85% 3.46% 4.42% 7.66% 6.16% 7.92% 4.65% 10.11% 4.92% 11.19% 
 
Max 
 to 0.3 cc 3864.34 0.09% 0.12% 8.10% 3.77% 5.74% 8.18% 7.38% 7.35% 5.30% 9.77% 5.60% 11.17% 
L Parotid Mean 1803.35 -8.12% -6.52% -7.49% -6.89% -11.86% 2.12% -6.86% -3.09% -17.80% 9.71% -8.49% -0.46% 
 
D50% 1232.46 -10.55% -8.69% -9.56% -9.52% -11.06% 1.78% -6.60% -3.81% -15.58% 10.23% -8.20% 0.35% 
R Parotid Mean 2371.41 -1.02% 0.78% -0.10% -0.67% -1.90% 4.27% 23.72% 7.03% -4.35% 7.51% -9.40% 13.69% 
 
D50% 1686.91 -1.14% 1.73% 0.18% 0.16% -0.69% 6.84% 46.68% 10.04% -2.86% 12.23% -8.19% 68.67% 
Mandible Max 7408.85 1.56% 4.31% 3.27% 2.96% 2.18% 1.61% 13.57% 3.23% 1.73% 0.90% 0.28% 4.05% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 70 D95% 6750.39 0.06% -0.75% 0.36% -0.75% -1.17% -0.29% -0.06% 0.00% -0.22% -0.01% -0.11% -0.05% 
PTV 60 D95% 6021.80 -2.23% -0.55% -0.42% -0.55% -1.48% -1.87% -0.07% 0.00% -0.35% -0.01% -0.19% -0.01% 
PTV 56 D95% 5670.80 -0.15% -0.81% 0.85% -0.81% -2.77% -1.22% -0.06% 0.00% -0.25% -0.01% -0.05% -0.08% 
OARs 
Brainstem Max 4732.41 0.41% 1.68% 3.63% 1.68% 2.16% 1.06% 0.00% 0.00% -0.22% -0.01% -0.17% 0.04% 
 
Max  
to 1 cc 4278.49 -0.10% 0.14% 0.59% 0.14% 3.14% -2.47% 0.00% 0.00% -0.29% -0.02% -0.03% -0.05% 
Spinal Cord Max 3982.58 1.68% 3.46% 1.00% 3.46% 5.06% 0.61% 0.10% -0.01% 0.25% -0.03% 0.17% -0.06% 
 
Max  
to 0.3 cc 3864.34 1.26% 3.47% 1.32% 3.47% 4.99% 0.95% 0.13% 0.00% 0.27% -0.02% 0.20% -0.08% 
L Parotid Mean 1803.35 14.31% -7.17% 11.16% -7.17% -8.04% 12.92% -0.03% -0.01% -0.26% -0.01% 0.44% -0.27% 
 
D50% 1232.46 18.70% -5.39% 15.54% -5.39% -6.28% 21.63% 0.07% -0.02% -0.13% -0.04% 0.77% -0.44% 
R Parotid Mean 2371.41 -8.50% 8.70% -4.84% 8.70% 6.49% -2.21% -0.08% 0.00% -0.36% -0.01% 0.14% -0.17% 
 
D50% 1686.91 -2.85% 16.44% -3.07% 16.44% 14.50% 3.41% -0.13% -0.02% -0.43% -0.04% 0.15% -0.28% 
Mandible Max 7408.85 0.54% 0.78% -0.13% 0.78% 1.06% -1.24% 0.01% 0.00% -0.20% -0.01% 0.11% -0.07% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 
15 cm 
radius = 20 
cm 
+2% -2% PET CT 
PTVs 
PTV 70 D95% 6750.39 -0.19% 0.34% 0.00% 0.06% 0.73% -1.27% -0.84% 0.04% 0.04% 0.04% 
PTV 60 D95% 6021.80 -0.29% 1.04% -0.14% 0.34% 1.92% -2.99% -2.16% 0.08% 0.08% 0.08% 
PTV 56 D95% 5670.80 -1.32% 0.29% -1.17% -0.49% 0.78% -4.42% -3.16% -1.06% -1.06% -1.06% 
OARs 
Brainstem Max 4732.41 -0.12% 1.93% 0.24% 0.25% 3.05% -1.63% -1.29% 0.24% 0.24% 0.24% 
 
Max  
to 1 cc 4278.49 0.27% 2.93% 0.73% 0.27% 2.08% 0.61% 0.50% 0.64% 0.64% 0.64% 
Spinal Cord Max 3982.58 4.40% 6.70% 5.65% 3.08% 9.42% 2.95% 3.38% 4.78% 4.78% 4.78% 
 
Max 
 to 0.3 cc 3864.34 4.92% 5.27% 6.00% 8.48% -4.15% -18.16% 10.32% 7.25% 3.54% 6.37% 
L Parotid Mean 1803.35 -6.45% 6.03% -6.04% -1.39% 6.31% -12.60% -10.72% -5.25% -5.25% -5.25% 
 
D50% 1232.46 -7.38% 13.48% -6.83% 1.27% 12.08% -12.67% -11.27% -5.41% -5.41% -5.41% 
R Parotid Mean 2371.41 -0.23% 11.21% 0.15% 4.53% 13.16% -7.09% -5.03% 1.07% 1.07% 1.07% 
 
D50% 1686.91 0.62% 20.71% 1.31% 8.90% 24.83% -7.27% -5.22% 2.79% 2.79% 2.79% 
Mandible Max 7408.85 1.74% 1.51% 1.90% 2.34% 1.76% 1.13% 1.85% 1.86% 1.86% 1.86% 
Table 110: Patient 5 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 6 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: 
Beam Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
PTVs 
PTV 66 D95% 6555.71 0.27% 0.03% -0.09% -0.05% 0.07% 0.12% 0.03% 0.21% 0.18% 0.25% 
PTV 60 D95% 5770.01 0.68% -0.61% -0.39% 0.06% -0.08% 0.00% -0.29% 0.38% 0.01% 0.12% 
PTV 54 D95% 5269.47 -0.06% -1.70% -0.81% -0.45% -0.18% -0.27% -0.64% -0.24% -0.18% -0.21% 
OARs 
Brainstem Max 3788.73 -0.25% -3.36% -2.41% -0.05% -0.72% -0.88% -2.08% 0.79% -1.02% -1.25% 
 
Max 
 to 1 cc 3462.73 0.03% -2.60% -2.26% -0.17% -0.75% -0.84% -2.10% 0.72% -1.05% -1.11% 
Spinal Cord Max 4313.56 -0.37% 0.16% -0.88% -0.69% -0.56% -0.47% -0.34% -0.13% -0.21% -0.18% 
 
Max  
to 0.3 cc 4210.19 -0.35% 0.50% -0.78% -0.59% -0.43% -0.36% -0.28% -0.24% -0.17% -0.05% 
L Parotid Mean 1820.60 -4.22% -3.81% -3.05% -1.93% -2.39% -2.35% -2.65% -1.31% -2.13% -2.05% 
 
D50% 1023.41 -9.05% -5.30% -5.71% -4.27% -4.77% -4.95% -5.06% -2.86% -4.29% -4.59% 
R Parotid Mean 2244.12 -3.41% -4.31% -3.36% -2.04% -2.77% -2.40% -3.05% -1.24% -2.36% -1.94% 
 
D50% 1230.34 -11.62% -7.02% -7.31% -5.99% -6.59% -6.39% -6.70% -4.65% -6.07% -5.82% 
Mandible Max 6759.36 0.14% -1.93% -0.72% 0.44% 0.10% 0.12% -0.54% 0.61% 0.05% 0.10% 
L Submandibular Max 5956.60 1.14% 1.84% -0.06% 0.02% 0.06% 0.08% 0.36% 0.29% 0.26% 0.21% 
 
Mean 5130.42 -0.21% 1.19% -0.07% -0.21% -0.29% -0.18% 0.18% 0.01% -0.06% 0.08% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right 
to left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95% 6555.71 -0.19% -0.19% 0.02% -0.09% -0.46% 0.37% -0.44% 0.78% -1.12% 0.83% -1.52% 1.11% 
PTV 60 D95% 5770.01 -0.64% 0.30% 0.19% 0.14% -0.38% 0.41% -0.99% 1.42% -1.06% 0.84% -2.72% 2.12% 
PTV 54 D95% 5269.47 -1.48% -0.95% -0.14% -0.77% -0.74% 0.44% -0.99% 0.68% -2.01% 0.47% -3.09% 0.67% 
OARs 
Brainstem Max 3788.73 -3.70% 3.82% 1.78% 1.02% -0.49% 1.33% -0.71% 2.49% -1.04% 1.45% -1.86% 4.35% 
 
Max  
to 1 cc 3462.73 -3.43% 3.56% 1.33% 1.04% -0.15% 1.81% -0.04% 2.50% -0.56% 2.17% -0.77% 3.43% 
Spinal Cord Max 4313.56 -0.80% -0.06% -0.52% -0.50% -0.36% 0.05% -0.44% 1.49% -1.07% 1.32% -1.21% 3.24% 
 
Max 
 to 0.3 cc 4210.19 -1.29% -0.15% -0.52% -0.50% -1.12% 0.47% -0.85% 1.31% -1.21% 1.80% -1.71% 2.64% 
L Parotid Mean 1820.60 -2.90% 0.47% -1.15% -1.01% -3.04% 3.57% -1.57% 2.39% -6.03% 7.88% -3.52% 4.65% 
 
D50% 1023.41 -6.30% -0.28% -1.99% -3.07% -5.55% 3.85% -1.08% 2.32% -5.32% 9.69% -2.93% 4.85% 
R Parotid Mean 2244.12 -3.44% 0.88% -1.50% -0.70% -1.46% 3.08% -1.93% 4.63% -2.78% 5.71% -4.43% 8.40% 
 
D50% 1230.34 -8.45% -1.62% -3.90% -3.55% -4.07% 6.69% -1.17% 7.02% -6.18% 12.51% -3.89% 12.81% 
Mandible Max 6759.36 -1.07% 1.78% 0.83% 0.71% -0.82% 1.81% -1.10% 1.31% -1.04% 3.35% -2.59% 1.94% 
L Submandibular Max 5956.60 -0.02% 0.05% -0.14% -0.19% -0.29% -0.14% -0.75% 0.74% -0.93% 0.70% -1.06% 2.53% 
 
Mean 5130.42 0.10% -0.38% -0.52% -0.34% -0.87% 0.85% -0.57% 0.91% -2.05% 2.33% -1.69% 2.08% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degree
s 
-2 
degree
s 
+ 2 
degree
s 
-2 
degree
s 
+ 2 
degree
s 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95% 6555.71 -0.05% -0.23% 0.34% -0.99% 1.33% 0.42% -0.09% 0.00% -0.05% -0.01% 0.12% 0.15% 
PTV 60 D95% 5770.01 -0.33% -0.22% 1.24% -1.44% 0.38% -1.29% -0.05% 0.00% -0.07% -0.01% 0.27% 0.09% 
PTV 54 D95% 5269.47 -0.38% -0.17% -0.08% -0.79% -2.90% -5.11% -0.17% -0.01% -0.31% 0.00% 0.16% 0.07% 
OARs 
Brainstem Max 3788.73 0.09% -0.15% 3.33% -0.96% 17.26% 12.84% -0.39% 0.00% -0.44% 0.01% -0.71% 0.36% 
 
Max 
 to 1 cc 3462.73 1.09% -0.89% 2.94% -2.92% 11.77% 7.88% -0.12% 0.00% -0.09% -0.02% -0.33% 0.36% 
Spinal Cord Max 4313.56 0.54% 0.00% 0.74% -0.54% 11.27% 6.43% -0.28% 0.00% -0.47% 0.01% 0.19% 0.05% 
 
Max 
 to 0.3 cc 4210.19 0.63% 0.48% 0.64% 0.12% 9.41% 6.10% -0.33% 0.00% -0.50% 0.02% 0.31% 0.02% 
L Parotid Mean 1820.60 7.08% -5.46% 3.59% -2.38% -2.21% 2.31% 0.34% -0.03% 0.25% -0.03% 1.91% -0.31% 
 
D50% 1023.41 5.19% -3.25% 1.15% -0.87% -0.55% 0.75% 0.25% -0.04% 0.01% -0.04% 1.67% -0.32% 
R Parotid Mean 2244.12 -3.88% 5.57% 1.73% 3.06% 11.01% 1.48% 0.06% 0.00% 0.21% -0.02% 0.29% 0.12% 
 
D50% 1230.34 -3.50% 7.90% 2.83% 1.68% 22.26% 8.57% -0.06% 0.00% 0.04% 0.00% -0.37% 0.00% 
Mandible Max 6759.36 -1.48% 1.30% -1.55% 2.32% 1.57% 2.65% -0.31% 0.00% -0.37% 0.01% -0.39% 0.27% 
L Submandibular Max 5956.60 -0.03% 0.53% 1.86% -1.28% 3.04% -1.87% -0.12% -0.01% -0.26% 0.01% 0.39% -0.04% 
 
Mean 5130.42 0.66% -0.50% 2.05% -1.66% -0.11% -0.40% -0.02% -0.01% -0.13% 0.00% 0.75% -0.14% 
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Structures 
Evaluatio
n Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95% 6555.71 0.20% 0.67% 0.18% 0.11% 0.71% -0.38% 0.13% 0.00% 0.00% 0.00% 
PTV 60 D95% 5770.01 0.16% 1.23% 0.16% 0.01% 1.59% -0.96% -0.36% 0.00% 0.00% 0.00% 
PTV 54 D95% 5269.47 0.02% 1.40% 0.15% -0.20% 0.80% -1.28% -0.63% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 3788.73 -0.09% 2.91% 0.23% 0.24% 2.89% -1.05% -0.63% 0.00% 0.00% 0.00% 
 
Max  
to 1 cc 3462.73 -0.11% 3.75% 0.37% 0.25% 2.83% -0.83% -0.46% 0.00% 0.00% 0.00% 
Spinal Cord Max 4313.56 0.00% 2.62% 0.11% 0.27% 2.63% -0.84% -0.32% 0.00% 0.00% 0.00% 
 
Max  
to 0.3 cc 4210.19 0.02% 2.78% 0.26% -0.26% 3.09% -1.14% -0.50% 0.00% 0.00% 0.00% 
L Parotid Mean 1820.60 -0.83% 9.76% -0.34% 2.27% 8.39% -4.37% -3.22% 0.00% 0.00% 0.00% 
 
D50% 1023.41 -1.80% 20.81% -1.01% 6.00% 17.53% -5.99% -4.67% 0.00% 0.00% 0.00% 
R Parotid Mean 2244.12 -0.43% 8.39% -0.14% 1.58% 8.01% -4.24% -2.85% 0.00% 0.00% 0.00% 
 
D50% 1230.34 -1.54% 19.51% -1.05% 5.45% 21.86% -8.13% -6.54% 0.00% 0.00% 0.00% 
Mandible Max 6759.36 0.22% 0.36% 0.06% 0.35% 1.46% -0.71% -0.32% 0.00% 0.00% 0.00% 
L Submandibular Max 5956.60 0.06% 0.96% 0.19% -0.44% 1.13% -0.13% 0.14% 0.00% 0.00% 0.00% 
 
Mean 5130.42 -0.08% 1.87% 0.01% 0.33% 2.35% -1.44% -0.85% 0.00% 0.00% 0.00% 
Table 111: Patient 6 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 7 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: 
Beam Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom to 
top 
Left to 
right 
Right to left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right 
to left 
PTVs 
PTV 66 D95 6555.71 -0.06% -0.73% -0.15% -0.16% -0.50% -0.06% -0.04% -0.05% -0.29% 0.12% 
PTV 60 D95 5770.01 -0.34% -0.16% -0.03% -0.02% 0.16% -0.07% 0.17% 0.18% 0.46% 0.17% 
PTV 54 D95 5269.47 -0.27% -0.93% -0.25% -0.07% 0.22% -0.31% 0.09% 0.32% 0.37% -0.31% 
OARs 
Brainstem Max 3839.33 0.81% -1.40% -1.38% -1.33% -2.72% -0.27% -1.43% -1.46% -2.19% 1.25% 
 
Max to 1 cc 3666.80 0.47% -1.00% -1.55% -1.50% -2.76% -0.57% -1.49% -1.47% -2.09% 0.99% 
Cord Max 4326.81 -0.48% -0.04% -0.05% -0.26% -0.26% 0.13% 0.02% -0.23% 0.20% 0.67% 
 
Max 
to 0.3 cc 4242.28 -0.60% 0.03% -0.24% -0.39% -0.59% 0.03% -0.18% -0.42% -0.37% 0.63% 
L Parotid Mean 3550.33 -2.19% -1.65% -2.01% -2.07% -2.43% -1.53% -1.70% -1.77% -2.14% -0.88% 
 
D50 2526.12 -6.15% -3.20% -3.18% -3.21% -3.80% -2.56% -3.21% -3.33% -4.82% -2.06% 
R Parotid Mean 1969.74 -5.43% -2.00% -3.02% -2.78% -3.26% -2.43% -2.66% -2.37% -2.72% -1.78% 
 
D50 1139.00 -11.59% -1.67% -6.50% -6.41% -6.94% -5.97% -5.79% -5.62% -10.97% -4.74% 
L Cochlea Mean 2418.05 -4.03% -5.23% -2.56% -2.66% -4.25% -1.22% -2.61% -2.75% -3.85% -0.24% 
 
D05 2743.95 -2.95% -4.77% -2.37% -2.19% -3.94% -0.84% -2.48% -2.33% -3.66% 0.07% 
R Cochlea Mean 1579.52 -3.70% -3.66% -3.75% -3.75% -5.37% -2.42% -3.97% -3.94% -4.77% -1.22% 
 
D05 2087.93 -1.94% -2.71% -2.35% -2.25% -3.93% -1.01% -2.44% -2.44% -3.39% 0.38% 
L Submandibular Mean 7176.21 -0.41% 0.97% 0.01% -0.08% 0.70% -0.29% 0.31% 0.21% 0.84% -0.41% 
 
Max to 1 cc 7348.09 -0.43% 1.19% 0.03% -0.04% 0.81% -0.27% 0.35% 0.24% 0.94% -0.41% 
R Submandibular Mean 5955.18 -0.78% 0.27% 0.02% 0.18% 0.68% -0.25% 0.25% 0.47% 0.98% -0.32% 
 
Max to 1 cc 6755.93 -0.35% 0.79% 0.15% 0.23% 0.93% -0.10% 0.45% 0.55% 1.16% -0.17% 
L Eye Max 251.57 -1.94% 12.26% -14.51% -14.61% -15.49% -13.74% -12.61% -12.71% -13.14% -10.96% 
R Eye Max 219.09 -0.21% 13.57% -12.30% -12.47% -13.19% -11.65% -10.68% -10.85% -11.32% -9.25% 
L Lens Max 151.82 2.98% 19.46% -11.99% -12.14% -12.82% -11.55% -9.45% -9.61% -9.85% -8.21% 
R Lens Max 136.56 3.49% 18.00% -9.68% -9.83% -10.39% -9.21% -7.79% -7.97% -8.32% -6.71% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95 6555.71 0.08% 0.13% -1.74% -0.76% -0.31% 0.28% -0.25% 0.14% -1.29% 0.45% -0.76% 0.36% 
PTV 60 D95 5770.01 0.05% 0.04% -0.23% -0.60% -0.03% 0.15% 0.22% -0.01% -0.34% 0.24% 0.16% 0.16% 
PTV 54 D95 5269.47 -0.43% 0.13% 0.50% -0.88% -0.75% 0.32% -2.77% 0.05% -2.25% 0.48% -12.17% 0.19% 
OARs 
Brainstem Max 3839.33 0.51% 0.61% -5.35% 3.38% -0.34% 0.88% -0.30% 0.85% -0.46% 1.43% -0.75% 1.89% 
 
Max to 1 cc 3666.80 0.39% 0.50% -5.11% 3.03% -0.13% 0.43% -0.32% 0.33% -0.61% 0.92% -0.65% 1.07% 
Cord Max 4326.81 1.33% 0.49% -1.35% 1.12% 0.20% 0.33% -0.66% 1.10% 0.00% 0.53% -1.88% 2.13% 
 
Max to 0.3 cc 4242.28 1.19% 0.47% -1.54% 1.28% -0.23% 0.52% -0.84% 0.81% -0.72% 1.19% -1.67% 1.73% 
L Parotid Mean 3550.33 -0.46% -0.68% -2.97% 0.88% -3.36% 3.56% -0.12% 0.21% -6.88% 7.21% -0.34% 0.54% 
 
D50 2526.12 -0.99% -1.11% -4.34% 0.70% -7.79% 9.02% 0.40% -0.22% -15.10% 18.77% 0.46% -0.25% 
R Parotid Mean 1969.74 -1.94% -1.13% -3.44% -0.28% -3.90% 4.34% -0.05% 0.26% -7.94% 8.77% -0.27% 0.59% 
 
D50 1139.00 -4.13% -3.78% -6.41% -2.46% -2.90% 3.51% -0.61% 0.79% -5.79% 7.81% -0.97% 1.67% 
L Cochlea Mean 2418.05 0.46% -0.02% -5.79% 3.82% -1.61% 2.25% -0.13% 0.13% -3.42% 5.19% 0.24% 0.60% 
 
D05 2743.95 0.29% 0.66% -5.65% 4.07% -1.06% 2.11% -0.14% 0.26% -2.24% 5.25% 0.33% 0.86% 
R Cochlea Mean 1579.52 -1.21% -1.15% -7.16% 2.42% -5.67% 4.24% -0.85% 1.10% -11.15% 9.67% -1.70% 2.44% 
 
D05 2087.93 -0.10% -0.05% -6.13% 3.50% -3.60% 5.68% -1.87% 1.68% -8.40% 13.02% -3.78% 2.68% 
L 
Submandibular Mean 7176.21 -0.46% -0.72% 1.26% -1.50% 0.45% -0.05% 0.31% -0.03% 0.52% -0.05% 0.33% 0.11% 
 
Max to 1 cc 7348.09 -0.58% -0.76% 1.45% -1.60% 0.56% -0.15% 0.42% -0.10% 0.77% -0.22% 0.59% -0.05% 
R 
Submandibular Mean 5955.18 -0.59% -0.03% 1.30% -1.18% 0.36% 0.22% 0.18% 0.34% 0.25% 0.32% -0.12% 0.76% 
 
Max to 1 cc 6755.93 -0.56% -0.21% 1.48% -1.30% 0.66% -0.09% 0.35% 0.16% 0.93% -0.24% 0.27% 0.44% 
L Eye Max 251.57 -9.97% -10.34% -13.95% -7.71% -6.72% 8.59% -3.74% 7.23% -10.72% 16.21% -4.29% 14.83% 
R Eye Max 219.09 -8.05% -8.69% -11.96% -6.23% -7.04% 10.17% -4.13% 7.91% -10.78% 19.60% -4.58% 16.24% 
L Lens Max 151.82 -9.86% -10.35% -12.99% -8.47% -7.37% 12.53% -5.65% 9.92% -10.22% 25.46% -6.19% 19.61% 
R Lens Max 136.56 -7.02% -7.57% -10.08% -5.79% -7.74% 13.91% -6.08% 11.32% -10.29% 27.23% -6.63% 21.96% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degrees 
-2 
degree
s 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95 6555.71 -0.05% -0.03% -0.57% -0.17% -3.19% -1.20% -0.05% 0.11% 0.13% 0.10% 0.00% 0.11% 
PTV 60 D95 5770.01 0.49% -0.40% -1.28% 1.24% 0.26% -1.43% -0.01% 0.15% 0.19% 0.12% 0.03% 0.14% 
PTV 54 D95 5269.47 -0.85% 0.52% -1.16% -0.70% -2.06% -1.65% 0.03% 0.11% 0.25% 0.09% 0.07% 0.11% 
OARs 
Brainstem Max 3839.33 1.06% -0.29% 1.49% 10.09% 14.22% 0.97% 0.05% 0.20% 0.38% 0.17% 0.14% 0.19% 
 
Max to 1 cc 3666.80 0.14% 0.31% -1.79% 2.85% 0.63% -0.73% 0.05% 0.21% 0.39% 0.19% 0.12% 0.21% 
Cord Max 4326.81 1.06% -0.26% 2.18% 2.76% 2.41% 1.23% 0.06% 0.18% 0.17% 0.17% 0.09% 0.18% 
 
Max to 0.3 cc 4242.28 0.80% -0.06% 1.50% 1.37% 2.41% 1.47% -0.08% 0.17% 0.12% 0.17% -0.01% 0.17% 
L Parotid Mean 3550.33 0.11% 0.79% 0.14% 2.38% 0.97% 2.21% -0.17% 0.09% -0.06% 0.08% -0.15% 0.09% 
 
D50 2526.12 -0.43% 3.40% 2.79% 4.17% 5.61% 5.02% -0.49% 0.15% -0.09% 0.14% -0.25% 0.15% 
R Parotid Mean 1969.74 -6.13% 7.85% -1.47% 5.03% 8.52% -4.03% -0.05% 0.09% 0.07% 0.08% -0.02% 0.09% 
 
D50 1139.00 -1.58% 3.95% -0.88% 6.50% 12.99% -2.46% -0.70% 0.18% 0.18% 0.18% -0.44% 0.18% 
L Cochlea Mean 2418.05 1.97% 0.14% 12.85% -6.16% 23.04% -13.27% 0.00% 0.22% 0.10% 0.21% 0.05% 0.22% 
 
D05 2743.95 0.57% 1.12% 6.62% -4.96% 23.14% -16.62% -0.16% 0.20% -0.29% 0.20% -0.12% 0.20% 
R Cochlea Mean 1579.52 -1.23% 2.60% -3.67% 10.83% -16.49% 29.34% -0.03% 0.08% 0.24% 0.06% 0.02% 0.08% 
 
D05 2087.93 0.12% 1.14% -4.41% 9.55% -14.94% 30.65% -0.12% 0.10% 0.19% 0.05% -0.07% 0.10% 
L 
Submandibular Mean 7176.21 0.34% -0.20% 0.25% -0.20% 0.99% -0.36% 0.06% 0.08% 0.34% 0.06% 0.11% 0.08% 
 
Max to 1 cc 7348.09 0.02% 0.24% 0.30% 0.09% 1.30% -0.41% 0.05% 0.08% 0.33% 0.05% 0.10% 0.08% 
R 
Submandibular Mean 5955.18 0.63% -0.30% -2.46% 3.01% 1.65% -0.86% 0.01% 0.18% 0.24% 0.16% 0.05% 0.18% 
 
Max to 1 cc 6755.93 0.60% -0.33% -1.26% 2.11% 0.38% 0.19% 0.09% 0.19% 0.39% 0.16% 0.13% 0.18% 
L Eye Max 251.57 1.09% -0.90% -4.04% 2.61% -2.35% 0.03% -0.07% 0.06% 0.04% 0.05% -0.02% 0.06% 
R Eye Max 219.09 -0.14% 0.78% -0.12% -1.11% 0.27% -3.88% -0.17% 0.10% 0.05% 0.08% -0.11% 0.09% 
L Lens Max 151.82 0.94% -0.79% -2.17% 1.33% -0.76% -2.15% -0.13% 0.08% -0.01% 0.06% -0.08% 0.07% 
R Lens Max 136.56 -0.52% 1.72% 0.90% -0.22% -0.41% -2.77% -0.20% 0.06% -0.06% 0.05% -0.16% 0.06% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 
4 cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95 6555.71 0.24% -0.22% 0.05% 0.43% 0.58% -0.88% -0.90% 0.00% 0.00% 0.00% 
PTV 60 D95 5770.01 0.24% -0.30% -0.03% 0.60% 0.37% -0.15% -0.04% 0.00% 0.00% 0.00% 
PTV 54 D95 5269.47 0.29% -0.17% 0.03% 0.99% 0.44% -0.50% -0.07% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 3839.33 0.27% 0.16% -0.22% 3.56% 4.15% 0.01% -0.40% 0.00% 0.00% 0.00% 
 
Max to 1 cc 3666.80 0.11% 0.48% -0.32% 4.07% 3.34% -0.07% -0.42% 0.00% 0.00% 0.00% 
Cord Max 4326.81 0.53% -0.36% -0.05% 2.97% 1.41% -1.43% -1.21% 0.00% 0.00% 0.00% 
 
Max to 0.3 cc 4242.28 0.29% -0.04% -0.11% 3.02% 1.54% -1.56% -1.20% 0.00% 0.00% 0.00% 
L Parotid Mean 3550.33 -0.17% 1.43% -0.43% 5.17% 5.52% -3.62% -3.04% 0.00% 0.00% 0.00% 
 
D50 2526.12 -0.25% 0.96% -0.90% 9.70% 13.93% -8.95% -8.83% 0.00% 0.00% 0.00% 
R Parotid Mean 1969.74 -0.50% 2.48% -1.01% 11.30% 6.38% -4.31% -3.68% 0.00% 0.00% 0.00% 
 
D50 1139.00 -1.32% -0.61% -2.28% 22.65% 11.94% -4.92% -5.79% 0.00% 0.00% 0.00% 
L Cochlea Mean 2418.05 -0.39% 2.06% -0.57% 8.01% 14.01% -1.94% -1.96% 0.00% 0.00% 0.00% 
 
D05 2743.95 -0.22% 1.48% -0.48% 6.52% 11.90% -1.63% -1.62% 0.00% 0.00% 0.00% 
R Cochlea Mean 1579.52 -0.93% 3.62% -1.15% 12.33% 23.87% -5.13% -6.16% 0.00% 0.00% 0.00% 
 
D05 2087.93 -0.96% 2.37% -1.06% 10.73% 21.74% -6.05% -6.53% 0.00% 0.00% 0.00% 
L Submandibular Mean 7176.21 0.21% 0.38% 0.09% 0.40% -0.01% 0.50% 0.60% 0.00% 0.00% 0.00% 
 
Max to 1 cc 7348.09 0.21% 0.49% 0.11% 0.30% -0.20% 0.75% 0.79% 0.00% 0.00% 0.00% 
R Submandibular Mean 5955.18 0.39% -0.50% 0.02% 1.15% 0.55% 0.18% 0.32% 0.00% 0.00% 0.00% 
 
Max to 1 cc 6755.93 0.28% 0.15% 0.08% 0.63% 0.12% 0.62% 0.59% 0.00% 0.00% 0.00% 
L Eye Max 251.57 0.06% 0.10% -0.19% 1.23% 3.12% -0.32% -0.69% 0.00% 0.00% 0.00% 
R Eye Max 219.09 -0.05% 0.40% -0.24% 1.68% 3.73% -0.82% -0.98% 0.00% 0.00% 0.00% 
L Lens Max 151.82 0.01% 0.03% -0.23% 1.30% 3.12% -0.70% -1.02% 0.00% 0.00% 0.00% 
R Lens Max 136.56 -0.13% 0.41% -0.31% 1.93% 3.98% -1.24% -1.32% 0.00% 0.00% 0.00% 
Table 112: Patient 7 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 8 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: 
Beam Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
PTVs 
PTV 70 D95 6742.59 -0.27% -0.05% 0.23% 0.24% 0.29% 0.17% 0.20% 0.13% 0.24% 0.18% 
PTV 66 D95 6373.08 -0.76% -0.13% 0.43% 0.53% 0.28% 0.68% 0.46% 0.44% -0.06% 0.65% 
PTV 63 D95 6141.76 -1.39% 0.80% 0.56% 0.50% 0.03% 1.04% 0.62% 0.43% -0.20% 1.12% 
PTV 60 D95 6134.02 -0.11% -1.80% -0.84% 0.16% 0.90% -0.59% -0.10% -0.10% 1.42% -0.68% 
PTV 57 D95 5339.39 -0.50% -1.38% 0.32% 0.27% 0.50% 0.02% 0.35% 0.08% 0.73% 0.04% 
OARs 
Brainstem Max 4138.24 -0.61% -0.11% -0.15% -0.34% 0.10% -0.85% -0.14% -0.57% 0.85% -0.71% 
 
Max to 1 cc 3716.32 -0.66% -0.55% -0.79% -0.84% -0.18% -1.71% -0.99% -1.20% 0.56% -1.40% 
Spinal cord Max 3966.48 -1.31% 1.20% -0.30% -0.53% -0.16% -0.55% -0.06% -0.52% 0.18% -0.11% 
 
Max to 0.3 cc 3730.08 0.14% 1.23% 0.00% -0.21% 0.38% 0.31% 0.38% -0.31% 3.36% 1.33% 
L parotid Mean 2544.98 -3.64% -0.96% -2.07% -1.90% -1.97% -2.17% -1.64% -1.64% -1.36% -1.69% 
 
D50 2228.97 -5.51% -6.27% -3.27% -2.52% 0.73% 1.00% -2.15% 0.31% 2.83% -0.20% 
R parotid Mean 2518.84 -5.11% -2.06% -2.43% -2.59% -2.36% -2.57% -1.80% -2.08% -1.63% -2.11% 
 
D05 1754.00 -4.45% -3.25% -2.74% -2.91% -1.82% 0.97% -1.60% -2.68% 8.72% 1.82% 
L cochlea Mean 1506.44 -5.74% -5.34% -2.65% -3.06% -2.20% -3.92% -2.32% -2.93% -0.64% -3.23% 
 
D05 1715.00 -0.93% -6.53% -0.06% -0.35% 1.28% 2.62% 0.76% -0.76% 12.77% 3.67% 
R cochlea Mean 3269.92 -2.25% -4.29% -1.02% -0.66% -0.15% -2.19% -1.34% -1.04% 1.04% -1.73% 
 
D05 3507.80 -1.07% -4.99% -0.11% 0.25% 1.09% 0.26% -0.35% -0.43% 6.00% 0.73% 
L submandibular Max 7475.57 -0.51% 1.63% 0.90% 0.80% -0.01% 1.89% 0.93% 0.83% -0.41% 1.89% 
 
Mean 6982.24 -0.70% 1.10% 0.54% 0.50% 0.14% 1.28% 0.65% 0.50% -0.29% 1.21% 
R. 
submandibular Max 7354.29 -0.62% 1.09% 0.25% 0.51% 0.09% 0.80% 0.34% 0.63% -0.12% 0.96% 
 
Mean 6915.01 -0.87% 1.46% 0.37% 0.50% -0.02% 1.20% 0.46% 0.59% -0.32% 1.17% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Botto
m to 
top 
Left to 
right 
Right 
to left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 70 D95 6742.59 0.30% 0.07% -0.14% -0.55% 0.07% 0.55% -0.04% 0.61% -0.04% 0.20% -0.37% 0.29% 
PTV 66 D95 6373.08 0.01% -0.03% -1.21% -0.06% -1.82% 0.30% -0.35% 0.75% -6.69% -0.22% -1.32% 0.73% 
PTV 63 D95 6141.76 -0.23% -0.66% -1.78% 1.04% -0.34% 0.63% -0.50% 0.88% -1.33% 0.32% -1.39% 0.64% 
PTV 60 D95 6134.02 1.27% 1.73% 3.37% -2.22% 0.00% -0.53% -1.99% 1.07% 0.20% -0.96% -3.54% 1.85% 
PTV 57 D95 5339.39 0.93% 0.51% 1.06% -0.94% -0.04% 0.49% -0.61% 1.00% -2.53% 0.28% -1.76% 1.20% 
OARs 
Brainstem Max 4138.24 1.66% 0.64% 1.87% -2.16% -0.08% 0.50% -0.27% 0.59% -0.35% 0.23% -0.99% 0.96% 
 
Max to 1 cc 3716.32 1.20% 0.58% 2.00% -3.41% -0.38% 0.77% -0.20% 0.58% -0.80% 1.17% -0.66% 0.91% 
Spinal cord Max 3966.48 0.33% -0.67% -0.41% -1.54% 0.13% 0.58% -0.36% 0.72% 0.01% 0.71% -1.29% 0.70% 
 
Max to 0.3 cc 3730.08 4.72% 2.51% 2.63% 2.86% 2.39% 3.29% 0.00% 3.50% 2.01% 2.41% 0.02% 1.57% 
L parotid Mean 2544.98 -1.56% -1.03% -0.27% -2.14% 0.08% 0.74% -0.72% 1.61% 0.01% 0.54% -1.55% 2.33% 
 
D50 2228.97 -0.27% 1.02% 2.02% 1.75% 1.36% 3.04% 1.93% 5.33% -1.73% 2.06% 1.68% 5.83% 
R parotid Mean 2518.84 -1.46% -2.16% -1.05% -2.67% -0.21% 0.91% -0.84% 1.59% -0.43% 1.24% -1.65% 2.60% 
 
D05 1754.00 3.71% 5.02% 3.93% 7.13% 0.40% 2.17% -1.08% 4.16% 1.03% 4.68% -2.11% 6.39% 
L cochlea Mean 1506.44 1.35% -0.07% 3.11% -3.85% 0.74% 0.06% -14.53% 12.48% 1.31% -0.73% -26.90% 25.80% 
 
D05 1715.00 8.98% 9.50% 10.61% 8.45% 1.69% 0.82% -10.26% 19.45% 10.09% 1.98% -30.26% 28.98% 
R cochlea Mean 3269.92 0.77% 1.72% 3.47% -3.83% -0.85% 1.17% -5.21% 4.13% -2.07% 1.24% -12.02% 7.77% 
 
D05 3507.80 3.61% 5.22% 6.20% 0.92% -0.64% 1.00% -4.22% 4.80% -1.08% 1.44% -8.94% 8.83% 
L submandibular Max 7475.57 -0.24% -0.38% -1.59% 3.67% -0.31% 1.17% -0.30% 1.93% -0.55% 1.44% -0.15% 2.82% 
 
Mean 6982.24 -0.28% -0.43% -1.13% 2.09% -0.01% 0.83% 0.12% 0.72% -0.28% 0.63% -0.01% 0.42% 
R. submandibular Max 7354.29 -0.63% -0.12% -0.71% 2.21% -0.33% 1.02% -0.01% 0.78% -0.11% 1.03% 0.08% 0.82% 
 
Mean 6915.01 -0.73% -0.56% -1.70% 1.74% 0.04% 0.64% 0.39% 0.31% 0.01% 0.47% 0.74% -0.22% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degree
s 
-2 
degree
s 
+ 2 
degrees 
-2 
degree
s 
+ 2 
degree
s 
-2 
degree
s 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 70 D95 6742.59 -0.42% 0.01% -0.54% -1.66% 0.01% -0.36% 0.13% -0.01% 0.15% -0.01% 0.07% -0.07% 
PTV 66 D95 6373.08 0.63% -2.08% -2.47% -2.88% -4.32% 0.26% 0.18% -0.01% 0.24% -0.01% 0.16% -0.07% 
PTV 63 D95 6141.76 0.12% -0.19% -1.03% 0.33% -0.19% 0.00% 0.15% 0.00% 0.27% -0.01% 0.02% -0.05% 
PTV 60 D95 6134.02 0.80% -0.99% -0.99% -7.64% -6.81% -0.38% 0.15% -0.01% 0.22% -0.01% -0.08% -0.02% 
PTV 57 D95 5339.39 -1.08% 0.50% -1.98% -3.60% -0.27% -2.23% 0.12% -0.01% 0.17% -0.01% -0.11% -0.05% 
OARs 
Brainstem Max 4138.24 1.29% -0.26% 3.50% 6.14% 0.59% 7.03% -0.12% 0.00% -0.27% 0.02% -0.71% 0.03% 
 
Max to 1 cc 3716.32 1.03% -1.02% 0.69% 3.00% 0.51% 2.05% 0.00% 0.00% -0.06% 0.00% -0.52% -0.01% 
Spinal cord Max 3966.48 -0.07% 0.90% 5.77% 1.06% -2.03% 2.85% -0.17% 0.01% -0.34% 0.02% -0.78% 0.04% 
 
Max to 0.3 cc 3730.08 1.40% 3.80% 6.84% 2.93% -2.64% 3.68% 1.38% 0.00% 1.14% 0.03% 1.97% 0.04% 
L parotid Mean 2544.98 2.61% -0.33% 0.07% 5.71% 13.01% -8.01% 0.10% 0.00% 0.18% -0.01% -0.12% -0.03% 
 
D50 2228.97 5.99% 0.32% -6.19% 19.28% 12.73% 
-
13.92% -2.24% -1.41% 4.36% -2.67% -4.62% 3.57% 
R parotid Mean 2518.84 2.42% -0.12% 6.90% 0.75% -12.18% 18.27% 0.50% -0.03% 0.59% -0.04% 1.20% -0.21% 
 
D05 1754.00 7.92% 7.01% 23.83% 6.84% -18.07% 33.75% 0.51% -0.06% 0.11% -0.06% 0.80% -0.29% 
L cochlea Mean 1506.44 -3.38% 3.16% -1.53% 12.62% -24.56% 37.01% -0.17% 0.01% -0.30% 0.02% -0.77% 0.06% 
 
D05 1715.00 6.85% 9.21% 7.32% 15.71% -25.51% 39.48% -0.41% 0.00% -1.05% 0.00% -1.92% 0.00% 
R cochlea Mean 3269.92 3.69% -3.01% -6.34% 21.09% 8.97% 1.47% 0.28% -0.02% 0.25% -0.02% 0.43% -0.14% 
 
D05 3507.80 6.25% -0.48% -8.14% 22.75% 9.60% 6.92% -0.37% 0.00% -0.04% 0.00% -0.11% -0.17% 
L submandibular Max 7475.57 1.09% -0.67% -0.32% 1.33% -0.51% 1.91% 0.19% -0.01% 0.24% -0.01% 0.32% -0.10% 
 
Mean 6982.24 -0.95% 1.14% 0.99% -0.30% 0.80% -0.30% 0.23% -0.01% 0.31% -0.02% 0.34% -0.11% 
R. 
submandibular Max 7354.29 1.36% -0.46% -0.67% 2.99% -0.18% 1.14% 0.21% -0.01% 0.19% -0.01% 0.47% -0.12% 
 
Mean 6915.01 1.33% -0.88% -0.71% 1.32% -0.61% 1.15% 0.32% -0.02% 0.37% -0.02% 0.72% -0.15% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 
cm 
width = 
0.200 
cm 
radius = 
4 cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 70 D95 6742.59 0.31% 0.70% -0.05% 0.16% 0.36% -0.44% -0.04% 0.00% 0.00% 0.00% 
PTV 66 D95 6373.08 0.25% 0.80% -0.08% -0.02% 1.25% -0.59% -0.28% 0.00% 0.00% 0.00% 
PTV 63 D95 6141.76 0.28% 1.15% -0.06% 0.15% 1.11% -0.63% -0.10% 0.00% 0.00% 0.00% 
PTV 60 D95 6134.02 0.26% 0.69% -0.20% -0.46% 0.99% -1.37% -1.58% 0.00% 0.00% 0.00% 
PTV 57 D95 5339.39 0.31% 1.67% 0.03% -0.35% 0.93% -1.04% -0.62% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 4138.24 -0.01% 2.68% 0.07% 0.38% 0.53% -0.64% -0.41% 0.00% 0.00% 0.00% 
 
Max to 1 cc 3716.32 -0.20% 3.43% -0.49% 1.45% 1.00% -0.82% -0.93% 0.00% 0.00% 0.00% 
Spinal cord Max 3966.48 0.08% 3.13% -0.07% 0.89% 0.37% -0.04% 0.40% 0.00% 0.00% 0.00% 
 
Max to 0.3 cc 3730.08 3.31% 6.80% 2.88% 4.58% 4.23% 2.51% 3.00% 3.17% 3.17% 3.17% 
L parotid Mean 2544.98 -0.23% 6.77% -0.25% 0.43% 2.23% -1.53% -0.94% 0.00% 0.00% 0.00% 
 
D50 2228.97 4.36% 13.34% 4.48% 4.75% 6.64% 3.45% 3.92% 4.53% 4.53% 4.53% 
R parotid Mean 2518.84 -0.38% 7.05% -0.19% -0.31% 2.19% -1.76% -1.09% 0.00% 0.00% 0.00% 
 
D05 1754.00 11.12% 23.72% 11.46% 12.09% 15.56% 9.29% 10.03% 11.57% 11.57% 11.57% 
L cochlea Mean 1506.44 -1.17% 6.91% -2.07% 3.47% 11.23% -8.85% -11.74% 0.00% 0.00% 0.00% 
 
D05 1715.00 11.55% 19.59% 10.44% 16.01% 22.58% 3.56% 1.71% 11.84% 11.84% 11.84% 
R cochlea Mean 3269.92 -0.45% 2.84% -1.04% 1.15% 5.43% -4.43% -5.13% 0.00% 0.00% 0.00% 
 
D05 3507.80 4.26% 7.68% 3.46% 5.20% 9.82% -1.10% -1.24% 4.63% 4.63% 4.63% 
L submandibular Max 7475.57 0.17% 0.28% -0.21% 0.41% 0.84% 0.06% 0.26% 0.00% 0.00% 0.00% 
 
Mean 6982.24 0.32% 0.75% 0.02% 0.35% 0.64% -0.08% 0.31% 0.00% 0.00% 0.00% 
R. 
submandibular Max 7354.29 0.36% 0.54% -0.11% 0.68% 0.30% -0.20% 0.18% 0.00% 0.00% 0.00% 
 
Mean 6915.01 0.35% 0.73% -0.17% 1.07% 0.15% 0.25% 0.57% 0.00% 0.00% 0.00% 
Table 113: Patient 8 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 9 
Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: Beam 
Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
PTVs 
PTV 70 D95 7007.01 -0.88% -0.54% -0.14% -0.14% -0.42% -0.37% -0.25% -0.24% -0.37% -0.05% 
PTV66 D95 6512.64 -1.83% 2.13% 0.10% -0.05% -0.81% 0.86% 0.16% 0.00% -0.94% 1.16% 
PTV63 D95 6123.06 -0.28% -0.86% -0.19% -0.38% -0.37% -0.35% -0.10% -0.35% -0.32% -0.12% 
PTV57 D95 5466.70 -0.28% -1.89% -0.46% -0.39% -0.38% -0.95% -0.45% -0.42% -0.22% -0.57% 
OARs 
Brainstem Max 3804.72 0.72% -1.72% -1.44% -1.42% -0.42% -3.26% -1.73% -1.71% 1.12% -2.59% 
 
Max to 1 cc 3491.02 0.44% -1.29% -1.09% -1.08% -0.01% -2.76% -1.39% -1.38% 1.36% -2.18% 
spinal cord Max 3473.37 -1.74% -0.27% -1.44% -1.51% -1.28% -2.14% -1.37% -1.44% -0.34% -1.43% 
 
Max to 0.3 cc 3254.01 1.36% 4.79% 1.13% 2.02% 1.23% 1.22% 0.88% 2.18% 2.19% 1.99% 
L Parotid Mean 3179.66 -1.79% -1.83% -2.02% -1.88% -1.46% -2.70% -1.73% -1.58% -0.73% -2.09% 
 
D05 2354.24 -2.48% -0.77% -1.55% -1.25% -0.64% -2.44% -1.27% -0.93% 0.30% -1.76% 
R Parotid Mean 1439.25 -8.99% -1.23% -4.60% -4.62% -4.16% -5.46% -3.86% -3.91% -2.68% -4.26% 
 
D50 1014.42 -10.83% 2.34% -5.45% -5.45% -4.88% -6.44% -4.11% -4.15% -2.77% -4.61% 
L Cochlea Mean 859.37 -9.11% -7.22% -4.68% -4.55% -3.18% -6.51% -5.18% -4.98% -2.05% -6.09% 
 
D05 1182.70 -4.60% -2.57% -1.04% -0.88% 0.56% -2.90% -0.96% -0.71% 2.34% -1.97% 
R Cochlea Mean 804.55 -7.56% -8.13% -3.01% -3.08% -1.66% -4.93% -3.90% -3.98% -0.79% -4.85% 
 
D05 1020.60 -4.14% -4.51% 2.64% 2.62% 4.11% 0.58% 2.25% 2.22% 5.65% 1.24% 
L submandibular Max 7338.10 0.07% 0.61% -0.79% -0.78% -0.67% -0.33% -0.69% -0.68% -0.34% -0.28% 
 
Mean 7109.58 -0.65% 0.65% -0.40% -0.32% -0.70% -0.06% -0.36% -0.25% -0.70% 0.17% 
R submandibular Max 7352.05 -1.07% -0.42% -0.29% -0.35% -0.60% -0.20% -0.36% -0.32% -0.38% 0.17% 
 
Mean 6344.45 -1.57% -0.63% -0.33% -0.34% -0.59% -0.20% -0.37% -0.38% -0.51% 0.06% 
esophagus D15 3855.20 -0.35% 1.82% -1.31% -0.07% -1.50% -0.60% -1.77% 0.18% -1.01% 0.33% 
 
D33 3716.70 -0.24% 0.76% -1.45% -0.32% -1.96% -0.55% -1.96% -0.04% -1.49% 0.48% 
larynx Max 7112.80 -1.13% 1.81% 0.16% 0.15% -0.78% 1.03% -0.06% -0.10% -1.16% 1.05% 
 
Mean 2384.19 -3.53% 6.04% -4.41% -4.14% -4.98% -3.70% -3.84% -3.42% -4.34% -2.71% 
 
D27 2940.24 -5.48% 2.28% -3.81% -3.06% -3.40% -3.40% -3.33% -2.14% -2.41% -2.28% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 70 D95 7007.01 -0.76% -0.67% -1.45% -0.44% -0.42% -0.46% -0.57% -0.28% -0.70% -0.85% -1.18% -0.62% 
PTV66 D95 6512.64 -1.21% -1.59% -3.03% 2.11% -0.38% -0.68% -0.18% -0.53% -1.53% -1.22% 0.07% -1.00% 
PTV63 D95 6123.06 -0.07% -0.67% -0.59% 0.08% -0.89% -0.01% -1.23% 0.41% -2.17% -0.32% -2.41% 0.52% 
PTV57 D95 5466.70 -0.44% 0.00% -0.22% -1.47% -1.21% 0.03% -1.37% 0.65% -4.97% -0.08% -2.90% 1.05% 
OARs 
Brainstem Max 3804.72 0.64% 0.81% 3.38% -5.42% -1.03% 0.89% -1.01% 0.52% -2.44% 1.54% -2.27% 1.18% 
 
Max to 1 cc 3491.02 1.11% 1.15% 3.72% -4.78% -0.78% 1.00% -0.74% 0.55% -1.63% 1.62% -1.69% 1.46% 
spinal cord Max 3473.37 -0.38% -0.62% 0.31% -2.98% -1.42% 1.28% -0.73% 1.38% -2.68% 2.23% -1.56% 2.28% 
 
Max to 0.3 cc 3254.01 2.15% 4.16% 3.44% 1.09% 1.81% 3.55% 1.29% 3.67% 1.28% 4.76% 0.73% 4.51% 
L Parotid Mean 3179.66 -0.55% -0.08% 1.38% -2.54% -0.32% -0.08% -3.73% 3.35% -0.33% -0.15% -7.09% 6.71% 
 
D05 2354.24 1.05% 1.74% 3.72% -1.74% 1.58% 1.53% -7.15% 10.88% 1.71% 1.30% -14.84% 20.42% 
R Parotid Mean 1439.25 -2.87% -2.96% -1.20% -5.41% -0.39% 0.09% -3.53% 3.37% -0.53% 0.22% -6.65% 6.89% 
 
D50 1014.42 -3.45% -3.46% -1.52% -6.51% 1.86% 2.74% 0.06% 4.64% 1.60% 3.01% -1.74% 6.82% 
L Cochlea Mean 859.37 1.00% 1.44% 5.34% -5.27% -0.04% -0.11% -7.18% 9.09% -0.02% -0.28% -12.80% 21.60% 
 
D05 1182.70 3.69% 4.11% 8.17% -2.90% 3.10% 2.68% -8.06% 18.23% 3.27% 2.34% -16.26% 41.91% 
R Cochlea Mean 804.55 3.45% 3.18% 7.41% -3.44% 0.70% 0.72% -6.02% 7.29% 0.72% 0.47% -12.11% 15.47% 
 
D05 1020.60 8.42% 8.20% 12.63% 1.07% 6.14% 5.85% -3.07% 15.89% 6.34% 5.48% -10.02% 31.23% 
L submandibular Max 7338.10 -0.39% -0.74% 0.04% 1.05% -0.42% 0.02% -0.20% -0.34% 0.05% 0.34% 0.21% -0.18% 
 
Mean 7109.58 -1.23% -0.98% -1.52% 0.79% -0.08% -0.52% -0.02% -0.58% 0.36% -0.86% 0.50% -1.01% 
R submandibular Max 7352.05 -0.95% -0.88% -0.87% 0.86% -0.15% 0.07% -0.04% -0.57% 0.01% 0.78% 0.66% 0.12% 
 
Mean 6344.45 -0.88% -0.86% -1.06% 0.62% -0.53% -0.09% -0.43% -0.19% -0.53% 0.07% -0.33% -0.15% 
esophagus D15 3855.20 -2.30% 2.25% -3.33% 0.21% 0.32% 1.05% -0.34% 0.10% 0.15% 1.10% -0.67% 0.62% 
 
D33 3716.70 -2.06% 2.56% -3.90% 0.72% 0.14% 0.69% -0.26% -0.17% -0.01% 0.60% -0.78% 0.37% 
larynx Max 7112.80 -1.36% -1.30% -2.86% 2.71% 0.64% 1.63% 0.18% -0.03% -0.88% 10.19% 0.94% 6.63% 
 
Mean 2384.19 -6.28% -5.23% -7.26% -3.10% 21.63% 52.38% -2.37% 2.38% 12.38% 70.36% -3.33% 6.39% 
 
D27 2940.24 -5.75% -2.45% -4.39% -4.32% 30.35% 89.86% -3.67% 4.64% 22.34% 110.21% -5.22% 12.05% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2° -2° + 2° -2° + 2° -2° 1A 1B 2A 2B 3A 3B 
PTVs 
PTV 70 D95 7007.01 0.00% -0.25% -0.37% -0.47% -2.87% -1.40% 0.02% 0.00% -0.25% -0.01% -0.11% 0.03% 
PTV66 D95 6512.64 -0.06% 0.15% 0.49% -0.58% -0.77% 0.54% 0.07% 0.00% -0.22% -0.01% -0.04% 0.02% 
PTV63 D95 6123.06 -0.82% 0.41% -1.44% -0.66% -1.92% -1.27% 0.07% 0.00% -0.16% -0.01% 0.03% 0.01% 
PTV57 D95 5466.70 -0.79% -0.30% -2.74% -1.55% -4.92% -6.88% 0.06% 0.00% -0.06% -0.01% 0.03% 0.01% 
OARs 
Brainstem Max 3804.72 -0.22% -0.14% -0.45% -0.37% 5.19% 15.20% -0.03% 0.00% -0.14% 0.00% 0.01% -0.01% 
 
Max to 1 cc 3491.02 0.13% -0.08% -0.17% -0.54% -3.22% 5.45% -0.05% 0.00% -0.16% 0.01% -0.07% 0.01% 
spinal cord Max 3473.37 1.09% -1.02% 3.53% 1.12% -1.40% 4.02% 0.17% 0.00% 0.13% -0.03% 0.13% 0.00% 
 
Max to 0.3 cc 3254.01 3.53% 1.73% 7.35% 3.60% 2.51% 7.89% 0.34% 0.01% -5.96% -0.07% -5.77% -0.03% 
L Parotid Mean 3179.66 4.67% -3.58% 4.64% -2.30% -4.09% 8.23% -0.06% 0.00% -0.39% 0.01% -0.10% 0.01% 
 
D05 2354.24 15.67% -6.62% 13.18% -4.42% -3.42% 22.26% 0.95% 0.03% -0.32% -0.03% 1.14% 0.03% 
R Parotid Mean 1439.25 -2.60% 5.35% -6.07% 11.60% 10.32% -0.36% -0.01% 0.00% -0.34% 0.00% 0.03% -0.01% 
 
D50 1014.42 3.20% 2.87% -2.20% 12.27% 13.97% 4.80% -2.96% 0.04% -0.75% -0.04% 1.28% -0.58% 
L Cochlea Mean 859.37 -1.42% 1.15% -3.56% 13.32% 9.07% 2.72% 0.20% -0.01% 0.03% -0.01% 0.59% -0.09% 
 
D05 1182.70 0.39% 7.24% 4.99% 27.45% 29.23% 13.11% 0.31% 0.05% -0.14% -0.05% 0.54% -0.03% 
R Cochlea Mean 804.55 1.00% -1.37% 10.75% -6.49% -1.07% 4.02% 0.12% -0.01% -0.31% 0.00% 0.51% -0.09% 
 
D05 1020.60 5.60% 2.13% 19.30% 2.45% 0.26% 20.47% 0.17% 0.07% -0.67% -0.07% 0.22% -0.03% 
L submandibular Max 7338.10 -0.14% 0.25% 0.23% -0.31% 0.47% 3.42% -0.02% 0.00% -0.27% -0.01% -0.18% 0.03% 
 
Mean 7109.58 -0.11% 0.07% 0.25% -0.44% 0.13% -0.21% 0.01% 0.00% -0.31% -0.01% -0.16% 0.04% 
R submandibular Max 7352.05 0.23% -0.26% -0.49% 0.37% 0.36% 0.00% 0.00% 0.00% -0.23% -0.01% -0.19% 0.04% 
 
Mean 6344.45 1.99% -1.99% -2.32% 2.30% -2.48% 2.44% 0.01% 0.00% -0.25% -0.01% -0.19% 0.04% 
esophagus D15 3855.20 0.15% 0.21% 1.59% -0.85% 1.62% -0.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
 
D33 3716.70 -0.14% 0.22% 1.58% -1.17% 1.59% -1.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 
larynx Max 7112.80 -0.42% 0.12% 0.85% -1.12% -0.08% -0.15% 0.09% 0.00% -0.14% -0.02% -0.05% 0.03% 
 
Mean 2384.19 0.51% -0.54% 0.83% -0.75% 0.09% 0.08% 0.04% 0.00% -0.17% -0.01% -0.06% 0.02% 
 
D27 2940.24 1.77% -1.36% 0.99% -4.29% 4.79% -3.69% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 
4 cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 70 D95 7007.01 -0.08% -0.67% -0.34% -0.29% -0.34% -0.69% -0.90% 0.00% 0.00% 0.00% 
PTV66 D95 6512.64 0.01% -0.61% -0.32% -0.21% 1.92% 0.98% 0.09% 0.00% 0.00% 0.00% 
PTV63 D95 6123.06 -0.05% -0.60% -0.41% 0.48% 1.16% -0.76% -1.03% 0.00% 0.00% 0.00% 
PTV57 D95 5466.70 -0.13% -0.53% -0.47% 1.24% 1.44% -1.12% -1.62% 0.00% 0.00% 0.00% 
OARs 
Brainstem Max 3804.72 -0.28% 0.02% -0.68% 3.55% 1.36% -0.54% -2.07% 0.00% 0.00% 0.00% 
 
Max to 1 cc 3491.02 -0.29% 0.75% -0.72% 4.21% 1.28% -0.26% -1.80% 0.00% 0.00% 0.00% 
spinal cord Max 3473.37 0.00% -0.42% -0.77% 4.50% 1.64% -2.29% -1.69% 0.00% 0.00% 0.00% 
 
Max to 0.3 cc 3254.01 -6.12% 1.61% -0.67% -1.61% -3.61% -8.03% 0.51% 0.00% 0.00% 0.00% 
L Parotid Mean 3179.66 -0.50% 1.17% -0.93% 6.05% 4.33% -3.76% -3.62% 0.00% 0.00% 0.00% 
 
D05 2354.24 1.08% -0.22% -2.56% 10.16% 13.81% -8.57% -7.87% 0.00% 0.00% 0.00% 
R Parotid Mean 1439.25 -1.31% 5.15% -2.08% 18.86% 5.12% -3.45% -3.54% 0.00% 0.00% 0.00% 
 
D50 1014.42 -0.70% 7.99% -4.83% 28.35% 7.10% -4.78% -6.33% 0.00% 0.00% 0.00% 
L Cochlea Mean 859.37 -1.43% 6.13% -1.85% 15.49% 16.11% -6.33% -7.65% 0.00% 0.00% 0.00% 
 
D05 1182.70 -1.28% 5.28% -3.24% 16.85% 30.27% -11.17% -15.11% 0.00% 0.00% 0.00% 
R Cochlea Mean 804.55 -0.96% 3.88% -1.24% 9.25% 8.99% -2.53% -4.19% 0.00% 0.00% 0.00% 
 
D05 1020.60 -0.36% 6.27% -2.98% 12.87% 17.74% -5.31% -11.82% 0.00% 0.00% 0.00% 
L submandibular Max 7338.10 -0.07% -0.12% -0.32% -0.43% -0.52% 0.47% -0.39% 0.00% 0.00% 0.00% 
 
Mean 7109.58 -0.13% 0.03% -0.34% -0.28% -0.87% 0.74% -0.03% 0.00% 0.00% 0.00% 
R submandibular Max 7352.05 0.27% -1.25% -0.32% -0.41% -0.24% 0.70% -0.07% 0.00% 0.00% 0.00% 
 
Mean 6344.45 -0.03% -0.75% -0.39% 0.28% -0.15% 0.01% -0.59% 0.00% 0.00% 0.00% 
esophagus D15 3855.20 -0.03% -0.30% -0.11% 0.33% 0.20% -0.24% -0.23% 0.00% 0.00% 0.00% 
 
D33 3716.70 0.02% -0.36% -0.09% 0.22% 0.02% -0.15% -0.14% 0.00% 0.00% 0.00% 
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larynx Max 7112.80 -0.09% 0.21% -0.31% -0.40% 1.67% 1.33% 0.36% 0.00% 0.00% 0.00% 
 
Mean 2384.19 -0.11% -0.08% -0.51% 2.15% 6.46% -1.56% -1.83% 0.00% 0.00% 0.00% 
 
D27 2940.24 1.36% -4.05% -0.07% 0.17% 5.44% -3.78% -2.39% 0.00% 0.00% 0.00% 
Table 114: Patient 9 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Patient 10 
Structures 
Evaluatio
n Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 1: Beam 
Energy 
Failure Mode 2: Beam Symmetry 
2 degrees 3.5 degrees 
+10% -10% 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
Top to 
bottom 
Bottom 
to top 
Left to 
right 
Right to 
left 
PTVs 
PTV 66 D95 6391.40 0.07% -0.83% -0.71% -0.10% -0.25% -0.21% -0.54% 0.04% -0.16% -0.45% 
PTV 60 D95 5820.33 -0.39% -1.79% -1.01% -0.07% -0.40% -0.43% -0.84% 0.12% -0.32% -0.63% 
PTV  54 D95 5277.46 -0.19% -2.37% -1.14% -0.03% -0.47% -0.45% -1.02% 0.15% -0.33% -0.56% 
OARs 
Brainstem D100 246.00 -3.25% 4.88% 1.22% 3.66% 2.03% 2.03% 2.44% 5.28% 3.66% 3.25% 
 
Max to 1 cc 3898.80 -0.28% -1.96% -2.35% -0.41% -1.39% -1.48% -1.91% 0.19% -1.19% -1.34% 
Spinal Cord Max 4236.31 -0.90% -0.28% -1.12% -0.87% -0.66% -0.79% -0.91% -0.23% -0.36% -0.86% 
L Parotid Mean 1846.32 -5.54% -3.80% -4.08% -3.03% -3.50% -3.39% -3.52% -2.31% -2.78% -3.11% 
 
D50 932.71 -10.09% -2.70% -8.38% -6.95% -7.24% -7.31% -6.49% -4.69% -5.66% -6.11% 
R parotid Mean 1364.51 -7.46% -3.54% -5.23% -4.15% -4.46% -4.57% -4.41% -3.06% -3.61% -4.00% 
 
D50 932.71 -10.09% -2.70% -8.38% -6.95% -7.24% -7.31% -6.49% -4.69% -5.66% -6.11% 
L Eye Max 149.05 1.58% 24.62% 7.38% 9.81% 8.67% 8.81% 11.23% 14.47% 12.48% 12.38% 
R Eye Max 154.87 0.41% 20.37% 14.13% 16.57% 15.49% 15.28% 16.06% 19.36% 17.50% 16.88% 
L lens Max 89.39 5.06% 23.41% -1.89% -0.48% -1.05% -1.08% 2.27% 4.28% 3.21% 2.94% 
R lens Max 85.15 4.42% 21.50% 1.79% 3.35% 2.71% 2.63% 5.55% 7.69% 6.57% 6.09% 
L Optic 
Nerve Max 201.67 -0.35% 17.97% 24.40% 27.80% 26.17% 26.20% 26.06% 30.42% 27.71% 27.35% 
R Optic 
Nerve Max 195.40 -0.49% 17.84% 23.16% 26.55% 24.90% 24.92% 25.57% 29.89% 27.17% 26.85% 
Chiasm Max 299.29 -2.36% 7.17% 16.81% 20.04% 18.54% 18.52% 16.89% 20.85% 18.32% 17.99% 
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Structures 
Evaluation 
Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 2: Beam Symmetry Failure Mode 3: MLC Position 
10 degrees 1 mm Errors 2 mm Errors 
Top to 
botto
m 
Botto
m to 
top 
Left to 
right 
Right 
to left 
X1 + 
1mm 
X1 - 
1mm 
X2 
+1mm 
X2 - 
1mm 
X1 + 
2mm 
X1 - 
2mm 
X2 
+2mm 
X2 - 
2mm 
PTVs 
PTV 66 D95 6391.40 0.21% 0.21% 0.21% 0.21% -0.32% 0.18% -0.23% -0.06% -0.58% 0.38% -0.71% -0.37% 
PTV 60 D95 5820.33 0.55% 0.55% 0.55% 0.55% -1.30% -0.08% -1.13% -0.28% -2.26% 0.66% -2.37% -0.45% 
PTV  54 D95 5277.46 0.60% 0.60% 0.60% 0.60% -4.45% -3.98% -4.14% -4.18% -5.42% -3.73% -4.88% -4.39% 
OARs 
Brainstem D100 246.00 9.35% 9.35% 9.35% 9.35% 11.79% 15.45% 11.79% 15.04% 11.38% 16.67% 11.38% 16.26% 
 
Max to 1 cc 3898.80 1.02% 1.02% 1.02% 1.02% 7.80% 7.21% 7.64% 6.82% 8.38% 7.21% 7.98% 6.62% 
Spinal Cord Max 4236.31 -0.30% -0.30% -0.30% -0.30% 10.76% 12.58% 10.66% 12.40% 8.90% 13.91% 9.37% 13.19% 
L Parotid Mean 1846.32 -2.11% -2.11% -2.11% -2.11% 29.61% 33.42% 30.94% 32.41% 27.84% 36.71% 30.09% 34.48% 
 
D50 932.71 -5.53% -5.53% -5.53% -5.53% -1.97% 1.91% -2.39% 2.30% -3.13% 4.50% -4.47% 4.72% 
R parotid Mean 1364.51 -2.91% -2.91% -2.91% -2.91% -3.71% 0.78% -4.98% 2.31% -5.48% 3.71% -8.02% 6.74% 
 
D50 932.71 -5.53% -5.53% -5.53% -5.53% -1.97% 1.91% -2.39% 2.30% -3.13% 4.50% -4.47% 4.72% 
L Eye Max 149.05 15.21% 15.21% 15.21% 15.21% 46.45% 57.11% 46.16% 58.50% 46.31% 57.99% 45.28% 60.71% 
R Eye Max 154.87 24.80% 24.80% 24.80% 24.80% 35.32% 44.84% 35.15% 44.08% 34.24% 47.49% 33.40% 45.45% 
L lens Max 89.39 1.16% 1.16% 1.16% 1.16% 33.90% 38.72% 34.46% 41.91% 33.45% 39.69% 33.45% 45.26% 
R lens Max 85.15 6.00% 6.00% 6.00% 6.00% 25.26% 30.15% 24.49% 30.38% 24.58% 31.95% 22.70% 32.35% 
L Optic Nerve Max 201.67 38.10% 38.10% 38.10% 38.10% 51.28% 59.12% 50.90% 58.88% 50.88% 60.56% 50.01% 59.80% 
R Optic Nerve Max 195.40 36.24% 36.24% 36.24% 36.24% 44.44% 52.34% 44.57% 51.80% 43.20% 54.30% 43.42% 52.98% 
Chiasm Max 299.29 30.25% 30.25% 30.25% 30.25% 31.96% 36.29% 31.55% 36.22% 32.08% 37.10% 31.18% 36.64% 
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Structures 
Evaluatio
n Criteria 
Baseline 
Dose 
(cGy) 
Failure Mode 4: 
Gantry Angle 
Failure Mode 5: 
Collimator Angle 
Failure Mode 6: 
Couch Angle 
Failure Mode 7: MU Linearity 
+ 2 
degrees 
-2 
degree
s 
+ 2 
degrees 
-2 
degrees 
+ 2 
degrees 
-2 
degrees 
1A 1B 2A 2B 3A 3B 
PTVs 
PTV 66 D95 6391.40 -0.02% -0.20% -0.70% -1.57% -0.51% -0.63% -0.17% 0.01% -0.13% 0.01% -0.12% -0.01% 
PTV 60 D95 5820.33 0.24% -0.39% -2.35% 0.93% -1.08% 0.11% -0.20% 0.01% -0.18% 0.01% -0.07% -0.08% 
PTV  54 D95 5277.46 -1.01% -0.48% -2.42% 2.16% -1.48% -0.18% -0.04% 0.00% 0.08% -0.01% 0.17% -0.13% 
OARs 
Brainstem D100 246.00 0.00% -1.22% -2.03% 2.85% -0.81% -0.41% 0.00% 0.00% 0.00% 0.00% 0.00% -0.41% 
 
Max to 1 
cc 3898.80 0.10% -0.19% 0.80% 13.09% 0.22% 0.42% 0.16% 0.00% 0.44% -0.03% 0.33% -0.32% 
Spinal Cord Max 4236.31 -0.30% 0.53% 1.01% 12.71% -0.23% -0.26% 0.03% 0.00% 0.22% -0.01% 0.36% -0.09% 
L Parotid Mean 1846.32 6.70% -4.99% -1.22% 9.41% 0.85% 3.24% 0.04% 0.00% 0.13% -0.01% 0.70% -0.08% 
 
D50 932.71 -0.62% 1.60% 3.53% 12.72% -2.74% 4.41% -0.16% 0.00% -0.26% 0.01% 0.44% -0.09% 
R parotid Mean 1364.51 -5.99% 8.55% 5.88% 13.98% 1.16% 2.90% -0.11% 0.01% -0.11% 0.01% 0.30% -0.15% 
 
D50 932.71 -0.62% 1.60% 3.53% 12.72% -2.74% 4.41% -0.16% 0.00% -0.26% 0.01% 0.44% -0.09% 
L Eye Max 149.05 0.91% -0.33% -0.75% 20.28% -0.82% 3.00% -0.01% 0.01% 0.13% -0.01% 0.01% -0.04% 
R Eye Max 154.87 -0.45% -0.27% 1.53% 13.26% 3.56% -2.26% -0.05% 0.01% 0.07% 0.00% 0.15% 0.00% 
L lens Max 89.39 2.81% -0.25% 0.05% 26.89% -0.07% -2.11% 0.03% 0.00% 0.21% -0.01% 0.22% 0.04% 
R lens Max 85.15 1.30% 1.02% 4.64% 12.96% 2.59% -1.48% -0.03% 0.01% 0.09% -0.01% 0.23% 0.05% 
L Optic Nerve Max 201.67 -1.32% -1.10% -3.02% 13.85% 0.53% -3.59% -0.07% 0.01% 0.01% 0.00% -0.01% -0.11% 
R Optic Nerve Max 195.40 0.04% -0.67% -2.09% 8.23% -1.63% 3.64% -0.13% 0.01% -0.09% 0.01% -0.06% -0.08% 
Chiasm Max 299.29 0.16% -0.34% -0.91% 8.77% -0.54% -1.17% -0.11% 0.01% -0.06% 0.00% -0.07% -0.14% 
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Structures 
Evaluatio
n Criteria 
Baseline 
Dose 
(cGy) 
MLC Modeling 
Failure Mode 11: CT Table Failure Mode 8: 
Leakage & 
Transmission 
Failure Mode 9: 
Tongue-and-groove 
Failure Mode 10: 
Leaf End 
0% 10% 
width = 
0.005 cm 
width = 
0.200 cm 
radius = 4 
cm 
radius = 
15 cm 
radius = 
20 cm 
+2% -2% PET CT 
PTVs 
PTV 66 D95 6391.40 -0.30% -0.18% -0.09% -0.23% 0.74% -0.47% -0.52% 0.00% 0.00% 0.00% 
PTV 60 D95 5820.33 -0.37% 0.25% -0.06% -0.43% 1.86% -1.41% -1.22% 0.00% 0.00% 0.00% 
PTV  54 D95 5277.46 -0.40% 0.79% -0.17% 0.14% 1.76% -1.73% -1.43% 0.00% 0.00% 0.00% 
OARs 
Brainstem D100 246.00 -0.41% 0.41% 0.00% -0.41% 0.81% 0.00% -0.41% 0.00% 0.00% 0.00% 
 
Max to 1 
cc 3898.80 -0.49% 1.88% 0.05% -0.35% 1.60% 0.23% -0.16% 0.00% 0.00% 0.00% 
Spinal Cord Max 4236.31 -0.50% 1.85% -0.42% 0.66% 3.00% -1.39% -1.28% 0.00% 0.00% 0.00% 
L Parotid Mean 1846.32 -1.28% 10.44% -0.64% 2.48% 10.14% -4.93% -3.99% 0.00% 0.00% 0.00% 
 
D50 932.71 -2.36% 22.21% -1.78% 8.17% 15.46% -3.51% -3.25% 0.00% 0.00% 0.00% 
R parotid Mean 1364.51 -1.68% 14.60% -1.14% 4.72% 12.43% -5.75% -4.73% 0.00% 0.00% 0.00% 
 
D50 932.71 -2.36% 22.21% -1.78% 8.17% 15.46% -3.51% -3.25% 0.00% 0.00% 0.00% 
L Eye Max 149.05 -0.37% 0.68% -0.16% 0.34% 1.54% -0.97% -0.92% 0.00% 0.00% 0.00% 
R Eye Max 154.87 -0.36% 0.79% -0.15% 0.50% 2.26% -1.46% -1.26% 0.00% 0.00% 0.00% 
L lens Max 89.39 -0.38% 0.95% -0.19% 0.49% 2.50% -1.77% -1.54% 0.00% 0.00% 0.00% 
R lens Max 85.15 -0.43% 1.57% -0.25% 0.63% 3.64% -2.25% -1.88% 0.00% 0.00% 0.00% 
L Optic Nerve Max 201.67 -0.31% 0.12% -0.07% 0.08% 1.49% -0.85% -0.82% 0.00% 0.00% 0.00% 
R Optic Nerve Max 195.40 -0.32% 0.18% -0.13% 0.25% 1.69% -1.07% -0.97% 0.00% 0.00% 0.00% 
Chiasm Max 299.29 -0.24% -0.70% 0.02% -0.51% 0.40% -0.08% -0.29% 0.00% 0.00% 0.00% 
Table 115: Patient 10 dose differences from baseline at evaluation criteria for PTVs and OARs for each failure mode. 
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Appendix C: Failure Mode Patient DVH graphs 
 
Figure 112: Failure mode 1 DVHs for patient 1. 
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Figure 113: Failure mode 1 DVHs for patient 2. 
 
Figure 114: Failure mode 1 DVHs for patient 3. 
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Figure 115: Failure mode 1 DVHs for patient 4. 
 
Figure 116: Failure mode 1 DVHs for patient 5. 
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Figure 117: Failure mode 1 DVHs for patient 6. 
 
Figure 118: Failure mode 1 DVHs for patient 7. 
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Figure 119: Failure mode 1 DVHs for patient 8. 
 
Figure 120: Failure mode 1 DVHs for patient 9. 
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Figure 121: Failure mode 1 DVHs for patient 10. 
 
Figure 122: Failure mode 2 (with 2% symmetry errors) DVHs for patient 1. 
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Figure 123: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 1. 
 
Figure 124: Failure mode 2 (with 10% symmetry errors) DVHs for patient 1. 
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Figure 125: Failure mode 2 (with 2% symmetry errors) DVHs for patient 2. 
 
Figure 126: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 2. 
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Figure 127: Failure mode 2 (with 10% symmetry errors) DVHs for patient 2. 
 
Figure 128: Failure mode 2 (with 2% symmetry errors) DVHs for patient 3. 
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Figure 129: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 3. 
 
Figure 130: Failure mode 2 (with 10% symmetry errors) DVHs for patient 3. 
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Figure 131: Failure mode 2 (with 2% symmetry errors) DVHs for patient 4. 
 
Figure 132: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 4. 
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Figure 133: Failure mode 2 (with 10% symmetry errors) DVHs for patient 4. 
 
Figure 134: Failure mode 2 (with 2% symmetry errors) DVHs for patient 5. 
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Figure 135: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 5. 
 
Figure 136: Failure mode 2 (with 10% symmetry errors) DVHs for patient 5. 
285 
 
 
Figure 137: Failure mode 2 (with 2% symmetry errors) DVHs for patient 6. 
 
Figure 138: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 6. 
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Figure 139: Failure mode 2 (with 10% symmetry errors) DVHs for patient 6. 
 
Figure 140: Failure mode 2 (with 2% symmetry errors) DVHs for patient 7. 
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Figure 141: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 7. 
 
Figure 142: Failure mode 2 (with 10% symmetry errors) DVHs for patient 7. 
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Figure 143: Failure mode 2 (with 2% symmetry errors) DVHs for patient 8. 
 
Figure 144: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 8. 
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Figure 145: Failure mode 2 (with 10% symmetry errors) DVHs for patient 8. 
 
Figure 146: Failure mode 2 (with 2% symmetry errors) DVHs for patient 9. 
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Figure 147: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 9. 
 
Figure 148: Failure mode 2 (with 10% symmetry errors) DVHs for patient 9. 
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Figure 149: Failure mode 2 (with 2% symmetry errors) DVHs for patient 10. 
 
Figure 150: Failure mode 2 (with 3.5% symmetry errors) DVHs for patient 10. 
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Figure 151: Failure mode 2 (with 10% symmetry errors) DVHs for patient 10. 
 
Figure 152: Failure mode 3 (with 1 mm errors) DVHs for patient 1. 
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Figure 153: Failure mode 3 (with 2 mm errors) DVHs for patient 1. 
 
Figure 154: Failure mode 3 (with 1 mm errors) DVHs for patient 2. 
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Figure 155: Failure mode 3 (with 2 mm errors) DVHs for patient 2. 
 
Figure 156: Failure mode 3 (with 1 mm errors) DVHs for patient 3. 
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Figure 157: Failure mode 3 (with 2 mm errors) DVHs for patient 3. 
 
Figure 158: Failure mode 3 (with 1 mm errors) DVHs for patient 4. 
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Figure 159: Failure mode 3 (with 2 mm errors) DVHs for patient 4. 
 
Figure 160: Failure mode 3 (with 1 mm errors) DVHs for patient 5. 
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Figure 161: Failure mode 3 (with 2 mm errors) DVHs for patient 5. 
 
Figure 162: Failure mode 3 (with 1 mm errors) DVHs for patient 6. 
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Figure 163: Failure mode 3 (with 2 mm errors) DVHs for patient 6. 
 
Figure 164: Failure mode 3 (with 1 mm errors) DVHs for patient 7. 
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Figure 165: Failure mode 3 (with 2 mm errors) DVHs for patient 7. 
 
Figure 166: Failure mode 3 (with 1 mm errors) DVHs for patient 8. 
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Figure 167: Failure mode 3 (with 2 mm errors) DVHs for patient 8. 
 
Figure 168: Failure mode 3 (with 1 mm errors) DVHs for patient 9. 
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Figure 169: Failure mode 1 (with 2 mm errors) DVHs for patient 9. 
 
Figure 170: Failure mode 3 (with 1 mm errors) DVHs for patient 10. 
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Figure 171: Failure mode 3 (with 2 mm errors) DVHs for patient 10. 
 
Figure 172: Failure mode 4 DVHs for patient 1. 
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Figure 173: Failure mode 4 DVHs for patient 2. 
 
Figure 174: Failure mode 4 DVHs for patient 3. 
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Figure 175: Failure mode 4 DVHs for patient 4. 
 
Figure 176: Failure mode 4 DVHs for patient 5. 
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Figure 177: Failure mode 4 DVHs for patient 6. 
 
Figure 178: Failure mode 4 DVHs for patient 7. 
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Figure 179: Failure mode 4 DVHs for patient 8. 
 
Figure 180: Failure mode 4 DVHs for patient 9. 
307 
 
 
Figure 181: Failure mode 4 DVHs for patient 10. 
 
Figure 182: Failure mode 5 DVHs for patient 1. 
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Figure 183: Failure mode 5 DVHs for patient 2. 
 
Figure 184: Failure mode 5 DVHs for patient 3. 
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Figure 185: Failure mode 5 DVHs for patient 4. 
 
Figure 186: Failure mode 5 DVHs for patient 5. 
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Figure 187: Failure mode 5 DVHs for patient 6. 
 
Figure 188: Failure mode 5 DVHs for patient 7. 
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Figure 189: Failure mode 5 DVHs for patient 8. 
 
Figure 190: Failure mode 5 DVHs for patient 9. 
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Figure 191: Failure mode 5 DVHs for patient 10. 
 
Figure 192: Failure mode 6 DVHs for patient 1. 
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Figure 193: Failure mode 6 DVHs for patient 2. 
 
Figure 194: Failure mode 6 DVHs for patient 3. 
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Figure 195: Failure mode 6 DVHs for patient 4. 
 
Figure 196: Failure mode 6 DVHs for patient 5. 
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Figure 197: Failure mode 6 DVHs for patient 6. 
 
Figure 198: Failure mode 6 DVHs for patient 7. 
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Figure 199: Failure mode 6 DVHs for patient 8. 
 
Figure 200: Failure mode 6 DVHs for patient 9. 
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Figure 201: Failure mode 6 DVHs for patient 10. 
 
Figure 202: Failure mode 7 DVHs for patient 1. 
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Figure 203: Failure mode 7 DVHs for patient 2. 
 
Figure 204: Failure mode 7 DVHs for patient 3. 
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Figure 205: Failure mode 7 DVHs for patient 4. 
 
Figure 206: Failure mode 7 DVHs for patient 5. 
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Figure 207: Failure mode 7 DVHs for patient 6. 
 
Figure 208: Failure mode 7 DVHs for patient 7. 
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Figure 209: Failure mode 7 DVHs for patient 8. 
 
Figure 210: Failure mode 7 DVHs for patient 9. 
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Figure 211: Failure mode 7 DVHs for patient 10. 
 
Figure 212: Failure mode 8 DVHs for patient 1. 
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Figure 213: Failure mode 8 DVHs for patient 2. 
 
Figure 214: Failure mode 8 DVHs for patient 3. 
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Figure 215: Failure mode 8 DVHs for patient 4. 
 
Figure 216: Failure mode 8 DVHs for patient 5. 
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Figure 217: Failure mode 8 DVHs for patient 6. 
 
Figure 218: Failure mode 8 DVHs for patient 7. 
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Figure 219: Failure mode 8 DVHs for patient 8. 
 
Figure 220: Failure mode 8 DVHs for patient 9. 
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Figure 221: Failure mode 8 DVHs for patient 10. 
 
Figure 222: Failure mode 9 DVHs for patient 1. 
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Figure 223: Failure mode 9 DVHs for patient 2. 
 
Figure 224: Failure mode 9 DVHs for patient 3. 
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Figure 225: Failure mode 9 DVHs for patient 4. 
 
Figure 226: Failure mode 9 DVHs for patient 5. 
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Figure 227: Failure mode 9 DVHs for patient 6. 
 
Figure 228: Failure mode 9 DVHs for patient 7. 
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Figure 229: Failure mode 9 DVHs for patient 8. 
 
Figure 230: Failure mode 9 DVHs for patient 9. 
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Figure 231: Failure mode 9 DVHs for patient 10. 
 
Figure 232: Failure mode 10 DVHs for patient 1. 
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Figure 233: Failure mode 10 DVHs for patient 2. 
 
Figure 234: Failure mode 10 DVHs for patient 3. 
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Figure 235: Failure mode 10 DVHs for patient 4. 
 
Figure 236: Failure mode 10 DVHs for patient 5. 
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Figure 237: Failure mode 10 DVHs for patient 6. 
 
Figure 238: Failure mode 10 DVHs for patient 7. 
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Figure 239: Failure mode 10 DVHs for patient 8. 
 
Figure 240: Failure mode 10 DVHs for patient 9. 
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Figure 241: Failure mode 10 DVHs for patient 10. 
 
Figure 242: Failure mode 11 DVHs for patient 1. 
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Figure 243: Failure mode 11 DVHs for patient 2. 
 
Figure 244: Failure mode 11 DVHs for patient 3. 
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Figure 245: Failure mode 11 DVHs for patient 5. 
 
Figure 246: Failure mode 11 DVHs for patient 6. 
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Figure 247: Failure mode 11 DVHs for patient 7. 
 
Figure 248: Failure mode 11 DVHs for patient 8. 
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Figure 249: Failure mode 11 DVHs for patient 9. 
 
Figure 250: Failure mode 11 DVHs for patient 10. 
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